"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
1,"NCT03701932","Mental Activity During (TMS) Therapy for Depression",,"Recruiting","No Results Available","Cognitive Impairment","Behavioral: TMS and Lumosity®cognitive retraining|Behavioral: TMS and non cognitive computer games","The University of Pennsylvania Computerized Neuropsychological Testing Battery (Penn CNP)|The Lumosity® Brain Performance Test (BPT)|Inventory of Depressive Symptoms- Self Report|Hamilton Depression Rating Scale 17 item","Augusta University|Lumos Labs, Inc.","All","18 Years and older   (Adult, Older Adult)","Not Applicable","25","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","663245","March 6, 2015","March 6, 2019","March 6, 2019","October 10, 2018","null","October 10, 2018","Augusta University, Augusta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03701932"
2,"NCT03701061","Durability and Impact of the Seasonal Influenza Vaccine on H5 Induced B Cell Response","HIPCVAX-010S","Recruiting","No Results Available","Influenza A Subtype H5N1 Infection","Biological: Seasonal Influenza Vaccine","Number of participants with a four-fold increase in stem-specific antibody titers (H5, Hemagglutinin Antibody) against H5N1 at day 29 after vaccination with the seasonal influenza vaccine among all the participants in both arms|Number of solicited (AE's) grade 2 and above at day 8 after vaccination with the seasonal influenza vaccine among the participants in both arms|Number of unsolicited adverse events (AE's) grade 2 and above at day 29 after vaccination with the seasonal influenza vaccine among the participants in both arms|Number of serious adverse events at day 365 among the participants in both arms","Emory University|National Institute of Allergy and Infectious Diseases (NIAID)","All","Child, Adult, Older Adult","Phase 4","50","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","IRB00100804|U19AI090023","October 2018","May 30, 2019","May 30, 2020","October 9, 2018","null","October 9, 2018","The Hope Clinic of Emory University, Decatur, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03701061"
3,"NCT03686514","The Impact of Imprinting and Repeated Influenza Vaccination on Adaptive Immunity, Transcriptomics, and Metabolomics","FLU2","Not yet recruiting","No Results Available","Influenza","Biological: Seasonal influenza vaccine 2018-2019","The proportion of subjects achieving seroprotection (titer of ≥ 40) or seroconversion (four-fold rise in HAI post- compared to pre-vaccination, or a titer of ≥40 if the pre-vaccination titer was <10) against each strain|Geometric Mean Titers (GMTs) of serum HAI against each strain|The proportion of subjects achieving seroprotection (titer of ≥ 40) or seroconversion (four-fold rise in NAb post- compared to pre-vaccination, or a titer of ≥40 if the pre-vaccination titer was <10) against each strain|Geometric Mean Titers (GMTs) of serum NAb against each strain","Emory University","All","41 Years to 70 Years   (Adult, Older Adult)","Phase 1","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","IRB00106407","October 2018","July 2019","July 2020","September 27, 2018","null","September 27, 2018","The Hope Clinic of the Emory Vaccine Center, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03686514"
4,"NCT03680144","Utility of Perfusion MRI to Detect Radiation Necrosis in Patients With Brain Metastases",,"Not yet recruiting","No Results Available","Invasive Malignant Neoplasm|Metastatic Malignant Neoplasm in the Brain","Procedure: Dynamic Susceptibility Contrast-MRI (DSC-MRI)|Procedure: Magnetic Resonance Imaging (MRI)","Change in dynamic susceptibility contrast (DSC)-magnetic resonance imaging (MRI) parameters: relative cerebral blood volume (rCBV)|Change in dynamic susceptibility contrast (DSC)-magnetic resonance imaging (MRI) parameters: relative peak height (rPH)|Change in dynamic susceptibility contrast (DSC)-magnetic resonance imaging (MRI) parameters: percentage of signal intensity recovery (PSR)|Change in dynamic susceptibility contrast (DSC)-magnetic resonance imaging (MRI) parameters: mean transit time (MTT)","Emory University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","45","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","IRB00102506|NCI-2018-01722|RAD4391-18","September 1, 2019","September 30, 2020","September 30, 2020","September 21, 2018","null","September 21, 2018","Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03680144"
5,"NCT03674489","Local and Widespread Hypoalgesic Effects of Neurodynamic Mobilization in Healthy Controls",,"Not yet recruiting","No Results Available","Pain|Pain, Neuropathic","Other: Neurodynamic Slider Mobilization|Other: Neurodynamic Tensioner Mobilization|Other: Sham Neurodynamic Mobilization","Pressure Pain Threshold (PPT)|Thermal Pain Threshold (TPT)|Thermal Pain Tolerance (TPTol)|Elbow Extension ROM Obtained on Neurodynamic Testing","Brenau University","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","1208684-5","October 2018","June 2019","June 2019","September 17, 2018","null","September 17, 2018","Brenau University, Gainesville, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03674489"
6,"NCT03673865","The Use of 3D Printing in Orbital Fractures",,"Not yet recruiting","No Results Available","Orbital Fractures","Device: office-based 3-dimensional printers (OB3DP)|Device: standard stock orbital plate","Change in the orbital volume of the injured orbit compared to the contralateral uninjured orbit as assessed by CT scan between the treatment and control groups|Number of subjects with reduction of orbital volume to less than 2 cm3 between the treatment and control groups|Number of subjects with a difference of more than 2 mm between the two orbits between the treatment and control groups|Number of subjects with infection between the treatment and control groups|Number of subjects with infraorbital nerve injury between the treatment and control groups|Number of subjects with Intraocular pressure (IOP) > 40 mmHg between the treatment and control groups|Mean operating time in minutes between the treatment and control groups|Mean length of stay in hospital measured in days between the treatment and control groups|Mean treatment amount in dollars between the treatment and control groups|Number of subjects that develop restricted extraocular motility that was not present before between the treatment and control groups|Number of subjects with inability to achieve the normal orbital contour between the treatment and control groups","Emory University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00103655","September 2018","September 2020","September 2020","September 17, 2018","null","September 17, 2018","Grady Memorial Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03673865"
7,"NCT03673501","A Study of DCC-2618 vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib","intrigue","Not yet recruiting","No Results Available","Gastrointestinal Stromal Tumors","Drug: DCC-2618|Drug: Sunitinib","Progression free survival (PFS)|Objective response rate (ORR)|Overall Survival (OS)","Deciphera Pharmaceuticals LLC","All","18 Years and older   (Adult, Older Adult)","Phase 3","358","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DCC-2618-03-002","December 2018","June 2021","March 2022","September 17, 2018","null","September 17, 2018","Georgia Cancer Specialists, Sandy Springs, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03673501"
8,"NCT03665532","Youth Engagement Study: Intervention to Increase HIV Treatment Engagement and Adherence for Young People Living With HIV","YES","Recruiting","No Results Available","HIV/AIDS","Behavioral: Youth Engagement in Services","HIV suppression|Medication Adherence","University of Connecticut|Mercer University","All","16 Years to 35 Years   (Child, Adult)","Not Applicable","400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","H16-130","July 1, 2017","June 30, 2020","June 30, 2021","September 11, 2018","null","September 11, 2018","Southeast HIV/AIDS Research & Evaluation Project, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03665532"
9,"NCT03664817","Social Capital and Engagement in Care Among Young Black Men Who Have Sex With Men Living With HIV",,"Recruiting","No Results Available","HIV Infections","Behavioral: social capital intervention|Behavioral: group-based health promotion intervention","Change in Modified Social Capital Scale (MSCS) between the social capital intervention group and group-based health promotion intervention|Change in viral load suppression measured as copies/ml at baseline, post-intervention 3 months and 9 months between the social capital intervention group and group-based health promotion intervention|Change in number of receiving two or more cluster of differentiation 4 (CD4) tests at baseline, post-intervention 3 months and 9 months between the social capital intervention group and group-based health promotion intervention|Number of HIV visits at baseline, post-intervention 3 months and 9 months between the social capital intervention group and group-based health promotion intervention|Change in subjects self report to question at baseline, post-intervention 3 months and 9 months between the social capital intervention group and group-based health promotion intervention|Number of viral load tests at post-intervention 3 months and 9 months between the social capital intervention group and group-based health promotion intervention","Emory University|Centers for Disease Control and Prevention","Male","18 Years to 29 Years   (Adult)","Not Applicable","120","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","IRB00088255","July 26, 2018","April 2020","April 2021","September 11, 2018","null","September 11, 2018","Emory University 1518 Clifton Rd, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03664817"
10,"NCT03650452","A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 (OV935) as an Adjunctive Therapy in Pediatric Patients With Developmental and/or Epileptic Encephalopathies","ELEKTRA","Recruiting","No Results Available","Epilepsy|Dravet Syndrome|Lennox-Gastaut Syndrome","Drug: TAK-935|Drug: Placebo","Percent change from baseline in frequency of all seizures (convulsive and drop) per 28 days in patients receiving TAK-935 (OV935) as compared to placebo during the Treatment Period|Percent change from baseline in all seizures (convulsive and drop) in patients receiving TAK-935 (OV935) as compared to placebo during Maintenance Period|Percent change from baseline in frequency of convulsive seizures in Dravet patients and drop seizures in LGS patients, respectively, receiving TAK-935 (OV935) as compared to placebo during Treatment Period|Proportion of patients receiving TAK-935 (OV935) as compared to placebo in the Dravet patients and LGS patients, respectively, considered treatment responders|Change in Clinician's and Caregiver's Clinical Global Impression of Severity and Change|Correlation of TAK-935 concentration and plasma 24S-hydroxycholesterol (24HC) levels","Takeda|Ovid Therapeutics","All","2 Years to 17 Years   (Child)","Phase 2","126","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TAK-935-2002|U1111-1206-5522","August 8, 2018","March 21, 2021","April 21, 2021","August 28, 2018","null","September 26, 2018","Center for Rare Neurological Diseases, Norcross, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03650452"
11,"NCT03647930","The Effect of Arista on Post-Operative Bleeding and Wound Drainage Following Mastectomy",,"Completed","No Results Available","Seroma","Device: Microporous Polysaccharide Hemospheres (MPH)","Total Drain Days|Total Drain Output","Memorial Health University Medical Center","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","MHUMC 2012.05.05","May 15, 2012","March 6, 2015","March 6, 2015","August 27, 2018","null","August 27, 2018","Memorial Health University Medical Center, Savannah, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03647930"
12,"NCT03634579","MRI Guided Prostate Cancer Focal Laser Ablation",,"Recruiting","No Results Available","Prostate Cancer","Device: MRI Guided Focal Laser Interstitial Thermal Ablation","Number of recurrences of Prostate Cancer at the end of 1 year among the subjects treated with MRI Guided Focal Laser Interstitial Thermal Ablation|Percentage of grade 3 or higher complications as defined as National cancer institute's common toxicity criteria version 4 among the subjects treated with MRI Guided Focal Laser Interstitial Thermal Ablation|Change in erectile function|Change in urinary function|Number of recurrences of Prostate Cancer at the end of 2nd year among the subjects treated with MRI Guided Focal Laser Interstitial Thermal Ablation","Emory University","Male","18 Years and older   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00094958","June 1, 2018","July 2020","July 2020","August 16, 2018","null","August 16, 2018","Emory University Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03634579"
13,"NCT03629145","Music Therapy With Intubated and Sedated Pediatric Patients",,"Recruiting","No Results Available","Respiratory Syncytial Virus Infections","Behavioral: Live Music Therapy|Behavioral: Recorded Music Therapy","Heart Rate|Respiratory Rate|Blood Pressure","Children's Healthcare of Atlanta","All","up to 2 Years   (Child)","Not Applicable","28","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","MUSIC02","January 16, 2018","May 1, 2019","August 1, 2019","August 14, 2018","null","August 14, 2018","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/45/NCT03629145/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/45/NCT03629145/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT03629145"
14,"NCT03628976","Noninvasive VNS for Neuromotor Adaptations",,"Not yet recruiting","No Results Available","Healthy Young Adults","Other: tVNS","Change in MEP amplitude","Georgia Institute of Technology|National Institute of Neurological Disorders and Stroke (NINDS)","All","18 Years to 39 Years   (Adult)","Not Applicable","24","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","H18151|1R03NS106088-01A1","September 1, 2018","September 1, 2020","September 1, 2021","August 14, 2018","null","August 14, 2018","Human Neuromuscular Physiology Lab, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03628976"
15,"NCT03625011","Gabapentin Premedication to Reduce Postoperative Pain for Pediatric Tonsillectomy",,"Recruiting","No Results Available","Tonsillitis|Tonsillectomy","Drug: Gabapentin","Narcotic Consumption|First Analgesic Timing|Pain Scale Scores","Children's Healthcare of Atlanta","All","3 Years to 18 Years   (Child, Adult)","Phase 4","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Health Services Research","IRB 18-052","July 31, 2018","December 31, 2018","December 31, 2018","August 10, 2018","null","August 16, 2018","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT03625011/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT03625011/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT03625011"
16,"NCT03623256","Comparison of Intrathecal Versus Epidural Fentanyl on Fetal Bradycardia in Labor Combined Spinal Epidural Analgesia",,"Not yet recruiting","No Results Available","Labor Pain|Obstetric Pain","Drug: Spinal fentanyl|Drug: Spinal bupivacaine|Drug: Spinal Fentanyl and Bupivacaine|Drug: Epidural fentanyl /spinal bupivacaine","Fetal heart rate|Blood pressure|Dermatomal level|Maternal Pain level: visual analogue scale|Patient satisfaction level: Likert Scale|Uterine tone","Augusta University","Female","18 Years and older   (Adult, Older Adult)","Phase 4","558","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","1238162","October 1, 2018","October 1, 2021","October 31, 2021","August 9, 2018","null","August 9, 2018","Augusta University, Augusta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03623256"
17,"NCT03616171","A Sleep Intervention (SLEEP-Extend) for Young Adults At-Risk for Type 2 Diabetes",,"Recruiting","No Results Available","Diabetes Mellitus, Type 2","Behavioral: SLEEP-Extend intervention|Other: Control","Feasibility of the Study measured by number of enrollments in the study over 1 year|Feasibility of the SLEEP-Extend intervention among young adults measured by number of subjects enrolled in the intervention arm and complete the study|Change in Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) scores among the SLEEP-Extend intervention group compared to control group|Change in Sleep Extension among the subjects that received SLEEP-Extend intervention","Emory University|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","18 Years to 25 Years   (Adult)","Not Applicable","20","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","IRB00105390|5P30DK111024-02","September 2018","September 2019","September 2019","August 6, 2018","null","September 6, 2018","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03616171"
18,"NCT03609957","Exercise and Pain in Non-Hispanic Blacks and Whites",,"Not yet recruiting","No Results Available","Pain, Acute|Pain, Neuropathic|Analgesia|Aerobic Exercise|Exercise Training","Other: Aerobic Exercise Training|Other: Interval Training","Change in skin blood flow response to local heating","Georgia State University","All","18 Years to 40 Years   (Adult)","Not Applicable","120","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","H18343","February 2019","December 2019","December 2019","August 1, 2018","null","August 31, 2018","Georgia State University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03609957"
19,"NCT03605719","Dexamethasone, Carfilzomib, Nivolumab, & Pomalidomide With Reovirus for Relapsed/Refractory Multiple Myeloma",,"Not yet recruiting","No Results Available","Recurrent Plasma Cell Myeloma","Drug: Carfilzomib|Drug: Dexamethasone|Biological: Nivolumab|Drug: Pomalidomide|Biological: Wild-type Reovirus","Dose-limiting toxicity (DLT) of 4-drug regimen evaluated according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE)|Maximum tolerated dose (MTD) of 4-drug regimen|DLT of 3-drug regimen evaluated according to NCI CTCAE version 5.0|DLT of 5-drug regimen evaluated according to NCI CTCAE version 5.0|Time to progression|Progression-free survival|Overall survival","Emory University|Bristol-Myers Squibb|Oncolytics Biotech|University of Utah|City of Hope Medical Center|Phylogeny","All","18 Years and older   (Adult, Older Adult)","Phase 1","62","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00104234|NCI-2018-01217|Winship4398-18","July 1, 2019","July 31, 2022","July 31, 2025","July 30, 2018","null","July 30, 2018","Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03605719"
20,"NCT03596450","Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial",,"Recruiting","No Results Available","Diabetes Mellitus, Type 2","Drug: Semaglutide|Drug: Standard of care","Hemoglobin A1c (HbA1c) less than 7.0% (53 mmol/mol) (yes/no)|Change in HbA1c|HbA1c less than 7.0% (53 mmol/mol) (yes/no)|Individualized HbA1c target attained (yes/no)|HbA1c less than 7.0% (53 mmol/mol) or at least 1% point improvement in HbA1c compared to baseline (yes/no)|HbA1c target attainment per Healthcare Effectiveness Data and Information Set (HEDIS) criteria (yes/No)|Change in body weight|Change in systolic blood pressure (SBP)|Change in diastolic blood pressure (DBP)|Time to first study drug discontinuation|Time to first treatment intensification (add-on) or change (switch)|Study drug medication adherence for the first year of the study, as measured by medication possession ratio (MPR)|Number of hypoglycemic episodes leading to an inpatient admission or emergency room (ER) encounter|Diabetes Treatment Satisfaction Questionnaire, change version (DTSQc), Total treatment satisfaction score|DTSQc, Total treatment satisfaction score|Change from baseline in Short Form 12-Item Version 2 Survey (SF-12 v2), Physical summary component (PCS-12) score|Change from baseline in SF-12 v2, PCS-12 score|Change from baseline in SF-12 v2, Mental summary component (MCS-12) score|Change from baseline in SF-12 v2, MCS-12 score|Change from baseline in Work Productivity and Activity Impairment, General Health questionnaire (WPAI-GH) Absenteeism (work time missed) score|Change from baseline in WPAI-GH Absenteeism (work time missed) score|Change from baseline in WPAI-GH Presenteeism (impairment at work / reduced on-the-job effectiveness) score|Change from baseline in WPAI-GH Work productivity loss (overall work impairment / absenteeism plus presenteeism) score|Change from baseline in WPAI-GH Activity Impairment score|All cause healthcare resource utilization (HCRU): Number of inpatient admissions|All cause HCRU: Cumulative length of stay for inpatient admissions|All cause HCRU: Number of ER encounters|All cause HCRU: Number of outpatient encounters|All cause HCRU: Number of medications|All cause HCRU: Occurrence of inpatient admission (yes/no)|All cause HCRU: Occurrence of ER encounter (yes/no)|All cause HCRU: Occurrence of outpatient encounter (yes/no)|Diabetes related HCRU: Number of diabetes related inpatient admissions|Diabetes related HCRU: Cumulative length of stay for diabetes related inpatient admissions|Diabetes related HCRU: Number of diabetes related ER encounters|Diabetes related HCRU: Number of diabetes related outpatient encounters|Diabetes related HCRU: Number of diabetes related medications|Diabetes related HCRU: Occurrence of diabetes related inpatient admission (yes/no)|Diabetes related HCRU: Occurrence of diabetes related ER encounter (yes/no)|Diabetes related HCRU: Occurrence of diabetes related outpatient encounter (yes/no)","Novo Nordisk A/S","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","2250","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NN9535-4416|U1111-1207-6474","July 13, 2018","November 20, 2020","November 19, 2021","July 23, 2018","null","August 27, 2018","Novo Nordisk Investigational Site, Statesboro, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03596450"
21,"NCT03596333","Color Doppler Ultrasound to Locate Needle in Labor Epidural",,"Completed","No Results Available","Labor Pain|Obstetric Pain","Other: Retrospective chart review","Epidural needle tip position|Epidural catheter position|Epidural failure rate","Augusta University","Female","18 Years and older   (Adult, Older Adult)","","35","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","1230080","May 28, 2018","June 28, 2018","June 30, 2018","July 23, 2018","null","July 23, 2018","Augusta University, Augusta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03596333"
22,"NCT03595384","Soccer-based Adaptation of the Diabetes Prevention Program",,"Recruiting","No Results Available","Diabetes","Behavioral: Soccer-based adaptation to the DPP","Number of participants completing the study|Session attendance|Participant Satisfaction Questionnaire|Change in weight|Change in steps per day|Change in dietary behaviors|Change in International Physical Activity Questionnaire (IPAQ) score|Change in waist circumference","Emory University|Georgia Center for Diabetes Translation Research|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|University of Southern Denmark","Male","30 Years to 60 Years   (Adult)","Not Applicable","40","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","IRB00100342|P30DK111024","April 29, 2018","December 2018","December 2018","July 23, 2018","null","August 6, 2018","Emory University Rollins School of Public Health, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03595384"
23,"NCT03590951","Anesthetic and Obstetric Outcomes in Morbidly Obese Pregnancy and Cesarean Delivery",,"Completed","No Results Available","Morbid Obesity|Cesarean Section Complications|Pregnancy Related","Other: Retrospective chart review","Obstetric complications|Anesthetic complications|Neonatal complications|Other anesthetic complications","Augusta University","Female","18 Years and older   (Adult, Older Adult)","","771","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","1053583","May 3, 2017","February 13, 2018","February 13, 2018","July 18, 2018","null","July 18, 2018","Augusta University, Augusta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03590951"
24,"NCT03583866","Adiposity and Endothelin Receptor Function","END-RF","Recruiting","No Results Available","Hypertension","Drug: Candesartan|Drug: Placebo","Percentage Change in Flow-Mediated Dilation (FMD)","Augusta University|National Heart, Lung, and Blood Institute (NHLBI)","All","18 Years to 40 Years   (Adult)","Early Phase 1","200","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","1148277|5P01HL069999","May 21, 2018","June 2020","June 2021","July 12, 2018","null","July 12, 2018","Georgia Prevention Institute/ Laboratory of Integrative and Exercise Physiology, Augusta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03583866"
25,"NCT03583151","Corticosteroid vs. Amniotic Fluid Injections in Patients With Trigger Finger",,"Enrolling by invitation","No Results Available","Stenosing Tenosynovitis","Biological: Amniotic fluid injection|Biological: Steroid injection","Patient reported pain level|Trigger frequency|Disabilities of the Arm Shoulder and Hand score","J&M Shuler|Vivex Biomedical","All","18 Years and older   (Adult, Older Adult)","Phase 3","100","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Random TF","May 10, 2018","December 2018","December 2019","July 11, 2018","null","July 11, 2018","Athens Orthopedic Clinic, Athens, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03583151"
26,"NCT03582722","Weight Loss Aid in an Exposed Population",,"Recruiting","No Results Available","Polybrominated Biphenyl Poisoning","Drug: Orlistat|Drug: Placebo capsule","Change in weight|Change in Body Mass Index|Change in dietary intake using Automated Self-administered 24-hour Recall score|Change in physical activity|Change in serum concentration of PBB (polybrominated biphenyl) 153|Change in serum concentration of PBDE (Polybrominated diphenyl ether) 47|Change in serum concentration of PCB (polychlorinated biphenyl) 118|Change in serum concentration of PCB (polychlorinated biphenyl) 138|Change in serum concentration of PCB (polychlorinated biphenyl) 153|Change in serum concentration of PCB (polychlorinated biphenyl) 180|Change in serum concentration of DDT/DDE (Dichlorodiphenyldichloroethylene/Dichlorodiphenyltrichloroethane)","Emory University|Healthway Compounding Pharmacy in central Michigan|Michigan Public Health Departments","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRB00099231","September 14, 2018","April 30, 2021","April 30, 2022","July 11, 2018","null","September 25, 2018","Michele Marcus, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03582722"
27,"NCT03581981","Improving Function Through Primary Care Treatment of PTSD","PE-PC","Not yet recruiting","No Results Available","Posttraumatic Stress Disorder","Behavioral: Prolonged Exposure for Primary Care (PE-PC)|Behavioral: Treatment as Usual","World Health Organization Disability Assessment Scale Change|World Health Organization Disability Assessment Scale|Clinician Adminstered PTSD Scale for DSM 5 (CAPS5) Change|PTSD Checklist for DSM5 (PCL-5) Change|Patient Health Questionnaire- 9 (PHQ-9) Change|Clinician Adminstered PTSD Scale for DSM 5 (CAPS5)|Clinician Adminstered PTSD Scale for DSM 5 (CAPS5|PTSD Checklist for DSM5 (PCL-5)|Patient Health Questionnaire- 9 (PHQ-9)","VA Office of Research and Development|Ralph H. Johnson VA Medical Center|VA Ann Arbor Healthcare System","All","18 Years and older   (Adult, Older Adult)","Phase 3","120","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","D2625-R","November 1, 2018","September 30, 2022","September 30, 2022","July 10, 2018","null","July 10, 2018","Atlanta VA Medical and Rehab Center, Decatur, GA, Decatur, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03581981"
28,"NCT03581461","Trauma-Informed Mindfulness-Based Yoga","TIMBY","Not yet recruiting","No Results Available","Trauma","Behavioral: Trauma-Informed Mindfulness-Based Yoga","Changes in self-regulation as assessed by the Abbreviated Dysregulation Inventory (ADI)|Changes in externalizing and internalizing behavior as assessed by The Child Behavior Checklist - Youth Self-Report (YSR).|Changes in anger as assessed by the State-Trait Anger Expression Inventory (STAXI-2)|Changes in trauma-related symptoms as assessed by the Structured Trauma-Related Experiences and Symptoms Screener (STRESS)|Changes in impulsivity as assessed by the Barratt Impulsiveness Scale (BIS)|Changes in psychological flexibility as assessed by the Acceptance and Action Questionnaire (AAQ-II)|Changes in mindfulness as assessed by the Cognitive and Affective Mindfulness Scale-Revised (CAMS-R)","Georgia State University|Kaiser Foundation Research Institute|UConn Health|Emory University","Male","13 Years to 17 Years   (Child)","Not Applicable","130","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R34AT009538","September 2018","February 2020","March 2020","July 10, 2018","null","August 22, 2018","Georgia State University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03581461"
29,"NCT03575975","3D X-ray Motion Analysis of Ankle-foot Motion After Total Ankle Arthroplasty",,"Enrolling by invitation","No Results Available","Ankle Arthroplasty|Prosthesis User|Joint Disease","Device: Total Ankle Replacement Prosthesis","Tibiotalar joint kinematics|Subtalar joint kinematics","Georgia Institute of Technology|Emory University|Stryker Orthopaedics","All","18 Years to 79 Years   (Adult, Older Adult)","","15","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","Ankle XMA Project","May 30, 2018","May 29, 2019","May 29, 2019","July 3, 2018","null","July 3, 2018","Georgia Institute of Technology, Atlanta, Georgia, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/75/NCT03575975/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/75/NCT03575975/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT03575975"
30,"NCT03574441","Intrapartum Epidural Catheter Displacement: Dressing Methods",,"Completed","No Results Available","Analgesia, Obstetrical","Device: Tegaderm dressing + catheter support pad|Device: Tegaderm dressing + Steri-strip dressing|Device: Tegaderm dressing only","Epidural catheter migration in centimeters|Rate of epidural catheter replacement","Augusta University","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","91","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","1048027","December 4, 2017","March 11, 2018","March 18, 2018","July 2, 2018","null","July 2, 2018","Augusta University, Augusta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03574441"
31,"NCT03564587","Improving Health-Promoting Behaviors in Adolescent Cancer Survivors Using AWAKE: A Feasibility Trial","CHOA AWAKE","Recruiting","No Results Available","Health Behavior","Behavioral: AWAKE","Change in the he Children's Hope Scale score|Change in the Pediatric Quality of Life Inventory (PedsQL), 4.0 scale score|Change in number of servings of fruits and vegetables|Change in number of physical activity hours per day|Change in number of screen time hours per day|Change in PROMIS score|Usability of AWAKE|Satisfaction with AWAKE","Emory University","All","13 Years to 17 Years   (Child)","Not Applicable","48","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","IRB00099050","June 20, 2018","February 2021","February 2021","June 21, 2018","null","June 25, 2018","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03564587"
32,"NCT03562767","Cognitive Behavioral Therapy for African Americans With Uncontrolled Type-2 Diabetes",,"Recruiting","No Results Available","Diabetes Mellitus, Type 2","Behavioral: Group-based Cognitive Behavioral Intervention|Behavioral: Web-based Cognitive Behavioral Intervention|Behavioral: Usual Care","Percentage of participants that complete the study compared to enrolled|Percentage of participants that are enrolled and attend the study the study sessions compared to enrolled|Change in Hemoglobin A1c (HbA1C) Level|Change in Patient Health Questionnaire (PHQ-9) Score|Change in Diabetes Distress Scale (DDS17) Score|Change in 12-Item Short Form Health Survey (SF-12) Score|Change in Generalized Anxiety Disorder 7-item (GAD-7) Scale Score|Change in Self Efficacy for Diabetes|Change in Diabetes Health Belief Scale","Emory University|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","45","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care","IRB00101847|P30DK111024","October 2018","July 2019","November 2019","June 19, 2018","null","October 8, 2018","Emory Dunwoody Clinic, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03562767"
33,"NCT03556579","The Effects of Contact Lenses With Experimental Dye on Visual Function",,"Recruiting","No Results Available","Ametropia","Device: senofilcon A with new UV blocker|Device: senofilcon A","Light Scattering (Two-point Light Spread Function)|Starbursts|Halos|Photostress Recovery Time (Seconds)|Disability Glare Threshold (Change in log relative energy level)|Discomfort Glare (change in palpebral fissure height (mm))|Heterochromatic Contrast Threshold (HCT)","Johnson & Johnson Vision Care, Inc.","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","66","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","CR-6100","May 15, 2018","August 31, 2018","August 31, 2018","June 14, 2018","null","June 14, 2018","Georgia Center for Sight, Statesboro, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03556579"
34,"NCT03555799","Evaluation of Changes of Venous Return After Spinal and Epidural Analgesia and Anesthesia by Ultrasound Guided Vena Cava Diameter Measurement",,"Recruiting","No Results Available","Pregnancy Related|Hypotension, Orthostatic","Diagnostic Test: Inferior vena cava ultrasound","IVC diameter|Mean arterial pressure|Nausea","Augusta University","Female","18 Years and older   (Adult, Older Adult)","","89","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","1194575","May 18, 2018","May 31, 2019","June 15, 2019","June 14, 2018","null","June 14, 2018","Augusta University, Augusta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03555799"
35,"NCT03555630","Thromboelastogram in Postdelivery Preeclamptic Patients",,"Recruiting","No Results Available","Preeclampsia|Coagulation Disorder|Pregnancy Complications","Diagnostic Test: Thromboelastogram","R time|K time|Maximum amplitude|LY-30","Augusta University","Female","18 Years and older   (Adult, Older Adult)","","150","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","[1167446","May 22, 2018","October 31, 2019","December 31, 2019","June 13, 2018","null","June 13, 2018","Augusta University, Augusta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03555630"
36,"NCT03555604","Evaluation of the Effect of Body Mass Index on Gastric Volume With Ultrasound in Term Pregnant Women",,"Recruiting","No Results Available","Pregnancy Related|Aspiration|Airway Aspiration","Diagnostic Test: Gastric ultrasound","Cross sectional area of gastric antrum|BMI|Fasting time","Augusta University","Female","18 Years and older   (Adult, Older Adult)","","50","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","1184342","May 29, 2018","May 31, 2019","June 15, 2019","June 13, 2018","null","June 13, 2018","Augusta University, Augusta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03555604"
37,"NCT03552146","Evaluating the Effects of Propofol vs. Dexmedetomidine",,"Recruiting","No Results Available","Sedative Adverse Reaction","Drug: Propofol|Drug: Dexmedetomidine","Procedural times to achieve optimal sedation|Sedation related events","Children's Healthcare of Atlanta|Morehouse School of Medicine","All","3 Months to 36 Months   (Child)","","60","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","17-136","July 24, 2018","December 31, 2018","March 31, 2019","June 11, 2018","null","July 25, 2018","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03552146"
38,"NCT03543878","Stimulating Neural Activity to Improve Blood Flow and Reduce Amyloid: Path to Clinical Trials","FLICKER","Not yet recruiting","No Results Available","Alzheimer Disease","Device: Flicker","Feasibility: amount of time of device use per day.|Tolerability: participant report","Emory University|Georgia Institute of Technology","All","50 Years to 90 Years   (Adult, Older Adult)","Not Applicable","10","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Supportive Care","IRB00101694","October 2018","December 2018","December 2018","June 1, 2018","null","October 1, 2018","12 Executive Park Drive, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03543878"
39,"NCT03539835","Resistance Training to Improve Fatigue and Physical Function in Postmenopausal Breast Cancer Survivors",,"Recruiting","No Results Available","Cancer","Other: Resistance training (RT)|Behavioral: Cognitively-based compassion training control (CBCT)","Change in fatigue assessed by Multidimensional Fatigue Inventory (MFI) score|Change in depression assessed by Hamilton Depression Rating Scale (HAM-D) score|Change in balance test score|Change in muscle function assessed by Isometric Handgrip test.|Change in muscle function assessed by Lower Extremity Endurance test|Change in muscle function assessed by Lower Extremity Strength test|Change in Timed Up and Go (TUG) completion time|Change in 30 meter walk velocity|Change in Functional Gait Assessment score|Change in 6 min walk distance|Change in Resting Metabolic Rate (RMR)|Change in peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) level|Change in kynurenic acid level|Change in interleukin-6 (IL-6) level|Change in tumor necrosis factor-α (TNF-α) protein level","Emory University","Female","50 Years to 75 Years   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","IRB00103558","October 2018","May 2019","May 2019","May 28, 2018","null","October 12, 2018","Winship Cancer Institute, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03539835"
40,"NCT03539796","Epidural Technique: Does it Really Matter to the Patient",,"Recruiting","No Results Available","Anesthesia","Procedure: Dural puncture epidurals (DPE)|Procedure: Traditional epidurals (EPI)|Procedure: Combined-spinal epidural technique (CSE)","Percent of patients with Numeric Pain Rating Score (NPRS)<1 in the DPE vs. EPI group|Percent of patients with Numeric Pain Rating Score (NPRS) <3 in the DPE vs. EPI group.|Percent of patients with Numeric Pain Rating Score (NPRS)<1 in the DPE vs. CSE group|Percent of patients required rescue analgesia in the DPE vs. EPI group|Percent of patients required rescue analgesia in the DPE vs. CSE group","Emory University","Female","18 Years to 60 Years   (Adult)","Not Applicable","210","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRB00098730","May 26, 2018","November 2018","November 2018","May 28, 2018","null","July 26, 2018","Grady Health System (CRN), Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03539796"
41,"NCT03538990","Effect of DASH Eating Pattern on Heart Failure Outcomes","DASH HF","Recruiting","No Results Available","Heart Failure NYHA Class III","Other: DASH Eating Pattern","Change in Mean Pulmonary Artery Pressure between Calibration and DASH Diet Intervention Phase|Change in Cardiometabolic Markers between Calibration and DASH Diet Intervention Phase","University of Georgia|Emory University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","36","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STUDY00005216","June 2018","May 2019","May 2019","May 28, 2018","null","May 28, 2018","University of Georgia Clinical and Translational Research Unit, Athens, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03538990"
42,"NCT03530098","Validation of an Artificial Intelligence-based Algorithm for Skeletal Age Assessment",,"Enrolling by invitation","No Results Available","Bone Age","Device: BoneAgeModel","Paired Difference of Skeletal Age Estimate|Time Saved","Stanford University","All","1 Year to 18 Years   (Child, Adult)","Not Applicable","1000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","IRB #44764","July 12, 2018","May 2019","June 2019","May 21, 2018","null","July 17, 2018","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03530098"
43,"NCT03529825","Rifaximin for Infection Prophylaxis in Hematopoietic Stem Cell Transplantation",,"Recruiting","No Results Available","Microbial Colonization","Drug: Rifaximin","Alterations to microbiome diversity in children treated with rifaximin compared to the historical cohort.|Rates of BSI pathogen infection/colonization frequency during the treatment period compared to the historical cohort.|Transplant related mortality (TRM)|Number of patients with Acute GVHD|Number of patients with Chronic GVHD including overlap syndrome|Number of patients with other Infections|Number of patients with relapse free survival at 1 year|Overall number of patients survived at 1 year","Emory University","All","2 Years to 21 Years   (Child, Adult)","Early Phase 1","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00101158","July 18, 2018","May 2020","May 2020","May 18, 2018","null","September 26, 2018","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03529825"
44,"NCT03529578","A Case Series to Investigate the Safety and Efficacy of Weekly Application of Dehydrated Human Amnion/Chorion Membrane in the Treatment of Pressure Ulcers",,"Enrolling by invitation","No Results Available","Pressure Ulcer","Procedure: dHACM","Percentage of subjects with complete wound closure of study ulcer|Wound healing kinetics: Complete wound healing|Wound healing kinetics: Weekly percentage of wounds with total closure|Wound healing kinetics: rate of closure/week|Incidence of Treatment-Emergent Adverse Events [Safety]|Wound Infection Rate [Safety]","MiMedx Group, Inc.","All","18 Years and older   (Adult, Older Adult)","Not Applicable","20","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EFPU002","June 6, 2017","October 1, 2018","October 1, 2018","May 18, 2018","null","May 18, 2018","Infectious Disease Specialists of Atlanta, PC, Decatur, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03529578"
45,"NCT03524183","Virtual Fitness Buddy Ecosystem","VFB Ecosystem","Enrolling by invitation","No Results Available","Physical Activity","Behavioral: Virtual Fitness Buddy Ecosystem","Physical Activity|Height|Weight|Waist circumference|Body fat percentage|Self-efficacy|Motivation|Parent-child relationship","University of Georgia|YMCA of Metropolitan Atlanta","All","6 Years to 10 Years   (Child)","Phase 2","720","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","00004611","August 27, 2018","May 30, 2022","May 30, 2022","May 14, 2018","null","October 11, 2018","YMCA of Metropolitan Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03524183"
46,"NCT03522779","Antioxidant Responses to Exercise and Cherry Consumption",,"Completed","No Results Available","Dietary Modification","Dietary Supplement: Tart cherry Juice|Other: High-fat meal|Other: Exercise","Change in Antioxidant levels|Change in oxidative stress levels","University of Georgia","Male","18 Years to 30 Years   (Adult)","Not Applicable","13","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","STUDY00003902","November 2016","July 1, 2017","July 1, 2017","May 11, 2018","null","May 11, 2018","University of Georgia - Department of Foods and Nutrition, Athens, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03522779"
47,"NCT03519672","Prospective Psychometric Evaluation Study of a Patient-reported Outcomes (PRO) Instrument for Congenital Thrombotic Thrombocytopenic Purpura (cTTP, Upshaw-Schulman Syndrome [USS], Hereditary Thrombotic Thrombocytopenic Purpura [hTTP]",,"Recruiting","No Results Available","Congenital Thrombotic Thrombocytopenic Purpura","Other: No intervention","Change from baseline of Quality of life (QoL) outcomes: cTTP-specific PRO instrument|Change from baseline of Quality of life (QoL) outcomes: PROMIS®-29|Change from baseline of Quality of life (QoL) outcomes: Pediatric PROMIS® Subscales for adolescents|Change from baseline of Quality of life (QoL) outcomes: HIT-6|Change from baseline of Quality of life (QoL) outcomes: Condensed MCMDM-1VWD Bleeding Questionnaire: Bruising Subscale|Change from baseline of Quality of life (QoL) outcomes: PDQ-5|Change from baseline of Quality of life (QoL) outcomes: NEI-VFQ-25|Change from baseline of Quality of life (QoL) outcomes: WPAI-GH|Change from baseline of Quality of life (QoL) outcomes: WPAI-GH plus Classroom Impairment questions for adolescents|Change from baseline of Quality of life (QoL) outcomes: PGI-S|Change from baseline of Quality of life (QoL) outcomes: PGI-Change","Baxalta now part of Shire|Shire","All","12 Years and older   (Child, Adult, Older Adult)","","40","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","281701","July 12, 2018","November 30, 2018","November 30, 2018","May 9, 2018","null","October 5, 2018","AutoCruitment, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03519672"
48,"NCT03506048","Lenvatinib and Iodine Therapy in Treating Patients With Radioactive Iodine-Sensitive Differentiated Thyroid Cancer",,"Not yet recruiting","No Results Available","Differentiated Thyroid Gland Carcinoma|Thyroid Gland Follicular Carcinoma|Thyroid Gland Papillary Carcinoma","Drug: Lenvatinib","Time-to-progression|Best objective response|Change in thyroglobulin levels|Change in thyroglobulin antibody levels","Emory University|Eisai Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","30","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00101617|NCI-2018-00144|Winship4271-18","July 1, 2018","April 30, 2020","April 30, 2021","April 23, 2018","null","April 23, 2018","Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03506048"
49,"NCT03505203","Sleep-Safe: A Strong African American Families Study",,"Recruiting","No Results Available","Weight Gain","Behavioral: Sleep Soothe|Behavioral: Sleep Safe","Change in infants' weight for age from 3 weeks to 16 weeks (conditional weight gain)|Change in infants' weight for age|Weight-for-age z scores|Weight-for-length z scores|Infant BMI z scores","University of Georgia|Augusta University|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","300","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","20180320|R01DK112874","March 4, 2018","July 31, 2021","July 31, 2021","April 23, 2018","null","April 23, 2018","University of Georgia, Athens, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03505203"
50,"NCT03502031","Spironolactone & RAAS: Effect on Urinary Proteinuria & Mean Epidermal Growth Factor Receptor",,"Recruiting","No Results Available","Renal Insufficiency, Chronic|Diabetic Nephropathy Type 2","Drug: ACE inhibitor|Drug: ARB","Long term change in eGFR with combination treatment with ACE/ARB and Spironolactone|Will combination therapy with RAAS blockers and Spironolactone be superior to RAAS inhibitor alone to lower UP/Cr ratio|Will combination therapy with RAAS blockers and Spironolactone have same protein lower effect in both African Americans versus Caucasians?|3) To determine whether the incidence of hyperkalemia defined as a serum K+ level > 5.5 meq/L is higher among African American versus Caucasian patients receiving combination RAAS blockade & Spironolactone therapy|Apolipoprotein L1 (APOL-1) gene mutation sub-study will look at genetic markers as potential biomarkers that predict progressive diabetic nephropathy","NephroNet, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 4","164","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NN-01","March 1, 2018","December 2020","December 2020","April 18, 2018","null","April 18, 2018","NephroNet, Buford, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03502031"
51,"NCT03501576","Evaluation of Human Immune Responses to Influenza Virus Vaccination in Patients With Lymphoma",,"Recruiting","No Results Available","Chronic Lymphocytic Leukemia|Diffuse Large B-Cell Lymphoma|Follicular Lymphoma|Mantle Cell Lymphoma|Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma","Biological: Inactivated Influenza Vaccine","Percentage of subjects achieving seroprotection defined as the percentage of subjects with a post-vaccination hemagglutination inhibition (HI) titer > 1:40|Percentage of subjects achieving seroconversion|Measurement of influenza-specific serum antibody levels after influenza vaccination|Measurement of influenza-specific plasmablasts (PBs) after influenza vaccination|Measurement of influenza-specific memory B-cells (MBCs) after influenza vaccination|Maximum fold rise in antibody titer","Emory University","All","18 Years and older   (Adult, Older Adult)","Phase 1","100","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","IRB00101067|NCI-2017-02313|Winship4236-17","April 6, 2018","April 30, 2021","April 30, 2021","April 18, 2018","null","April 18, 2018","Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03501576"
52,"NCT03495726","Meditation for Pain",,"Recruiting","No Results Available","Chronic Pain","Behavioral: Headspace app","Change in Pain Catastrophizing Scale Score|Change in Pain Anxiety Symptom Scale Short Form Score|Change in Brief Pain Inventory|Change in Five Facet Mindfulness Questionnaire (FFMQ-24) Score|Change in Depression Anxiety and Stress Scale (DASS) Score|Change in Revised UCLA Loneliness Scale (R-UCLA) Score","Emory University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","1000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","IRB00095434","June 5, 2018","April 2020","April 2020","April 12, 2018","null","June 6, 2018","Emory University Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03495726"
53,"NCT03493789","Fludeoxyglucose F-18-PET in Planning Lung Cancer Radiation Therapy",,"Recruiting","No Results Available","Stage I Lung Cancer|Stage I Non-Small Cell Lung Cancer AJCC v7|Stage IA Non-Small Cell Lung Carcinoma AJCC v7|Stage IB Non-Small Cell Lung Carcinoma AJCC v7|Stage II Lung Cancer|Stage II Non-Small Cell Lung Cancer AJCC v7|Stage IIA Non-Small Cell Lung Carcinoma AJCC v7|Stage IIB Non-Small Cell Lung Carcinoma AJCC v7","Drug: Fludeoxyglucose F-18|Procedure: Positron Emission Tomography (PET)|Radiation: Stereotactic Body Radiation Therapy (SBRT)","Change in metabolic tumor volumes measuring inter-fraction variability of fludeoxyglucose F-18-PET (FDG) - positron emission tomography (PET) activity of thoracic stereotactic body radiation therapy (SBRT) target volumes|Change in total lesion glycolysis values measuring inter-fraction variability of fludeoxyglucose F-18-PET (FDG) - positron emission tomography (PET) activity of thoracic stereotactic body radiation therapy (SBRT) target volumes|Change in metabolic tumor volumes measuring inter-fraction variability of fludeoxyglucose F-18-PET (FDG) - positron emission tomography (PET) activity of non-thoracic stereotactic body radiation therapy (SBRT) target volumes|Change in total lesion glycolysis values measuring inter-fraction variability of fludeoxyglucose F-18-PET (FDG) - positron emission tomography (PET) activity of non-thoracic stereotactic body radiation therapy (SBRT) target volumes","Emory University|RefleXion Medical","All","18 Years and older   (Adult, Older Adult)","Phase 1","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","IRB00101066|NCI-2018-00375|RAD4267-17","April 13, 2018","April 30, 2020","April 30, 2020","April 11, 2018","null","April 20, 2018","Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03493789"
54,"NCT03484078","Effect of Vibration on Muscle Properties, Physical Activity and Balance in Children With Cerebral Palsy",,"Recruiting","No Results Available","Cerebral Palsy, Spastic","Device: Vibration Platform|Device: Placebo Platform","Change in fat concentration|Change in muscle size|Change in physical activity|Change in dynamic balance|Change in static balance","University of Georgia|Emory University","All","5 Years to 11 Years   (Child)","Not Applicable","44","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","STUDY00004873","November 2, 2018","May 31, 2022","May 31, 2022","March 30, 2018","null","October 8, 2018","University of Georgia, Athens, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03484078"
55,"NCT03479255","Smartphone-Enabled Supervised Exercise Therapy for the Treatment of Symptomatic Peripheral Arterial Disease",,"Recruiting","No Results Available","Peripheral Arterial Disease","Behavioral: Smartphone-enabled structured exercise therapy (SE-SET)|Behavioral: Standard exercise therapy","Change in 6-minute walk test (6MWT) distance completed|Change in Walking Impairment Questionnaire (WIQ) score|Change in Physical Health Composite Score of SF-36|Change in claudication onset time during 6MWT|Change in ankle-brachial pressure index (ABPI)|Change in number of steps/week|Critical Limb Ischemia|Other Cardiovascular Outcomes|Exercise-Related Injury|Mortality","Emory University|Woodruff Health Sciences Center Foundation","All","18 Years to 89 Years   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00102543","August 24, 2018","February 2020","February 2020","March 27, 2018","null","August 27, 2018","Grady Health System (non-CRN), Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03479255"
56,"NCT03472963","Body Compartment Pharmacokinetics of Anti- Retroviral Agents That May be Used for Future HIV Post- Exposure Prophylaxis.","PEP2","Recruiting","No Results Available","HIV Infections","Drug: Single dose of Genvoya® and a single 800 mg dose of Darunavir®","Median Genvoya plasma concentration|Median Darunavir plasma concentration|Median Genvoya rectal tissue distribution|Median Darunavir rectal tissue distribution|Median Genvoya rectal secretion concentration|Median Darunavir rectal secretion concentration|Median Genvoya urethral secretion concentration|Median Darunavir urethral secretion concentration","Emory University|Centers for Disease Control and Prevention","Male","18 Years to 49 Years   (Adult)","Phase 1","58","Other|U.S. Fed","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","IRB00101179","April 27, 2018","January 15, 2019","January 15, 2019","March 21, 2018","null","May 3, 2018","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03472963"
57,"NCT03467750","Effect of Ketorolac on Post Adenotonsillectomy Pain",,"Recruiting","No Results Available","Obstructive Sleep Apnea","Drug: Ketorolac|Drug: Standard of Care","Post-Anesthesia Care Unit (PACU) Morphine Requirements|Face, Legs, Activity, Cry, Consolability (FLACC) Scale Score|Post-Anesthesia Care Unit (PACU) Recovery Time|Incidence of Post-Tonsillectomy Bleeding|Pain Medication Administration","Emory University","All","2 Years to 18 Years   (Child, Adult)","Phase 4","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Supportive Care","IRB00097738","July 19, 2018","August 24, 2020","August 24, 2020","March 16, 2018","null","July 25, 2018","Childrens Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03467750"
58,"NCT03466372","Innovative Gait Biofeedback Strategies for Stroke Rehabilitation",,"Recruiting","No Results Available","Stroke, Cardiovascular|Gait, Hemiplegic","Behavioral: biofeedback","paretic pushoff (AGRF)|non-paretic peak AGRF|paretic trailing limb angle","Emory University","All","18 Years to 90 Years   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","IRB00102559","March 22, 2018","March 30, 2021","March 30, 2022","March 15, 2018","null","April 17, 2018","Emory Univeristy, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03466372"
59,"NCT03464630","Reducing Maternal Depression and Promoting Infant Social-Emotional Health & Development","MBN","Recruiting","No Results Available","Depression, Postpartum","Behavioral: Mom & Baby Net|Behavioral: Developmental Awareness System","Landry Parent Child Interaction Rating Scales|PHQ9","Georgia State University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Oregon Research Institute|The University of Texas Health Science Center, Houston","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","150","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","H18217|R01HD086894-01A1","February 15, 2018","June 30, 2021","August 31, 2021","March 14, 2018","null","March 16, 2018","Georgia State University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03464630"
60,"NCT03463980","Compassion Meditation and ReliefLink App for Suicidal, Low-Income, African Americans",,"Recruiting","No Results Available","Suicidal Ideation","Behavioral: Compassion meditation (CM)|Behavioral: Support group (SG)","Change in Beck Scale for Suicide Ideation (BSS) score|Change in Beck Depression Inventory II (BDI-II) score|Change in Experience of Shame Scale (ESS) score|Change in Levels of Self-Criticism Scale (LOSC) score|Change in Social Support Behaviors Scale (SSB) score|Change in Self-Compassion Scale (SCS) score|Change in Five Facet Mindfulness Questionnaire (FFMQ) score|Change in Behavior Monitoring Form (BMF) score","Emory University","All","18 Years to 64 Years   (Adult)","Not Applicable","350","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","IRB00038057","May 13, 2010","March 2028","March 2028","March 13, 2018","null","April 17, 2018","Grady Health System (non-CRN), Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03463980"
61,"NCT03462680","GPR109A and Parkinson's Disease: Role of Niacin in Outcome Measures",,"Recruiting","No Results Available","Parkinson's Disease","Dietary Supplement: niacin|Other: placebo","Unified Parkinson's Disease Rating Scale (UPDRS) change|Mini-Mental State Examination (MMSE) change|Stroop test change|Sleep test change|Macrophage changes|Niacin changes|Cerebrospinal Fluid (CSF) changes","VA Office of Research and Development","All","35 Years and older   (Adult, Older Adult)","Not Applicable","80","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Health Services Research","N1613-I","September 28, 2016","September 30, 2019","September 30, 2019","March 12, 2018","null","August 10, 2018","Charlie Norwood VA Medical Center, Augusta, GA, Augusta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03462680"
62,"NCT03459794","Ivermectin and Human Immunity",,"Active, not recruiting","No Results Available","Ivermectin","Drug: Ivermectin|Other: Placebo","Changes in cytokine levels|Changes in gene expression|Complete Blood counts","University of Georgia","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","12","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","STUDY00005069","February 12, 2018","April 9, 2018","November 30, 2018","March 9, 2018","null","October 10, 2018","University of Georgia, Athens, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03459794"
63,"NCT03456778","Achilles Tendinopathy Shear Wave Elastography Study",,"Recruiting","No Results Available","Achilles Tendinopathy","Procedure: Platelet-Rich Plasma Injection","Change in tendinopathy assessed by SWE|Change in tendinopathy assessed by B mode sonographic imaging|Change in Victorian Institute of Sport Assessment - Achilles (VISA-A) scale score","Emory University","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00096405","February 27, 2018","December 2019","December 2019","March 7, 2018","null","March 7, 2018","Emory Orthopaedics and Spine Center, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03456778"
64,"NCT03455309","Evaluation of NDV-3A Vaccine in Preventing S. Aureus Colonization",,"Recruiting","No Results Available","Staphylococcus Aureus","Biological: NDV-3A|Biological: Placebo","Efficacy|Evaluation of the efficacy of the NDV-3A vaccine|Evaluation of safety and tolerability in all subjects|Measurement and characterization of immunogenicity of NDV-3A|Describe the impact of NDV-3A on S. aureus acquisition and transmission","NovaDigm Therapeutics, Inc.|Infectious Diseases Clinical Research Program|Uniformed Services University of the Health Sciences","Male","17 Years to 35 Years   (Child, Adult)","Phase 2","420","Industry|Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","NDV3A-006|IDCRP-104","January 30, 2018","November 21, 2018","February 21, 2019","March 6, 2018","null","March 6, 2018","Fort Benning, Fort Benning, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03455309"
65,"NCT03452761","Effects of Exogenous Ketones in Healthy Young Adults",,"Completed","No Results Available","Healthy Young Adults","Dietary Supplement: Ketone Salts","Blood health parameters|Blood health parameter|Blood ketone levels|Cardiovascular|Body Composition","Augusta University|Funding source: Pruvit Ventures, Inc","All","18 Years to 35 Years   (Adult)","Not Applicable","22","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Screening","10414835","July 14, 2017","October 27, 2017","October 27, 2017","March 2, 2018","null","March 2, 2018","Augusta University, Augusta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03452761"
66,"NCT03452670","Contemplative Well-being Apps for the Workplace",,"Recruiting","No Results Available","Social Behavior|Depression|Inflammation","Behavioral: Active Group|Other: Waitlist Group","Change in Incivility in Nursing Education Revised Survey score|Change in School-Burnout Inventory score|Change in Depression score on the Depression Anxiety and Stress Scale (DASS)|Change in Anxiety score on the Depression Anxiety and Stress Scale (DASS)|Change in Empathic Accuracy (EA) Task|Change in gray matter density in the brain stem|Change in white matter density in the brain stem|Change in Gene (mRNA) expression in peripheral blood mononuclear cells (PBMCs)","Emory University","All","21 Years and older   (Adult, Older Adult)","Not Applicable","52","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention","IRB00088349","June 6, 2016","December 2018","March 31, 2019","March 2, 2018","null","August 23, 2018","Emory University, Wesley Woods Health Center, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03452670"
67,"NCT03449303","Chemotherapy-Induced Peripheral Neuropathy-Essential Oil Intervention","CIPN-EOI","Recruiting","No Results Available","Breast Cancer|Peripheral Neuropathies","Other: EOI|Other: Placebo","Short-Form McGill Pain Questionnaire-2 (SF-MPQ-2)|Visual Analogue Scale - Pain (VAS)|Quality of Life Adult Cancer survivor (QLACS)|Quality of Life: Chemotherapy-Induced Peripheral Neuropathy-20 (QOL:CIPN20)","Augusta University|American Holistic Nurses Association|American Nurses Foundation|Ananda Apothecary|The Jojoba Company","All","21 Years and older   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care","1028595","June 25, 2018","December 30, 2018","April 30, 2019","February 28, 2018","null","June 29, 2018","Augusta University, Augusta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03449303"
68,"NCT03448458","Gallium Ga 68-DOTATATE PET/CT in Diagnosing Patients With Metastatic Castration Resistant Prostate Cancer",,"Recruiting","No Results Available","Castration-Resistant Prostate Carcinoma|Metastatic Prostate Carcinoma|Stage IV Prostate Cancer AJCC v7","Procedure: CT (Computed Tomography)|Drug: Gallium Ga 68-DOTATATE|Procedure: Positron Emission Tomography","Gallium Ga 68-DOTATATE uptake|Progression free survival","Emory University","Male","18 Years and older   (Adult, Older Adult)","Phase 2","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","IRB00099167|NCI-2017-02055|Winship4165-17","February 22, 2018","February 28, 2022","February 28, 2022","February 28, 2018","null","February 28, 2018","Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03448458"
69,"NCT03447119","Living Well With a Disability Curriculum Adaptation Evaluation Plan",,"Recruiting","No Results Available","Health Education|Community Health Services|Health Services for Persons With Disabilities|Developmental Disabilities","Behavioral: Living Well with a Disability","Global Health|Family Relationships|Life Satisfaction|Physical Activity|Psychological Stress Experiences|Peer Relationships","Georgia Southern University","All","3 Years and older   (Child, Adult, Older Adult)","Not Applicable","100","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","H18234","March 24, 2018","February 2019","February 2019","February 27, 2018","null","August 2, 2018","B and B Care Services, Springfield, Georgia, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/19/NCT03447119/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03447119"
70,"NCT03436420","Gemcabene for the Treatment of Pediatric NAFLD",,"Recruiting","No Results Available","Non-Alcoholic Fatty Liver Disease","Drug: Gemcabene","Percent change in alanine aminotransferase (ALT)|Absolute change in ALT|Percent change in ALT between study visits|Change in hepatic steatosis|Change in aspartate aminotransferase (AST)|Change in Liver Inflammation and Fibrosis (LIF) score|Change in abdominal visceral fat and abdominal subcutaneous fat|Change in insulin sensitivity|Change in Gamma-glutamyltransferase (GGT)|Change in total cholesterol|Change in Apolipoprotein B (ApoB)|Change in non-high-density lipoprotein cholesterol (non-HDL-C)|Change in high-density lipoprotein (HDL) cholesterol|Change in very-low-density lipoprotein cholesterol (VLDL-C)|Change in low-density lipoprotein (LDL) cholesterol|Change in triglycerides (TG)|Change in apolipoprotein A-1 (ApoA-1)|Change in Apolipoprotein C-II (ApoC-II)|Change in Apolipoprotein E (ApoE)|Change in particle size of VLDL|Change in Apolipoprotein CIII (ApoCIII)|Change in High Sensitivity C-Reactive Protein (hsCRP)|Change in interleukin 1 beta (IL-1B)|Change in Interleukin 6 (IL-6)|Change in procollagen III|Change in particle size of HDL|Change in particle size of LDL|Change in particle size of chylomicrons|Change in rate of de novo lipogenesis (DNL)|Change in height|Change in weight|Change in body mass index (BMI)|Change in waist circumference|Pill count|Number of participants completing the study","Emory University|Gemphire Therapeutics, Inc.","All","12 Years to 17 Years   (Child)","Phase 2","40","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00099844","March 29, 2018","January 2019","January 2019","February 16, 2018","null","April 10, 2018","Children's Healthcare of Atlanta / Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03436420"
71,"NCT03417479","Gabapentin Premedication for ACL Reconstruction: RCT",,"Recruiting","No Results Available","Anterior Cruciate Ligament (ACL) Reconstruction","Other: Gabapentin","Effective Dose determination","Children's Healthcare of Atlanta","All","12 Years to 18 Years   (Child, Adult)","","100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CHOA IRB 15-094","October 9, 2015","June 6, 2018","September 1, 2018","January 31, 2018","null","July 23, 2018","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03417479"
72,"NCT03416634","Exercise is Medicine at Emory Seavey Internal Medicine Clinic","EIM","Recruiting","No Results Available","Physical Activity","Behavioral: App|Behavioral: Wearable Device|Behavioral: Automated Motivational Message|Behavioral: Personalized Motivational Message","Change in Physical Activity|Change in weight|Change in triglycerides|Change in total cholesterol|Change in hypertension status|Change in blood glucose|Change in hemoglobin A1c (HbA1c)|Change in Center for Epidemiologic Studies Depression Scale (CES-D) Score|Change in Eating Habits Confidence Survey Score|Change in Exercise Confidence Survey Score|Change in Social Support and Exercise Survey Score|Change in Short-Form Patient Satisfaction Questionnaire (PSQ-18) Score|Change in 12-Item Short-Form Health Survey (SF-12) Score|Change in 36-Item Short-Form Health Survey (SF-36) Score","Emory University","All","20 Years to 80 Years   (Adult, Older Adult)","Not Applicable","180","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","IRB00101370","August 20, 2018","December 2018","December 2018","January 31, 2018","null","September 10, 2018","Paul W. Seavey Internal Medicine Clinic, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03416634"
73,"NCT03408340","Paravertebral Nerve Blocks in Neonates",,"Recruiting","No Results Available","Congenital Heart Disease","Procedure: Paravertebral Nerve Block|Drug: Standard of Care Anesthesia","Morphine equivalents|Near infrared spectroscopy (NIRS) values|Postoperative ventilation time|Time to first feeding|Change in plasma epinephrine levels","Emory University","All","up to 12 Months   (Child)","Phase 4","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","IRB00093442","July 18, 2018","February 2019","February 2019","January 24, 2018","null","July 26, 2018","Children's Healtcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03408340"
74,"NCT03392532","Comparison of Two Silicone Hydrogel Toric Contact Lenses",,"Completed","No Results Available","Astigmatism","Device: Toric contact lenses 1|Device: Toric contact lenses 2","Percentage of lenses with axis orientation within ±30 degrees from the 90 degree axis (ideal location)","Alcon Research","All","18 Years and older   (Adult, Older Adult)","Not Applicable","36","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other","CLC127-C001","January 4, 2018","January 26, 2018","January 26, 2018","January 8, 2018","null","May 2, 2018","Alcon Investigative Site, Johns Creek, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03392532"
75,"NCT03389971","ULTRAsound-assisted Catheter vs. STAndaRd Catheter Thrombolysis for Submassive Pulmonary Embolism","UltraStar sPE","Recruiting","No Results Available","Submassive Pulmonary Embolism","Procedure: catheter-directed thrombolysis","thrombus load reduction|cardiopulmonary and clinical outcomes - echocardiographic|cardiopulmonary and clinical outcomes - hemodynamic|cardiopulmonary and clinical outcomes - respiratory|cardiopulmonary and clinical outcomes - decompensation|cardiopulmonary and clinical outcomes - mortality|cardiopulmonary and clinical outcomes - complications|cardiopulmonary and clinical outcomes - ICU stay|San Diego Shortness of Breath questionnaire|SF36|PE QOL|utilization cost|resource utilization","Piedmont Healthcare","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","10","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UltraStar sPE","December 6, 2017","February 1, 2020","February 1, 2020","January 4, 2018","null","January 5, 2018","Piedmont Healthcare, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03389971"
76,"NCT03387319","Stress and CKD Among African Americans",,"Enrolling by invitation","No Results Available","Chronic Kidney Disease","Behavioral: Racialized Stressful Event Recall|Behavioral: Non-Racialized Stressful Event Recall","Subjective Units of Distress Scale (SUDS) Score|Change in Monocyte Chemoattractant Protein-1 (MCP-1)|Change in Interleukin-6 (IL-6)|Change in soluble urokinase-type plasminogen activator receptor (suPAR)|Change in systolic blood pressure|Change in diastolic blood pressure","Emory University|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","25 Years to 65 Years   (Adult, Older Adult)","Not Applicable","100","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","IRB00099892|1R21DK112108","April 27, 2018","June 2019","June 2019","January 2, 2018","null","May 24, 2018","Emory University Hospital Midtown, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03387319"
77,"NCT03384069","CBT for African Americans With Cognitive Impairment",,"Recruiting","No Results Available","Alzheimer Disease","Behavioral: Group-based Cognitive Behavioral Therapy (CBT)|Behavioral: Phone-based Cognitive Behavioral Therapy (CBT)","Number of participants attending CBT sessions (participants retention)|Percentage of patients enrolled as per target (feasibility)|Change in attitudes of patients regarding a CBT intervention for Mild Cognitive Impairment (MCI)|Change in C-reactive protein level|Change in the Center for Epidemiological Studies-Depression (CESD-R) score|Change in Perceived Stress Scale (PSS) score|Change in the quality of life scale (36-Item Short-Form Health Survey (SF-36)) score|Change in Patient-Reported Outcomes Measurement Information System (PROMIS) score|Change in activities of daily living (ADL)|Change in Instrumental activities of daily living (IADL)","Emory University|Alzheimer's Association","All","50 Years and older   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00099440","January 10, 2018","March 31, 2020","March 31, 2020","December 27, 2017","null","February 26, 2018","Emory Clinic, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03384069"
78,"NCT03383029","iEAT 2.0 Open Trial",,"Recruiting","No Results Available","Gastrointestinal Disorders","Behavioral: iEAT Program","Change in Percent Oral Intake|Change in Total Oral Grams Consumed During Meal|Change in Percent Needs Met by Formula or Feeding Tube|Clinical Global Impression Scale - Improvement (CGI-I) Score|Change in Parenting Stress Index (PSI) Score","Emory University","All","12 Months to 6 Years   (Child)","Not Applicable","40","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00099562","November 29, 2017","December 1, 2018","December 1, 2018","December 26, 2017","null","December 26, 2017","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03383029"
79,"NCT03381989","Bioprosthetic or Native Aortic Scallop Intentional Laceration to Prevent Iatrogenic Coronary Artery Obstruction (BASILICA) Prospective Investigation",,"Enrolling by invitation","No Results Available","Aortic Valve Failure","Device: ASHI_INTECC Astato XS 20 0.014 guidewire","The primary efficacy endpoint is clinical success at exit from catheterization lab|The primary safety endpoint is freedom from major adverse clinical events (MACE) at 30days.|Clinical success irrespective of coronary artery stenting|Clinical success without stroke|Technical success of BASILICA only|Coronary instantaneous wave-free pressure ratio (iFR)|Survival|Stroke or TIA|Access and vascular complications|Peri-procedural and spontaneous acute myocardial infarction|Pericardial effusion or tamponade|VARC-2 bleeding complications|AKIN acute kidney injury|Freedom from hemolytic anemia related to BASILICA TAVR|BASILICA Device or Procedure related technical failure|Rotational orientation|Hemodynamic instability caused by BASILICA before TAVR|TAVR thrombosis|Endocarditis","National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)","All","21 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","60","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","999918018|18-H-N018","February 14, 2018","November 30, 2018","September 30, 2019","December 22, 2017","null","October 5, 2018","Emory University Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03381989"
80,"NCT03381235","Exercise and RP (AVAMC and Emory)",,"Recruiting","No Results Available","Retinitis Pigmentosa","Other: Spin exercise","Change in Brain-Derived Neurotrophic Factor (BDNF) level before and after exercise|Change in retina vasculature before and after exercise|Change in retinal thickness before and after exercise|Change in retinal pigment epithelium (RPE) pigmentation before and after exercise|Change in degrees of vascular attenuation before and after exercise|Change in amount of autofluorescence before and after exercise|Change in Goldmann Visual Field (GVF) scores|Change in the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) score","Emory University","All","18 Years to 60 Years   (Adult)","Not Applicable","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","IRB00093690","February 23, 2018","August 28, 2018","August 28, 2018","December 21, 2017","null","March 5, 2018","Emory Clinic, Atlanta VA Medical Center, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03381235"
81,"NCT03373188","VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer",,"Recruiting","No Results Available","Colon Carcinoma Metastatic in the Liver|Colorectal Adenocarcinoma|Pancreatic Adenocarcinoma|Resectable Pancreatic Carcinoma|Stage I Pancreatic Cancer|Stage IA Pancreatic Cancer|Stage IB Pancreatic Cancer|Stage II Pancreatic Cancer|Stage IIA Pancreatic Cancer|Stage IIB Pancreatic Cancer|Stage III Pancreatic Cancer|Stage IV Colorectal Cancer|Stage IVA Colorectal Cancer|Stage IVB Colorectal Cancer","Biological: Anti-SEMA4D Monoclonal Antibody VX15/2503|Biological: Ipilimumab|Biological: Nivolumab|Procedure: Surgery","Evaluate treatment effects of the study drugs on tumor cluster of differentiation 8+ (CD8+) T cell infiltration between the treatment groups.|Incidence of adverse events according to National Cancer Institute Common Terminology Criteria for Adverse Events scale version 4.0","Emory University|Vaccinex Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","32","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00098707|NCI-2017-01618|Winship4142-17","December 15, 2017","December 31, 2022","December 31, 2022","December 14, 2017","null","May 23, 2018","Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03373188"
82,"NCT03370471","Exercise Effects on Word Learning",,"Recruiting","No Results Available","Aging|Aphasia","Behavioral: Moderate Intensity Exercise|Behavioral: Gentle Stretching","Study-specific word recall task (informal assessment that comprises the words trained in each intervention and arm)|Serum BDNF|Plasma dopamine","VA Office of Research and Development","All","65 Years to 89 Years   (Older Adult)","Not Applicable","40","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","C2238-P","December 9, 2016","September 28, 2018","September 28, 2018","December 12, 2017","null","June 25, 2018","Atlanta VA Medical and Rehab Center, Decatur, GA, Decatur, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03370471"
83,"NCT03366493","The Study of Folate Receptor-Mediated Staining Solution (FRD™) In Cervical Lesion Detection",,"Recruiting","No Results Available","Cervical Intraepithelial Neoplasia Grade 2/3","Combination Product: FRD|Other: Cytology|Other: HPV testing|Procedure: Colposcopy|Procedure: ECC|Procedure: Biospy","Subjects diagnosed with CIN2+|Subjects without CIN2+ after colposcopy","GY Highland Biotech LLC","Female","20 Years to 60 Years   (Adult)","Phase 3","200","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Screening","GYFRD-001","December 7, 2017","December 7, 2018","December 7, 2018","December 8, 2017","null","December 8, 2017","Augusta University, Augusta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03366493"
84,"NCT03359096","HGNS on Cardiovascular Outcomes",,"Recruiting","No Results Available","Obstructive Sleep Apnea","Device: Therapeutic HGNS|Device: Subtherapeutic 'Sham' HGNS","Change in mean 24-HOUR systolic ambulatory blood pressure values|Change in mean 24-HOUR diastolic ambulatory blood pressure values|Change in mean SLEEP systolic and diastolic ambulatory blood pressure values|Change in Muscle Sympathetic Nerve Activity (MSNA) frequency (bursts/minute)|Change in Muscle Sympathetic Nerve Activity (MSNA) ) tonal activity (units/minute)|Change in Pre-Ejection Period (PEP) duration|Change in Flow-mediated dilation (FMD)|Change in Peripheral arterial stiffness (PAS)|Change in C reactive protein|Change in fibrin degradation products (FDPs)|Change in 70 kilodalton heat shock proteins (Hsp70s)|Change in high-sensitivity-troponin|Change in soluble urokinase-type plasminogen activator receptor (SUPAR)","Emory University|American Heart Association|American Academy of Sleep Medicine","All","21 Years and older   (Adult, Older Adult)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRB00097589","December 13, 2017","June 30, 2020","June 30, 2020","December 2, 2017","null","March 21, 2018","Raj C. Dedhia, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03359096"
85,"NCT03340610","IAI for Persistent DME After Treatment With Bevacizumab And Ranibizumab","ROTATED","Recruiting","No Results Available","Diabetic Macular Edema","Drug: Alflibercept","Reduction in Macular Edema","Southeast Retina Center, Georgia","All","18 Years to 95 Years   (Adult, Older Adult)","Phase 4","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VGFTe-DME-1519","June 2015","January 2019","July 2019","November 13, 2017","null","November 13, 2017","Southeast Retina Center, Augusta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03340610"
86,"NCT03338595","Longitudinal Assessment of Exercise Capacity and Vascular Function in Patients With CF",,"Recruiting","No Results Available","Cystic Fibrosis","","Maximal exercise capacity|Flow mediated dilation","Augusta University|Vertex Pharmaceuticals Incorporated","All","7 Years and older   (Child, Adult, Older Adult)","","30","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","CF-Long","May 2014","May 2020","May 2020","November 9, 2017","null","November 9, 2017","Georgia Prevention Institute, Augusta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03338595"
87,"NCT03328104","AflacLL1602 ENCERT",,"Recruiting","No Results Available","Lymphoblastic Leukemia|Lymphoblastic Lymphoma","Drug: Everolimus|Drug: Nelarabine|Drug: Cyclophosphamide|Drug: Etoposide","Determine the maximum tolerated dose (MTD).|Determine area under the concentration versus time curve (AUC)|Determine maximum observed concentration (Cmax)|Determine elimination half-life (t1/2)|Changes in phosphoprotein (pAkt and p4EBP1) expression at time points pre- and post everolimus therapy in peripheral blood mono-nuclear cells (PBMCs) and bone marrow.|Changes in Mer expression at time points pre- and post everolimus therapy in peripheral blood mono-nuclear cells (PBMCs) and bone marrow.|Determine the response rate|Mean time from start of study treatment to transplant in patients with bone marrow relapse of T-ALL or relapsed T-LLy.","Emory University","All","2 Years to 29 Years   (Child, Adult)","Phase 1","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00095500","July 24, 2018","September 5, 2019","December 31, 2019","November 1, 2017","null","July 30, 2018","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03328104"
88,"NCT03316963","Neostigmine For Snoring During DISE",,"Recruiting","No Results Available","Snoring","Drug: Neostigmine Methylsulfate","Change in decibel sound after injection of neostigmine|Change in soft palate motion after injection of neostigmine","Emory University","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00096770","November 14, 2017","August 2019","August 2019","October 23, 2017","null","August 20, 2018","Raj C. Dedhia, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03316963"
89,"NCT03311711","Two-Phased Study of SPIRIT in Mild AD",,"Recruiting","No Results Available","Alzheimer Disease and Related Dementias","Behavioral: SPIRIT-in person|Behavioral: SPIRIT-remote|Behavioral: Usual care","Change in dyad congruence among Phase I participants|Change in dyad congruence among Phase II participants|Change in Patient's Decisional Conflict Scale (DCS) Score among Phase I participants|Change in Patient's Decisional Conflict Scale (DCS) Score among Phase II participants|Change in Surrogate's Decision Making Confidence (DMC) scale score among Phase I participants|Change in Surrogate's Decision Making Confidence (DMC) scale score among Phase II participants|Completion of Advance Directives among Phase I participants|Completion of Advance Directives among Phase II participants","Emory University|National Institute on Aging (NIA)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","264","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","IRB00099738|1R01AG057714","May 4, 2018","May 31, 2022","May 31, 2022","October 17, 2017","null","May 10, 2018","Emory Brain Health Center, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03311711"
90,"NCT03311321","Vitamin K to Slow Progression of Cardiovascular Disease Risk in Hemodialysis Patients",,"Recruiting","No Results Available","Cardiovascular Diseases|Chronic Kidney Disease Stage 3|Chronic Kidney Disease Stage 4|Chronic Kidney Disease Stage 5|Vitamin K Deficiency|Hemodialysis","Dietary Supplement: Vitamin K2 (menaquinone-7; 360-mcg/d)|Dietary Supplement: Placebo-Control","Flow-Mediated Dilation (FMD)|Pulse Wave Velocity (PWV)|Prothrombin Time","Augusta University","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","683534","September 13, 2017","December 2018","December 2018","October 17, 2017","null","May 17, 2018","Augusta University, Augusta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03311321"
91,"NCT03307694","Thyroid Ultrasound Elasticity (TrUE) Imaging",,"Recruiting","No Results Available","Cancer, Thyroid","Diagnostic Test: Ultrasound|Diagnostic Test: Shear wave elasticity imaging|Diagnostic Test: Multi-angle compound shear wave elasticity imaging","Determination of Malignancy by SWEI Imaging|Determination of Malignancy by Pathological Proof|Accuracy of differentiating benign from malignant lesions between SWEI techniques","Emory University","All","18 Years and older   (Adult, Older Adult)","","36","Other","Observational","Observational Model: Other|Time Perspective: Prospective","IRB00092785","October 23, 2017","August 31, 2019","August 31, 2019","October 12, 2017","null","November 8, 2017","Emory Univeristy Hospital Midtown, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03307694"
92,"NCT03307057","Promoting Transactional Supports to Optimize Social Communication Outcomes for Infants and Their Families",,"Recruiting","No Results Available","Autism Spectrum Disorder","Behavioral: Social Communication Growth Charts (SCGC)|Behavioral: Parent-Implemented (P-I) Condition|Behavioral: Clinician-Implemented (C-I) Condition","Measure of Active Engagement and Transactional Supports (MAETS)|Communication and Symbolic Behavior Scales (CSBS) Score|Autism Diagnostic Observation Schedule Score|Mullen Scales of Early Learning Score|Vineland-3 Adaptive Behavior Scales Score|Measure of Active Engagement and Transactional Supports (MAETS) in Parents of Children Showing Signs of ASD|Communication and Symbolic Behavior Scales (CSBS) Score in Children Showing Signs of ASD|Autism Diagnostic Observation Schedule Score in Children Showing Signs of ASD|Mullen Scales of Early Learning Score in Children Showing Signs of ASD|Vineland-3 Adaptive Behavior Scales Score in Children Showing Signs of ASD","Emory University","All","6 Months to 6 Months   (Child)","Not Applicable","250","Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","IRB00098127","February 1, 2018","September 2022","September 2022","October 11, 2017","null","February 27, 2018","Marcus Autism Center, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03307057"
93,"NCT03304821","Granulocyte-Macrophage Stimulating Factor (GM-CSF) in Peripheral Arterial Disease","GPAD-3","Recruiting","No Results Available","Peripheral Artery Disease (PAD)","Drug: GM-CSF|Drug: Placebo","Change in 6-minute walk distance|Change in Peak Walking Time (PWT)|Change in Walking Impairment Questionnaire (WIQ): Walking Distance Score|Change in Walking Impairment Questionnaire (WIQ): Walking Speed Score|Change in Walking Impairment Questionnaire (WIQ): Stair Climbing Score|Change in 36-item Short-Form Health Survey (SF-36) Score|Change in Claudication Onset Time (COT)|Change in Ankle-Brachial Index (ABI)|Change in Foot Transcutaneous Oxygen Tension (TcPO2)","Emory University|National Heart, Lung, and Blood Institute (NHLBI)","All","21 Years to 80 Years   (Adult, Older Adult)","Phase 2","176","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","IRB00087198|1R61HL138657","December 19, 2017","June 2022","June 2022","October 9, 2017","null","December 21, 2017","Emory University Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03304821"
94,"NCT03287180","Adolescent Community Reinforcement Approach in Combination With Buprenorphine/Naloxone for Severe Opioid Use","A-CRA/MAT","Not yet recruiting","No Results Available","Opioid-Related Disorders|Behavior, Addictive","Behavioral: Adolescent Community Reinforcement Approach (A-CRA)|Other: Combination of Buprenorphine/naloxone 4/1","Proportion of opiates-negative urine drug screens over the total number of urine drug screens at each stage|Percent of days of opioid use within the past 90 days as indicated by self-report on the GAIN-Q3-Standard|Completion of the final phase of treatment defined as final study session (yes/no)|Number of clinic visits by patient and any expected joint family member sessions","Emory University","All","18 Years to 25 Years   (Adult)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00093907","September 7, 2018","April 1, 2019","April 1, 2019","September 19, 2017","null","September 19, 2017","Executive Park, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03287180"
95,"NCT03272568","Extended Half Life Factor (EHF) Products For Heavy Menstrual Bleeding in Hemophilia Carriers",,"Recruiting","No Results Available","Hemophilia|Menstrual Flow Excessive","Drug: Recombinant FVIII Fc fusion product Eloctate|Drug: Recombinant FIX Fc fusion product Alprolix|Device: Patient-operated diagnostic device for anemia AnemoCheck.","Reduction in menstrual bleeding measured by the Pictorial Bleeding Assessment Chart (PBAC).|Change in Patient-Reported Outcomes Measurement Information Systems (PROMIS-43) score.|Change in Short Form 36 (SF-36) score.|Change in Menorrhagia Impact Questionnaire (MIQ) score.|Number of hypersensitivity reactions.|Accuracy of hemoglobin levels detection by Anemocheck.|Change in FVIII level after the first dose of Eloctate.|Change in FIX level after the first dose of Alpolix.","Emory University|Bioverativ Therapeutics Inc.","Female","14 Years to 55 Years   (Child, Adult)","Early Phase 1","16","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00095067","February 14, 2018","July 31, 2019","September 30, 2019","September 5, 2017","null","March 12, 2018","Emory University Hospital Clinical Research Network, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03272568"
96,"NCT03269149","Tango for Alzheimer's Disease Patients' Caregivers",,"Recruiting","No Results Available","Alzheimer's Disease","Other: Adapted Tango Dance|Behavioral: Educational lectures","Change in interleukin-7|Change in interleukin-8|Change in interleukin-9|Change in Interleukin-10|Change in interferon induced protein 10|Change in macrophage derived chemokine|Change in monocyte chemoattractant protein 1|Change in transforming growth factor alpha|Change in tumor necrosis factor alpha|Change in C-reactive protein|Change in serum amyloid protein|Change in Montreal Cognitive Assessment (MoCA)|Change in the Tower of London test|Change in the Stroop interference test|Change in Trails B test|Change in Digit Span test|Change in Buschke Selective Reminding Test|Change in Reverse Corsi Blocks test|Change in Brooks spatial memory test|Change in the Body position spatial task (BPST)|Change in Fullerton Advanced Balance Scale|Change in 30-second chair stand|Change in gait speed|Change in Positive Aspects of Caregiving (PAC) Scale|Change in Pearlin Caregiver Stress Scale|Change in the Zarit Burden Interview|Change in the Center for Epidemiologic Studies Depression Scale (CES-D)|Change in DEMQOL: Dementia Quality of Life measure (Carer v4)","Emory University","Female","45 Years to 65 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","IRB00097348","September 19, 2017","July 2019","July 2019","August 31, 2017","null","August 22, 2018","Atlanta VA Medical Center, Emory University, Executive Park, Wesley Woods, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03269149"
97,"NCT03268395","Correlation of CO2 Measured by Blood Gas vs Transcutaneous Monitor",,"Recruiting","No Results Available","Respiratory Complication","Diagnostic Test: Arterial Blood Gas and Transcutaneous CO2 Monitor","Observed mean CO2 difference","Memorial Health University Medical Center","All","Child, Adult, Older Adult","Not Applicable","266","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2017.07.02","August 29, 2017","August 29, 2018","December 30, 2018","August 31, 2017","null","August 31, 2017","Memorial University Medical Center, Savannah, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03268395"
98,"NCT03268070","Transcranial Magnetic Stimulation in Stroke Motor Rehabilitation Treatment",,"Withdrawn","No Results Available","Stroke","Device: Repetitive TMS over contralateral premotor cortex.|Device: Repetitive TMS over ipsilateral premotor cortex.|Device: Repetitive TMS over contralateral primary motor cortex.|Device: Sham Repetitive TMS over contralateral premotor cortex.|Device: Single TMS over extensor carpi ulnaris spot of motor cortex","Change in wrist velocity|Change in Stimulus Response Curve parameters|Change in wrist force|Change in reaction time|Change in task accuracy|Change in Short interval intracortical inhibition (SICI) of the primary motor cortex|Change in Resting Motor Threshold","Emory University|American Heart Association","All","30 Years to 80 Years   (Adult, Older Adult)","Not Applicable","0","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","IRB00097855","March 2018","June 28, 2019","June 28, 2019","August 31, 2017","null","April 11, 2018","Emory Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03268070"
99,"NCT03267888","Pembrolizumab and Radiation Therapy in Patients With Relapsed or Refractory Multiple Myeloma",,"Recruiting","No Results Available","ISS Stage I Plasma Cell Myeloma|ISS Stage II Plasma Cell Myeloma|ISS Stage III Plasma Cell Myeloma|Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma","Biological: Pembrolizumab|Radiation: Radiation Therapy","Incidence of adverse events|Number of patients achieving any response|Overall response based on baseline changes on positron emission to positron emission tomography/computed tomography|Overall survival","Emory University|Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Older Adult)","Phase 1","24","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00097324|NCI-2017-01485|RAD4106-17","May 29, 2018","May 31, 2021","May 31, 2021","August 30, 2017","null","July 25, 2018","Emory University/Winship Cancer Institute, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03267888"
100,"NCT03257722","Pembrolizumab + Idelalisib for Lung Cancer Study","PIL","Recruiting","No Results Available","Non Small Cell Lung Cancer|Metastasis|Recurrence","Drug: Pembrolizumab|Drug: Idelalisib","Number of Participants With Dose-Limiting Toxicity (DLT) Events as Assessed by CTCAE v4.03|Dose-Finding Assessment for optimum dose of idelalisib in combination with pembrolizumab|Overall Response Rates (ORR) to combination therapy","Zhonglin Hao|Merck Sharp & Dohme Corp.|Gilead Sciences|Augusta University","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","40","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GCC-16053","September 26, 2017","August 2020","August 2021","August 22, 2017","null","September 29, 2017","Georgia Cancer Center at Augusta University, Augusta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03257722"
101,"NCT03254186","Safety and Efficacy of Propranolol in the Treatment of Tardive Dyskinesia",,"Recruiting","No Results Available","Tardive Dyskinesia","Drug: Propranolol Hydrochloride|Drug: Placebo Oral Tablet","Change in the Abnormal Involuntary Movement Scale (AIMS) score.|Change in the Clinical Global Impression of Severity (CGI-S) score.|Change in the Clinical Global Impression -Improvement (CGI-I) score.","Emory University|Atlanta Clinical and Translational Science Institute","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2|Phase 3","15","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","IRB00096912","September 18, 2017","February 1, 2019","February 1, 2019","August 18, 2017","null","September 28, 2018","Emory Clinic, Executive Park, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03254186"
102,"NCT03251495","Immunologic Responses to a Live Attenuated Oral Cholera Vaccine",,"Recruiting","No Results Available","Cholera","Drug: Vaxchora","Percentage of Positive Responders|Plasmablast Levels|Activated B Cell Levels|Memory B-Cell Levels|Memory T-Cell Levels|Number of Samples from which Monoclonal Antibodies Produced|Number of Adverse Events|Number of Serious Adverse Events","Emory University","All","18 Years to 49 Years   (Adult)","Phase 2","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","IRB00097012","August 29, 2017","November 30, 2020","November 30, 2021","August 16, 2017","null","July 19, 2018","The Hope Clinic of Emory University, Atlanta, Georgia, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/95/NCT03251495/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03251495"
103,"NCT03244267","App Reminder on ASA Adherence",,"Recruiting","No Results Available","Thromboembolic Event","Behavioral: Standard Education|Behavioral: Medication Reminder App","Proportion of Pills Taken|AIDS Clinical Trials Group (ACTG) Adherence Questionnaire Score|Aspirin (ASA) Self-Efficacy Scale Score|Number of Thromboembolic Events|Aspirin (ASA) General Adherence Scale Score|Unified Theory of Acceptance and Use of Technology (UTAUT2) Survey Score|Performance Expectancy Subscale Score|Effort Expectancy Subscale Score|Hedonic Motivation Subscale Score|Behavioral Intent Subscale Score","Emory University|National Association of Orthopedic Nurses","All","18 Years to 64 Years   (Adult)","Not Applicable","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","IRB00094970","October 3, 2017","April 24, 2020","April 24, 2020","August 9, 2017","null","October 11, 2018","Emory Orthopedic and Spine Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03244267"
104,"NCT03240601","Spinal Cord Stimulation to Augment Activity Based Therapy",,"Recruiting","No Results Available","Spinal Cord Stimulation|Walking|Spasticity|Human|Spinal Cord Injuries","Device: Transcutaneous spinal cord stimulation","Change in Spasticity - Pendulum/Leg-drop Test|Change in Walking Function - 10m Walk/Walking Speed|Change in Spasticity - Ankle Clonus Test/Foot-drop test|Change in Spasticity - Co-contraction|Change in Spasticity - Persistent Involuntary Activity|Change in Spasticity - Spinal Cord Assessment Tool for Spastic Reflexes (SCATS) Test|Change in Spasticity - Questionnaires|Change in Walking Function - 2 Minute Walk|Change in Heart Rate|Change in Borg Rating of Perceived Exertion (RPE) Scale|Tolerance of stimulation","Shepherd Center, Atlanta GA|Foundation Wings For Life","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","28","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","696","July 1, 2017","July 2019","July 2019","August 7, 2017","null","September 10, 2018","Shepherd Center, Inc., Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03240601"
105,"NCT03237234","Enhancing Corticospinal Activation for Improved Walking Function",,"Recruiting","No Results Available","Spinal Cord Injuries","Other: Motor Skill Training|Device: Transcranial direct current stimulation (tDCS)","10 Meter Walk Test|Maximal Isometric Dorsiflexor Strength|Gait Kinematics|Berg Balance Scale|Falls Efficacy Scale-International Version|Spinal Cord Assessment Tool for Spastic Reflexes|Modified 5-Times Sit-to-Stand|Maximal Isometric Quadriceps Strength|2 Minute Walk Test","Shepherd Center, Atlanta GA|National Institute on Disability, Independent Living, and Rehabilitation Research","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","35","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SCIMS1-703","March 1, 2017","November 1, 2020","March 1, 2021","August 2, 2017","null","September 6, 2018","Shepherd Center, Inc., Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03237234"
106,"NCT03237091","Enhancing Corticospinal Excitability to Improve Functional Recovery",,"Recruiting","No Results Available","Spinal Cord Injuries|Tetraplegia","Device: bihemispheric transcranial pulsed current stimulation (tPCS)|Device: unihemispheric transcranial pulsed current stimulation (tPCS)|Device: bihemispheric transcranial direct current stimulation (tDCS)|Device: unihemispheric transcranial direct current stimulation (tDCS)|Device: sham-control","Change from Baseline Motor Control & Strength|Change from Baseline Corticospinal Excitability|Stimulation Questionnaire","Shepherd Center, Atlanta GA|The Craig H. Neilsen Foundation","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","19","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","723","May 3, 2018","July 2019","July 2019","August 2, 2017","null","September 6, 2018","Shepherd Center, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03237091"
107,"NCT03226548","Health Outcomes Tied to the Expansion of EITC in Single Adults",,"Not yet recruiting","No Results Available","Poverty|Tax Policy","Other: Paycheck Plus","Mean Score on the Patient Health Questionnaire-9 (PHQ-9)|Mean Total Cholesterol|Mean Body Mass Index (BMI)|Mean Blood Pressure (BP)|Blood Quality of Life Score|Mean HbA1c|Mean C-reactive Protein|Prevalence of Mortality","Columbia University|MDRC","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","4000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","AAAQ9663 (ADD-ON)","September 2018","September 2020","November 2021","July 21, 2017","null","July 21, 2017","Westat, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03226548"
108,"NCT03224234","A Randomized Study to Evaluate the Efficacy of Insulclock® in Patients With Uncontrolled Type 2 Diabetes",,"Recruiting","No Results Available","Diabetes","Device: Insulclock with feedback|Device: Insulclock without feedback","Number of insulin injection irregularities.|Change in Diabetes Treatment Satisfaction Questionnaire (DTSQs-status and DTSQc-change) scores.|Change in Diabetes Related Quality of Life (DRQoL) scores.|Change in mean HbA1c.|Number of episodes of hypoglycemia.|Number of episodes of severe hypoglycemia.|Change in daily fasting glucose profile averages.|Change in 7-point Self Monitoring of Blood Glucose (SMBG) profile.|Change in Diabetes Quality of Life Clinical Trial Questionnaire-Revised (DQLCTQ-R) score","Emory University|Insulcoud S.L.","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00094393","November 29, 2017","December 30, 2018","December 30, 2019","July 21, 2017","null","April 27, 2018","Emory Clinic, Emory University Hospital (non-CRN), Emory University Hospital Clinical Research Network, Emory University Hospital Midtown, Grady Health System (non-CRN), Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03224234"
109,"NCT03216291","Home Versus Office Biofeedback Therapy for Fecal Incontinence",,"Recruiting","No Results Available","Fecal Incontinence","Behavioral: biofeedback therapy|Device: Home Biofeedback therapy","number of episodes of fecal incontinence|Squeeze anal sphincter pressure|Overall quality of life and symptom perception on previously validated Fecal Incontinence questionnaires","Augusta University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HomeVOfficeFI","October 2015","March 2018","September 2018","July 13, 2017","null","June 27, 2018","Augusta University, Augusta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03216291"
110,"NCT03214848","Evaluation of an Intervention to Increase Post-abortion LARC Uptake.",,"Completed","No Results Available","Post Abortion Contraception","Behavioral: Contraceptive education prior to abortion","Proportion of Long-Acting Reversible Contraception (LARC) methods inserted immediately post abortion in the intervention and standard of care arms.|Proportion of Long-Acting Reversible Contraception (LARC) methods used in the intervention and standard of care arms three months post abortion.|Cost-effectiveness analysis of the study intervention.","Emory University|Woodruff Health Sciences Center Foundation","Female","16 Years and older   (Child, Adult, Older Adult)","Not Applicable","1314","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention","IRB00094882","September 13, 2017","February 21, 2018","February 21, 2018","July 12, 2017","null","June 20, 2018","Atlanta Women's Center, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03214848"
111,"NCT03207763","Microneedle Patch Study in Healthy Infants/Young Children",,"Recruiting","No Results Available","Vaccination|Skin Absorption","Device: Microneedle Formulation 1|Device: Microneedle Formulation 2","Number of placebo microneedle patch-related serious adverse events (SAE).|Number of Grade 3 placebo microneedle patch-related solicited adverse events (AE).|Number of solicited application site reactogenicity events.|Number of Grade 3 placebo microneedle patch-related unsolicited adverse events.|Number of new-onset medical conditions (NOMC)|Number of solicited and unsolicited adverse events described at the site at which the placebo microneedle patch was applied.|Legally Authorized Representative (LAR)'s acceptability of vaccination using a microneedle patch assessed by survey.","Emory University|Micron Biomedical","All","6 Weeks to 24 Months   (Child)","Not Applicable","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","IRB00096635","July 11, 2017","December 31, 2018","July 31, 2019","July 5, 2017","null","August 14, 2018","Emory Children's Center, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03207763"
112,"NCT03204955","A Low ChloridE hyperTonic Solution for Brain Edema","ACETATE","Active, not recruiting","No Results Available","Subarachnoid Hemorrhage|Acute Kidney Injury","Drug: Sodium chloride /sodium acetate (16.4%)|Drug: Sodium chloride (23.4%)|Drug: PlasmaLyte","Difference between serum chloride level on randomization day and the peak afterwards|Number of patients with acute kidney injury (AKI)|All causes of in-hospital mortality.|All causes of 90 day mortality.|Change in intracerebral pressure (ICP) measured by ICP monitor following hypertonic treatment.|Change in serum sodium level following the administration of the hypertonic solution.","Emory University","All","18 Years and older   (Adult, Older Adult)","Phase 1","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRB00090456","June 28, 2017","September 2018","September 2018","July 2, 2017","null","August 29, 2018","Emory University Hospital's Neurointensive Care Unit, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03204955"
113,"NCT03199560","Tilmanocept vs Sulfur Colloid in Sentinel Lymph Node Biopsy",,"Recruiting","No Results Available","Sentinel Lymph Node Biopsy|Breast Cancer","Drug: Tc 99m tilmanocept|Drug: Tc 99m filtered sulfur colloid","Number of harvested lymph nodes","Memorial Health University Medical Center","Female","18 Years and older   (Adult, Older Adult)","Phase 4","86","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Diagnostic","2016.12.1","June 22, 2017","June 22, 2019","August 22, 2019","June 27, 2017","null","August 24, 2018","Memorial Health University Medical Center, Savannah, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03199560"
114,"NCT03197922","Encopresis & MIE (DoD #2)",,"Recruiting","No Results Available","Encopresis|Autism Spectrum Disorder","Combination Product: MIE Treatment","Change in Continence|Clinical Global Impression Scale - Improvement (CGI-I) Score|Caregiver Strain Questionnaire","Emory University|United States Department of Defense","All","5 Years to 12 Years   (Child)","Phase 3","150","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","IRB00095849","October 25, 2017","October 1, 2021","October 1, 2021","June 23, 2017","null","December 4, 2017","Marcus Autism Center, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03197922"
115,"NCT03187275","Efficacy of Massage for the Treatment of Cancer-Related Fatigue (CRF) in Prostate Cancer Survivors","mProstate","Recruiting","No Results Available","Cancer-related Problem/Condition","Other: Swedish Massage Therapy|Other: Light Touch Intervention","Change in Multidimensional Fatigue Inventory (MFI) score|Change in Patient-Reported Outcome Measurement System (PROMIS) Fatigue Scale score|Change in plasma IL-6|Change in Quality of Life, Enjoyment, and Satisfaction Questionnaire - short form (Q-LES-Q) score|Change in Quick Inventory of Depressive Symptomatology - Self-Report (QIDS-SR) score|Change in Generalized Anxiety Disorder 7-item (GAD-7) Scale score|Change in circadian variation of activity|Change in step count|Change in sleep duration|Change in sleep latency|Change in Automated Monitoring of Symptom Severity (AMoSS) survey score","Emory University","Male","45 Years and older   (Adult, Older Adult)","Not Applicable","15","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","IRB00095260","January 22, 2018","February 28, 2019","February 28, 2019","June 14, 2017","null","August 29, 2018","Executive Park 12, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03187275"
116,"NCT03181763","""Evaluation of MDMA on Startle Response",,"Recruiting","No Results Available","Startle Response","Drug: Placebo|Drug: MDMA|Behavioral: Acoustic startle","EMG of right orbicularis oculi muscle|Systolic blood pressure pre-drug|Systolic blood pressure 45 min post-drug|Systolic blood pressure 1 h 15 min post-drug|Systolic blood pressure 1 h 45 min post-drug|Systolic blood pressure 3 h post-drug|Systolic blood pressure 4 h post-drug|Systolic blood pressure 5 h post-drug|Systolic blood pressure 6 h post-drug|Diastolic blood pressure pre-drug|Diastolic blood pressure 45 min post-drug|Diastolic blood pressure 1 h 15 min post-drug|Diastolic blood pressure 1 h 45 min post-drug|Diastolic blood pressure 3 h post-drug|Diastolic blood pressure 4 hours post-drug|Diastolic blood pressure 5 hours post-drug|Diastolic blood pressure 6 hours post-drug|Pulse pre-drug|Pulse 45 min post-drug|Pulse 1 h 15 min post-drug|Pulse 1 h 45 min post-drug|Pulse 3 h post-drug|Pulse 4 h post-drug|Pulse 5 h post-drug|Pulse 6 h post-drug|Body temperature pre-drug|Body temperature 45 minutes post-drug|Body temperature 1 h 15 minutes post-drug|Body temperature 1 h 45 minutes post-drug|Body temperature 3 hours post-drug|Body temperature 4 hours post-drug|Body temperature 5 hours post-drug|Body temperature 6 hours post-drug","Multidisciplinary Association for Psychedelic Studies","All","21 Years to 50 Years   (Adult)","Phase 1","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","MPVA-4","September 21, 2017","November 10, 2018","January 10, 2019","June 9, 2017","null","September 13, 2018","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03181763"
117,"NCT03167736","Dry Needling and Spinal Manipulation vs. Conventional PT for Lumbar Spinal Stenosis",,"Recruiting","No Results Available","Lumbar Spinal Stenosis","Other: electric dry needling, manipulation|Other: conventional physical therapy","Change in low back pain (NPRS) (Rating Score)|Change in Oswestry Disability Index|Change in Roland Morris Disability Index|Change in Global Rating of Change Score|Change in Medication Intake (Frequency of medication intake in last week)","Alabama Physical Therapy & Acupuncture|Universidad Rey Juan Carlos","All","50 Years and older   (Adult, Older Adult)","Not Applicable","110","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","AAMT0011","March 15, 2017","March 15, 2019","March 15, 2019","May 30, 2017","null","August 24, 2018","Benchmark PT - Canton, Canton, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03167736"
118,"NCT03167359","Hypofractionated Radiotherapy in Breast Cancer",,"Recruiting","No Results Available","Cancer, Breast|Inflammation","Radiation: Hypofractionated Simultaneous Integrated Boost Radiotherapy","Cutaneous Toxicity Rate|Arm Lymphedema Rate|Grade 3 Brachial Plexopathy Rate|Cutaneous Toxicity Rate assessed by Ultrasound Tissue Characterizations (UTC)|Tumor Necrosis Factor (TNF) - Alpha Levels|Soluble TNF Receptor 2 (sTNFR2) Levels|Interleukin (IL)-6 Levels|Interleukin 1 Receptor Agonist (IL-1ra) Levels|C - reactive protein (CRP) Levels|Change in Multidimensional Fatigue Inventory (MFI) Score|Change in Pittsburgh Sleep Quality Index (PSQI) Score|Change in Perceived Stress Scale (PSS) Score|Change in Patient Reported Outcomes Measurement Information System (PROMIS) Fatigue Short Form Score|Change in an Inventory of Depressive Symptomatology-Self Reported (IDS-SR) score|Change in Short Form-36 (SF-36) Health Survey Score|Change in Godin Leisure-Time Exercise Questionnaire (GLTEQ) Score|Change in Lent Soma Scale Patient Questionnaire Score|Change in Breast Pain Level|Change in Breast Appearance Satisfaction Score|Difference in Radiated Breast Appearance Score","Emory University","Female","up to 50 Years   (Child, Adult)","Not Applicable","86","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00047240","December 2010","October 2019","October 2019","May 30, 2017","null","July 3, 2018","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03167359"
119,"NCT03166371","Glutathione (GSH) Supplementation After Hospitalization",,"Recruiting","No Results Available","Malnutrition","Dietary Supplement: Liposomal Glutathione (GSH)|Other: Placebo","Change in Plasma Concentrations of GSH|Change in GSH/glutathione Disulfide (GSSG) Concentration Ratio|Change in GSH/GSSH Pool Redox Potential (Eh)|Body Composition assessed by Dual Energy X-ray Absorptiometry (DEXA) Scan|Change in Waist Circumference|Change in Hip Circumference|Change in Body Mass Index (BMI)|Change in Total Body Water (TBW) Volume|Change in Intracellular Water Volume assessed by Bioelectrical Impedance Analysis (BIA)|Change in Extracellular Water Volume assessed by Bioelectrical Impedance Analysis (BIA)|Change in Phase Angle Measurements assessed by Bioelectrical Impedance Analysis (BIA)|Change in Short Physical Performance Battery Score|Change in Timed Up and Go Test Score|Change in Grip Strength assessed by Hand-Grip Dynamometry|Change in Life Space Assessment Questionnaire Score|Change in Iowa Fatigue Scale Score|Change in Edmonton Frail Scale Score|Change in Fatigue Symptom Inventory (FSI) Score|Plasma Concentrations of Cysteine (Cys)|Plasma Concentrations of Cistine (CySS)|Cys/CySS Ratio|Cys/CySS Pool Redox Potential","Emory University|Your Energy Systems, LLC","All","60 Years and older   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","IRB00095819","September 2019","October 2020","January 2021","May 25, 2017","null","October 11, 2018","Emory University Hospital Clinical Research Center, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03166371"
120,"NCT03165747","Effect of VSL#3 on Bone Mineral Density in Postmenopausal Women","ProBoneVSL","Recruiting","No Results Available","Menopausal Osteoporosis","Drug: VSL#3|Other: Placebo","Change in bone mineral density (BMD) of the lumbar spine (L1-L4 segment) as measured by DEXA (dual energy X-ray absorptiometry).|Change in bone density of the non-dominant hip (femoral neck and total hip area) as measured by DEXA (dual energy X-ray absorptiometry).|Change in serum collagen type 1 cross-linked C-telopeptide (CTX) concentrations (a marker of bone resorption).|Change in serum procollagen type I N propeptide (PINP) - a marker of bone formation - concentrations.|Change in serum free receptor activator of nuclear factor kappa-B ligand (RANKL) concentrations.|Change in serum osteoprotegrin (OPG) concentrations.|Change in serum tumor necrosis factor-TNF.|Change in serum interleukin-17 (IL-17) concentrations.|Number of unused study drug satchets.|Gastrointestinal Symptom Rating|Study retention rate.","Emory University","Female","50 Years to 65 Years   (Adult, Older Adult)","Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","IRB00095798","October 1, 2017","December 2019","December 2019","May 24, 2017","null","July 6, 2018","Emory University Hospital Clinical Research Network, Emory Clinic, Emory St. Joseph's Hospital, Emory University Hospital (non-CRN), Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03165747"
121,"NCT03161262","SMS-Based Follow-Ups to Improve Post-Discharge Surgical Outcomes",,"Recruiting","No Results Available","Surgical Site Infection","Behavioral: SMS-based reminders","Medication adherence assessed with patient responses to medication reminders|Medication adherence assessed by Adherence to Refills and Medications Survey (ARMS)|Participant Satisfaction|Early detection of surgical site infection (SSI)|Early intervention of surgical site infection (SSI)|Care Transitions Measure (CTM-15) Score|Number of visits with provider|Number of appointments for routine care|Satisfaction with time spent by provider on care|Overall rating of provider|30-Day Readmission","Emory University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","IRB00094000","June 9, 2017","November 1, 2018","November 1, 2018","May 19, 2017","null","August 21, 2018","Grady Health System, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03161262"
122,"NCT03158428","CSD170202: A Study to Evaluate the Exposure to Tobacco Constituents From Two Moist Snuff Products",,"Completed","No Results Available","Tobacco Use","Other: CSD170202AA|Other: CSD170202AB","Mouth-Level Exposure (MLE) of nicotine per gram (or product)","RAI Services Company|Inflamax Research Limited","All","21 Years and older   (Adult, Older Adult)","Not Applicable","55","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","CSD170202","May 8, 2017","July 25, 2017","July 25, 2017","May 18, 2017","null","September 8, 2017","Clinical Research Atlanta, Stockbridge, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03158428"
123,"NCT03156361","21 Day Comparison of Continuous Insulin Infusion Using HDV Insulin to Standard Insulin in Type 1 Diabetes Mellitus",,"Completed","No Results Available","Type1 Diabetes Mellitus","Drug: HDV insulin lispro 100 UNIT/mL|Drug: Insulin Lispro 100 Units/mL","Glucose area under the curve|total units Insulin","Diasome Pharmaceuticals|Integrium","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DP 01-2017-02","May 18, 2017","January 15, 2018","March 15, 2018","May 17, 2017","null","July 31, 2018","Atlanta Diabetes Association, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03156361"
124,"NCT03152383","Examination of Differential Valuation of Leisure Items and Attention as Reinforcers in Children With Autism",,"Recruiting","No Results Available","Autism","Behavioral: Training trials|Behavioral: Progressive Ratio Session|Behavioral: Re-test|Behavioral: Pairing Protocol","Breakpoint achieved for each stimulus|Change in breakpoints","Emory University|National Institute of Mental Health (NIMH)","All","2 Years to 6 Years   (Child)","Not Applicable","100","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","IRB00056563|R21MH108873","June 22, 2012","March 31, 2019","March 31, 2019","May 15, 2017","null","June 1, 2018","Marcus Autism Center, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03152383"
125,"NCT03150069","Pregnancy With Morquio Syndrome - What Are Patients' Perspectives and Has ERT Changed Them?","MorqPreg","Recruiting","No Results Available","Morquio Disease|MPS - Mucopolysaccharidosis","Other: Interview","Completion of in-depth interview","Emory University|BioMarin Pharmaceutical","Female","15 Years to 100 Years   (Child, Adult, Older Adult)","","12","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","IRB00088777","May 10, 2017","December 2018","December 2018","May 11, 2017","null","June 8, 2018","Emory University, Decatur, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03150069"
126,"NCT03146806","Intranasal (NAS) Ketamine for Cancer Pain",,"Recruiting","No Results Available","Cancer|Pain","Drug: Intranasal ketamine","Bioavailability of intranasal (NAS) ketamine|Peak concentration (Cmax) of intranasal (NAS) ketamine|Elimination of intranasal (NAS) ketamine|Time to peak concentration (Tmax) of intranasal (NAS) ketamine|Half life of intranasal (NAS) ketamine|Clearance of intranasal (NAS) ketamine|Change in Numerical Pain Rating Scale (NPRS) score|Change in fatigue assessed by Side Effect Rating Scale for Dissociative Anesthetics (SERSDA) score|Change in dizziness assessed by Side Effect Rating Scale for Dissociative Anesthetics (SERSDA) score|Change in nausea assessed by Side Effect Rating Scale for Dissociative Anesthetics (SERSDA) score|Change in headache assessed by Side Effect Rating Scale for Dissociative Anesthetics (SERSDA) score|Change in feeling of unreality assessed by Side Effect Rating Scale for Dissociative Anesthetics (SERSDA) score|Change in hearing assessed by Side Effect Rating Scale for Dissociative Anesthetics (SERSDA) score|Change in vision assessed by Side Effect Rating Scale for Dissociative Anesthetics (SERSDA) score|Change in mood assessed by Side Effect Rating Scale for Dissociative Anesthetics (SERSDA) score|Change in general discomfort assessed by Side Effect Rating Scale for Dissociative Anesthetics (SERSDA) score|Change in hallucinations assessed by Side Effect Rating Scale for Dissociative Anesthetics (SERSDA) score|Change in Montgomery Asberg Depression Rating Scale (MADRS) score|Change in Edmonton Symptom Assessment System (ESAS) score|Change in Eastern Cooperative Oncology Group (ECOG) score|Change in Patient-Reported Outcomes Measurement Information System (PROMIS) scales|Frequency of rescue medication use|Total opioid consumption","Emory University","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","25","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","IRB00086610","July 25, 2017","June 1, 2019","June 1, 2019","May 10, 2017","null","March 15, 2018","Winship Cancer Institute, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03146806"
127,"NCT03125408","Clinical Performance Evaluation of DxN HCV Assay",,"Terminated","No Results Available","Hepatitis C","Diagnostic Test: HCV Assay","Sustained Virologic Response (SVR)","Beckman Coulter, Inc.","All","18 Years and older   (Adult, Older Adult)","","210","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","HCV 2.7.3.001","May 2, 2012","August 30, 2017","August 30, 2017","April 24, 2017","null","July 12, 2018","SC Liver Research Consortium, Duluth, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03125408"
128,"NCT03107910","Stigma and Online Counseling to Increase HIV/STI Testing",,"Recruiting","No Results Available","HIV/STI Testing","Behavioral: Stigma and Structural Interventions|Behavioral: Health Information Seeking","HIV/STI testing uptake","University of Connecticut|National Institute of Mental Health (NIMH)","Male","18 Years and older   (Adult, Older Adult)","Not Applicable","500","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Screening","H16-087|R01MH109409","December 2016","December 2019","May 2021","April 11, 2017","null","May 9, 2018","SHARE Project, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03107910"
129,"NCT03090542","GPur- Luminating Oral Cholesterol Kinetics Pilot Study","GLOCK-pilot","Completed","No Results Available","Cholesterol Absorption","Dietary Supplement: clinoptilolite","Percent change in fractional cholesterol absorption in human subjects taking clinoptilolite over 6 days|Percent change from baseline by gender to determine gender difference in fractional cholesterol absorption rates|Percent change from baseline to end of treatment to evaluate for safety changes in metabolic profile measurements","Canadian Collaborative Research Network|GLOCK HEALTH, Science and Research, G.m.b.h.","All","18 Years and older   (Adult, Older Adult)","Not Applicable","22","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GLOCK-Pilot 2017","June 1, 2017","November 30, 2017","January 15, 2018","March 24, 2017","null","January 25, 2018","Atlanta Heart Specialists, Cumming, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03090542"
130,"NCT03086252","Patient-Driven Transfusion Thresholds in Hematological Disorders: A Pilot Study",,"Withdrawn","No Results Available","Anemia|Aplastic Anemia|Bone Marrow Failure|Hematopoietic and Lymphoid Cell Neoplasm|Leukemia|Myelodysplastic Syndrome","Procedure: Red Blood Cell Transfusions (RBCT)","Incidence of laboratory and clinical adverse events (AEs) assessed by the Common Terminology Criteria for Adverse Events version 4.03.|Frequency of RBC units transfused|Hemoglobin concentration at the time subject requests RBCT|Number of RBC units transfused|QoL scores from the Functional Assessment of Cancer Therapy - Anemia/Fatigue (FACT-An) questionnaire at the time hemoglobin is 8 +/- 0.5 g/dL|QoL scores from the Functional Assessment of Cancer Therapy - Anemia/Fatigue (FACT-An) questionnaire at the time subjects request RBCT","Emory University","All","19 Years and older   (Adult, Older Adult)","Not Applicable","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","IRB00090306|NCI-2016-01059|Winship3145-16","July 24, 2017","May 31, 2018","May 31, 2018","March 22, 2017","null","July 26, 2018","Emory University/Winship Cancer Institute, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03086252"
131,"NCT03082612","Overcoming Psychological Distress Through Hymns",,"Recruiting","No Results Available","Cancer","Behavioral: Overcoming Psychological Distress through Hymns Intervention|Behavioral: Usual care","Change in Hospital Anxiety and Depression Scale (HADS) score|Change in Interpersonal Processes of Care Survey (IPC-18) score|Change in Supportive Family Relationships (Mutuality) Scale score|Change in Functional Assessment of Chronic Illness Therapy - Spiritual Well-Being (FACIT-SP-12) score|Change in Short Form-12 Health Survey Questionnaire (SF-12) score","Emory University","All","50 Years to 89 Years   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","IRB00093110","June 28, 2018","May 28, 2019","May 28, 2019","March 17, 2017","null","July 19, 2018","Grady Cancer Center for Excellence, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03082612"
132,"NCT03081884","Validation of FACBC for Detection of Metastasis Among High-risk Prostate Cancer Patients With Presumed Localized Disease","EDRN-FACBC","Recruiting","No Results Available","Cancer","Drug: FACBC PET-CT Imaging","Positivity rate of FACBC PET|Correlation between FACBC PET findings and results of other tests|Correlation between FACBC uptake in the prostate with presence of FACBC-detected metastasis","Emory University|National Cancer Institute (NCI)","Male","18 Years and older   (Adult, Older Adult)","Phase 2","88","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","IRB00092595|U01CA113913-11","March 1, 2017","January 2027","January 2027","March 16, 2017","null","May 14, 2018","Emory University Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03081884"
133,"NCT03078452","Evaluating Effectiveness of Powered Drill Bone Marrow Biopsy",,"Recruiting","No Results Available","Plasma Cell Myeloma","Device: Power drill|Device: Jamshidi needle","Bone marrow core biopsy length (in mm) and artifacts assessed by the pathologist|Intensity of pain measured using visual analogue scale (VAS) pain questionnaire|Time taken by the procedure measured in seconds using a stopwatch","Emory University","All","Child, Adult, Older Adult","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","IRB00075658|NCI-2017-00308|Winship2656-14","February 14, 2017","March 31, 2019","March 31, 2020","March 13, 2017","null","April 2, 2018","Emory University/Winship Cancer Institute, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03078452"
134,"NCT03076125","Stroke COunseling for Risk REduction","SCORRE","Recruiting","No Results Available","Stroke","Behavioral: SCORRE|Behavioral: Attention-Control Activity","Accuracy of perceived stroke risk|Targeted health behaviors","Georgia State University","All","20 Years to 35 Years   (Adult)","Not Applicable","116","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","CON008407","March 1, 2017","December 20, 2017","July 31, 2018","March 10, 2017","null","March 19, 2018","Georgia State University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03076125"
135,"NCT03067116","Posturography Changes During Pregnancy",,"Completed","No Results Available","Pregnant Women","Diagnostic Test: Posturography Evaluation|Diagnostic Test: Anthropometrics|Diagnostic Test: Vitals|Other: Health and daily activity questionnaires","Stability Score|Center of Pressure (CoP) coordinates","Caps Research Network","Female","18 Years and older   (Adult, Older Adult)","","4","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CI-IRB-20160524-01","May 2016","April 2017","April 2018","March 1, 2017","null","April 25, 2018","Innova Brain Rehabilitation, Marietta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03067116"
136,"NCT03060772","A Study of Pleiotropic Pioglitazone Effects on the Alcoholic Lung (APPEAL Study)","APPEAL","Recruiting","No Results Available","Alcoholism","Drug: Pioglitazone","Change in phagocytic index|Change in nicotinamide adenine dinucleotide phosphate-oxidase (NADPH oxidase)|Change in alveolar macrophage oxidative stress|Change in redox couple glutathione/glutathione disulfide (GSH/GSSG)|Change in cysteine/cystine (Cys/CySS) redox potential|Comparison of nicotinamide adenine dinucleotide phosphate-oxidase (NADPH oxidase)|Comparison of alveolar macrophage oxidative stress|Comparison of redox couple glutathione/glutathione disulfide (GSH/GSSG)|Comparison of cysteine/cystine (Cys/CySS) redox potential","Emory University|National Institute on Alcohol Abuse and Alcoholism (NIAAA)","All","18 Years to 60 Years   (Adult)","Phase 2","36","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00071908|1R01AA025857","January 3, 2018","March 20, 2019","March 20, 2019","February 23, 2017","null","January 9, 2018","Atlanta VA Medical Center, Decatur, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03060772"
137,"NCT03055533","Headsprout Reading Program in Children With Autism Spectrum Disorder and Reading Delay",,"Suspended","No Results Available","Autism Spectrum Disorder","Behavioral: Headsprout reading program","Change in Kaufman Test of Educational Achievement score (KTEA-3)|Change in the Dynamic Indicators of Basic Early Literacy Skills (DIBELS) assessment score|Change in words read correctly while reading Headsprout Supplemental Books","Emory University","All","7 Years to 10 Years   (Child)","Not Applicable","18","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","IRB00089584","February 27, 2017","May 2018","May 2018","February 16, 2017","null","February 27, 2018","Marcus Autism Center, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03055533"
138,"NCT03051165","Effect of Upper Airway Stimulation on Vascular Function in Obstructive Sleep Apnea",,"Active, not recruiting","No Results Available","Obstructive Sleep Apnea","Device: Hypoglossal Nerve Stimulation Treatment Withdrawal","Change in peripheral arterial tonometry (PAT)|Change in flow mediated dilation|Change in peripheral arterial stiffness|Change in 24-hour ambulatory blood pressure|Change in C-reactive protein|Change in fibrin degradation products|Change in heat shock protein 70 (HSP70)|Change in high sensitivity cardiac troponin (HS-troponin)|Change in soluble urokinase-type plasminogen activator receptor (suPAR)","Emory University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00088693","November 21, 2016","October 4, 2021","October 4, 2021","February 13, 2017","null","October 9, 2017","Emory Sleep Center, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03051165"
139,"NCT03047018","Open Trial Obesity CHANGE Program ASD",,"Recruiting","No Results Available","Autism Spectrum Disorder|Obesity","Behavioral: The Changing Health in Autism through Nutrition, Getting fit and Expanding variety (CHANGE) Program","Willingness to Participate|Attendance Rate|Percent Homework Adherence|Percent Demonstration of Skills|Attrition Rate|Percent Satisfaction|Therapist Fidelity to the Treatment Manual|Difference in Body Mass Index (BMI) Percentile|Change in Food Preference Inventory (FPI) Score|Change in physical activity|Change in Parenting Stress Index- Short Form (PSI-SF) Score","Emory University","All","5 Years to 12 Years   (Child)","Not Applicable","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00090911","October 6, 2017","December 2019","December 2019","February 8, 2017","null","October 10, 2017","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03047018"
140,"NCT03042767","Anti-LPS Antibody Treatment for Pediatric NAFLD",,"Recruiting","No Results Available","Nonalcoholic Fatty Liver Disease (NAFLD)","Biological: IMM-124E|Other: Placebo","Percent Change in Alanine Aminotransferase (ALT) Level|Change in Fasting Glucose Level|Change in Fasting Insulin Level|Change in Hemoglobin A1C Level|Change in Adipose Tissue Insulin Resistance (Adipo-IR)|Change in Triglyceride/HDL (TG/HDL) Ratio|Change in Blood Glucose Level|Change in Insulin Levels|Change in Body Mass Index (BMI) Z-Score|Change in Visceral Adiposity|Change in Hepatic Fat Percent|Change in Waist Circumference|Change in PROMIS Fatigue Questionnaire Score|Change in PROMIS Depression Questionnaire Score|Change in PROMIS Anxiety Questionnaire Score|Composite Metabolic Improvement","Miriam Vos, MD|Advanced MR Analytics AB|Immuron Ltd.|Emory University","All","6 Years to 19 Years   (Child, Adult)","Phase 2","40","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","IRB00084686","February 1, 2017","May 2019","May 2019","February 3, 2017","null","September 6, 2018","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03042767"
141,"NCT03040024","Delirium Prevention With Ketamine in Ear, Nose, and Throat (ENT) Patients",,"Recruiting","No Results Available","Otolaryngeal Cancer","Drug: Ketamine|Drug: Placebo|Device: Electroencephalogram (EEG)","Change in Confusion Assessment Method fo Intensive Care Unit (CAM-ICU) Delirium Score|Richmond Agitation and Sedation (RASS) Score|Change in Behavioral Pain Scale (Non-Intubated) Score|Change in Pain Level assessed by the Visual Analog Scale (VAS) Score|Change in Mini Cog Score|Change in Mini-Mental Status Examination (MMSE) Score|Change in Cognitive Failure Questionnaire (CFQ) Score|Post Operative Narcotics Use|Average Length of Intensive Care Unit (ICU) Stay|Average Length of Hospital Stay","Emory University","All","18 Years and older   (Adult, Older Adult)","Phase 4","60","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Other","IRB00086609","March 17, 2017","August 2019","September 2019","February 1, 2017","null","August 16, 2018","Emory University Hospital Midtown, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03040024"
142,"NCT03039712","Longitudinal Coverage With Evidence Development Study on Micra Leadless Pacemakers","Micra CED","Active, not recruiting","No Results Available","Bradycardia","","Acute complication rate|The 2-year survival rate of patients implanted with a Micra leadless pacemaker|Chronic complication rate|Device-related re-intervention rates","Medtronic","All","Child, Adult, Older Adult","","37000","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","Micra CED Study","March 10, 2017","June 2021","June 2021","February 1, 2017","null","February 14, 2018","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03039712"
143,"NCT03034083","An Evaluation of Healthy Marriage and Relationship Education Program: Elevate",,"Withdrawn","No Results Available","Family Relations","Behavioral: Elevate","Elevate Pre-post program survey subscale measuring change in couple functioning and stability|Elevate Pre-post survey subscale measuring change in parenting skills","University of Georgia|Department of Health and Human Services","All","18 Years and older   (Adult, Older Adult)","","0","Other|U.S. Fed","Observational","Observational Model: Cohort|Time Perspective: Prospective","90FM0081","January 2017","December 2019","December 2020","January 27, 2017","null","June 15, 2018","University of Georgia, Athens, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03034083"
144,"NCT03033875","Testing Tele-Savvy, an On-line Psychoeducation Program for Dementia Family Caregivers",,"Recruiting","No Results Available","Alzheimer Disease|Dementia","Behavioral: Tele-Savvy|Behavioral: Healthy Living Education Program","Change in Cornell Scale for Depression in Dementia (CSDD) Score|Change in Alzheimer's Disease Related Quality of Life (ADRQL) Score|Change in Perceived Stress Scale (PSS) Score|Change in Center for Epidemiological Studies Depression Scale - Revised (CESD-R) Score|Change in State-Trait Anxiety Inventory (STAI) Score|Change in Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety - short form Score|Change in Zarit Burden Inventory (ZBI) Score|Change in Dyadic Relationship Scale Score|Change in Ways of Coping Scale Score|Change in Revised Memory and Behavior Problem Checklist (RMBPC) Score|Change in Self-Rated Health Score|Change in the Caregiver Assessment of Behavioral Skill - Self Report (CAB-SR) Measure Score|Change in the Pearlin Measure Score","Emory University|National Institute on Aging (NIA)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","75","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","IRB00092812|1R01AG054079-01","May 18, 2017","November 30, 2020","November 30, 2020","January 27, 2017","null","June 25, 2018","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03033875"
145,"NCT03033784","Autism Oxytocin Brain Project",,"Completed","No Results Available","Autism|Autism Spectrum Disorder","Drug: Oxytocin|Drug: Placebo","Difference in Resting State Functional Connectivity (rsFC)|Difference in Blood Oxygen Level Dependent (BOLD) Activity in Response to Social Cues|Difference in Blood Oxygen Level Dependent (BOLD) Activity in Response to Dynamic Social Cues|Adapted Version of the Global Clinical Interview|Eye Gaze|Social Learning Test (SLT) Score|Emotion Matching Test (EMT) Score|Toronto Alexithymia Scale (TAS) Score","Emory University|National Institute of Mental Health (NIMH)","Male","18 Years to 45 Years   (Adult)","Phase 2","54","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","IRB00093455|P50MH100023","May 10, 2017","June 10, 2018","June 10, 2018","January 27, 2017","null","October 4, 2018","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03033784"
146,"NCT03032081","High Intensity Interval Training in Heart Failure",,"Withdrawn","No Results Available","Heart Failure|Physical Activity","Other: High intensity exercise|Other: Moderate intensity exercise","Cardiac output|Ejection fraction|Pulmonary diffusing capacity|Global longitudinal strain|Heart rate variability|Number of arrhythmic events|Quality of Life","Georgia State University|Emory University","All","40 Years to 65 Years   (Adult, Older Adult)","Not Applicable","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UL1TR000454|CRN 00091835","March 2, 2017","July 1, 2018","July 1, 2018","January 26, 2017","null","August 23, 2017","Grady Memorial Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03032081"
147,"NCT03029819","iQuit Mindfully: Text Messaging for Smoking Cessation",,"Completed","No Results Available","Cigarette Smoking","Behavioral: Mindfulness-based Addiction Treatment|Behavioral: iQuit Mindfully|Behavioral: Self-Help guide|Drug: Nicotine Patch","Smoking Abstinence|Participant engagement|Participant ratings|Attrition","Georgia State University|National Center for Complementary and Integrative Health (NCCIH)|University of Utah|The Catholic University of America|George Washington University|University of Chicago","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","72","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","K23AT008442","January 18, 2017","August 10, 2017","October 3, 2017","January 24, 2017","null","October 19, 2017","Georgia State University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03029819"
148,"NCT03027115","Hernia Surgery Urinary Retention",,"Recruiting","No Results Available","Hernia|Urinary Retention","Drug: Tamsulosin","Post-operative urinary retention|Effect of IPSS","Memorial Health University Medical Center","Male","18 Years and older   (Adult, Older Adult)","Phase 4","140","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","MHUMC 2016.10.05","January 13, 2017","January 13, 2020","January 27, 2020","January 20, 2017","null","March 23, 2018","Memorial Health University Medical Center, Savannah, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03027115"
149,"NCT03014362","TMS for Suicidal Crisis in Active Duty SMs","TMS4SI","Recruiting","No Results Available","Suicide|Suicidal Ideation|Suicidal Impulses|Suicidal Intention|Suicidal and Self-Injurious Behavior|Suicidal Depression","Device: Neuronetics NeuroStar XPLOR magnetic stimulator - Active|Device: Neuronetics NeuroStar XPLOR magnetic stimulator - Sham","Change in Suicidal Ideation|Impact on Depressive symptoms|Impact on post-traumatic anxiety|Impact on Quality of Life measures","Eisenhower Army Medical Center|Congressionally Directed Medical Research Programs|Augusta University|The Geneva Foundation","All","18 Years to 60 Years   (Adult)","Not Applicable","110","U.S. Fed|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","1604023","June 12, 2017","June 2019","December 2019","January 9, 2017","null","February 21, 2018","Eisenhower Army Medical Center, Augusta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03014362"
150,"NCT03014037","Comparing Mesenchymal Stem Cell Counts in Unilateral vs. Bilateral Posterior Superior Iliac Spine Bone Marrow Aspiration",,"Recruiting","No Results Available","Osteoarthritis","Procedure: Unilateral Bone Marrow Procurement|Procedure: Bilateral Bone Marrow Procurement","Change Quality of Life assessed by the Emory Quality of Life (EQOL) Survey Score|Change in the Knee Injury and Osteoarthritis Outcome Score (KOOS)|Capacity of Isolated Cells to Differentiate Down Cell Lineages","Emory University","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","IRB00093044","September 7, 2017","December 2018","December 2018","January 9, 2017","null","January 4, 2018","The Emory Clinic, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03014037"
151,"NCT03008889","A Feasibility Study of N-acetylcysteine for Self-injurious Behavior in Children With Autism Spectrum Disorder","NAC","Recruiting","No Results Available","Autism Spectrum Disorder","Drug: N-acetylcysteine|Drug: Placebo","Randomization rate|Attrition rate|Study medication compliance|Successful collection of outcome measures|Parent satisfaction rating|Positive Predictive Value of screening method of classifying self-injurious behavior (SIB) by type.|Change in Aberrant Behavior Checklist Irritability Subscale score|Number of Self-Injurious Behavior Events|Change in the Improvement item of the Clinical Global Impression (CGI-I) scale|To evaluate biomarkers and possible mechanisms of action of NAC in children with ASD.","Emory University","All","5 Years to 12 Years   (Child)","Phase 2","14","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRB00088115","July 5, 2018","May 31, 2019","December 31, 2019","January 4, 2017","null","July 9, 2018","Marcus Autism Center, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03008889"
152,"NCT03008837","Feasibility Study: fMRI Evaluation of Auricular PENFS for Fibromyalgia","fMRI","Recruiting","No Results Available","Fibromyalgia","Device: Military Field Stimulator|Other: Standard Therapy","fcMRI as a biomarker to investigate functionally correlated neural substrates of pain in patients undergoing PENFS|Defense Veterans Pain Rating Scale (DVPRS)|PROMIS measures|Analgesic Consumption|International Classification of Functioning, Disability, and Health|Functional Tests","VA Office of Research and Development","All","20 Years to 60 Years   (Adult)","Not Applicable","20","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","F2113-M|1IK1RX002113-01A2","June 1, 2017","December 7, 2018","May 31, 2019","January 4, 2017","null","April 12, 2018","Atlanta VA Medical and Rehab Center, Decatur, GA, Decatur, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03008837"
153,"NCT03006393","Dynamics of Inflammation and Its Blockade on Motivational Circuitry in Depression",,"Recruiting","No Results Available","Depression","Drug: Infliximab|Other: Placebo","Change in Reward Motivation assessed by the Behavioral Effort-Expenditure for Rewards Task (behEEfRT) Score|Change in the Columbia Suicide Severity Rating Scale (C-SSR) Score|Change in the Multidimensional Fatigue Inventory (MFI) Score|Change in Inventory of Depressive Symptoms Self-Report (IDS-SR) Score|Change in the Positive Affect/Negative Affect Scale - Now (PANAS-X) Score|Change in the Snaith-Hamilton Pleasure Scale (SHAPS) Score|Change in the Fatigue Severity Scale (FSS) Score|Change in the Mood and Pleasure Scale (MAP-SR) Score|Change in the Go No-Go Variant Task Score|Change in Finger Tapping Task (FTT) Score|Change in Reaction Time Task (RTT) Score|Change in Digit Symbol Task (DST) Score.|Change in Plasma C-reactive Protein (CRP) Level|Change in Plasma Tumor Necrosis Factor (TNF) Alpha Level|Change in Plasma Soluble Tumor Necrosis Factor (TNF) Receptor 1 Level|Change in Plasma Soluble Tumor Necrosis Factor (TNF) Receptor 2 Level|Change in Plasma Interleukin-1 (IL-1) Level|Change in Plasma Interleukin-1 (IL-1) Receptor Agonist Level|Change in Plasma Interleukin-6 (IL-6) Level|Change in Plasma Soluble Interleukin-6 Receptor (sIL-6R) Level","Emory University","All","21 Years to 65 Years   (Adult, Older Adult)","Phase 1","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","IRB00087941","August 2016","March 2021","March 2021","December 30, 2016","null","September 25, 2017","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03006393"
154,"NCT03004443","Inflammation-Induced CNS Glutamate Changes in Depression",,"Recruiting","No Results Available","Depression","Drug: Infliximab|Drug: Placebo","Change in CNS glutamate|Change in Effort-Expenditure for Rewards Task (EEfRT) Score|Change in Snaith-Hamilton Pleasure Scale (SHAPS-C) Score|Change in Mood and Pleasure Scale (MAP) Score|Change in Finger Tapping Task (FTT) Score|Change in Reaction Time Task (RTT) Score|Change in Digit Symbol Substitution Task (DSST) Score|Change in Trails Making Test A (TMT-A) Score|Change in Retardation Rating Scale a (RRS) Score|Change in Multidimensional Fatigue Inventory (MFI) Score|Change in Inventory of Depressive Symptoms-Clinician Rating (IDS-SR) Item 20 Score|Change in plasma inflammatory markers|Correlation between basal ganglia glutamate and anhedonia and psychomotor speed|Correlation between basal ganglia glutamate and plasma inflammatory markers|Cerebrospinal fluid (CSF) inflammatory markers|Correlation between basal ganglia glutamate and CSF inflammatory markers","Emory University","All","25 Years to 60 Years   (Adult)","Phase 4","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRB00090667","May 15, 2017","November 2021","November 2021","December 28, 2016","null","August 23, 2018","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03004443"
155,"NCT03002324","Tailoring of Vaccine-Focused Messages: Disease Salience",,"Completed","No Results Available","Human Papillomavirus","Behavioral: Baseline Survey|Behavioral: Current CDC Message|Behavioral: Cervical Cancer Message|Behavioral: Control Message|Behavioral: Post-Intervention Survey","Overall change in attitude towards the human papilloma virus (HPV) vaccine|Intent to have their child vaccinated against HPV","Emory University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","1320","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","IRB00087211a","January 2017","May 1, 2017","May 1, 2017","December 23, 2016","null","May 10, 2017","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03002324"
156,"NCT02999529","Health Literacy Multi-media Study",,"Completed","No Results Available","Cancer","Other: Educational Video","Number of Correct Responses|Number of Incorrect Responses","Emory University","All","Child, Adult, Older Adult","Not Applicable","100","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","IRB00085515","December 2016","April 2017","April 2017","December 21, 2016","null","May 17, 2017","Grady Health System, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02999529"
157,"NCT02992899","Closed Loop Vagal Nerve Stimulation for Patients With Posttraumatic Stress Disorder",,"Recruiting","No Results Available","PostTraumatic Stress Disorder","Other: gammaCore/electroCore|Other: Sham gammaCore/electroCore","Change in Interleukin-6 (IL6) Level|Change in Tryptophan Level|Change in Kynurenine Level|Change in Kynurenic Acid Level|Change in 3-3 Hydroxykynurenine Level|Change in Anthranilic Acid Level|Change in Tumor Necrosis Factor (TNF)-alpha Level|Change in Interferon-Gamma Level|Change in Interleukin-1 Beta Level|Change in Interleukin-2 (IL2) Level|Change in Interleukin-4 (IL4) Level|Change in Interleukin-8 (IL8) Level|Change in Interleukin-10 (IL10) Level|Change in Interleukin-12p70 (IL12p70) Level|Change in Interleukin-12p (IL12p) Level|Change in Interleukin-13 (IL13) Level|Change in Macrophage Migration Inhibitory Factor|Change in High-Mobility Group Protein B1 Level|Change in Adrenocortitropic Hormone Level|Change in Cortisol Level|Change in Epinephrine Level|Change in Dopamine Level|Change in Norepinephrine Level","Emory University|Georgia Institute of Technology","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","75","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Other","IRB00091171","April 19, 2017","July 2019","July 2019","December 14, 2016","null","May 16, 2018","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02992899"
158,"NCT02988661","Women Empowered to Live With Lupus Study","WELL","Recruiting","No Results Available","Lupus Erythematosus, Systemic","Behavioral: Chronic Disease Self-Management Program (CDSMP)","Change in Communication with Physicians assessed by the Stanford 3Q Scale|Change in Self-efficacy for Managing Medications assessed by the PROMIS SF8a score|Change in Global Health assessed by the PROMIS Global Health score|Change in Physical Function assessed by the PROMIS SF10b score|Change in Pain Interference assessed by the PROMIS SF8a score|Change in Fatigue assessed by the PROMIS SF8a score|Change in Sleep Disturbance assessed by the PROMIS SF8a score|Change in Anxiety Level assessed by the PROMIS SF8a score|Change in Ability to Participate in Social Roles and Activities assessed by the PROMIS SF8a score|Change in the Patient Activation Measure (PAM SF 10) score|Change in Self-Efficacy assessed by the PROMIS SF4a score|Change in Angry Mood assessed by the PROMIS SF5 score|Change in Perceived Stress Scale (PSS) Score|Hospitalization Rate|Emergency Department Visit Rate","Emory University","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","400","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00003656","January 19, 2017","August 2021","August 2021","December 9, 2016","null","March 1, 2018","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02988661"
159,"NCT02985996","Body Compartment PK for New HIV Pre-exposure Prophylaxis Modalities",,"Recruiting","No Results Available","HIV Infections","Drug: Truvada|Drug: Genvoya","Changes in Intracellular emtricitabine triphosphate (FTC-TP) for Persons on Genvoya Compared to Truvada|Changes in Intracellular tenofovir diphosphate (TFV-DP) for Persons on Genvoya Compared to Truvada|Change in plasma emtricitabine (FTC) Concentration|Change in plasma tenofovir disoproxil fumarate (TDF) Concentration|Change in plasma tenofovir alafenamide (TAF) Concentration|Change in plasma elvitegravir (EVG) Concentration|Change in Rectal emtricitabine (FTC) Concentration|Change in Rectal tenofovir disoproxil fumarate (TDF) Concentration|Change in Rectal tenofovir alafenamide (TAF) Concentration|Change in Rectal elvitegravir (EVG) Concentration|Change in Intracellular emtricitabine (FTC) Concentration in peripheral blood mononuclear cells (PBMCs)|Change in Intracellular tenofovir disoproxil fumarate (TDF) Concentration in peripheral blood mononuclear cells (PBMCs)|Change in Intracellular tenofovir alafenamide (TAF) Concentration in peripheral blood mononuclear cells (PBMCs)|Change in Intracellular elvitegravir (EVG) Concentration in peripheral blood mononuclear cells (PBMCs)|Change in Intracellular emtricitabine (FTC) Concentration in Rectal Tissue|Change in Intracellular tenofovir disoproxil fumarate (TDF) Concentration in Rectal Tissue|Change in tenofovir alafenamide (TAF) Concentration in Rectal Tissue|Change in elvitegravir (EVG) Concentration in Rectal Tissue|Change in emtricitabine (FTC) Concentration in Penile Secretions|Change in tenofovir disoproxil fumarate (TDF) Concentration in Penile Secretions|Change in tenofovir alafenamide (TAF) Concentration in Penile Secretions|Change in elvitegravir (EVG) Concentration in Penile Secretions|PrEP Efficacy as measured by Inhibition of in vitro infection of rectal biopsies to HIV","Emory University|Centers for Disease Control and Prevention","Male","18 Years to 49 Years   (Adult)","Phase 1","90","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","IRB00092488","February 6, 2017","September 2018","September 2018","December 7, 2016","null","April 10, 2018","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02985996"
160,"NCT02976012","Endolaserless Vitrectomy With Intravitreal IAI for PDR-Related VH","LASERLESS","Recruiting","No Results Available","Proliferative Diabetic Retinopathy","Drug: Aflibercept|Procedure: Endolaserless Vitrectomy","• Ocular and systemic safety evaluation for adverse events at any time point through 52 weeks:|Mean change in BCVA letter score|Mean BCVA letter score|Proportion of eyes with progression of PDR|Mean OCT CSF thickness|Proportion of eyes with OCT CSF thickness <300um|Proportion of eyes with absence of Optos widefield fluorescein angiographic macular leakage|Proportion of eyes with absence of active neovascularization|Proportion of eyes with unchanged, worsened, or improved fluorescein angiographic macular leakage|Proportion of eyes with unchanged, worsened, or improved fluorescein angiographic neovascularization|Proportion of eyes with unchanged, worsened, or improved fundus photographic DME appearance|Mean cumulative score and change for the combined 30-2 and 60-4 HVF test|Proportion of eyes requiring additional IAI other than mandatory injections|Proportion of eye with progression of PDR requiring rescue PRP standard of care|Proportion of eyes requiring PRP or retinopexy|Proportion of eyes requiring additional vitrectomy|Proportion of enrolled eyes requiring intraoperative endolaser in a PRP pattern at the time of initial vitrectomy","Southeast Retina Center, Georgia","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VGFTe-DR-1548","June 2016","June 2018","June 2018","November 29, 2016","null","November 29, 2016","Southeast Retina Center, PC, Augusta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02976012"
161,"NCT02964559","Pembrolizumab in Patients With Locally Advanced or Metastatic Skin Cancer",,"Recruiting","No Results Available","Recurrent Skin Carcinoma|Skin Squamous Cell Carcinoma","Biological: Pembrolizumab","Response rate of pembrolizumab|Overall survival|Progression-free survival","Emory University|Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Older Adult)","Phase 2","29","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00087412|NCI-2016-00831|Winship3185-16","January 27, 2017","February 2020","February 2020","November 16, 2016","null","February 2, 2018","Emory University/Winship Cancer Institute, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02964559"
162,"NCT02959762","Vitamin K to Slow Progression of Dyslipidemia and Diabetes Risk (Vita-K 'n' Kids Study II)",,"Recruiting","No Results Available","Obesity|Insulin Resistance|Obesity in Diabetes|Nutritional and Metabolic Diseases|Hyperlipidemia|Hyperglycemia|Cardiovascular Diseases","Dietary Supplement: Placebo-Control|Dietary Supplement: Low-Dose Vitamin K2 (menaquinone-7; 45-mcg/d)|Dietary Supplement: High-Dose Vitamin K2 (menaquinone-7; 90 mcg/d)","Change in serum lipid concentrations|Change in insulin sensitivity|Change in beta-cell function|Change in coagulation|Change in arterial stiffness (pulse wave velocity)|Change in endothelial function (flow-mediated dilation)","Augusta University","All","8 Years to 17 Years   (Child)","Phase 1|Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","931430|16GRNT31090037","October 2016","December 1, 2018","December 30, 2018","November 9, 2016","null","July 12, 2018","Medical College of Georgia; Augusta University, Augusta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02959762"
163,"NCT02956122","A Phase 2/3 Study of GLASSIA for the Treatment of Acute GvHD",,"Terminated","No Results Available","Graft Versus Host Disease","Biological: GLASSIA|Drug: methylprednisolone or equivalent steroid|Biological: Albumin","Proportion of participants achieving overall response at Day 28|Proportion of participants achieving gastrointestinal (GI) response at Day 28|Proportion of participants achieving overall response at Day 56|Acute graft-versus-host disease (GvHD) grading at Days 28, 56 and 180|Chronic graft-versus-host disease (GvHD) at Days 100, 180 and 365|Duration of any overall response|Duration of any Gastrointestinal (GI) response|Survival through Days 100, 180 and 365|Transplant-related mortality|Survival at Days 100 and 180|Graft-versus-host disease (GvHD)-free survival|Infection-related mortality|Graft-versus-host disease (GvHD)-related mortality|All-cause mortality|All AEs, related AEs, all SAEs, related SAEs and temporally-associated AEs|Clinically significant changes in clinical laboratory assessments|Changes from baseline in vital signs|Recurrence of primary malignancies through Days 180 and 365|Infections (eg, bacterial, fungal, viral, etc) at Days 28, 56, 180 and 365|Pharmacokinetics: Area under the plasma concentration curve (AUC) from time zero to the last quantifiable activity|Pharmacokinetics: Area under the plasma concentration curve (AUC) from time zero to time ""t""|Pharmacokinetics: Systemic clearance|Pharmacokinetics (PK): Maximum plasma concentration|Pharmacokinetics (PK): Area under the plasma concentration curve (AUC) from time zero to infinity|Pharmacokinetics: Apparent volume of distribution|Pharmacokinetics: The terminal half-life|Pharmacokinetics: Mean residence time|Pharmacokinetics: Trough plasma A1PI levels","Baxalta now part of Shire|Kamada, Ltd.|Shire","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","1","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","471501","April 26, 2017","May 3, 2018","May 3, 2018","November 7, 2016","null","June 1, 2018","Georgia Cancer Center, Augusta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02956122"
164,"NCT02947737","Amniotic Membrane for Donor Site Healing",,"Completed","No Results Available","Burns","Other: Amniotic membrane dressing|Other: Gentamicin and xeroform dressing","Change in postoperative pain|Change in re-epithelialization|Comparison of scarring between donor sites|Comparison of hypopigmentation between donor sites","Emory University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","4","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","IRB00088758","February 1, 2017","August 31, 2017","August 31, 2017","October 28, 2016","null","May 21, 2018","Grady Health System, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02947737"
165,"NCT02944656","Gabapentin as an Adjunct to Paracervical Block for Perioperative Pain Management","Gaba","Completed","No Results Available","Pain","Drug: Gabapentin|Drug: Placebo","Pain at time of uterine evacuation|Change in perioperative pain level|Change in perioperative nausea|Change in perioperative vomiting|Change in anxiety levels|Anxiety level|General satisfaction with the procedure","Emory University|Society of Family Planning","Female","18 Years and older   (Adult, Older Adult)","Phase 4","116","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","IRB00084198","December 8, 2016","June 26, 2018","June 26, 2018","October 26, 2016","null","September 12, 2018","Atlanta Women's Center, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02944656"
166,"NCT02940288","Acupuncture for Postoperative Analgesia in Laparoscopic Surgery","Acu-Pilot","Recruiting","No Results Available","Surgery","Other: Auricular Acupuncture|Other: Sham Acupuncture","Time to First Analgesic Request|Total Amount of Postoperative Pain Medication|Pain Intensity assessed by the Visual Analog Scale (VIS)|Time to Discharge","Emory University","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Supportive Care","IRB00086184","September 2016","February 2019","February 2020","October 20, 2016","null","April 18, 2018","Atlanta Veterans Affairs (VA) Medical Center, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02940288"
167,"NCT02933684","D-Cycloserine and Virtual Reality Exposure Therapy",,"Withdrawn","No Results Available","Social Anxiety Disorder","Drug: Seromycin|Behavioral: Virtual Reality Exposure Therapy|Drug: Placebo","Change in scores on the Liebowitz Social Anxiety Scale-self report version (LSAS-SR)|Change in behavioral avoidance|Change in scores on the Clinical Global Improvement Scale, Patient Report|Change in scores on the Social Phobia Scale|Change in scores on the Social Interaction Anxiety Scale|Change in scores on the Patient Health Questionnaire|Change in scores on the Sheehan Disability Scale|Change in scores on the Quality of Life Inventory","Georgia State University|Emory University","All","18 Years and older   (Adult, Older Adult)","Phase 2","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","ULTR000454","January 1, 2015","December 31, 2016","December 31, 2016","October 14, 2016","null","April 13, 2018","Georgia State University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02933684"
168,"NCT02922816","FMT for MDRO Colonization After Infection in Renal Transplant Recipients","PREMIX","Recruiting","No Results Available","Infection Due to Resistant Organism","Biological: Fecal Microbiota Transplant (FMT)|Procedure: Bowel preparation|Procedure: Stool or perirectal swab sampling|Other: Fasting","The safety and feasibility of using FMT in adult participants with Target MDRO colonization after infection will be measured by comparing the number of adverse events (assessed by CTCAE v4.0) after Day 1 of each cycle as compared to baseline.|Determine the rate of Target MDRO colonization between the control and experimental arms at screening and on Day 36 of each cycle.","Emory University|Cepheid","All","18 Years and older   (Adult, Older Adult)","Phase 1","20","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00090101","December 1, 2016","June 2019","December 2019","October 4, 2016","null","September 24, 2018","Emory University Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02922816"
169,"NCT02915692","Study to Compare CAUTI Rates Following ERASE CAUTI Tray Silver vs Silver Coated Foley Catheters",,"Terminated","No Results Available","Surgery","Device: ERASE Silver Coated Foley Catheter|Device: Comparator Silver Coated Catheter","Urinary tract infection rates|Catheter use|Catheter Associated Urinary Track Infection Costs","Medline Industries","All","18 Years and older   (Adult, Older Adult)","","753","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","MII-002","October 2012","September 2016","September 2016","September 27, 2016","null","September 27, 2016","Oconnee Regional Medical Center, Milledgenville, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02915692"
170,"NCT02911805","Bridging Animal and Human Models of Exercise-induced Visual Rehabilitation",,"Active, not recruiting","No Results Available","Vision Disorders","Behavioral: Aerobic exercise|Behavioral: Balance exercise","Visual acuity|serum BDNF|Retinal morphology|Contrast sensitivity","VA Office of Research and Development","All","18 Years to 89 Years   (Adult, Older Adult)","Not Applicable","20","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Basic Science","C1924-P","June 10, 2015","March 29, 2019","March 29, 2019","September 22, 2016","null","October 1, 2018","Atlanta VA Medical and Rehab Center, Decatur, GA, Decatur, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02911805"
171,"NCT02909387","Adapting Project UPLIFT for Blacks in Georgia",,"Recruiting","No Results Available","Depressive Symptoms","Behavioral: Project UPLIFT","Change in Depressive Symptoms","Morehouse School of Medicine|Emory University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","GRANT11643642","August 2016","August 2019","September 2019","September 21, 2016","null","September 12, 2017","Demetrius Geiger, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02909387"
172,"NCT02897375","Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors",,"Recruiting","No Results Available","Solid Neoplasm|Stage III Pancreatic Cancer|Stage IIIA Breast Cancer|Stage IIIA Non-Small Cell Lung Cancer|Stage IIIB Breast Cancer|Stage IIIB Non-Small Cell Lung Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer|Stage IV Non-Small Cell Lung Cancer|Stage IVA Pancreatic Cancer|Stage IVB Pancreatic Cancer|Sarcoma|Colorectal Cancer|Head and Neck Cancer|Cancer of Unknown Primary|Bladder Cancer|Ovarian Cancer","Drug: Carboplatin|Drug: Cisplatin|Drug: Palbociclib","Incidence of adverse events according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0|Incidence of dose limiting toxicities defined as grade 3 or higher toxicity|Recommended phase 2 dose (RP2D) as the highest doses of palbociclib and cisplatin or palbociclib and carboplatin|Overall response rate (complete response + partial response) assessed by Response Evaluation Criteria in Solid Tumors 1.1 criteria|Pharmacokinetic (PK) characteristics of carboplatin including maximum concentration (Cmax)|Pharmacokinetic (PK) characteristics of cisplatin including maximum concentration (Cmax)","Emory University|Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 1","90","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00089583|NCI-2016-01037|Winship3263-16","October 2016","February 2019","February 2021","September 13, 2016","null","November 27, 2017","Emory University/Winship Cancer Institute, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02897375"
173,"NCT02895997","Turning Night Into Day: Transcontinental Provision of Telehealth By and For the Emory Community",,"Active, not recruiting","No Results Available","Mental Fatigue","Other: Travel Telehealth Delivery","Change in Salivary Cortisol Levels|Change in Stanford Sleepiness Scale Score|Change in the Trail Making Test A Score|Change in the Trail Making Test B Score|Change in Physical Activity assessed by Multi-Scale Entropy|Change in Physical Activity assessed by Multi-Scale Complexity|Change in Heart Rate Variability assessed by Deceleration Capacity|Change in Heart Rate Variability assessed by Acceleration Capacity|Frequency of Arrhythmias|Change in Sleep Latency|Number of Awakenings per Hour|Change in Percent of Non Rapid Eye Movement (REM) Sleep|Change in Mood Symptom Questionnaire Score|Change in Patient Health Questionnaire-9 (PHQ-9) Score|Change in Number of Camera Sessions|Change in Duration of Camera Sessions|Change in Urgency of Clinical Contacts|Change in Number if Clinical Record Entries|Change in Duration of Service","Emory University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","7","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","IRB00088367","July 2016","December 2018","December 2018","September 12, 2016","null","October 17, 2017","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02895997"
174,"NCT02895334","MyHeartBaby: An Initial Evaluation of the MyHeartBaby Psychosocial Telemedicine Program",,"Completed","No Results Available","Congenital Heart Disease","Behavioral: MyHeartBaby Program","Change in Levels Stress for Caregivers of 1-Ventricle Cardiac Defect Infants|Change in Levels Stress for Caregivers of 2-Ventricle Cardiac Defect Infants|Change in Levels of Caregiver Confidence in Feeding Management for 1-Ventricle Cardiac Defect Infants|Change in Levels of Caregiver Confidence in Feeding Management for 2-Ventricle Cardiac Defect Infants|Change in Infant Weight for 1-Ventricle Cardiac Defect Infants|Change in Infant Weight for 2-Ventricle Cardiac Defect Infants|Number of Unplanned Hospital Admissions","Emory University|Pediatric Heart Network|National Heart, Lung, and Blood Institute (NHLBI)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","25","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","IRB00082281","July 2015","April 7, 2017","April 7, 2017","September 9, 2016","null","July 12, 2017","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02895334"
175,"NCT02893345","Safe@Home: A Self-Management Program for Individuals With TBI and Their Families",,"Active, not recruiting","No Results Available","Brain Injuries, Traumatic","Behavioral: Safe@Home Intervention Group|Other: Usual Care Group","Number of Unsafe Events for Each Participant|Change in Mayo-Portland Participation Scale Score|Change in Supervision Rating Scale Score|Change in Carrying Out Activities Scale Score","Shepherd Center, Atlanta GA","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","627-605210-2","August 8, 2015","August 15, 2017","November 15, 2017","September 8, 2016","null","October 6, 2017","Shepherd Center, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02893345"
176,"NCT02892474","HCR vs. CABG Study",,"Active, not recruiting","No Results Available","Coronary Artery Disease","Procedure: Hybrid Coronary Revascularization (HCR)|Procedure: Coronary Artery Bypass Grafting (CABG)","Comparison of major adverse cardiac and cerebrovascular events (MACCE) between groups|Comparison of all-cause mortality between groups|Comparison of repeat revascularization between groups|Comparison of stroke between groups|Comparison of ischemia-driven repeat revascularization between groups|Comparison of ventilator time between groups|Comparison of surgical re-exploration between groups|Comparison of chest tube drainage complications between groups|Comparison of hospital length of stay between groups|Comparison of wound infection between groups|Comparison of atrial fibrillation between groups|Comparison of blood transfusion between groups|Comparison of hospital readmission between groups|Comparison of Angina Score between groups|Comparison of Duke Activity Scale Index (DASI) scores between groups|Comparison of EuroQol EQ-5D scores between groups","Emory University","All","Child, Adult, Older Adult","","75","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","IRB00089868","August 2016","July 27, 2018","December 2019","September 8, 2016","null","September 26, 2018","Emory University Hospital Midtown, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02892474"
177,"NCT02891980","MVA-BN®-Filo and Ad26.ZEBOV Vaccines in Healthy Volunteers",,"Active, not recruiting","No Results Available","Ebola Disease|Marburg Disease","Biological: Ad26 Zaire Ebola Vaccine|Biological: MVA Multi-Filo Ebola Vaccine","Determine the differential expression from baseline in mRNA after each study vaccination by study group|Determine the number of subjects with a vaccine-related serious adverse event (SAE) from the time of first study vaccination by study group through the duration of the study|Determine the number of subjects with a vaccine-related unsolicited adverse event (AE) from the time of each study vaccination by study group|Determine the number of subjects with solicited local and systemic reactogenicity events from the time of study vaccination by study group.|Determine the peak antibody response against filovirus glycoproteins (GPs) for each study group|Determine the change in CMI response from baseline against filovirus antigen using peptide pools and measurement by intracellular cytokine staining (ICS) in each of the study groups|Determine the change in the ADCC from baseline in each of the study groups","National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years to 45 Years   (Adult)","Phase 1","65","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","14-0094|HHSN272201300018I","March 24, 2017","March 15, 2019","March 15, 2019","September 8, 2016","null","September 7, 2018","Emory Children's Center - Pediatric Infectious Diseases, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02891980"
178,"NCT02877082","Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients",,"Terminated","Has Results","Acute Leukemia|Chronic Lymphocytic Leukemia|Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Diffuse Large B-Cell Lymphoma|Follicular Lymphoma|Graft Versus Host Disease|Mantle Cell Lymphoma|Marginal Zone Lymphoma|Myelodysplastic Syndrome|Myelofibrosis|Myeloproliferative Neoplasm|Small Lymphocytic Lymphoma","Biological: Thymoglobulin|Drug: Bortezomib|Drug: Tacrolimus","Total Number of Serious Adverse Events and Adverse Events Related to This Immunosuppressive Regimen|Number of Patients Alive and Free of Severe Acute GVHD Following HLA Matched Related or Unrelated Donor Hematopoietic Peripheral Blood Transplant|Cumulative Incidence of Grade III-IV aGVHD|Incidence of Chronic GVHD|Overall Survival","Emory University","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","5","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","IRB00082499|NCI-2016-01035|Winship3258-16","September 2016","July 2017","July 2017","August 24, 2016","April 30, 2018","April 30, 2018","Emory University/Winship Cancer Institute, Atlanta, Georgia, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/82/NCT02877082/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02877082"
179,"NCT02876159","The Immunologic Basis for an Attenuated Immune Response to the Influenza Vaccine After Repeated Annual Vaccination","FLU1","Active, not recruiting","No Results Available","Influenza","Biological: 2016-2017 Influenza Vaccine","Change in Serum Hemagglutination Inhibition (HAI) Titer|Change in Mean Level of Circulating Follicular Helper T (TFH) Cells|Change in Mean Levels of Plasmablasts|Change in Mean Levels of Memory B Cells|Change in Mean Levels of antigen-specific CD4 T Cells|Change in Mean Levels of antigen-specific CD8 T Cells","Emory University","All","20 Years to 30 Years   (Adult)","Phase 4","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","IRB00090196","July 2016","June 28, 2018","December 2018","August 23, 2016","null","August 24, 2017","The Hope Clinic of the Emory Vaccine Center, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02876159"
180,"NCT02874573","Tocilizumab in Schizophrenia",,"Recruiting","No Results Available","Schizophrenia|Psychotic Disorders","Drug: Tocilizumab|Drug: Normal saline","Change in Cognition|Change in Total Psychotic Symptoms","Brian Miller|Brain & Behavior Research Foundation|Augusta University","All","18 Years to 55 Years   (Adult)","Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","944642","September 2016","June 2019","September 2019","August 22, 2016","null","July 9, 2018","Augusta University, Augusta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02874573"
181,"NCT02873741","New Strategies to Assess Anal Cancer Risk In Women","ANCAR-WIHS","Active, not recruiting","No Results Available","Human Immunodeficiency Virus (HIV)|Human Papillomavirus (HPV)","Procedure: Perianal and Digital Anorectal Exam|Procedure: Cervical Swabs|Procedure: Anal Swabs|Procedure: High Resolution Anoscopy (HRA)","Anal Cancer Risk Index Score|Presence of Anal hr-HPV","Emory University","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","143","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","IRB00083800","July 2016","December 31, 2019","December 31, 2019","August 19, 2016","null","October 5, 2018","The Ponce Center, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02873741"
182,"NCT02861560","Case Series of Weekly Applications of dHACM in Treatment of Pressure Ulcers",,"Completed","No Results Available","Pressure Ulcer","Other: dHACM","Healing Rate|Adverse Events|Quality of Life","MiMedx Group, Inc.","All","16 Years and older   (Child, Adult, Older Adult)","Not Applicable","10","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EFPU001","May 2016","May 2018","May 2018","August 10, 2016","null","August 24, 2018","Shepherd Spine Center, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02861560"
183,"NCT02851459","Tailoring of Vaccine-Focused Messages: Moral Foundations",,"Completed","No Results Available","Childhood Vaccinations","Behavioral: Baseline Survey|Behavioral: Pre-intervention Survey|Behavioral: Morally Congruent Message|Behavioral: Morally Non-Congruent Message|Behavioral: Control Message|Behavioral: Post-Intervention Survey","Overall change in attitude towards vaccines|Intent to have their children vaccinated","Emory University","All","18 Years to 50 Years   (Adult)","Not Applicable","850","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","IRB00087211","August 2016","October 2016","October 2016","August 1, 2016","null","March 10, 2017","Emory University School Of Public Health - Only Online Recruitment, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02851459"
184,"NCT02838355","Employing End Tidal Capnography in Continuous Flow Ventricular Assist Device Patients",,"Withdrawn","No Results Available","Cardiomyopathy|Cardiovascular Disease|Heart Disease","Device: Respiratory Depression Monitoring with End Tidal Carbon Dioxide Nasal Cannula (ETCO2- NC)|Other: Standard Non-invasive Respiratory Depression Monitoring","Respiratory Distressed assessed by Respiratory Distress Observation Scale (RDOS)|Dyspnea Rate assessed by the Dyspnea Visual Analogue Scale (DVAS)|Incidence of Respiratory Depression|Severity of Respiratory Depression","Emory University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","IRB00082202","October 2016","February 2018","February 2018","July 20, 2016","null","March 20, 2018","Emory University Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02838355"
185,"NCT02834052","Pembrolizumab + Poly-ICLC in MRP Colon Cancer",,"Recruiting","No Results Available","Metastatic Colon Cancer|Solid Tumor","Drug: pembrolizumab|Drug: Poly-ICLC","Phase 1: Determine the maximum tolerated dose of poly-ICLC that can be combined with pembrolizumab|Phase 1 and 2: Determine the response rate of metastatic MRP colon cancer (that has progressed following two lines of therapy in the metastatic setting) to the combination of pembrolizumab and poly-ICLC|Determine the adverse event profile and dose limiting toxicities of the combination of pembrolizumab and poly-ICLC|Determine the progression free survival rate of recurrent metastatic MRP colon cancer to the combination of pembrolizumab and poly-ICLC|Determine the 20-week progression free survival rate of recurrent metastatic MRP colon cancer to the combination of pembrolizumab and poly-ICLC|Determine the overall survival rate for recurrent metastatic MRP colon cancer response to the combination of pembrolizumab and poly-ICLC|Determine the duration of response of recurrent metastatic MRP colon cancer to the combination of pembrolizumab and poly-ICLC","Asha Nayak|Oncovir, Inc.|Merck Sharp & Dohme Corp.|Augusta University","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","42","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GCC-16047","January 10, 2018","January 2020","January 2021","July 15, 2016","null","March 22, 2018","Georgia Cancer Center at Augusta University, Augusta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02834052"
186,"NCT02833324","Fitbit for Postoperative Ambulation",,"Completed","No Results Available","Postoperative Care","Behavioral: Education regarding ambulation|Behavioral: Ambulation reminder alarms|Other: Fitbit","Comparison of number of steps taken between study arms|Comparison of time to first ambulation between study arms|Comparison of incidence of prolonged postoperative ileus between study arms|Comparison of incidence of pulmonary complications between study arms|Comparison of incidence of venous thromboembolism between study arms|Comparison of length of postoperative hospital stay between study arms","Emory University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","48","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","IRB00088864","July 2016","December 2016","December 2016","July 14, 2016","null","October 17, 2017","Emory University Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02833324"
187,"NCT02832856","Testing the Effectiveness of the Full and Abridged Relationship Smarts Curriculum for 9th Grade Students",,"Enrolling by invitation","No Results Available","Attitudes|Knowledge","Behavioral: Healthy Relationship Education|Behavioral: Job Readiness Curriculum","Knowledge about Healthy Romantic Relationships|Romantic Relationship Stability|Conflict Management Skills|Exposure to Dating Violence|Sexual Risk Behaviors","Mathematica Policy Research, Inc.|Department of Health and Human Services","All","11 Years to 16 Years   (Child)","Not Applicable","1840","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MPR-500098-MTC","August 2016","August 2019","August 2019","July 14, 2016","null","November 3, 2016","More Than Conquerors, Inc., Conyers, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02832856"
188,"NCT02830997","Total Knee Arthroplasty Guidance Systems Study",,"Enrolling by invitation","No Results Available","Osteoarthritis, Knee|Arthroplasty, Replacement, Knee","Device: Stereotactic guidance system","Accuracy of total knee arthroplasty component placement in the coronal, axial, and sagittal planes measured by computed tomography scan|Skin-to-skin surgical time in minutes|Patient reported physical function measured by 2011 Knee Society Scoring System|Patient reported health related quality of life measured by the Veteran's Rand 12-item Health Survey|Patient reported satisfaction measured by 2011 Knee Society Scoring System","Ormonde M. Mahoney, MD|Stryker Orthopaedics|Athens Orthopedic Clinic, P.A.","All","45 Years and older   (Adult, Older Adult)","","150","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","AOC-OM-St-2015-026","July 12, 2016","March 1, 2018","December 31, 2019","July 13, 2016","null","December 19, 2017","Athens Orthopedic Clinic, P.A., Athens, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02830997"
189,"NCT02830880","FACBC Prostate Therapy Response",,"Recruiting","No Results Available","Prostate Cancer","Drug: FACBC PET-CT|Other: MRI, CT, or Bone Scan","Change in Clinical Response assessed by FACBC PET scan|Change in Clinical Response Assessed by PSA|Change in Clinical Response Assessed by MRI|Change in Clinical Response Assessed by CT Scan|Change in Clinical Response Assessed by Bone Scan|Mortality Rate","Emory University|Blue Earth Diagnostics|Nihon Medi Physics","Male","18 Years and older   (Adult, Older Adult)","Phase 2","30","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","IRB00073616","July 2016","December 2021","December 2021","July 13, 2016","null","July 31, 2018","Emory University Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02830880"
190,"NCT02827383","Pilot Stair Climbing Study",,"Completed","No Results Available","Prediabetic State","Behavioral: Stair Climbing Frequency","Continuous Glucose Monitor|Heart Rate","Jennifer Gay|University of Illinois at Urbana-Champaign|University of Georgia","All","40 Years to 64 Years   (Adult)","Not Applicable","10","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","ID#STUDY00002685","February 2016","September 2016","September 2016","July 11, 2016","null","October 25, 2016","Clinical and Translational Research Unit, University of Georgia, Athens, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02827383"
191,"NCT02807376","An Evaluation of a Powered Vascular Stapler in Laparoscopic Nephrectomies and Nephroureterectomies",,"Completed","No Results Available","Excision of Kidney","Device: Surgeon's 'standard of care' stapler|Device: Ethicon Powered Vascular Stapler","Incidence of hemostatic interventions/procedures completed for intra-operative bleeding related to the transection of the vessel|Incidence of hemostatic interventions /procedures completed for post-operative bleeding related to the transection of the vessel","Ethicon Endo-Surgery","All","18 Years and older   (Adult, Older Adult)","Not Applicable","250","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15-002","July 5, 2016","August 23, 2017","August 23, 2017","June 21, 2016","null","February 7, 2018","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02807376"
192,"NCT02796859","Siltuximab in Schizophrenia",,"Recruiting","No Results Available","Schizophrenia|Psychotic Disorders","Drug: Siltuximab|Drug: normal saline","Change in Cognition|Change in Total Psychotic Symptoms","Brian Miller|Stanley Medical Research Institute|Augusta University","All","18 Years to 55 Years   (Adult)","Phase 1|Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","15T-005","May 2016","November 2019","May 2020","June 13, 2016","null","July 9, 2018","Augusta University, Augusta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02796859"
193,"NCT02796755","Effects of Riluzole on CNS Glutamate and Fatigue in Breast Cancer Survivors With High Inflammation",,"Recruiting","No Results Available","Inflammation|Fatigue","Drug: Riluzole|Drug: Placebo","Change in Central Nervous System (CNS) glutamate measured by Magnetic Resonance Spectroscopy (MRS) between riluzole and placebo arms|Change in score of the Multidimensional Fatigue Inventory (MFI) between riluzole and placebo arms|Change in score of the Promise-Fatigue Short Form (PROMIS)","Emory University","Female","21 Years to 65 Years   (Adult, Older Adult)","Phase 4","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","IRB00086271","April 2016","November 2019","November 2019","June 13, 2016","null","June 7, 2018","Emory University Winship Cancer Institute, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02796755"
194,"NCT02791685","Smartphone Delivered In-home Cardiopulmonary Rehabilitation",,"Recruiting","No Results Available","Cardiovascular Disease|Coronary Artery Disease","Behavioral: MULTIFIT Cardiac Rehabilitation|Behavioral: Movn Pulmonary Rehabilitation|Behavioral: Standard of Care Cardiac Rehabilitation","Change in Functional Capacity assessed by the Six Minute Walk Test (6MWT)|Change in Measure of Exercise Intensity (MET)|Change in Weight|Change in Body Mass Index (BMI)|Change in Blood Pressure|Change in A1c Level|Change in Low-density Lipoprotein (LDL) Level|Change in Self-Efficacy Diet Survey Score|Change in Self-Efficacy Medication Survey Score|Change in Self-Efficacy Monitoring Survey Score|Change in Duke Activity Status Index (DASI) Score|Change in Short Form Health Survey (SF-12) Score|Change in Rate your Plate Assessment Score|Change in Seattle Angina Questionnaire (SAQ) Score|Change in Coronary Artery Disease Education Questionnaire (CADE-Q) Score|Change in St. George's Respiratory Questionnaire For COPD Patients (SGRQ-C) Score|Change in Patient Health Questionnaire (PHQ-9) Score|Change in the Number of Exercise Habits|Change in the Number of Cumulative Exercise Minutes Per Week|Change in Exercise Intensity Level|Change in the Number of Caffeinated Beverages Consumed per Day|Change in the Number of Alcoholic Beverages Consumed per Day","Emory University|Atlanta VA Medical Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","100","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00085938","May 2016","December 2019","December 2020","June 7, 2016","null","January 11, 2018","Atlanta VA Medical Center, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02791685"
195,"NCT02787655","Aerobic Exercise and Cognitive Training in Older Adults",,"Recruiting","No Results Available","Sedentary Lifestyle","Behavioral: Aerobic exercise|Behavioral: Cognitive training","Executive Language Functions (Verbal Fluency)","VA Office of Research and Development","All","18 Years to 89 Years   (Adult, Older Adult)","Not Applicable","80","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","B8034-W","February 1, 2013","December 31, 2018","July 31, 2019","June 1, 2016","null","September 26, 2018","Atlanta VA Medical and Rehab Center, Decatur, GA, Decatur, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02787655"
196,"NCT02787421","Nasal Dilator Strips for Rhinoplasty",,"Withdrawn","No Results Available","Nasal Valve Compromise","Device: Breathe-Rite Nasal Dilator Strip","Change in Nasal Obstruction and Septoplasty Effectiveness (NOSE) Instrument Score","Emory University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","IRB00086968","April 2016","May 2017","May 2017","June 1, 2016","null","June 14, 2017","Emory Aesthetic Center, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02787421"
197,"NCT02774226","Long Term Nitric Oxide Bioavailability on Vascular Health in Chronic Obstructive Pulmonary Disease","COPD-LT","Recruiting","No Results Available","Chronic Obstructive Pulmonary Disease (COPD)","Drug: Tetrahydrobiopterin (BH4)|Dietary Supplement: Antioxidant Cocktail","Change in Flow Mediated Dilation|Change in Biomarkers of Oxidative Stress|Femoral and Carotid tonometry measurements used to assess Arterial Stiffness|Iontophoresis and Local Heating used to Measure Microvascular Function","Augusta University","All","18 Years and older   (Adult, Older Adult)","Phase 2","12","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","COPD-LT","September 2015","September 2018","September 2018","May 17, 2016","null","November 14, 2017","Georgia Prevention Institute, Augusta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02774226"
198,"NCT02766478","Genistein Supplementation to Mitigate Cardiometabolic Dysfunction in Patients Undergoing Androgen Deprivation Therapy for Prostate Cancer","GeniPro","Recruiting","No Results Available","Prostate Cancer","Drug: Genistein|Drug: Placebo","Change in Matsuda Index of Whole-Body Insulin Sensitivity|Change in β-cell Insulin Secretion Capacity assessed by the Insulinogenic Index|Change in Arterial Stiffness|Change in Vascular Endothelial Function","Emory University","Male","18 Years and older   (Adult, Older Adult)","Phase 2","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","IRB00086186","October 16, 2017","October 2018","October 2018","May 9, 2016","null","October 25, 2017","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02766478"
199,"NCT02763124","Pseudophakic Astigmatic Reduction With Verion-LenSx Arcuate Incisions",,"Completed","No Results Available","Astigmatism","Procedure: Verion-LenSx","Uncorrected monocular distance visual acuity|Change in corneal astigmatism|Change in refraction|Spectacle independence at distance","Gainesville Eye Associates|Alcon, a Novartis Company","All","40 Years and older   (Adult, Older Adult)","Not Applicable","30","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CB-16-001","May 2016","October 2016","October 2016","May 5, 2016","null","August 14, 2017","Gainesville Eye Associates, Gainesville, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02763124"
200,"NCT02757898","Transfusion of Biotinylated Red Blood Cells","b-RBCs","Recruiting","No Results Available","Anemia","Drug: Biotin-Labeled Red Blood Cells (RBCs)","Length of time biotin-labeled RBCs can be detected following re-infusion|Length of time differentially labeled biotin-labeled RBCs can be distinguished from one another|Number of participants experiencing adverse events","Emory University","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","8","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","IRB00085954","April 2016","January 2020","January 2020","May 2, 2016","null","May 2, 2018","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02757898"
201,"NCT02757885","Transplantation Using Reduced Intensity Approach for Patients With Sickle Cell Disease From Mismatched Family Donors of Bone Marrow","TRANSFORM","Recruiting","No Results Available","Sickle Cell Disease","Procedure: Bone Marrow Transplant (BMT)|Procedure: Bone Marrow Harvest (Donation)|Drug: Hydroxyurea|Drug: Thiotepa|Drug: Fludarabine monophosphate|Drug: Cyclophosphamide|Other: Rabbit Anti-thymocyte Globulin|Radiation: Total Body Irradiation","Event-free Survival (EFS) Rate|Primary Graft Rejection Rate|Late Graft Rejection Rate|Rate of Disease Recurrence|Overall Survival Rate|Cumulative Incidence of Neutrophil Engraftment and Platelet Engraftment|Chimerism Rate following Hematopoietic Cell Transplantation for Sickle Cell Disease|Frequency of Idiopathic Pneumonia Syndrome (IPS)|Veno-occlusive Disease (VOD) Rate|Rate of Central Nervous System (CNS) Toxicity|Infection Rate|Frequency of Stroke","Emory University","All","15 Years to 40 Years   (Child, Adult)","Phase 2","15","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00080955","April 2016","December 2020","December 2020","May 2, 2016","null","May 22, 2018","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02757885"
202,"NCT02749266","The Impact of Chiropractic Activator Adjustments on Mental Rotation and Line Judgment Reaction Time",,"Completed","No Results Available","Cognition - Other","Other: Chiropractic adjustment|Other: Sham chiropractic adjustment","Reaction time|Response correctness","Life University|University of Georgia","All","18 Years to 35 Years   (Adult)","Not Applicable","16","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","I-0011","June 2014","August 2014","August 2014","April 22, 2016","null","April 22, 2016","Life University, Marietta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02749266"
203,"NCT02749214","Defining a PD-specific Breath Fingerprint of Underlying Inflammatory and Neurodegenerative Processes",,"Recruiting","No Results Available","Parkinson's Disease","Other: Blood Sample Collection|Other: Breath Sample Collection","Unified Parkinson's Disease Rating Scale Subscale II Score|Unified Parkinson's Disease Rating Scale Subscale III Score|Modified Hoehn and Yahr Scale Score|Overnight Questionnaire Score|Beck's Depression Scale Score|Montreal Cognitive Assessment (MOCA) Score","Emory University|Michael J. Fox Foundation for Parkinson's Research","All","25 Years to 85 Years   (Adult, Older Adult)","","100","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","IRB00086732","February 2016","August 2019","August 2019","April 22, 2016","null","September 12, 2018","The Emory Clinic Executive Park, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02749214"
204,"NCT02742532","Oxytocin Suppresses Substance Use Disorders Associated With Chronic Stress",,"Enrolling by invitation","No Results Available","Alcohol Abuse|Stress Disorders, Post-Traumatic|Anxiety Disorders","Drug: Oxytocin|Drug: Placebo","Craving to use alcohol (Visual Analog Scale)|Stress rating (Visual Analog Scale)","University of California, San Francisco|Eisenhower Army Medical Center|United States Department of Defense|Congressionally Directed Medical Research Programs","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","80","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science","Fort Gordon Oxytocin","April 20, 2017","December 2018","June 2019","April 19, 2016","null","October 18, 2017","Dwight D. Eisenhower Army Medical Center, Fort Gordon, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02742532"
205,"NCT02730195","Pioglitazone and Tyrosine Kinase Inhibitor in Treating Patients With Relapsed Chronic Myeloid Leukemia",,"Recruiting","No Results Available","Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive","Drug: Pioglitazone|Drug: Tyrosine Kinase Inhibitor (TKI)","Incidence of adverse events (AEs), graded according to Common Terminology Criteria for Adverse Events version 4.03|Proportion of subjects who achieve and maintain major molecular response (MMR) following a second discontinuation of TKI using blood quantitative reverse transcription polymerase chain reaction (qRT-PCR) for breakpoint cluster region-Abelson1 (BCR-ABL1)|Proportion of subjects who lose MMR following discontinuation of pioglitazone and TKI using blood qRT-PCR for BCR-ABL1","Emory University","All","16 Years and older   (Child, Adult, Older Adult)","Phase 2","26","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00086670|NCI-2016-00248|Winship3121-15","May 2016","May 2021","May 2021","April 6, 2016","null","July 24, 2018","Emory University/Winship Cancer Institute, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02730195"
206,"NCT02721901","Integrated Eating Aversion Treatment Manual-Parent Version","iEAT","Completed","No Results Available","Feeding and Eating Disorders of Childhood","Behavioral: iEAT Manual Intervention|Behavioral: Control group","Change in acceptance of food during a 10-minute meal|Change in disruptions during a 10-minute meal|Change in grams of food consumed during a 10-minute meal|Change in Clinical Global Impression - Improvement scale (CGI-I) score|Change in Parenting Stress Index-Short Form (PSI) score","Emory University","All","12 Months to 8 Years   (Child)","Not Applicable","17","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00086399","March 2016","June 26, 2017","August 1, 2017","March 29, 2016","null","October 16, 2017","Marcus Autism Center, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02721901"
207,"NCT02720198","Levomilnacipran ER vs. Adjunctive Quetiapine for Adults With Inadequate Relief With SSRIs in MDD",,"Completed","No Results Available","Major Depressive Disorder","Drug: Levomilnacipran|Drug: Quetiapine","Changes of Montgomery-Åsberg Depression Rating Scale (MADRS) total score|Response Rate|Remission Rate|Changes in neurocognition by changes in Scores on Reyes Verbal Learning Test|Changes in neurocognition by changes in Scores on Clinical Global Impression Scale- Severity (CGI-S)|Changes in neurocognition by changes in Scores on Clinical Global Impression Scale- Severity (CGI-I)|Changes in scores on Hamilton Anxiety Rating Scale (HAM-A) scores|Changes in scores on Sheehan Disability Scale (SDS) total score|Changes in neurocognition by changes in scores on Scores on Digit symbol substitution test (DSST)|Changes in scores on Apathy Evaluation Scale (AES).|Changes in neurocognition by changes in scores on Improvement (CGI-I) scores","Duke University|Forest Laboratories|Institute for Advanced Medical Research, Alpharetta, GA","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","60","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Pro00064983","January 23, 2017","June 12, 2018","June 12, 2018","March 25, 2016","null","June 19, 2018","Institute for Advanced Medical Research, Alpharetta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02720198"
208,"NCT02712346","The Role of Endothelin-1 in Sickle Cell Disease",,"Recruiting","No Results Available","Sickle Cell Anemia","Drug: Ambrisentan|Drug: Placebo","Safety and Tolerability of ambrisentan in patients with sickle cell disease measured by physical exam, vital signs, blood and urine testing, ECG (specified visits), concomitant medication review, adverse events review|Efficacy of ambrisentan in improving kidney function in patients with sickle cell disease measured by blood|Efficacy of ambrisentan in decreasing TRJ velocity|Efficacy of ambrisentan in decreasing inflammation|Efficacy of ambrisentan in improving micro-circulation|Efficacy of ambrisentan in improving macro-circulation|Efficacy of ambrisentan in improving nociception/pain|Efficacy of ambrisentan in improving kidney function in patients with sickle cell disease measured by urine testing for microalbuminuria/proteinuria","Augusta University|Gilead Sciences|National Heart, Lung, and Blood Institute (NHLBI)","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","30","Other|Industry|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Endothelin|5U01HL117684","September 2015","May 2018","May 2018","March 18, 2016","null","June 29, 2017","Augusta University, Augusta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02712346"
209,"NCT02712281","Autism MEAL Plan: Parent Training to Manage Eating Aversions & Limited Variety",,"Completed","No Results Available","Autism Spectrum Disorder","Behavioral: Autism MEAL Plan|Behavioral: Parent Education","Change in Clinical Global Impression - Improvement scale (CGI-I) score|Change in Parenting Stress Index- Short Form (PSI) score|Parent Satisfaction Rating|Change in Brief Autism Mealtime Behavior Inventory (BAMBI) scores|Change in Food Preference Inventory (FPI) scores|Change in nutritional intake|Change in Aberrant Behavior Checklist (ABC) scores|Change in rapid acceptance during 10 minute meal observation|Change in rapid swallowing during 10-minute meal observation|Change in disruptions during 10-minute meal observation|Change in crying during 10-minute meal observation|Change in volume of food consumed during 10-minute meal observation|Weight|Height|Body Mass Index","Emory University|Children's Healthcare of Atlanta","All","3 Years to 8 Years   (Child)","Not Applicable","37","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","IRB00085811","July 2016","March 2018","April 2018","March 18, 2016","null","May 8, 2018","Marcus Autism Center, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02712281"
210,"NCT02709083","Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia",,"Recruiting","No Results Available","Chronic Myelogenous Leukemia|Chronic Myeloid Leukemia|Leukemia","Drug: Dasatinib|Drug: Imatinib Mesylate|Drug: Nilotinib","The proportion of subjects who achieve major molecular response (MMR)|Accelerated phase (AP) or blast phase (BP) free survival|Change in PRO score extracted from the MD Anderson Symptom Inventory-Chronic Myelogenous Leukemia (CML)|Duration of adverse events (AEs) using the Common Terminology Criteria for Adverse Events (CTCAE) v4.03 criteria|Frequency of adverse events (AEs) using the Common Terminology Criteria for Adverse Events version 4.03 (CTCAE v4.03) criteria|Progression free survival (PFS)|Severity of adverse events (AEs) using the Common Terminology Criteria for Adverse Events (CTCAE) v4.03 criteria|The number of subjects with breakpoint cluster region-abelson murine leukemia viral oncogene homolog 1 (BCR-ABL1) transcript levels ≤ deep molecular responses (MR⁴)","Emory University","All","17 Years and older   (Child, Adult, Older Adult)","Phase 2","100","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00087045|NCI-2016-00162|Winship3143-16","October 2016","October 2019","October 2023","March 15, 2016","null","November 1, 2017","Emory University/Winship Cancer Institute, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02709083"
211,"NCT02706977","The Effect of Dopamine on Diabetic Retinopathy","Dopamine DR","Enrolling by invitation","No Results Available","Diabetes","Drug: Low Dose Sinemet CR|Drug: High Dose Sinemet CR|Device: RETeval Electroretinogram (ERG) Testing|Other: Contrast Sensitivity Testing|Other: Visual Acuity Testing","Change in Retinal Function assessed by Electroretinogram (ERG) Device|Change in Contrast Sensitivity assessed by the Contrast Sensitivity Function v1.0 (CSF v1.0) Tablet Application|Change in Contrast Sensitivity assessed by the Sine Wave Grafting Test (CSV-1000E)|Change in Visual Acuity assessed by the Standard Snellen Static Chart","Emory University","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","45","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","IRB00083672","January 2016","December 2018","December 2018","March 11, 2016","null","January 8, 2018","Atlanta VA Medical Center, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02706977"
212,"NCT02703532","Evaluation of a CarePartner-Integrated Telehealth Rehabilitation Program for Persons With Stroke","CARE-CITE","Recruiting","No Results Available","Stroke","Behavioral: CARE-CITE Education Program|Behavioral: Traditional Education|Behavioral: Constraint-Induced Movement Therapy (CIMT)","Change in Motor Ability and Impairments assessed by the Wolf Motor Function Test (WMFT)|Change in Upper Extremity Function and Use assessed by the Motor Activity Log (MAL)|Change in Family Conflict assessed by the Family Caregiver Conflict Scale (FCCS-F)|Change in Depression Status assessed by the Center for Epidemiologic Studies Depression Scale (CES-D)|Change in the Autonomy Support Family Care Climate Questionnaire for Stroke Survivor (FCC-SS) Score|Change in Upper Extremity Impairment assessed by the Fugl-Meyer Assessment (FMA)|Change in Upper Extremity Self-Efficacy assessed by the Confidence in Arm and Hand (CAHM) Scale|Change in Quality of Life assessed by the Stroke Impact Scale (SIS)|Change in the Family Assessment Device (FAD) Scale Score|Change in the Memory and Behavior Problems Checklist (MBPC) Score|Change in the Autonomy Support Family Care Climate Questionnaire for Stroke Survivor (FCC-CP) Scale Score|Change in Fatigue Level assessed by the Piper Fatigue Scale (PFS)|Change in Caregiver Strain assessed by the Caregiver Strain Index (CSI)|Change in Bakas Caregiving Outcomes Scale (BCOS) Score|Change in Caregiving Self Efficacy (Respite Scale) Score|Change in Modified Computer Self Efficacy Scale (CSES) Score|Change in Post Study System Usability Questionnaire (PSSUQ) Score","Emory University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","96","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care","IRB00070957","January 2016","March 2019","March 2019","March 9, 2016","null","September 18, 2018","Emory University Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02703532"
213,"NCT02702921","Powered Vascular Stapler in Video-Assisted Thoracoscopic (VAT) Lobectomies",,"Completed","Has Results","Non Small Cell Lung Cancer","Device: Surgeon's 'standard of care' stapler|Device: Ethicon Powered Vascular Stapler","Incidence of Intra-Operative Hemostatic Intervention|Post-operative Interventions or Procedures Related to Pulmonary Artery or Pulmonary Vein Bleeding","Ethicon Endo-Surgery","All","18 Years and older   (Adult, Older Adult)","Not Applicable","201","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ESC-15-001","February 1, 2016","March 31, 2017","March 31, 2017","March 9, 2016","June 29, 2018","October 11, 2018","Emory University, Atlanta, Georgia, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/21/NCT02702921/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/21/NCT02702921/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02702921"
214,"NCT02700841","Enhancing Anti-Myeloma Vaccine Response After Autologous Stem Cell Transplantation",,"Suspended","No Results Available","Plasma Cell Myeloma","Drug: Melphalan|Procedure: Peripheral Blood Stem Cell Transplantation--CD34 HSCT|Procedure: Peripheral Blood Stem Cell Transplantation--AHSCT|Biological: T Cell-Depleted Hematopoietic Stem Cell Transplantation|Biological: Tetanus Toxoid Vaccine|Biological: Therapeutic Autologous Lymphocytes|Biological: Trivalent Influenza Vaccine|Biological: XBP1-US/XBP1-SP/CD138/CS1 Multipeptide Vaccine PVX-410","Change in influenza antibody titer as measured by hemagglutination inhibition assay (HAI)|Change in absolute lymphocyte count (ALC)|Change in immune cells (T cells cluster of differentiation 8 [CD8], CD4)|Change in NK cells|Change in XBP1-US/XBP1-SP/CD138/CS1 multipeptide vaccine PVX-410 (PVX-410) tetramer+/interferon (IFN) gamma+ cell levels|Changes in absolute monocyte counts (AMC)|Engraftment time|Functional benefit of depleting immune suppressive cells from granulocyte-colony stimulating factor (G-CSF) (filgrastim) mobilized autologous peripheral blood stem grafts|Incidence of auto immune side effects using the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.02|Incidence of infections|Progression-free survival","Emory University|OncoPep, Inc.","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","26","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00079982|NCI-2015-00743|WINSHIP2905-15","May 2016","December 1, 2018","December 1, 2019","March 7, 2016","null","February 21, 2018","Emory University/Winship Cancer Institute, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02700841"
215,"NCT02696044","Treatment of Mitochondrial Dysfunction in Rett Syndrome With Triheptanoin",,"Recruiting","No Results Available","Rett Syndrome","Drug: triheptanoin","Change in Clinical Seizure Frequency|Change in Dystonia frequency|Change in Dystonia Severity|Change in Burke-Fahn-Marsden Dystonia Rating Scale (BFM) Score|Change in Global Dystonia Rating Scale (GDRS) Score|Change in the PROMIS Fatigue Parent Proxy Score|Change in the PROMIS Pain Interference Parent Proxy Score|Change in the PROMIS Peer Relations Parent Proxy Score|Change in the PROMIS Physical Functional Mobility Parent Proxy Score|Change in the PROMIS Physical Function Upper Extremity Parent Proxy Score|Change in the PROMIS Anxiety Parent Proxy Score|Change in the PROMIS Depressive Symptoms Parent Proxy Score|Change in Child Health Questionnaire-50 (CHQ) Score|Change in the Clinician Clinical Global Impression - Improvement Scale (CGI-S) Score|Change in the Clinician Clinical Global Impression - Severity Scale Score|Change in the Parental Clinical Global Impression of Improvement Score|Change in Parent Top Three Concerns Visual Analog Scale Ranking|Change in the Clinical Severity Scale (CSS) Score|Change in the Motor Behavioral Assessment (MBA) Score|Change in the Rett Syndrome Behavioural Questionnaire (RSBQ) Score|Change in the Rett Syndrome Hand Apraxia Scale (RHAS) Score|Change in the Rett Syndrome Gross Motor Scale (RSGMS) Score|Change in Maximum Heart Rate as assessed by the Graded Maximal Treadmill Test|Change in Maximum Speed Acheived as assessed by the Graded Maximal Treadmill Test|Frequency of Epileptiform Electroencephalogram (EEG) Activity|Seizure Activity assessed by Change in Photoplethysmographic Heart Rate|Change in Daily 3-axis accelerometry|Seizure Activity assessed by Change in Electrodermal Activity (EDA)|Seizure Activity assessed by Change in Skin Temperature","Center for Rare Neurological Diseases, Norcross, GA|Ultragenyx Pharmaceutical Inc|Rett Syndrome Research Trust","Female","2 Years and older   (Child, Adult, Older Adult)","Phase 2","12","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00085194","June 2016","February 2019","February 2019","March 2, 2016","null","February 7, 2018","Center for Rare Neurological Diseases, Norcross, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02696044"
216,"NCT02694666","Vibration Training for Preventing Falls in Healthy Population and Multiple Sclerosis",,"Recruiting","No Results Available","Falls Prevention","Other: Controlled whole-body vibration training","Real life falls|Berg Balance Scale test|Slip-related falls on treadmill|Functional mobility|Sensation|Muscle strength|Range of motion|Bone density|Multiple Sclerosis Functional Composite score|Equiscale balance test","Georgia State University","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","440","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","514810","April 2015","June 2019","June 2020","February 29, 2016","null","July 31, 2018","Georgia State University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02694666"
217,"NCT02691221","ReliefLink: A Preventative Mobile Toolkit for Follow-Up Care of Psychiatric Patients",,"Completed","No Results Available","Suicide, Suicidal Ideation","Behavioral: Relief Link Application Daily Tasks","Change in scores on 6 item Columbia Suicide Severity Rating Scale Screener (C-SSRS)|Change in scores on 20-item Positive-Negative Affect Scale (PANAS)|Change in scores on 20-item R-UCLA Loneliness Scale|Change in scores on 14-item Mental Health Continuum Short Form (MHC-SF)|Change in scores on 12-item Flourishing Scale (FS)|Change in scores on 8-item Grit-S scale|Change in scores on 10-item Life Orientation Test - Revised|Change in scores on 25-item Connor Davidson Resilience Inventory|Change in scores on 21-item Posttraumatic Growth Inventory|11-item Effectiveness of Obtaining Resources scale (EOR)|Number of participants experiencing hospitalizations|Number of participants experiencing self-injury events|Number of participant reported barriers to care and resources|Participant adherence to assigned coping skills activities|Participant adherence to daily mood tracking|Participant usage of resource location functions|Participant positive feedback","Emory University|Georgia Tech Research Institute","All","18 Years to 64 Years   (Adult)","Not Applicable","13","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","IRB00083066","April 2016","October 2017","October 2017","February 25, 2016","null","December 15, 2017","Grady Health System, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02691221"
218,"NCT02690064","Mechanisms for Vascular Dysfunction and Exercise Tolerance in CF","CF-AOX","Recruiting","No Results Available","Cystic Fibrosis","Dietary Supplement: Acute Antioxidant Cocktail|Dietary Supplement: Chronic Antioxidant Cocktail|Other: Placebo","Acute Change in Flow mediated dilation|Chronic Change in Flow mediated dilation|Acute Change in exercise capacity (VO2 peak)|Chronic Change in exercise capacity (VO2 peak)|Acute Change in Biomarkers of oxidative stress|Acute Change in Arterial Stiffness|Chronic Change in Biomarkers of oxidative stress|Chronic Change in Arterial Stiffness","Augusta University","All","7 Years and older   (Child, Adult, Older Adult)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CF-AOX","April 2015","December 2018","December 2018","February 24, 2016","null","January 10, 2018","Georgia Prevention Institute, Augusta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02690064"
219,"NCT02682940","T1 Diabetes Hypoglycemia Prevention Pilot",,"Terminated","No Results Available","Diabetes Mellitus, Type 1|Hypoglycemia","Device: Vigilant Diabetes Management Application","Aggregate reduction in the rate of mild hypoglycemia (biochemical and logged) as measured by meter or logged home blood glucose values <56 mg/dL at 3 months, compared to the monthly rate of hypoglycemia in the baseline period.|An aggregate reduction in the rate of biochemical severe hypoglycemia as measured by meter or logged home blood glucose values <40 mg/dL, at 3 months, compared to the monthly rate in the baseline period|An aggregate (total study population) reduction in the LBGI and HBGI, as measured by percent of readings in and out of range calculated based on downloaded blood glucose meter download data.|An aggregate reduction in average HbA1will be measured at baseline using DCA 2000 or equivalent NGSP-certified point-of-care method or local laboratory at 3 months, compared to HbA1c levels obtained at study initiation.|An aggregate reduction in the survey self-reported rate of use of; 1) Glucagon 2) Emergency medical services for hypoglycemia, and 3) Hospital, urgent care or clinic visits for hypoglycemia or associated with hypoglycemia care visits.|An aggregate reduction in the mean glycemic variability, as measured by monthly ADRR (Average Daily Risk Range), calculated based on downloaded meter download data|Reduction in reported fear of hypoglycemia as compared to baseline Fear of Hypoglycemia Fear Survey. The Hypoglycemia Fear Survey II (HSF II) will be used.|Improvement in self-reported lost work productivity as a result of hypoglycemia. Individuals will complete a questionnaire about lost work days as a result of hypoglycemia at baseline and at 3 months.|Improvement in self-reported psychosocial self-efficacy as compared to baseline measured using the Diabetes Empowerment Scale Short Form (DES-SF).","InSpark Technologies, Inc.|Atlanta Diabetes Associates","All","11 Years to 74 Years   (Child, Adult, Older Adult)","Not Applicable","4","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VG2HT1US1","May 2016","December 2016","December 2016","February 17, 2016","null","March 3, 2017","Atlanta Diabetes Associates, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02682940"
220,"NCT02672579","Study of Kids Itch Severity (SKIS)","SKIS","Completed","No Results Available","Chronic Pruritus","","ItchyQoL (TotsItchyQoL) test-retest reliability|ItchyQoL (KidsItchyQoL) test-retest reliability|ItchyQoL (TotsItchyQoL) validity|ItchyQoL (KidsItchyQoL) validity|Psychometric properties of the ItchyQuant|Feasibility of harnessing an electronic platform as assessed by researcher judgement|Prevalence of ADHD symptoms","Emory University","All","4 Years to 17 Years   (Child)","","312","Other","Observational","Observational Model: Other|Time Perspective: Prospective","IRB00081076","May 2015","June 28, 2018","June 28, 2018","February 3, 2016","null","August 14, 2018","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02672579"
221,"NCT02669030","A Six Week, Randomized, Double-Blind Placebo-Controlled, Suvorexant Augmentation Study of Antidepressant Treatment of Major Depressive Disorder With Residual Insomnia",,"Unknown status","No Results Available","Depression|Major Depressive Disorder|MDD|Insomnia","Drug: suvorexant|Drug: Placebo","Total Sleep Time|Insomnia Severity Index (ISI)|Hamilton Depression Rating Scale|Sheehan Disability Scale|Wake After Sleep Onset (WASO)|Sleep Latency (SL)|Perceived Deficits Questionnaire (PDQ)","Institute for Advanced Medical Research, Alpharetta, GA|Jefferson Medical College of Thomas Jefferson University|Medical College of Georgia at Augusta University, Department of Psychiatry and Health Behavior, Augusta, GA","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 4","74","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","SVX-IIT2016-001","February 2016","March 2017","null","January 29, 2016","null","January 29, 2016","Institute for Advanced Medical Research, Alpharetta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02669030"
222,"NCT02646579","Effects of Dry Needling Using Spinal and Peripheral Sites Versus Peripheral Sites Only",,"Recruiting","No Results Available","Plantar Fasciitis|Achilles Tendinitis|Patellofemoral Pain Syndrome","Procedure: Spinal and Peripheral Dry Needling|Procedure: Peripheral Dry Needling","Change in Pain Level assessed using the Visual Analogue Scale (VAS)|Change in Muscle Strength of Hip Abductors assessed using a dynamometer|Change in Muscle Strength of Knee Extensors/Flexors assessed using a dynamometer|Change in Muscle Strength of Ankle Dorsiflexors/Platarflexors assessed using a dynamometer|Change in Unilateral Hop Distance|Change in Single-limb Standing Balance Test Time","Emory University","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","34","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","IRB00084277","October 27, 2017","December 2018","June 2019","January 5, 2016","null","August 15, 2018","The Emory Clinic, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02646579"
223,"NCT02642510","Improving Patient Education for Lymphoma and Leukemia Inpatients",,"Completed","No Results Available","Leukemia|Lymphoma","Other: Structured Education DVD + Verbal Teaching|Other: Verbal Teaching","Quality of Discharge Teaching Scale (QDTS) Score|Visual analog scale (VAS) Score","Emory University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","78","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","IRB00073387","June 2014","February 20, 2017","February 20, 2017","December 30, 2015","null","June 22, 2017","Emory University Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02642510"
224,"NCT02640690","Trauma-Sensitive Yoga for Female Veterans With PTSD Who Experienced Military Sexual Trauma","PSL II","Recruiting","No Results Available","Stress Disorders, Post-traumatic","Behavioral: Trauma Sensitive Yoga Intervention|Behavioral: Cognitive Processing Therapy-Cognitive Only","Determine the effectiveness of TSY compared to CPT-C in reducing PTSD symptoms, chronic pain, and insomnia|To evaluate the effectiveness of TSY as compared to CPT-C in improving quality of life and social functioning in women Veterans with PTSD related to MST.|To evaluate the effectiveness of TSY as compared to CPT-C on biological stress response and psychophysiological hyper-responsivity.|PTSD Checklist-5 (PCL-5)|PROMIS v2.0 Ability to Participate in Social Roles and Activities - Short Form 4a|PROMIS v2.0 Social Isolation - Short Form 4a|PROMIS v2.0 Satisfaction with Social Roles and Activities - Short Form 4a|PROMIS v2.0 Emotional Support - Short Form 4a|Interleukin-6 (IL-6) levels from plasma|Interleukin-10 (IL-10) levels from plasma|C-Reactive Protein (CRP) levels from plasma|Dark-Enhanced Startle Response|Heart Rate Variability","VA Office of Research and Development","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","210","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NRI 15-151","January 1, 2016","July 1, 2019","December 31, 2019","December 29, 2015","null","July 18, 2018","Atlanta VA Medical and Rehab Center, Decatur, GA, Decatur, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02640690"
225,"NCT02635984","Study of FOND Versus FOND+O for the Prevention of CINV in Hematology Patients Receiving Highly Emetogenic Chemotherapy Regimens","FOND-O","Completed","Has Results","Complications of Bone Marrow Transplant|Hematologic Neoplasms","Drug: Olanzapine|Drug: Placebo","Overall Percentage of Patients Who Had a Complete Response|Percent of Patients With no Significant Nausea in Overall Assessment Period|Percent of Patients Achieving Complete Protection in Overall Assessment Phase|Percent of Participants With no Significant Nausea in Acute Phase|Percent of Participants With no Significant Nausea in Delayed Phase|Percent of Patients With no Nausea in Overall Assessment Period|Percent of Patients With Complete Response in Acute Phase|Percent of Patients With Complete Response in Delayed Phase","Augusta University|University of Georgia","All","18 Years and older   (Adult, Older Adult)","Phase 3","108","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care","818888","November 2015","December 2017","December 2017","December 21, 2015","August 20, 2018","August 20, 2018","Augusta University Medical Center, Augusta, Georgia, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/84/NCT02635984/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02635984"
226,"NCT02630030","Phase 0 Analysis of Ixazomib (MLN9708) in Patients With Glioblastoma",,"Completed","No Results Available","Glioblastoma","Drug: Ixazomib","Concentration of ixazomib in tumor tissue|Concentration of ixazomib in blood and plasma samples|Incidence of adverse events after single dose administration of ixazomib, assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.03","Emory University|Takeda","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","3","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","IRB00083003|NCI-2015-01682|X16071|Winship3017-15","March 2016","July 2018","July 2018","December 15, 2015","null","August 15, 2018","Emory University/Winship Cancer Institute, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02630030"
227,"NCT02624908","Canagliflozin-Mealtime Insulin Rescue",,"Recruiting","No Results Available","Diabetes Mellitus, Type 2","Drug: canagliflozin|Drug: placebo","Number of patients who discontinue all pre-meal medications for at least one meal per day|Number of patients who replace mealtime insulin with an oral agent for at least one meal per day|Number of patients with a continuing need for insulin 4 times per day|Frequency and severity of hypoglycemia|Self monitoring and continuous monitoring blood glucose levels","Atlanta Research and Education Foundation|Janssen Scientific Affairs, LLC","All","30 Years to 70 Years   (Adult, Older Adult)","Phase 4","40","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","28431754DIA4008","April 2016","November 2018","November 2018","December 9, 2015","null","July 24, 2017","Atlanta VA Medical Center, Decatur, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02624908"
228,"NCT02623036","The Use of Ambulatory Blood Pressure Monitors to Assess Angiotensin Converting Enzyme Inhibitors",,"Recruiting","No Results Available","Hypertension, Resistant to Conventional Therapy","Drug: Equivalent dose enalapril|Drug: Equivalent dose lisinopril","Change from baseline nighttime blood pressure|Change from baseline night to day blood pressure ratio (dipping status)|Change from baseline 24 Hour Blood Pressure","Memorial Health University Medical Center","All","18 Years to 79 Years   (Adult, Older Adult)","Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MHUMC 2015.10.01","November 2015","April 2018","April 2018","December 7, 2015","null","May 25, 2017","Memorial Family Medicine Center, Savannah, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02623036"
229,"NCT02621983","Aerobic Exercise for Cognition in Schizophrenia",,"Active, not recruiting","No Results Available","Schizophrenia","Behavioral: Aerobic Exercise|Behavioral: Balance and Stretching","Change in cognitive function, assessed by scores on the MCCB|Change in functional ability|Change in MCCB scores|Change in scores on the University of California San Diego Performance-Based skills assessment (UPSA)","VA Office of Research and Development|Emory University","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","40","U.S. Fed|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","D1897-P|1I21RX001897-01A1|IRB00082701","January 1, 2016","July 1, 2018","December 31, 2019","December 4, 2015","null","July 19, 2018","Atlanta VA Medical and Rehab Center, Decatur, GA, Decatur, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02621983"
230,"NCT02620514","Medication Adherence in Patients With Inflammatory Bowel Disease (IBD)",,"Completed","No Results Available","Inflammatory Bowel Disease|Crohn's Disease|Ulcerative Colitis","Behavioral: Education and Reminders|Behavioral: Educational Visit|Behavioral: Medication Educational Visit|Behavioral: Financial Support","Change in Medication Possession Ratio (MPR)|Change in Modified Morisky Adherence Scale-8 (MMAS-8) Score|Change in Harvey Bradshaw Index (HBI) Score|Change in Simple Colitis Activity Index (SCAI) Score|Change in Short Inflammatory Bowel Disease Questionnaire (SIBDQ) Score|Change in Hospital Anxiety and Depression Scale (HADS) Score|Change in Disease Activity Assessed by the Number of Admissions|Change in Disease Activity Assessed by the Number of Clinic Visits|Change in Disease Activity Assessed by the Number of Emergency Visits|Change in Disease Activity Assessed by the Number of Surgeries","Emory University","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","77","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","IRB00075262","June 2015","November 1, 2016","November 1, 2016","December 3, 2015","null","October 1, 2018","The Emory Clinic, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02620514"
231,"NCT02614508","Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia",,"Active, not recruiting","No Results Available","Recurrent Chronic Lymphocytic Leukemia|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Small Lymphocytic Lymphoma","Drug: Buparlisib|Drug: Ibrutinib|Biological: Ofatumumab","Maximum tolerated dose (MTD) of buparlisib when combined with ibrutinib in relapsed/refractory CLL for ibrutinib naive patients defined as the dose level at which no more than 1 of 6 patients experiences a dose-limiting toxicity|MTD of buparlisib when combined with ofatumumab in relapsed/refractory CLL for ibrutinib pre-treated patients defined as the dose level at which no more than 1 of 6 patients experiences a dose-limiting toxicity|Complete response rate|Incidence of non-dose limiting toxicities and adverse events|Nodal response rate|Overall response rate|Overall survival|Progression-free survival","Emory University|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 1","1","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00071983|NCI-2015-00652|Winship2494-13/CBKM120ZUS36T","January 2016","September 2018","September 2018","November 25, 2015","null","October 2, 2017","Emory University/Winship Cancer Institute, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02614508"
232,"NCT02611375","Conditioning Neural Circuits to Improve Upper Extremity Function",,"Recruiting","No Results Available","Spinal Cord Injury|Tetraplegia","Device: transcranial direct current stimulation|Device: peripheral nerve somatosensory stimulation|Other: sham transcranial direct current stimulation","Change in Quantitative Prehension Ability (GRASSP subtest)|Change in Upper Extremity Strength (Grip and Pinch Strength)|Change in Upper Extremity Sensation (Semmes-Weinstein)|Change in Perceived Upper Extremity Performance & Satisfaction (COPM)|Short-term change in Quantitative Prehension Ability (Abbreviated GRASSP) subtest)|Classification of Upper Extremity Function (BHUEF)|Detection of Hand Muscle Activation (subclinical EMG)|Change in Perceived Quality of Life (SCI QoL Basic Data Set)|Change in Cortical Excitability (motor evoked potentials)|Change in Spinal Reflex Excitability (joint threshold angle)","Shepherd Center, Atlanta GA|United States Department of Defense","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","70","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","tDCS-668","January 2017","August 2020","December 2020","November 20, 2015","null","July 24, 2017","Shepherd Center, Inc., Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02611375"
233,"NCT02610699","Community Pediatric Acceptability Study (CPAS)","CPAS","Completed","No Results Available","Otitis","Other: Conventional otoscope|Other: Smartphone otoscope","Rate of antibiotic prescription following otic examination with smartphone otoscope device compared to conventional otoscope device|Time of antibiotic filling following otic examination with smartphone otoscope device compared to conventional otoscope device smartphone otoscope device compared to conventional otoscope device|Rate of completion of antibiotic course following otic examination with smartphone otoscope device compared to conventional otoscope device|Acceptability of management plan following examination with smartphone otoscope device compared to conventional otoscope device","Emory University|Georgia Institute of Technology|Children's Healthcare of Atlanta","All","6 Months to 18 Years   (Child, Adult)","Not Applicable","75","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","IRB00074526","November 2014","June 2015","June 2015","November 20, 2015","null","January 26, 2016","Emory Children's Center, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02610699"
234,"NCT02604550","Anterior Cruciate Ligament Pain Study",,"Completed","Has Results","Anterior Cruciate Ligament Reconstruction","Drug: Ropivacaine 0.5%|Drug: Percocet 7.5/325|Drug: Naprosyn 500 mg","Pain Score|Number of Percocet Tablets Consumed|Total Hours of Sleep|Patient-Reported Nausea|Patient-Reported Vomiting|Patient-Reported Constipation|Patient-Reported Sedation|Patient-Reported Itching|Time to Straight Less Raise|Percent of Patients Rating Their Satisfaction as ""Excellent"" or ""Good""","Emory University","All","Child, Adult, Older Adult","Phase 4","115","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","IRB00083740","November 2015","April 2016","April 2016","November 13, 2015","May 31, 2017","May 31, 2017","Emory Healthcare Orthopaedics and Spine Center, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02604550"
235,"NCT02604277","Suicidal Behavior in Patients Diagnosed With Bipolar Disorder",,"Recruiting","No Results Available","Depression|Alcoholism|Drug Abuse","Behavioral: Interpersonal and Social Rhythm Therapy (ISRT)|Behavioral: Bipolar-Specific Cognitive Behavioral Therapy (CBT)|Behavioral: Mindfulness-Based Stress Reduction (MBSR)|Behavioral: Psycho-education & Understanding Bipolar Medications Therapy","Change in Beck Scale for Suicide Ideation (BSS) Score|Change in Suicidal Behavior Questionnaire - Revised (SBQ-R) Score|The Beck Depression Inventory—II (BDI-II)|Change in Altman Self-Rating Mania Scale (ASRM) Score|Change in World Health Organization Quality of Life-Brief (WHOQOL-BREF) Score|Change in Impulsive/Premeditated Aggression Scale (IPAS) Score|Change in Interpersonal Needs Questionnaire-15 (INQ-15) Score|Acquired Capability for Suicide Scale (ACSS) Score|Psychache Scale Score|Change in the Demographic Data Form Answers","Emory University","All","18 Years to 64 Years   (Adult)","Not Applicable","130","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00084800","January 2016","November 2018","November 2018","November 13, 2015","null","November 20, 2017","Grady Health System, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02604277"
236,"NCT02589444","Vitamin D and Microbiota in Cystic Fibrosis",,"Completed","No Results Available","Vitamin D Deficiency|Cystic Fibrosis","Dietary Supplement: High-Dose Vitamin D3|Other: Stool Sample|Other: Sputum Sample|Other: Sham Comparator|Procedure: Blood draw","Shannon Index|Species Richness Index|Serum 25(OH)D levels (and other nutritional markers related to vitamin D including nutrient levels, parathyroid hormone, fibroblast growth factor-23, free 25(OH)D, vitamin D binding protein|Forced expiratory volume in 1 second (FEV1)|Measures of plasma oxidative stress by assessing plasma aminothiol concentrations (glutathione, glutathione disulfide, cysteine, cystine) and their redox potentials.|Measures of inflammation by assessing plasma IL-6, TNF-alpha, MCP-1, and IL-8 concentrations|Forced vital capacity (FVC)","Emory University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","41","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care","IRB00083796","December 2015","February 2017","April 2017","October 28, 2015","null","June 14, 2017","Emory Clinic, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02589444"
237,"NCT02583490","Low Pulse Amplitude Focal ECT (LAP Study)",,"Recruiting","No Results Available","Depression","Device: spectrum 5000Q ECT device (RUL ECT)|Device: spectrum 5000Q ECT device (RUL LAP ECT)","Memory (cognitive side effects)|Time to reorientation|Resilience|Suicidal Ideation|Depression|Trauma symptoms","Augusta University","All","20 Years and older   (Adult, Older Adult)","Not Applicable","10","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","Low Pulse Amplitude Focal ECT","March 2015","December 2019","December 2019","October 22, 2015","null","March 27, 2018","Medical Colleage of Georgia, Augusta University, Evans, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02583490"
238,"NCT02581007","RIC Transplant Using Haplo Donors",,"Recruiting","No Results Available","Chronic Myelogenous Leukemia|Acute Myelogenous Leukemia|Myelodysplastic Syndrome|Acute Lymphocytic Leukemia|Chronic Lymphocytic Leukemia|Hodgkin's Lymphoma|Non-Hodgkin's Lymphoma|Myelofibrosis|CMML|Multiple Myeloma","Drug: Fludarabine|Drug: Melphalan|Drug: Cyclophosphamide|Procedure: peripheral blood stem cell transplant","Graft Rejection|Overall Survival|Overall survival|Relapse incidence|GVHD incidence","Northside Hospital, Inc.|Blood and Marrow Transplant Group of Georgia","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NSH 1132","November 2015","October 2018","December 2019","October 20, 2015","null","June 29, 2018","Northside Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02581007"
239,"NCT02579629","Use of On-Q Pump for Pain Post C-Section",,"Enrolling by invitation","No Results Available","Pain","Drug: Ropivacaine 0.1%|Drug: Ropivacaine 0.2%|Drug: Normal saline|Device: On-Q ® elastomeric pump","Change in pain scores during cough|Change in pain scores during 20°straight leg raise|Change in intensity of pain|Change in McGill pain questionnaire score|Time to first dose of rescue medications|Breastfeeding success|Change in post-operative wound evaluation|Change in post-operative wound healing|Pain scores at rest|Cost analysis|Patient satisfaction|Dosing amount of non-steroidal anti-inflammatory drugs|Severity of opioid side effects|Amount of opioid use","Emory University","Female","18 Years and older   (Adult, Older Adult)","Phase 4","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care","IRB00073292","July 2015","July 2019","July 2019","October 19, 2015","null","August 20, 2018","Emory University Hospital Midtown, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02579629"
240,"NCT02577653","Posturographic Characteristics of Eccentric, Isometric and Concentric Movements",,"Withdrawn","No Results Available","Chronic Pain|Musculoskeletal Pain","Other: Posturographic evaluation","Stability Score|average velocity moment [mm^2/s]|sway path length [mm]|frequency content [Hz]","Carrick Institute for Graduate Studies","All","18 Years and older   (Adult, Older Adult)","Not Applicable","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","CI-IRB-20150818005","October 2015","January 2017","January 2017","October 16, 2015","null","February 20, 2017","Optim Orthopedics - DeRenne, Savannah, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02577653"
241,"NCT02575079","Parafilm to Prevent CLABSI in Pediatric Patients Undergoing HCT",,"Completed","No Results Available","Central Line Associated Bloodstream Infections (CLABSI)|Bone Marrow Transplant","Device: Parafilm","Feasibility of the use of parafilm in inpatients, assessed by subject compliance|Feasibility of the use of parafilm in outpatients, assessed by subject compliance|Change in the rate of central line associated bloodstream infections (CLABSI)|Number of pediatric HCT patients at risk of CLABSI as determined by pre and post-HCT factors","Emory University","All","up to 21 Years   (Child, Adult)","Not Applicable","48","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","IRB00080344","March 2015","March 29, 2018","March 29, 2018","October 14, 2015","null","June 20, 2018","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02575079"
242,"NCT02567292","Human Milk for Congenital Gastrointestinal Disorders","HM for CGD","Recruiting","No Results Available","Congenital Gastrointestinal Disorders","Other: Human Milk","Time to full enteral feeding|Number of days of parenteral nutrition|Length of hospital stay|Difference in conjugated bilirubin levels|Feeding intolerance|Feeding interruptions|Episodes of Necrotizing Enterocolitis|Number of sepsis episodes|Death rate","Emory University|Chatham Valley Foundation|Prolacta Bioscience","All","up to 1 Year   (Child)","Not Applicable","150","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","IRB00080481","July 26, 2018","May 31, 2020","April 30, 2021","October 2, 2015","null","August 6, 2018","Children's Healthcare of Atlanta-Egleston, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02567292"
243,"NCT02566577","Physiologic Effects of RBC Transfusion",,"Completed","No Results Available","Red Blood Cell Transfusion","Biological: Fresh red blood cell (RBC) transfusion|Biological: Storage-aged red blood cell (RBC) transfusion|Device: Electronic infusion pump","Change in flow-mediated vasodilation (FMD)|Change in reactive hyperemic index (RHI)|Maximal oxygen uptake (VO2Max)|Respiratory exchange ratio (RER):|O2 pulse|Peak VO2 lean|Change in oxidative stress markers|Change in levels of nitric oxide metabolites|Change in High-sensitivity C-reactive protein (hsCRP)hsCRP|Change in levels of IL-6|Change in levels of IL-2","Emory University","All","21 Years to 80 Years   (Adult, Older Adult)","Phase 4","15","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","IRB00064523","July 2013","March 2018","March 2018","October 2, 2015","null","July 3, 2018","Emory University Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02566577"
244,"NCT02565199","Premotor Cortex: A New Target for Stroke Motor Rehabilitation",,"Recruiting","No Results Available","Stroke","Device: rTMS over Premotor Cortex (Contralateral Hemisphere)|Device: rTMS over Premotor Cortex (Ipsilateral Hemisphere)|Device: rTMS (Control 1)|Device: rTMS (Control 2)|Device: rTMS (Control 3)|Other: Motor Training","Change in wrist acceleration|Change in stimulus response curve (SRC)|Change in short interval intracortical inhibition (SICI)|Change in wrist force|Change in reaction time|Change in task accuracy","Emory University|American Heart Association","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","IRB00081901","September 2015","August 1, 2019","August 1, 2019","October 1, 2015","null","August 29, 2018","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02565199"
245,"NCT02560805","Role of Sympathetic Overactivity and Angiotensin II in PTSD and CV","ANG-P","Recruiting","No Results Available","Stress Disorders, Post-Traumatic","Procedure: Microneurography|Behavioral: Combat virtual reality video clip|Procedure: Handgrip Exercise|Procedure: Cold Pressor Test (CPT)|Drug: Sodium Nitroprusside (SNP)|Drug: Phenylephrine|Drug: Losartan|Drug: Atenolol","Muscle sympathetic nerve activity at rest and during mental stress|Change in Baroreflex sensitivity (BRS) at rest and during mental stress|Change in inflammatory biomarkers|Change in Blood Pressure|Change in PTSD symptoms","Emory University|American Heart Association","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","134","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","IRB00082400","October 2015","August 2020","August 2020","September 25, 2015","null","October 5, 2018","Atlanta VA Medical Center, Decatur, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02560805"
246,"NCT02558712","Technology-based Eye Care Services (TECS) Compare",,"Completed","No Results Available","Cataract|Macular Degeneration|Glaucoma","Other: Technology-based Eye Care Services (TECS) Protocol","Number of patients with accurate diagnosis of eye diseases from TECS protocol versus face to face eye exam with and without OCT|Number of patients appropriately referred from the TECS protocol|Number of participants with an accurate diagnosis for anterior segment disease|Inter-reader variability of the TECS protocol|Intra-reader variability of the TECS protocol","Emory University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","256","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","IRB00080630","March 2016","September 2017","September 23, 2017","September 24, 2015","null","April 13, 2018","Atlanta VA Medical Center, Decatur, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02558712"
247,"NCT02548819","University Hospital Cardiac Device MR Registry: The Safety of MR Imaging in Patients With Implanted Cardiac Devices","CDMR","Completed","No Results Available","MRI|Pacemaker|Defibrillator","Other: MRI","Battery voltage|Pacing lead impedance|Shock impedance|P wave amplitude|R wave amplitude|Pacing lead threshold|Adverse event","University Health Care System, Augusta, Georgia","All","18 Years and older   (Adult, Older Adult)","","220","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","IORG0000351","September 2015","March 2017","March 2017","September 14, 2015","null","June 1, 2017","University Hospital, Augusta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02548819"
248,"NCT02519504","Intervention and Outcomes in Duarte Galactosemia",,"Completed","No Results Available","Duarte Galactosemia","","Children's Memory Scale|Auditory working memory using Wechsler Intelligence Scale for Children IV-Integrated (WISC-IV-Integrated): Digit Span|Spatial working memory using Wechsler Intelligence Scale for Children IV-Integrated (WISC-IV-Integrated): Spatial Span|Executive Functioning in Verbal Domain using A Developmental NEuroPSYchological Assessment-II (NEPSY-II): Word Generation|Planning Ability in the Visual-Spatial Domain using A Developmental NEuroPSYchological Assessment-II (NEPSY-II): Route-Finding|Behavior Rating Inventory of Executive Function (BRIEF)|Wechsler Abbreviated Scale of Intelligence-II (WASI-II): Vocabulary|Wechsler Abbreviated Scale of Intelligence-II (WASI-II): Matrix Reasoning|Auditory Brainstem Evoked Response (ABER)|Pure-tone hearing assessment|Diagnostic Evaluation of Articulation and Phonology (DEAP)|Word repetition task|A connected speech sample|Oral and Written Language Scales, 2nd edition (OWLS-II): Listening Comprehension (LC)|Oral and Written Language Scales, 2nd edition (OWLS-II): Oral Expression (OE)|Movement Assessment Battery for Children-2 (Movement ABC-2): Performance Test|Strength assessed using the Iowa Oral Performance Instrument (IOPI)|Essential Tremor Rating Assessment Scale (TETRAS)|Social Skills Improvement System (SSIS) Rating Scales|Child Behavior Checklist for Ages 6-18 (CBCL/6-18)|Revised Children's Manifest Anxiety Scale-2nd edition (RCMAS-2)|Participation in Special Education or Other Intervention Experiences|Parenting Stress Index - Short Form (PSI-SF)|Upper extremity steadiness|Pen pressure|Hand strength measurements|The Goldman Fristoe Test of Articulation-3 (GFTA-3) Score|The Children's Depression Inventory-2 (CDI-2) Score","Emory University|Patient-Centered Outcomes Research Institute","All","6 Years to 12 Years   (Child)","","600","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","IRB00081271","July 2015","November 12, 2017","November 12, 2017","August 11, 2015","null","November 29, 2017","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02519504"
249,"NCT02513485","Inflammation-related Alterations in Neurocircuitry: Reversal With Levodopa",,"Recruiting","No Results Available","Depression","Drug: Levodopa+carbidopa|Drug: Placebo","Change in functional corticostriatal connectivity|Correlation coefficient between change in corticostriatal connectivity and levels of plasma C-reactive protein and other immune markers|Correlation coefficient between change in cerebral blood flow (CBF) and change in functional connectivity|Effort-Expenditure for Rewards Task (EEfRT) neurocognitive test|The Trail Making Test (TMT) neurocognitive assessment|Digit Symbol Task neurocognitive test|Finger Tapping Task (FTT) neurocognitive test|Reaction Time Task (CANTAB) neurocognitive test|Multidimensional Fatigue Inventory (MFI) self-report questionnaire|Snaith-Hamilton Pleasure Scale (SHAPS) self-report questionnaire|Inventory of Depressive Symptoms-Self Report (IDS-SR) questionnaire|Beck Depression Inventory (BDI-II), Anhedonia Subscale questionnaire|Profile of Mood States (POMS) scale|State-Trait Anxiety Inventory (STAI) State Scale","Emory University|National Institute of Mental Health (NIMH)","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","80","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","IRB00081486|R01MH109637","July 2015","June 2020","June 2020","July 31, 2015","null","June 14, 2018","Emory University Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02513485"
250,"NCT02485639","Analysis of Bone Marrow and Blood B Cell Immune Responses to Influenza Vaccination",,"Recruiting","No Results Available","Influenza","Biological: Influenza Virus Vaccine Inactivated","Number of influenza-specific antibody secreting cells (ASC) present in the blood 7 days post-vaccination.|Number of influenza-specific antibody secreting cells (ASC) present in the bone marrow 28 days post vaccination|Number of influenza-specific antibody secreting cells (ASC) present in the bone marrow 365 days post vaccination|Number of influenza-specific antibody secreting cells (ASC) present in the bone marrow prior to vaccination|Number of influenza-specific memory B cells present in the blood prior to vaccination and at 14 days, 28 days, 90 days, and 365 days post-vaccination.|Percentage of seroconverting subjects who maintain an HAI titer >/=1:40 approximately 365 days after the study vaccination.|Percentage of subjects achieving seroconversion to each of the 3 strains in the vaccine. Defined as pre-vaccination HAI titer <1:40 against a particular strain.|Percentage of subjects achieving seroconversion to each of the 3 strains in the vaccine. Defined as day 28 post vaccination titer >/= 1:40 against the same strain|Frequency of hemagglutinin stem reactive responses to influenza vaccine among blood plasmablasts at 7 days post-vaccination.|Frequency of hemagglutinin stem reactive responses to influenza vaccine among the bone marrow plasma cells at 28 days post vaccination.|Frequency of hemagglutinin stem reactive responses to influenza vaccine among the bone marrow plasma cells at 365 days post vaccination","National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years to 49 Years   (Adult)","Phase 4","55","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","14-0059|HHSN272201400004C","December 23, 2015","June 4, 2019","June 4, 2020","June 30, 2015","null","September 24, 2018","Emory Clinic - Winship Cancer Institute, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02485639"
251,"NCT02483910","Direct Instruction Language for Learning in Autism Spectrum Disorder","DILL ASD","Recruiting","No Results Available","Autism Spectrum Disorder|Moderate Language Delay","Behavioral: Direct Instruction-Language for Learning (DI-LL)|Behavioral: Treatment as Usual","Change in the Clinical Evaluation of Language Fundamentals-4 (CELF-4) Score|Change in Clinical Evaluation of Language Fundamentals-Preschool 2 (CELF-P) Score|Change in Growth Scale Value score of the Expressive Vocabulary Test-2 (EVT-2)|Improvement item of the Clinical Global Impression scale (CGI-I)|Change in Direct Observation of Spoken Language (DOSL)|Change in Parent-nominated Language Problems (PLPs)|Change in Parent-rated Vineland Adaptive Behavior Scales II (Vineland-II)|Change in Clinician-rated Children's Yale-Brown Obsessive-Compulsive Scales-Autism Spectrum Disorder (CYBOCS-ASD)|Change in Parenting Stress Index - Short Form (PSI-SF)|Change in Caregiver Strain Questionnaire (CGSC)|Parent Satisfaction Survey","Emory University","All","4 Years to 7 Years   (Child)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","IRB00081144|AR140208","October 2015","June 2020","July 2020","June 29, 2015","null","July 25, 2018","Marcus Autism Center - Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02483910"
252,"NCT02482987","Comparison of Two Different Alveolar Ridge Preservation Techniques",,"Enrolling by invitation","No Results Available","Loss of Teeth Due to Extraction","Device: dense polytetrafluoroethylene (dPTFE) membrane Cytoplast|Device: human amniotic-tissue derived membrane BioXclude|Procedure: Ridge Preservation with overlay graft|Procedure: Ridge Preservation without overlay graft","Alveolar Ridge Width|Alveolar Ridge Height|Post-operative pain perception|Platform size of implant placed|Keratinized tissue width (baseline)|Keratinized tissue width (final)|Elian classification (anticipated)|Elian classification (actual)|Buccal plate thickness|Buccal plate fenestration|Complications after surgery (infection)|Complications after surgery (membrane exfoliation)|Peri-operative clinician's report (extraction difficulty)","Eisenhower Army Medical Center","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","150","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","408953-1","July 2015","July 2018","July 2018","June 26, 2015","null","February 7, 2017","Tingay Dental Clinic, Fort Gordon, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02482987"
253,"NCT02473224","Optimal Human Dose for GII.2 Norovirus (Snow Mountain) Challenge Studies",,"Active, not recruiting","No Results Available","Gastroenteritis Norovirus","Biological: Norovirus GII.2 Challenge|Other: Placebo","Infectious Dose-50 based on infection rate after challenge with various doses|Number of serious adverse events related to virus challenge|Number of subjects experiencing any mild reactogenicity outcomes|Number of subjects experiencing any moderate reactogenicity outcomes|Number of subjects experiencing any severe reactogenicity outcomes|Number of subjects experiencing Grade 3 adverse events|Proportion of subjects with GII.2 Snow Mountain norovirus-associated illness following GII.2 challenge|Duration of diarrhea related to the challenge strain|Duration of virus shedding in PCR-positive stool for each challenge dose|Duration of vomiting related to the challenge strain|Levels of pre-existing serum blockage IgG prior to challenge|Levels of pre-existing serum IgA prior to challenge|Levels of pre-existing serum IgG prior to challenge|Levels of pre-existing serum salivary IgA prior to challenge|Magnitude of virus shedding in PCR-positive stools, reported as GEC/ml|Proportion of subjects excreting challenge virus in stool|Proportion of subjects showing a >/= 4 fold rise in virus-specific serum IgG|Proportion of subjects with =/> 4 fold rise in virus-specific salivary IgA|Proportion of subjects with =/> 4 fold rise in virus-specific serum blockage IgG|Proportion of subjects with =/> 4 fold rise in virus-specific serum IgG|Proportion of subjects with >/= 4 fold rise in virus-specific serum IgA|Proportion of subjects with norovirus specific IgA-ASC/10^6 PBMC (freshly isolated PBMCs)|Proportion of subjects with norovirus specific IgG-ASC/10^6 PBMC (freshly isolated PBMCs)|Severity of diarrhea related to the challenge strain, determined using the Vesikari Score|Severity of vomiting related to the challenge strain, determined using the Vesikari Score","National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years to 49 Years   (Adult)","Phase 1","44","NIH","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other","12-0034","October 28, 2015","December 20, 2018","null","June 16, 2015","null","October 8, 2018","Emory Vaccine Center - The Hope Clinic, Decatur, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02473224"
254,"NCT02471833","Health Evaluation in African Americans Using RAS Therapy","HEART","Recruiting","No Results Available","Alzheimer's Disease","Drug: Telmisartan 20mg|Drug: Telmisartan 40mg|Drug: Placebo","Change in concentration of cerebrospinal fluid angiotensin metabolites|Change in levels of plasma angiotensinogen|Change in levels of plasma renin|Change in levels of plasma angiotensin converting enzyme|Change in levels of plasma aldosterone|Change in levels of cerebrospinal fluid amyloid β42|Change in levels of cerebrospinal fluid T-tau|Change in levels of cerebrospinal fluid P-tau|Change in arterial function|Flanker Inhibitory Control and Attention Test|Set-shifting Test|Spatial 1-Back Test|Montreal Cognitive Assessment|Mini Mental State Examination (MMSE)|Wechsler Adult Intelligence Scale (WAIS)-Working Memory subtests|Wechsler Memory Scale-III Faces Test|Wechsler Memory Scale-Revised Logical Memory Test|Rey Auditory Verbal Learning Test|Arterial Spin Labeling-Magnetic Resonance Imaging|Structural Magnetic Resonance Imaging and White Matter Hyperintensities","Emory University","All","45 Years and older   (Adult, Older Adult)","Phase 1","66","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","IRB00080192","April 2015","April 2019","April 2019","June 15, 2015","null","July 12, 2018","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02471833"
255,"NCT02466464","Microporous Polysaccharide Hemospheres Epistaxis",,"Withdrawn","No Results Available","Epistaxis","Device: Microporous Polysaccharide Hemospheres|Device: Nasal Tampon","Number of subjects with resolution of bleed|Time until resolution of bleeding","Emory University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","0","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00070733","January 1, 2015","December 31, 2015","December 31, 2015","June 9, 2015","null","January 26, 2017","Emory University Department of Otolaryngology Clinic, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02466464"
256,"NCT02465463","Early FMT for C.Difficile",,"Completed","Has Results","Clostridium Difficile","Procedure: Fecal microbiota transplant (FMT)|Device: flexible sigmoidoscopy","Clinical Remission Rates|Number of Participants That Experience Serious Adverse Events|Change in the Shannon Diversity Index|Mean Short Form - 36 (SF-36) Score|Mean Hospital Anxiety And Depression Scale (HADS) Score|Mean Cost of Treatment","Emory University","All","18 Years to 79 Years   (Adult, Older Adult)","Phase 1|Phase 2","13","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00077804","June 2015","November 2016","November 2016","June 8, 2015","January 31, 2018","January 31, 2018","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02465463"
257,"NCT02464527","Stimulus-Stimulus Pairing Study",,"Completed","No Results Available","Autism Spectrum Disorder","Behavioral: Stimulus-stimulus pairing|Other: Vocal recorder","Feasibility of intervention assessed by a change in frequency of target vocalizations and/or approximations during sessions|Change in frequency of target vocalizations and/or approximations at home|Change in parent-reported vocalizations|Feasibility of intervention assessed by reliability of delivery by therapists|Acceptability of stimulus-stimulus pairing (SSP) by parents|Feasibility of intervention assessed by compliance of the vocal recorder|Feasibility of the vocal recorder assessed by the utility of vocal recorder","Emory University","All","24 Months to 47 Months   (Child)","Not Applicable","16","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00073588","June 2014","May 2015","May 2015","June 8, 2015","null","July 15, 2016","Marcus Autism Center, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02464527"
258,"NCT02461212","Validation of HepaFat-Scan for Noninvasive Measurement of Steatosis in Youth",,"Completed","No Results Available","Non-alcoholic Fatty Liver Disease","Procedure: Magnetic Resonance Imaging (MRI)","Correlation between HepaFat-Scan and pathology based assessment of steatosis|Correlation of HepaFat-Scan measurement with magnetic resonance spectroscopy (MRS) and computerized steatosis|Correlation of HepaFat-Scan measurement with magnetic resonance spectroscopy (MRS) and grade of pathology of assessment|Repeatability of HepaFat-Scan","Emory University|Resonance Health","All","7 Years to 18 Years   (Child, Adult)","Not Applicable","50","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","IRB00078470","July 1, 2015","March 17, 2017","March 17, 2017","June 3, 2015","null","April 10, 2017","Children's Healthcare of Atlanta at Egleston, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02461212"
259,"NCT02457832","Motor Training in PD",,"Recruiting","No Results Available","Parkinson Disease","Behavioral: Adapted Tango Dancing|Behavioral: Behavioral Control (BC) Condition","Percent signal change|Connectivity strength","VA Office of Research and Development","All","40 Years and older   (Adult, Older Adult)","Not Applicable","99","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","N0870-W","November 3, 2014","August 31, 2019","December 31, 2019","May 29, 2015","null","October 4, 2018","Atlanta VA Medical and Rehab Center, Decatur, GA, Decatur, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02457832"
260,"NCT02454699","Safety and PK of MBX-400 (Cyclopropavir) in Normal Volunteers",,"Completed","No Results Available","Cytomegalovirus Infection","Drug: MBX400|Other: Placebo","Frequency of clinical and laboratory adverse events and serious adverse events related to the study product through Day 22.|Amount of drug excreted in urine with dose 1|Amount of drug excreted in urine with dose 7|Drug accumulation ratio|Pharmacokinetic characteristics of MBX-400: amount excreted in urine (Ae)|Pharmacokinetic characteristics of MBX-400: AUC0-inf|Pharmacokinetic characteristics of MBX-400: CI/F|Pharmacokinetic characteristics of MBX-400: Cmax|Pharmacokinetic characteristics of MBX-400: drug accumulation ratio between days 1 and 7.|Pharmacokinetic characteristics of MBX-400: t1/2|Pharmacokinetic characteristics of MBX-400: Tmax|Pharmacokinetic characteristics of MBX-400: total urine collection and clearance (Clu)|Pharmacokinetic characteristics of MBX-400: Vd/F","National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","24","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","13-0092|HHSN272201300018I","November 10, 2015","April 1, 2017","December 1, 2017","May 27, 2015","null","December 26, 2017","Emory Vaccine Center - The Hope Clinic, Decatur, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02454699"
261,"NCT02447861","Characterization of 3q29 Deletion Syndrome and 3q29 Duplication Syndrome",,"Recruiting","No Results Available","Microdeletion 3q29 Syndrome|Microduplication 3q29 Syndrome","","Range of medical conditions associated with the 3q29 deletion and duplication, assessed by the percent of patients reporting specific conditions present|Change in Autism Spectrum Screening Questionnaire (ASSQ)|Change in Social Responsiveness Scale (SRS)|Change in Social Communication Questionnaire (SCQ)|Change in the Child Behavior Checklist (CBCL)|Change in Developmental Profile, version 3 (DP-3)|Change in Prodromal Questionnaire - Brief Version (PQ-B)|Feeding questionnaire|Caregiver experiences|Assessment of behavior","Emory University","All","Child, Adult, Older Adult","","600","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","IRB00064133","July 2013","March 2021","March 2021","May 19, 2015","null","January 18, 2018","Internet-Based, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02447861"
262,"NCT02438423","Inactivated Influenza Vaccine Delivered by Microneedle Patch or by Hypodermic Needle",,"Unknown status","No Results Available","Influenza","Biological: Inactivated influenza vaccine|Other: Placebo","To evaluate the safety and reactogenicity following receipt of inactivated influenza vaccine delivered by microneedle patch (either by staff or self-administered).|To evaluate the HAI titers following receipt of inactivated influenza vaccine delivered either by microneedle patch or by hypodermic needle (both vaccines administered by study staff).|To evaluate unsolicited adverse events following receipt of IIV delivered by microneedle patch (administered by study staff or self-administered).|To evaluate new-onset chronic illnesses (NOCI) following receipt of IIV delivered by microneedle patch (administered by study staff or self-administered).","Mark Prausnitz|Emory University|Georgia Institute of Technology","All","18 Years to 49 Years   (Adult)","Phase 1","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention","2015 TIV-MNP","June 2015","March 2016","September 2016","May 8, 2015","null","August 9, 2016","The Hope Clinic, Decatur, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02438423"
263,"NCT02432339","Effects of an Immunosuppressant Mycophenolate Mofetil or MMF on the Urinary Sodium Excretion Response to Mental Stress","MMF","Recruiting","No Results Available","Psychological Stress|Hypertension, Renal","Drug: mycophenolate mofetil (MMF)|Drug: Placebo","Urinary sodium excretion rate|Hemodynamics- change in systolic blood pressure compared to changes in sodium excretion","Augusta University","All","18 Years to 50 Years   (Adult)","Phase 1|Phase 2","50","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","611878","April 2014","April 2019","April 2019","May 4, 2015","null","January 10, 2018","Augusta University, Augusta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02432339"
264,"NCT02431936","Effectiveness of Prazosin on the Urinary Sodium Excretion Response to Mental Stress",,"Recruiting","No Results Available","Hypertension|Stress, Psychological|Blood Pressure","Drug: Prazosin|Drug: Placebo","Urinary sodium excretion rate|Hemodynamics: change in systolic blood pressure","Augusta University|The University of Texas at Arlington","All","18 Years to 50 Years   (Adult)","Phase 2","50","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","611851","April 2015","April 2019","April 2019","May 1, 2015","null","January 10, 2018","Augusta University, Augusta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02431936"
265,"NCT02430337","A Technology-Enhanced Approach for Implementing Evidence-Based Practices in Child Welfare",,"Completed","No Results Available","Child Maltreatment|Implementation|Technology","Behavioral: Technology-Assisted SafeCare|Behavioral: SafeCare","Feasibility of Technology-Assisted SafeCare as measured by provider satisfaction surveys and qualitative interviews|Job demands and resources as measured by the Job Content Questionnaire and questions developed by the investigators - baseline measurement|Job demands and resources as measured by the Job Content Questionnaire and questions developed by the investigators - 3-month follow-up measurement|Job demands and resources as measured by the Job Content Questionnaire and questions developed by the investigators - 6-month follow-up measurement|Fidelity as measured by the SafeCare fidelity checklist|Phase of implementation completion|Time spent on SafeCare session preparation, completion, and follow-up as documented on a time diary form|Parent child abuse potential as measured by the Brief Child Abuse Potential Inventory - Baseline Measurement|Change in parent child abuse potential as measured by the Brief Child Abuse Potential Inventory at approximately 18 weeks|Child internalizing and externalizing problems as measured by the Child Behavior Checklist - Baseline measurement|Change in child internalizing and externalizing problems as measured by the Child Behavior Checklist at approximately 18 weeks|Parental use of SafeCare parent-child interaction skills as measured by standard SafeCare assessment (Child Planned Activities Training Checklist) - baseline measurement|Change in parental use of SafeCare parent-child interaction skills as measured by standard SafeCare assessment (Child Planned Activities Training Checklist) at six weeks post baseline|Parental use of SafeCare safety skills as measured by standard SafeCare assessment (Home Accident Prevention Inventory) - baseline measurement|Change in parental use of SafeCare safety skills as measured by standard SafeCare assessment (Home Accident Prevention Inventory) at six weeks post baseline|Parental knowledge of SafeCare health skills as measured by standard SafeCare assessment (Sick or Injured Child Checklist) - baseline measurement|Change in parental knowledge of SafeCare health skills as measured by standard SafeCare assessment (Sick or Injured Child Checklist) at six weeks post baseline|Parent Participant Satisfaction","Georgia State University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","62","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","5R21MH098244-02","April 2013","June 2014","December 2016","April 30, 2015","null","August 2, 2017","Georgia State University, School of Public Health, National SafeCare Training & Research Center, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02430337"
266,"NCT02424643","Improving Survey Procedures for Young Men Who Have Sex With Men in Web-based HIV Prevention: Retention Study",,"Completed","No Results Available","Healthy","Behavioral: Monetary Incentive|Behavioral: Altruistic Incentive|Behavioral: Dashboard Incentive","Proportion of survey completed before dropping out.","Emory University","Male","18 Years to 34 Years   (Adult)","Not Applicable","1131","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","IRB00065333a","April 2015","July 2015","July 2015","April 23, 2015","null","May 9, 2016","Rollins School of Public Health, Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02424643"
267,"NCT02422810","High-Shear Microfluidic Thrombosis Assay",,"Completed","No Results Available","Coagulation Defects, Other and Unspecified","","Thrombotic occlusion time","Emory University","All","45 Years and older   (Adult, Older Adult)","","16","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","IRB00075811","May 2015","October 2015","October 2015","April 21, 2015","null","June 7, 2018","Emory Clinic, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02422810"
268,"NCT02421978","Inflammation-Induced CNS Glutamate During Breast Cancer Treatment",,"Active, not recruiting","No Results Available","Breast Cancer","","Ratio of Glutamate to Creatine|Levels of peripheral blood markers of inflammation|Cognitive dysfunction|Behavioral assessments","Emory University","Female","21 Years to 65 Years   (Adult, Older Adult)","","90","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","IRB00080062","May 2015","December 2018","December 2018","April 21, 2015","null","June 7, 2018","Emory University Department of Psychiatry and Behavioral Sciences, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02421978"
269,"NCT02416206","High Dose Chemotherapy Using BeEAM for Autologous Transplant in Multiple Myeloma",,"Recruiting","No Results Available","Multiple Myeloma","Drug: BeEAM","To estimate the response at day 100 following transplant (rate of CR)|Number of patients with overall survival post-transplant|Number of patients with event-free survival|Number of patients with non-relapse mortality","Northside Hospital, Inc.|Teva Pharmaceuticals USA","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","65","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NSH 1107","April 2015","December 2019","May 2020","April 14, 2015","null","June 29, 2018","Blood and Marrow Transplant Group of Georgia, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02416206"
270,"NCT02411877","REperfusion With Cooling in CerebraL Acute IscheMia II","RECCLAIM-II","Withdrawn","No Results Available","Ischemic Stroke|Hypothermia","Procedure: Normothermia|Procedure: Mild hypothermia|Device: Trevo Pro Retriever (Stryker Corp.)|Device: Zoll Thermogard XP technology with the Quattro catheter","Hemorrhagic Conversion|Hyperintense Acute Reperfusion Marker (HARM)|National Institutes of Health Stroke Scale (NIHSS)|Modified Rankin Scale (mRS)|Number of participants with adverse events","WellStar Health System|Zoll Medical Corporation","All","18 Years to 79 Years   (Adult, Older Adult)","Phase 2","0","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","RECCLAIM II-S","February 2016","November 2017","November 2017","April 8, 2015","null","February 17, 2016","WellStar Kennestone Regional Medical Center, Marietta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02411877"
271,"NCT02411773","Sympatholysis in Chronic Kidney Disease","Sym-CKD","Recruiting","No Results Available","Chronic Kidney Disease","Drug: Sodium Bicarbonate|Drug: Placebo|Other: Exercise Training|Other: Stretching","Change in muscle oxygenation after exercise/stretching training|Change in muscle interstitial pH after exercise/stretching training|Change in venoconstriction after exercise/stretching training|Change in muscle oxygenation after handgrip exercise|Change in muscle interstitial pH after handgrip exercise|Change in venoconstriction after phenylephrine","Emory University","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","110","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00078214","May 2015","June 2021","June 2021","April 8, 2015","null","July 23, 2018","Atlanta VA Medical Center, Decatur, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02411773"
272,"NCT02406586","Free Fatty Acids-Induced Hypertension in Obese Subjects (Aim #2)","FFAADA","Completed","Has Results","Hypertension|Diabetes","Drug: Salsalate|Drug: Carvedilol|Drug: Placebo|Drug: Intralipid 20%","Change in Systolic Blood Pressure|Change in Flow-mediated Dilation|Change in Diastolic Blood Pressure From Baseline to 6 Weeks|Change in Oxidative Stress Markers|Change in Augmentation Index (AIx)|Change in Expression of Inflammatory Biomarkers (Interleukin-1 (IL-1), Interleukin-6 (IL-6), Interleukin-12 (IL-12), Tumor Necrosis Factor Alpha (TNF-alpha), and C-Reactive Protein (CRP))|Change in FFA (Free Fatty Acid) Levels From Baseline to 6 Weeks|Change in Pulse Wave Velocity (PWV)","Emory University|American Diabetes Association","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","36","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","IRB00009277a","July 2009","March 2011","March 2011","April 2, 2015","May 28, 2015","May 28, 2015","Grady Memorial Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02406586"
273,"NCT02404597","Cardiac Output Monitoring in Burn Patients",,"Withdrawn","No Results Available","Burns","Device: NICOM (non-invasive cardiac output monitor)","Total volume of fluid given|Rate of pressor use|Rate of pulmonary edema|Rate of acute renal failure|Length of stay in intensive care unit (ICU)|Length of hospital stay","Emory University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","0","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","IRB00078576","January 2018","March 2018","March 2018","March 31, 2015","null","February 28, 2018","Grady Memorial Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02404597"
274,"NCT02401230","PrEP, Lube, and the Rectal Mucosa in MSM at Risk of HIV",,"Completed","Has Results","HIV","Drug: Truvada|Device: Gel lubricant","Median Percentage of CD4 Positive T-Cells|Median Cumulative Amount of p24|Median Plasma Emtricitabine (FTC) Concentration|Median Plasma Tenofovir (TDF) Concentration|Median Rectal Secretion Emtricitabine (FTC) Concentration|Median Rectal Secretion Tenofovir (TDF) Concentration|Median Peripheral Blood Mononuclear Cell (PBMC) Emtricitabine (FTC) Concentration|Median Peripheral Blood Mononuclear Cell (PBMC) Tenofovir (TDF) Concentration|Median Rectal Tissue Emtricitabine (FTC) Concentration|Median Rectal Tissue Tenofovir (TDF) Concentration|Median Rectal Tissue Deoxyadenosine Triphosphate (dATP) Concentration|Median Rectal Tissue Deoxycytidine Triphosphate (dCTP) Concentration|Median Peripheral Blood Mononuclear Cell (PBMC) Deoxyadenosine Triphosphate (dATP) Concentration","Emory University|Centers for Disease Control and Prevention","Male","18 Years to 49 Years   (Adult)","Phase 4","86","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","IRB00077593","March 2015","January 25, 2017","January 25, 2017","March 27, 2015","February 16, 2018","February 16, 2018","The Hope Clinic of of Emory University, Decatur, Georgia, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/30/NCT02401230/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/30/NCT02401230/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02401230"
275,"NCT02397863","Epidiolex and Drug Resistant Epilepsy in Children","CBD","Available","No Results Available","Epilepsy","Drug: Cannabidiol (Epidiolex)","","Augusta University|State of Georgia","All","1 Year to 18 Years   (Child, Adult)","","null","Other","Expanded Access","","CBD02","December 2014","December 2019","January 2020","March 25, 2015","null","April 24, 2015","Georgia Regents University, Augusta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02397863"
276,"NCT02395289","Cognitive-Based Compassion Training (CBCT) for People Living With HIV (PLHIV)",,"Completed","No Results Available","Human Immunodeficiency Virus","Behavioral: Cognitive-Based Compassion Training (CBCT)|Behavioral: Health discussion","Change in plasma concentration of circulating inflammatory biomarker interleukin-6 (IL-6)|Change in plasma concentration of circulating inflammatory biomarker soluble cluster of differentiation 14 (sCD14)|Change in scores on the Perceived Stress Scale (PSS)|Change in scores on the General Well-Being (GWB) Schedule Scale|Change in scores on the Illness Cognition Questionnaire (ICQ)|Change in scores on the World Assumptions Scale (WAS)|Change in scores on the Life Regard Index - Revised (LRI-R).|Change in scores on the Rosenberg self-esteem scale|Change in scores on the Berger HIV Stigma Scale|Change in serum levels of C-reactive protein (CRP)|Acceptance of Cognitive-Based Compassion Training (CBCT), measured by participant satisfaction","Emory University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","54","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care","IRB00075221","March 2016","December 2016","December 2016","March 23, 2015","null","February 1, 2017","Grady Hospital - Ponce De Leon Clinic, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02395289"
277,"NCT02390843","Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors","AflacST1402","Recruiting","No Results Available","Retinoblastoma|Clear Cell Sarcoma|Renal Cell Carcinoma|Rhabdoid Tumor|Wilms Tumor|Hepatoblastoma|Neuroblastoma|Germ Cell Tumors|Ewings Sarcoma|Non-rhabdomyosarcoma Soft Tissue Sarcoma|Osteosarcoma|Rhabdomyosarcoma","Drug: Simvastatin|Drug: Cyclophosphamide|Drug: Topotecan|Drug: Myeloid growth factor","Maximum Tolerated Dose (MTD) of Simvastatin|Number of Dose-Limiting Toxicities (DLTs)|Percentage of Participants With Overall Tumor Response (Response Rate)|Change in Total Cholesterol Level|Change in serum interleukin-6 (IL-6) level|Change in soluble interleukin 6 receptor (sIL-6R)|Change in signal transducer and activator of transcription 3 (STAT-3) expression|Change in phospho-STAT3 expression","Emory University|Children's Healthcare of Atlanta","All","1 Year to 29 Years   (Child, Adult)","Phase 1","36","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00078790","February 2015","February 2019","February 2021","March 18, 2015","null","May 30, 2018","Children's Healthcare of Atlanta/Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02390843"
278,"NCT02386293","Effectiveness of Avapro in Obese Normotensive/Hypertensive African Americans","Avapro3","Recruiting","No Results Available","Hypertension|Obesity|Stress, Psychological|Blood Pressure","Drug: Irbesartan|Other: Placebo","Urinary sodium excretion rate|Hemodynamics","Augusta University","All","18 Years to 50 Years   (Adult)","Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","611881","September 2014","May 2019","May 2019","March 11, 2015","null","January 10, 2018","Augusta University, Augusta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02386293"
279,"NCT02385123","Evaluation of Human Immune Responses to Influenza Virus Vaccination in Healthy Volunteers",,"Recruiting","No Results Available","Influenza","Biological: Influenza Virus Vaccine Inactivated","Percentage of subjects achieving seroconversion (percentage of subject with either prevaccination HI titer < 1:10 and post-vaccination HI titer > 1:40 or pre-vaccination HI titer > 1:10 and minimum four-fold rise in post-vaccination HI antibody titer)|Expression of human influenza-specific monoclonal antibodies from Day 7 plasmablasts and assessing their functional by ELISA, HAI, and virus neutralization assays.|For memory B cells, determine the frequency of HA head or stem specific IgG secreting memory B cells per total IgG secreting cells|For serum antibody responses directed against the HA head or stem regions, determine the endpoint IgG titers|Measure influenza hemagglutinin stem-specific and head-specific memory B-cells and serum antibody levels.|Plasmablast responses against either the HA head or stem antigens will be determined by direct ex vivo ELISPOT","National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years to 49 Years   (Adult)","Phase 4","50","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","14-0071|HHSN272201400004C","April 1, 2015","April 1, 2021","April 1, 2022","March 11, 2015","null","September 24, 2018","Emory University Hospital - W. Dean Warren General Clinical Research Center (GCRC), Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02385123"
280,"NCT02383758","An Interdisciplinary Approach to the Treatment of Encopresis in Children With Autism Spectrum Disorders",,"Completed","Has Results","Encopresis|Autistic Disorder","Drug: Glycerin Suppository|Drug: Bisacodyl suppository|Drug: Senna","Percent Continent|Percent Independence|Mean Clinical Global Impression for Severity (CGI-S) Score|Mean Clinical Global Impression for Improvement (CGI-I) Score","Emory University|Organization for Autism Research","All","5 Years to 21 Years   (Child, Adult)","Not Applicable","22","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","IRB00076608","February 1, 2015","January 1, 2017","January 1, 2017","March 9, 2015","January 11, 2018","July 2, 2018","Marcus Autism Center, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02383758"
281,"NCT02383732","A Study of the Elopement Prevention and Safety Training Program",,"Completed","No Results Available","Elopement|Autism Spectrum Disorder","Behavioral: Universal Safety Measures Module (All participants)|Behavioral: Proximity Training Module (Bolting Prevention Participants)|Behavioral: Check-In Training Module (Wandering Prevention Participants)","Feasibility of intervention, assessed by change in severity on Clinical Global Impression for Severity (CGI-S)|Change in elopement behavior","Emory University","All","4 Years to 12 Years   (Child)","Not Applicable","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","IRB00076337","February 2015","January 31, 2017","January 31, 2017","March 9, 2015","null","March 30, 2017","Marcus Autism Center, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02383732"
282,"NCT02383485","Nonalcoholic Fatty Liver Disease and Atherosclerotic Risk in Children","SMART","Completed","No Results Available","Overweight and Obesity|Non-alcoholic Fatty Liver Disease","Behavioral: Exercise|Behavioral: After-school program","Change in Liver Fat|Change in Arterial Stiffness|Change in Liver Fibrosis|Change in Liver Inflammation|Change in Quality of Life|Associations among Liver Fat, Fibrosis and Inflammation, Arterial Stiffness, and Other Cardiovascular Risk Indices","Augusta University|National Heart, Lung, and Blood Institute (NHLBI)","All","8 Years to 11 Years   (Child)","Not Applicable","175","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","R01HL087923-02S1","May 2008","May 2013","April 2014","March 9, 2015","null","March 9, 2015","Georgia Prevention Institute, Augusta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02383485"
283,"NCT02381067","A Prospective Study of NuCel® in Cervical Spine Fusion",,"Terminated","No Results Available","Spondylosis|Spinal Stenosis|Spondylolisthesis|Intervertebral Disc Disease|Intervertebral Disc Degeneration","Other: NuCel with Allograft Bone","Interbody Fusion measured using CT scans and standard radiographs|Change from baseline pain using Visual Analogue Scale (VAS)|Change from baseline Neck Disability Index (NDI)|Patient Satisfaction Survey","NuTech Medical, Inc","All","21 Years and older   (Adult, Older Adult)","Not Applicable","61","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RD2015-01-01","March 2015","December 1, 2016","December 15, 2016","March 6, 2015","null","January 20, 2017","Wellstar Hospital, Marietta,, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02381067"
284,"NCT02379949","Virtual Reality Exposure Therapy for the Treatment of Social Phobia","FOPSII","Completed","No Results Available","Social Anxiety Disorder","Behavioral: Virtual Reality Exposure Therapy|Behavioral: Exposure Group Therapy","Personal Report of Confidence as a Speaker|Fear of Negative Evaluation—Brief Form|Behavioral Avoidance Test|Clinician Global Impressions of Improvement","Georgia State University|Virtually Better, Inc.","All","18 Years and older   (Adult, Older Adult)","Not Applicable","97","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R42MH060506-02","August 2004","August 2007","August 2007","March 5, 2015","null","March 5, 2015","Georgia State University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02379949"
285,"NCT02371798","Unilateral Meniere Disease: Can Double Dose Gadolinium and Delayed Imaging Make the Diagnosis?",,"Withdrawn","No Results Available","Meniere Disease","Drug: Gadopentetate dimeglumine","Grade of endolymphatic hydrops (EH) in the cochlea and vestibule","Emory University","All","18 Years to 90 Years   (Adult, Older Adult)","Not Applicable","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic","IRB00077659","February 2015","November 2016","November 2016","February 26, 2015","null","December 1, 2016","Emory University Department of Otolaryngology Clinic, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02371798"
286,"NCT02368067","Improved Method of Detecting Cancer Metastases","SITs","Unknown status","No Results Available","Endometrial Carcinoma","Procedure: Standard of Care Sentinal Node Dye|Procedure: Study Sentinal Node Dye","Number of sentinel nodes detected by each method.|Time to detection of 1st SN by each method.|Sensitivity of each method compared to full node dissection.","Southeastern Regional Medical Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SERMC- Endometrial Carcinoma","June 2014","June 2015","December 2015","February 20, 2015","null","February 20, 2015","Southeastern Regional Medical Center, Newnan, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02368067"
287,"NCT02366832","Cryoablation for Phantom Limb Pain",,"Completed","No Results Available","Phantom Limb Syndrome","Procedure: Cryoablation|Device: 17g Galil Medical Ice Sphere cryoablation needle","Feasibility of cryoablation, defined by number of participants, in which cryoablation was performed successfully|Safety of cryoablation procedure, measured by the number of subjects that had cryoablation procedure events (CPEs).|Change in pain scores on visual analogue scale (VAS )|Change in quality of life, measured using Roland-Morris Disability Questionnaire (RDQ)","Emory University|Galil Medical","All","18 Years and older   (Adult, Older Adult)","Not Applicable","23","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","IRB00078008","February 2015","December 16, 2016","December 16, 2016","February 19, 2015","null","March 22, 2017","Emory University Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02366832"
288,"NCT02366481","Vitamin K and Glucose Metabolism in Adults at Risk for Diabetes (Vita-K 'n' Adults Study)",,"Recruiting","No Results Available","Obesity|Insulin Resistance|Insulin Sensitivity|Beta-Cell Dysfunction|Prediabetes","Dietary Supplement: Placebo|Dietary Supplement: Low-Dose Vitamin K2 Supplement (menaquinone-7; 90-mcg/d)|Dietary Supplement: High-Dose Vitamin K2 Supplement (menaquinone-7; 180-mcg/d)","Change in insulin sensitivity|Change in beta-cell function|Change in prothrombin time (PT)|Change in activated partial thromboplastin time (aPTT)|Change in arterial stiffness (PWV)|Change in endothelial function (FMD)","Augusta University|University of Alabama at Birmingham|Yale University|Tufts University|Nattopharma ASA","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","30","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","620511|16GRNT31090037","February 2015","December 1, 2018","December 30, 2018","February 19, 2015","null","July 12, 2018","Medical College of Georgia; Augusta University, Augusta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02366481"
289,"NCT02359929","BMT Auto MSCs GvHD Ph 1",,"Recruiting","No Results Available","Graft Versus Host Disease|Acute Graft Versus Host Disease|Chronic Graft Versus Host Disease","Biological: Autologous mesenchymal stromal cells (MSCs)","Safety and Tolerability of EPIC MSC2014-002 based on dose limiting toxicities (DLTs)|Overall Response Rate for acute GVHD subjects|Overall Response Rate for chronic GVHD subjects|Transplant-related mortality|Incidence of Relapse|Disease-free survival|Overall-survival","Emory University|CURE Foundation","All","12 Years and older   (Child, Adult, Older Adult)","Phase 1","24","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00076372","January 2015","January 2019","January 2020","February 10, 2015","null","May 16, 2018","Children's Healthcare of Atlanta/Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02359929"
290,"NCT02355717","Role of Cardiometabolic Risk Factors in Childhood Bone Development",,"Recruiting","No Results Available","Obesity|Cardiovascular Disease|Type 2 Diabetes|Osteoporosis","Other: Observational Study","Bone mineral mass|Bone strength-strain index|Serum N-terminal propeptide of type 1 procollagen (P1NP)|Serum C-terminal telopeptide of type 1 collagen (CTX)","Augusta University","All","9 Years to 15 Years   (Child)","","400","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","616274","December 2014","January 2020","January 2020","February 4, 2015","null","June 28, 2017","Medical College of Georgia; Augusta University, Augusta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02355717"
291,"NCT02343224","Phase II Pegylated Interferon","Peg Interferon","Recruiting","No Results Available","Juvenile Pilocytic Astrocytomas|Optic Pathway Gliomas","Drug: Pegylated interferon alpha-2b","Change in response rate of subjects to Peg-Intron from baseline to 2 years|Event Free Survival|Change in toxicity, collected using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 of the National Cancer Institute (NCI)|Change in Quality of Life, assessed by using the Functional Assessment of Cancer Therapy-Brain (Peds-FACT-Br) questionnaire","Emory University|CURE Childhood Cancer, Inc.","All","3 Years to 18 Years   (Child, Adult)","Phase 2","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00074563","November 2014","December 2019","December 2021","January 21, 2015","null","June 5, 2018","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02343224"
292,"NCT02340910","Dose-Response Effects of Whole Body Vibration on Spasticity and Walking in SCI","WBV","Recruiting","No Results Available","Spinal Cord Injury","Procedure: Short Duration|Procedure: Long Duration","Spasticity Assessments|Walking ability|Strength|Pain perception|Upper Extremity Tests|Ankle Clonus Test/Foot","Shepherd Center, Atlanta GA|National Institutes of Health (NIH)","All","16 Years to 72 Years   (Child, Adult, Older Adult)","Not Applicable","57","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","WBV-612299","January 2015","March 2020","August 2020","January 19, 2015","null","August 17, 2018","Shepherd Center, Inc., Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02340910"
293,"NCT02337257","Periodontal and Cardiometabolic Responses to Vitamin D Intervention in African Americans With Periodontal Disease","GumD","Unknown status","No Results Available","Periodontal Disease|Vitamin D Deficiency","Drug: Cholecalciferol|Drug: Placebo","Change in Periodontal Disease Activity|Change in Cardiometabolic Risk Factors|Change in Blood Myeloid Dendritic Cells","Augusta University","All","18 Years to 60 Years   (Adult)","Early Phase 1","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Pro00001693","April 2014","September 2015","December 2015","January 13, 2015","null","January 13, 2015","Georgia Prevention Institute, Augusta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02337257"
294,"NCT02328638","Development of a Manual-based, Interdisciplinary Intervention for Youth With ASD and Obesity",,"Completed","No Results Available","Autism|Obesity","Behavioral: Parent Education Program|Behavioral: Manual-based Behavioral Treatment","Change in body mass index percentile/ratio|Change in intake of healthy food|Change in physical activity","Emory University","All","3 Years to 10 Years   (Child)","Not Applicable","10","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00073170","December 2014","August 2015","August 2015","December 31, 2014","null","January 20, 2016","Pediatric Feeding Disorders Program at the Marcus Autism Center, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02328638"
295,"NCT02326597","Decision Aid for Therapeutic Options In Sickle Cell Disease",,"Completed","Has Results","Sickle Cell Disease|Sickle Cell Anemia|Hemoglobin SS|Hemoglobin SC|Hemoglobin Beta Thalassemia","Other: Decision Aid Tool|Other: Standard Practice","Acceptability of Decision Aid Education Assessed by the Acceptability Survey|Mean Decisional Self-Efficacy Scale Score|Mean Difference in Decisional Conflict Scale Scores|Mean Values Survey Score|Mean Change in Preparation for Decision Making Scale Score|Mean Knowledge Survey Scores|Mean Decisional Regret Scale Score","Emory University|Patient-Centered Outcomes Research Institute","All","8 Years to 80 Years   (Child, Adult, Older Adult)","Not Applicable","134","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research","IRB00076096a","January 2015","April 17, 2017","April 17, 2017","December 29, 2014","October 8, 2018","October 8, 2018","Emory University, Atlanta, Georgia, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/97/NCT02326597/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02326597"
296,"NCT02319681","Reminiscence, Anxiety and Early Alzheimer's Disease",,"Withdrawn","No Results Available","Alzheimer's Disease","Behavioral: Simple Reminiscence (SR)|Behavioral: Attention Control (AC)","Acceptability of SR and AC|Number of times AC was used|Number of times SR was used|Change in Beck Depression Inventory-II (BDI-II) scale|Change in State-Trait Anxiety Inventory (STAI) scale|Change in Katz Instrumental Activities of Daily Living (IADL) scale|Change in Well-Being Picture Scale (WBPS) scale|Change in Short Psychological Well-Being Scale (SPWBS) scale|Change in Revised Memory and Behavior Problems Checklist (RMBPC) scale|Caregiver's mastery of SR intervention technique|Change in levels of cortisol","Emory University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","IRB00075912","January 2015","December 2016","June 2017","December 18, 2014","null","June 26, 2015","Emory Alzheimer's Disease Research Center, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02319681"
297,"NCT02301832","Reliability of Sensor Spacing for NIRS in Traumatic Tibia Fractures",,"Completed","No Results Available","Orthopedic Disorders|Tibial Fractures","","NIRS measurements as compared to clinical findings|Accuracy of NIRS measurements compared to Intracompartmental pressure (ICP) measurements|Correlation between NIRS measurements between injured and uninjured extremity","Emory University","All","18 Years to 65 Years   (Adult, Older Adult)","","14","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IRB00075483","December 2014","July 20, 2016","July 20, 2016","November 26, 2014","null","February 6, 2017","Grady Memorial Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02301832"
298,"NCT02300584","Distance Savvy: Testing Tele-Savvy, a Distance Dementia Family Caregiver Education Program",,"Completed","No Results Available","Dementia|Alzheimer's Disease|Depression","Behavioral: Tele-Savvy|Other: iPad","The number of participants who use at least half of the opportunities (half of the conferences and half of the daily lessons)|Change in Zarit Burden Interview Score|Change in Center for Epidemiological Studies-Depression Scale Score|Change in State Trait Anxiety Index (STAI) Score|Change in Connor Davidson Resilience Scale (CD-RISC)|Change in Perceived Stress Scale|Change in Caregiver Self-Efficacy Score|Change in Personal Mastery scale|Change in Revised Memory and Behavior Problem Checklist|Change in Lawton Activities of Daily Living (ADL) / Instrumental Activities of Daily Living (IADL) Scale","Emory University","All","21 Years and older   (Adult, Older Adult)","Not Applicable","42","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","IRB00074715","November 2014","October 2015","October 2015","November 25, 2014","null","September 8, 2016","Emory Alzheimer's Disease Research Center, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02300584"
299,"NCT02299193","Online CBT-I for High Blood Pressure",,"Completed","No Results Available","Hypertension|Prehypertension|Insomnia","Behavioral: Cognitive Behavioral Therapy|Behavioral: Healthy Sleep Habits","Change in Systolic Blood Pressure|Change in Insomnia Severity Index|Changes in Sleep Efficiency|Change in Depressive Symptoms|Change in mental functioning","Emory University|American Heart Association","All","18 Years and older   (Adult, Older Adult)","Not Applicable","58","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","IRB00073066","August 2014","August 2016","August 2016","November 24, 2014","null","August 31, 2016","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02299193"
300,"NCT02296840","Post-operative Pain Control After Pediatric Adenotonsillectomy",,"Terminated","Has Results","Recurrent Tonsillitis|Obstructive Sleep Apnea|Sleep Disordered Breathing|Adverse Reaction to Drug","Drug: Ibuprofen|Drug: Hydrocodone-Acetaminophen","Faces Pain Score|Number of Participants With Post-operative Bleeding","Emory University","All","4 Years to 17 Years   (Child)","Phase 4","45","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","IRB00070851","November 2014","November 30, 2016","November 30, 2016","November 20, 2014","March 27, 2018","April 25, 2018","Children's Healthcare of Atlanta (CHOA), Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02296840"
301,"NCT02291224","Development and Testing of a Clinic-Based Intervention to Increase Dual Protection Against Unintended Pregnancy and Sexually Transmitted Diseases (STDs) Among High Risk Female Teens","2Gether","Active, not recruiting","No Results Available","Pregnancy|Sexually Transmitted Diseases","Behavioral: Interactive multimedia platform|Behavioral: Intervention arm counseling|Behavioral: Standard of care counseling","Participant selection of an effective dual protection (DP) strategy|Participant report of adherence to DP strategy|Time to first biologic event (pregnancy or diagnosis with STI) in participants|Incidence of pregnancy and sexually transmitted infections (STIs)|Participant level of reproductive health knowledge (percentage correct of knowledge questions)|Participant intention to use DP strategy|Participant reproductive health self-efficacy|Participant report of STI testing|Participant report of partner communication","Centers for Disease Control and Prevention|Emory University|Grady Health System","Female","14 Years to 19 Years   (Child, Adult)","Not Applicable","710","U.S. Fed|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","CDC-NCCDPHP-6588|DP12-001","March 2015","September 2018","September 2018","November 14, 2014","null","March 12, 2018","Grady Health System Teen Services Clinic, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02291224"
302,"NCT02283528","A Comparison of Stryker Hybrid Arch Bars","Hybrid","Completed","No Results Available","Fracture Mandible","Device: Stryker Hybrid|Device: Erich","Time to place archbars|Fracture healing|Complications (to include loosening of archbars, loosening of MMF if stratified to closed reduction and damage to adjacent teeth and structures)","Emory University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00076048","May 2015","December 21, 2017","December 21, 2017","November 5, 2014","null","January 5, 2018","Grady Memorial Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02283528"
303,"NCT02280655","Adverse Effects of Red Blood Cell Transfusions: A Unifying Hypothesis (Aim 3)","INOBA","Completed","Has Results","Cardiovascular Diseases","Biological: Storage-aged red blood cells (saRBCs) units|Biological: Fresh red blood cells units","Brachial Artery Flow-mediated Dilation (FMD) After Fresh Red Blood Cells (RBCs) Transfusions vs. Storage-aged Red Blood Cells (saRBCs) Transfusions at Baseline|Brachial Artery Flow-mediated Dilation (FMD) After Fresh Red Blood Cells (RBCs) Transfusions vs. Storage-aged Red Blood Cells (saRBCs) Transfusions at 24 Hours After Transfusion","Emory University","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","43","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","IRB00015316a","April 2009","November 2012","October 2013","October 31, 2014","December 4, 2014","April 11, 2016","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02280655"
304,"NCT02270008","Reducing Perinatal Anal Incontinence Through Early Pelvic Floor Muscle Training: a Prospective Pilot Study",,"Completed","No Results Available","Perinatal and Postpartum Anal Incontinence","Other: Pelvic floor training","Incidence of fecal and/or flatal incontinence|Exercise compliance","Emory University","Female","20 Years to 40 Years   (Adult)","Not Applicable","15","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","IRB00065572","October 2014","June 2015","June 2015","October 21, 2014","null","January 29, 2016","Emory University Department of Obstetrics and Gynecology Clinic, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02270008"
305,"NCT02267850","Effect of Intra-Oral Photobiomodulation on Orthodontic Treatment Time",,"Completed","Has Results","Malocclusion","Other: Fixed Orthodontic Appliance Treatment|Device: OrthoPulse™|Device: Non-Functional OrthoPulse™","Overall Orthodontic Treatment Time for OrthoPulse™ and Non-OrthoPulse™ Treated Patients.","Biolux Research Ltd.","All","12 Years to 40 Years   (Child, Adult)","Not Applicable","29","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TS2","May 2013","May 2016","May 2016","October 20, 2014","March 27, 2018","September 21, 2018","Shaughnessy Orthodontics, Suwanee, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02267850"
306,"NCT02267837","OrthoPulse™ and Its Effect on the Rate of Orthodontic Tooth Alignment: A Pilot Feasibility Study",,"Completed","Has Results","Malocclusion","Device: OrthoPulse™","Rate of Orthodontic Anterior Alignment in Millimetres Per Week (mm/wk) by Means of Little's Irregularity Index (LII) for OrthoPulse™ and Non-OrthoPulse™ Treated Patients.","Biolux Research Ltd.","All","11 Years to 40 Years   (Child, Adult)","Not Applicable","20","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TS1.5","December 2012","December 2013","December 2013","October 20, 2014","September 11, 2015","August 27, 2018","Shaughnessy Orthodontics, Suwanee, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02267837"
307,"NCT02264860","Researching Alveolar Macrophage Improvements With Supplements in HIV","RAISe","Recruiting","No Results Available","HIV-1 Infection","Dietary Supplement: Zinc and SAMe","Dosage Efficacy|Change in exhaled breath condensate (EBC) levels of glutathione (GSH)","Emory University|National Institutes of Health (NIH)|National Heart, Lung, and Blood Institute (NHLBI)","All","21 Years and older   (Adult, Older Adult)","Not Applicable","60","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","IRB00062730a|1R01HL125042-01","October 2014","December 2018","December 2018","October 15, 2014","null","February 1, 2018","Ponce De Leon Center, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02264860"
308,"NCT02259101","RCT of CBT for Insomnia With PLWHA",,"Completed","No Results Available","Insomnia|HIV|Aids","Behavioral: CBT-I Treatment Condition|Behavioral: SH Comparison Condition","Insomnia Symptoms|Quality of Life|Blood Sample","Emory University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","34","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","IRB00065796","November 2013","February 2016","February 2016","October 8, 2014","null","May 6, 2016","Grady Memorial Hospital/Infectious Disease Program, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02259101"
309,"NCT02258490","Expanded Use of G-CSF Mobilized Donor CD34+ Selected Cells for Allogeneic Transplantation",,"Available","No Results Available","Chronic Myeloid Leukemia|Myelodysplastic Syndrome|Acute Myeloid Leukemia","Biological: G-CSF mobilized CD34+ selected cells for transplantation","","Emory University","All","17 Years to 75 Years   (Child, Adult, Older Adult)","","null","Other","Expanded Access","","IRB00051037|EPIC-HPC001","null","null","null","October 7, 2014","null","December 5, 2017","Emory University/Winship Cancer Institute, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02258490"
310,"NCT02257476","Extended Infusion Carfilzomib on a Weekly Schedule in Patients With Advanced Solid Tumors",,"Completed","No Results Available","Neoplasms|Malignancies","Drug: Carfilzomib|Drug: Dexamethasone","Maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of a weekly 4-hour carfilzomib infusion in patients with advanced solid malignancies|Pharmacokinetics (PK) of escalating doses of weekly intravenous carfilzomib|Changes in pharmacodynamic (PD) biomarkers before and during treatment with carfilzomib using peripheral blood mononuclear cells (PBMC) and paired tumor biopsies|Preliminary anti-tumor efficacy (objective response rate)|Preliminary anti-tumor efficacy (clinical benefit rate)|Preliminary anti-tumor efficacy (progression free survival)|Preliminary anti-tumor efficacy (overall survival)","Emory University|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1","22","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00071307|WINSHIP2598-13","August 2014","November 2016","November 2016","October 6, 2014","null","February 7, 2017","Emory University Winship Cancer Institute, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02257476"
311,"NCT02246972","BraveMind: Advancing the Virtual Iraq/Afghanistan PTSD Exposure Therapy",,"Completed","No Results Available","Trauma|Post-Traumatic Stress Disorder","Behavioral: Virtual Reality Exposure Therapy (VRET)","Safely deliverable|Reduction in PTSD and depression|Reduction in PTSD and depression: wait-list comparator","Emory University|Telemedicine & Advanced Technology Research Center|University of Southern California","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","15","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","IRB00072196","May 2015","July 2017","July 2017","September 23, 2014","null","August 9, 2017","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02246972"
312,"NCT02246933","Effects of a PUFA-rich Diet on Acute Metabolic and Inflammatory High-Fat Meal Responses",,"Completed","No Results Available","Inflammation|Obesity","Other: PUFA Diet|Other: Control Diet","Change in Blood Markers|Change in Energy Expenditure|Change in Substrate Oxidation|Change in Fasting Blood Lipids|Change in Systolic Blood Pressure","University of Georgia","All","18 Years to 35 Years   (Adult)","Not Applicable","26","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","503815","September 2013","August 2015","August 2015","September 23, 2014","null","October 8, 2015","University of Georgia - Department of Foods and Nutrition, Athens, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02246933"
313,"NCT02234037","Physical Conditioning and Decitabine for Newly Diagnosed AML Patients Age ≥ 60",,"Terminated","No Results Available","Leukemia","Drug: Decitabine|Behavioral: Exercise","Performance status|Proportion of patients with 25% improvement in fitness scores|Function|Activity|Number of patients with adverse events related to the intervention.|Response to treatment|Quality of life and depression scores among study subjects before and after the 8-week exercise program","Emory University","All","60 Years and older   (Adult, Older Adult)","Phase 1","3","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00064866|WINSHIP2381-12","November 2013","February 2016","May 2016","September 9, 2014","null","January 30, 2017","Winship Cancer Institute of Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02234037"
314,"NCT02230943","Rheumatology Informatics System for Effectiveness","RISE","Unknown status","No Results Available","Rheumatoid Arthritis|Osteoarthritis|Gout","","Controlling High Blood Pressure","American College of Rheumatology","All","18 Years and older   (Adult, Older Adult)","","100000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","RISE","April 2014","December 2015","null","September 3, 2014","null","September 3, 2014","American College of Rheumatology, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02230943"
315,"NCT02227979","Effects of PURPLE Cry Intervention",,"Completed","No Results Available","Shaken Baby Syndrome|Crying|Trauma","Behavioral: The Purple Cry Intervention|Behavioral: Control Intervention","Change in neural responses to infant cry stimuli|Change in aversiveness and in empathy|Change in neural activity in the anterior insula and amygdala during unknown infant cry|Change in neural activity in the dorsolateral prefrontal cortex (PFC) and orbitofrontal PFC|Change in neural activity in the amygdala in response to their own infant's cry stimuli","Emory University","Male","18 Years and older   (Adult, Older Adult)","Not Applicable","42","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","IRB00044782a","September 2013","February 2016","February 2016","August 28, 2014","null","April 8, 2016","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02227979"
316,"NCT02227160","Group Interventions for Suicidal African Americans",,"Withdrawn","No Results Available","Depression|Mental Illness|Suicide|Suicidal Ideation","Behavioral: 10 weekly group meetings|Behavioral: Outpatient counseling and support groups","Change in scores on Beck Scale for Suicidal Ideation|Change in scores on Beck Depression Inventory - II|Change in scores on Beck Hopelessness Scale|Change in scores on WHO Quality of Life Brief Instrument|Patient Satisfaction","Emory University","All","18 Years to 64 Years   (Adult)","Not Applicable","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00073021","May 2016","May 2017","May 2017","August 27, 2014","null","December 15, 2017","Grady Memorial Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02227160"
317,"NCT02227095","Exercise & Overweight Children's Cognition","SMART","Completed","No Results Available","Overweight and Obesity","Behavioral: Exercise|Behavioral: After-school program","Change in Planning Scale scores|Change in functional MRI|Change in BMI|Change in adiposity|Change in aerobic fitness|Change in Tower of London scores|Change in teacher ratings of classroom behavior|Change in academic achievement|Change in performance on executive function tasks","Augusta University|National Heart, Lung, and Blood Institute (NHLBI)|University of Georgia|San Francisco State University","All","8 Years to 11 Years   (Child)","Not Applicable","175","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)","R01HL087923","May 2008","May 2013","April 2014","August 27, 2014","null","March 6, 2015","Georgia Prevention Institute, Augusta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02227095"
318,"NCT02225899","BioEnergetics and Metabolomics in Cystic Fibrosis","BEAM-CF","Recruiting","No Results Available","Cystic Fibrosis","","Acylcarnitine analysis by high-resolution liquid chromatography mass spectrometry|quantitative plasma levels of specific plasma acylcarnitines","Emory University|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","18 Years to 50 Years   (Adult)","","130","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","IRB00073559|K01DK102851","September 2014","September 2019","December 2019","August 26, 2014","null","July 3, 2018","Emory university Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02225899"
319,"NCT02219581","Steroids in Total Knee Arthroplasty",,"Recruiting","No Results Available","Postoperative Pain|Inflammation|Osteoarthritis","Drug: Dexamethasone 10 mg|Drug: Dexamethasone 20 mg|Drug: Standard multimodal pain management regimen|Drug: Placebo","Change in pain scores|Pain scores as recorded by the smart device app|Opioid analgesic usage|Soft tissue swelling|Change in range of motion (ROM)|Time to clearance from physical therapy|Post-operative nausea|Post-operative vomiting|Levels of blood glucose|Functionality scores using Short Form using (SF)-36|Functionality scores using (WOMAC)|Length of hospital stay|Number of hospital readmissions|Number of subjects with wound infections","Emory University","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 4","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRB00066081","August 2014","September 25, 2018","September 25, 2018","August 19, 2014","null","July 25, 2018","Emory Orthopedic and Spine Hospital, Tucker, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02219581"
320,"NCT02217215","Initial Study With the CNDS Advanced Cervical Scan to Recalibrate Spectral Data for Use in Future Screening Studies","Spectral","Unknown status","No Results Available","Cervical Disease","Device: CNDS Advanced Cervical Scan","Diagnostic accuracy including sensitivity, specificity and predictive values|Number of Participants with Adverse Events as a Measure of Safety and Tolerability","Guided Therapeutics","Female","21 Years and older   (Adult, Older Adult)","","800","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","CLIN-4-CLP_0","August 2014","September 2015","December 2015","August 15, 2014","null","August 15, 2014","Georgia Regents University, Augusta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02217215"
321,"NCT02212613","Brexpiprazole (OPC 34712) Trial in the Treatment of Adults With Major Depressive Disorder and Irritability",,"Withdrawn","No Results Available","Major Depressive Disorder and Irritability","Drug: Brexpiprazole","Change from Phase B baseline to Phase B Week 6 in functional magnetic resonance imaging (fMRI) BOLD activation score in the ventromedial prefrontal cortex and amygdala, scanned by fMRI during performance of the Emotion-induction Task|Change from Phase B baseline to Phase B Week 6 in Montgomery Asberg Depression Rating Scale (MADRS) Total Score|Change from Phase B baseline to Phase B Week 6 in Spielberger State Trait Anger Expression Inventory (STAXI-2) Part 1|Change from Phase B baseline to Phase B Week 6 in Visual Analog Scale (VAS)|Change from Phase B baseline to Phase B Week 6 in Clinical Global Impression - Severity of Illness Scale (CGI-S) score|Clinical Global Impression - Improvement Scale (CGI-I) score at Phase B Week 6|MADRS response rate, where response is defined as ≥ 50% reduction in respective total scores from Phase B baseline to Phase B Week 6|MADRS remission rate, where remission is defined as MADRS Total Score ≤ 10 and 50% reduction in MADRS Total Score from Phase B baseline to Phase B Week 6|Change from Phase B baseline to Phase B Week 6 in Sheehan Disability Scale (SDS) 3-item mean score|Change from Phase B baseline to Phase B Week 6 in Anger Attacks Questionnaire (AAQ) score|Change from Phase B baseline to Phase B Week 6 in Symptoms of Depression Questionnaire (SDQ)|Change from Phase B baseline to Phase B Week 6 in Kellner Symptom Questionnaire (KSQ)|Change from Phase B baseline to Phase B Week 6 in Barratt Impulsiveness Scale 11 item (BIS-11) Total Score","Otsuka Pharmaceutical Development & Commercialization, Inc.|Otsuka Pharmaceutical Co., Ltd.","All","18 Years to 55 Years   (Adult)","Phase 3","0","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","331-13-004","September 2014","November 2015","November 2015","August 8, 2014","null","July 7, 2016","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02212613"
322,"NCT02208661","Psychological Concomitants of Morquio A Syndrome - Longitudinal Effects of Enzyme Replacement Therapy (The MAPLE Study)","MAPLE","Completed","No Results Available","Morquio A Syndrome|Mucopolysaccharidosis IV A","","ASEBA Self-Report|Brief Pain Inventory|SF-36","Nadia Ali, PhD|BioMarin Pharmaceutical|Emory University","All","18 Years and older   (Adult, Older Adult)","","12","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","IRB00072780","March 2014","March 2018","March 2018","August 5, 2014","null","April 11, 2018","Emory University, Decatur, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02208661"
323,"NCT02202876","Redox Imbalance and the Development of Cystic Fibrosis Diabetes","Redoxy","Recruiting","No Results Available","Diabetes Mellitus, Type 2|Cystic Fibrosis","Drug: Oral Glucose Tolerance Test|Other: High Glycemic Index Meal|Other: Low Glycemic Index Meal","acute oxidation","Emory University|Cystic Fibrosis Foundation Therapeutics","All","1 Year and older   (Child, Adult, Older Adult)","Not Applicable","98","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","IRB00060962","November 2014","September 2018","September 2018","July 29, 2014","null","November 14, 2017","Children's Healthcare of Atlanta and Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02202876"
324,"NCT02199652","Reducing Suicidal Ideation Through Treatment of Nightmares-Post Traumatic Stress Disorder (PTSD)","REST-ON PTSD","Completed","Has Results","Post Traumatic Stress Disorder|Suicidal Ideation|Nightmares","Drug: Prazosin|Drug: Placebo","Change Score for Scale for Suicide Ideation|Disturbing Dreams and Nightmare Severity Index|Insomnia Severity Index","Augusta University","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","00001365","March 2014","September 1, 2017","December 1, 2017","July 24, 2014","August 21, 2018","September 18, 2018","Georgia Regents University, Augusta, Georgia, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/52/NCT02199652/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02199652"
325,"NCT02194751","Oncoquest-L Vaccine in Patients With Previously Untreated Stage III or IV, Asymptomatic, Non-bulky Follicular Lymphoma",,"Not yet recruiting","No Results Available","Follicular Lymphoma","Biological: Oncoquest-L vaccine","Overall tumor response rate|Assessment of complete and partial tumor response rates|Assessment of time until initiation of radiotherapy or systemic therapy|Safety evaluation will include frequency, severity, and relationship of adverse events to vaccination; vital signs (blood pressure, respiration, pulse, and temperature); and laboratory test results (including, hematology and clinical chemistry)|Tests to measure tumor-specific antibody production and T cell and B cell responses to vaccination","XEME Biopharma Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","30","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","X13-21008","June 2018","May 2020","June 2020","July 18, 2014","null","June 27, 2017","Southeastern Regional Medical Center at CTCA, Newnan, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02194751"
326,"NCT02189317","Liposomal Bupivacaine for Pain Control Following Anterior Cruciate Ligament Reconstruction",,"Completed","Has Results","Anterior Cruciate Ligament Rupture","Drug: Exparel","Change in Numerical Rating Scale (NRS) Pain Score|Change in Home Opioid Use|Difference in Time to First Opioid Use","Emory University","All","18 Years to 50 Years   (Adult)","Phase 4","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","IRB00073168","August 2014","March 2015","March 2015","July 14, 2014","June 14, 2016","July 27, 2016","Emory University Orthopaedic and Spine Center, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02189317"
327,"NCT02185898","Evaluation of Environmental Emissions From Electronic Cigarettes and Tobacco-Burning Cigarettes",,"Completed","No Results Available","Smoking","Other: Leading U.S. non-menthol cigarette|Other: Leading U.S. menthol cigarette|Other: Electronic cigarette #1|Other: Electronic cigarette #2|Other: Electronic cigarette #3|Other: U.S. Market-sample electronic cigarettes","To assess differences in levels of selected SHS constituents in an environmental test chamber after human smoking of e-cigarette #1, #2, and #3 compared to after human smoking of tobacco-burning cigarettes.|To determine selected SHS constituent emission factors for each tobacco-burning cigarette, each e-cigarette, and the market-sample e-cigarettes (collectively).|To assess the differences in levels of selected SHS constituents in an environmental test chamber after human smoking of e-cigarettes and tobacco-burning cigarettes compared to after a non-smoking blank condition.|To assess differences in levels of additional selected SHS constituents in an environmental test chamber after human smoking of e-cigarettes compared to after human smoking of tobacco-burning cigarettes.","R.J. Reynolds Vapor Company|Covance|R.J. Reynolds Tobacco Company|Materials Analytical Services, LLC","All","21 Years to 99 Years   (Adult, Older Adult)","Not Applicable","71","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","CSD1302","May 2014","February 2015","February 2015","July 10, 2014","null","June 1, 2018","Clinical Research Atlanta, Stockbridge, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02185898"
328,"NCT02185742","Planning for SUCCESS","SUCCESS","Completed","No Results Available","HIV","Behavioral: Strength Based Case Management","HIV viral load|Show feasibility of conducting protocol","Emory University|National Institute on Drug Abuse (NIDA)","All","18 Years to 99 Years   (Adult, Older Adult)","Not Applicable","113","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","IRB00064852|1R34DA035728-01A1","July 2014","December 2016","December 2016","July 10, 2014","null","January 23, 2017","Fulton County Jail, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02185742"
329,"NCT02185729","Comparing Soybean Oil-Based (Intralipid) With an Olive Oil-Based (ClinOleic) Lipid Emulsion on Healthy Volunteers","TPN1","Completed","Has Results","Diseases, Metabolic|Insulin Sensitivity","Drug: Intralipid|Drug: ClinOleic|Drug: Dextrose|Other: Saline (control)","Flow Mediated Dilation","Emory University|Baxter Healthcare Corporation","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2|Phase 3","12","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","IRB00007543","June 2008","March 2012","March 2012","July 10, 2014","December 31, 2014","December 31, 2014","Grady Memorial Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02185729"
330,"NCT02171312","Clinical Evaluation of a Novel Balance, Vestibular and Oculomotor Assessment Tool",,"Completed","No Results Available","Mild Concussion|Post Concussion Syndrome|Vestibular Neuritis","Device: iDETECT Assessment|Behavioral: Routine Balance and Vestibular Testing","Simulator Sickness assessed by the Simulator Sickness Questionnaire (SSQ)|Presence of Post Concussive Symptoms assessed by the Post Concussion Symptoms Scale (PCSS)|User Experience assessed by the iDETECT User Experience Survey|Imbalance assessed by the Balance Error Scoring System (BESS) Score|Postural Stability assessed by Quantitative Balance Testing (BioSway) Score|Visual Acuity assessed by the Dynamic Visual Acuity (DVA) Test|Vestibular Function assessed by Vestibular/Ocular-Motor Screening (VOMS)|Dynamic Gait Ability assessed by Dynamic Gait Index (DGI) Score|High Level Balance assessed by the High-level Mobility Assessment Tool (HiMAT)|Mobility assessed by the High-level Mobility Assessment Tool (HiMAT)|Confidence in Balance assessed by the Activities-specific Balance Confidence (ABC) Scale|Dizziness assessed by the Dizziness Handicap Inventory (DHI)|Visual Vertigo Symptoms assessed by the Visual Vertigo Analog Scale (VVAS)","Emory University|U.S. Army Medical Research and Materiel Command|National Football League|General Electric|UnderArmour","All","12 Years and older   (Child, Adult, Older Adult)","","126","Other|U.S. Fed|Industry","Observational","Observational Model: Case Control|Time Perspective: Prospective","IRB00075343","April 2015","September 2015","September 2015","June 24, 2014","null","February 9, 2016","Sports Concussion Institute, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02171312"
331,"NCT02169791","Nonmyeloablative Haploidentical Transplant Followed by MLN9708",,"Active, not recruiting","No Results Available","Acute Leukemia|Chronic Leukemia|Myelodysplastic Syndrome|Lymphomas|Multiple Myeloma","Drug: MLN9708","Incidence of Relapse and progression|Overall Survival|Event Free|Non-relapsed mortality|Graft-versus-host disease","Northside Hospital, Inc.|Millennium Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","25","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","NSH 1074|X16035","September 2014","August 2018","August 2020","June 23, 2014","null","September 7, 2018","Northside Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02169791"
332,"NCT02168361","The SIM-SOF Trial for Hepatitis C",,"Completed","Has Results","Chronic Hepatitis C","Drug: Pegylated Interferon alfa-2b|Drug: Simeprevir|Drug: Ribavirin|Drug: Sofosbuvir","Proportion of Participants With Sustained Virologic Response 12 (SVR-12)|Serum HCV RNA Level","Center For Hepatitis C, Atlanta, GA","All","18 Years and older   (Adult, Older Adult)","Phase 4","93","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CHC-21","December 2013","December 2014","April 2015","June 20, 2014","March 4, 2016","March 14, 2016","Center for Hepatitis C, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02168361"
333,"NCT02167750","Effect of Phytochemicals on Aspects of Cognitive Performance",,"Unknown status","No Results Available","Cognitive Performance","Other: Cherry Flavored Beverage","The primary outcome will be the changes in the ratings from computer administered tasks within the domains of mood, short-term recognition memory, and attention from pre- to post-study product consumption and between treatment conditions","PepsiCo Global R&D","All","17 Years to 50 Years   (Child, Adult)","Not Applicable","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","PEP-1404","April 2014","October 2014","October 2014","June 19, 2014","null","June 19, 2014","Univerysity of Georgia, Athens, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02167750"
334,"NCT02163941","Meditation for Emotional Numbing in Post-Traumatic Stress Disorder",,"Completed","No Results Available","Prolonged Post-traumatic Stress Disorder","Behavioral: Compassion Training","Social connectedness|Empathic Accuracy|Social Interactions|messenger ribonucleic acid (mRNA)","Emory University|Brain & Behavior Research Foundation|Mind and Life Institute, Hadley, Massachusetts","Male","25 Years to 65 Years   (Adult, Older Adult)","Phase 1","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","IRB00070643","May 2014","May 2016","May 2016","June 16, 2014","null","August 2, 2016","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02163941"
335,"NCT02154061","Systems Biology of Flu Vaccine in Healthy Adults With and Without the Use of Antibiotics","VAX-002","Completed","Has Results","Influenza","Drug: IIV Flu Vaccine|Drug: Metronidazole|Drug: Neomycin|Drug: Vancomycin","Number of Participants With Four Fold Rise in HAI Titers or HAI 1:40 and Above in Each Group at D30","Emory University","All","18 Years to 40 Years   (Adult)","Not Applicable","33","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","IRB00074239","April 2015","May 26, 2017","May 26, 2017","June 3, 2014","June 27, 2018","August 15, 2018","Emory Vaccine Center, Atlanta, Georgia, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/61/NCT02154061/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02154061"
336,"NCT02153541","Assessing the Efficacy of CREWS01 to Decrease Usage of Rescue Inhalers in Moderate to Severe Asthmatic Adults","CREWS01","Unknown status","No Results Available","Asthma","Drug: Antipyrine-benzocaine otic solution|Other: Mineral oil","Efficacy of CREWS01 (topical auricular anesthesia of the vagus nerve) to decrease usage of rescue inhalers in moderate to severe asthmatic adults Change in usage of rescue inhalers in moderate to severe asthmatic adults in four weeks|Improvement of spirometry scores in moderate to severe asthmatic adults","Global United Pharmaceutical Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","50","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","CREWS01","July 2014","September 2014","September 2014","June 3, 2014","null","June 3, 2014","Georgia Regents University, Augusta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02153541"
337,"NCT02151266","Exercise and Cognitive Retraining to Improve Cognition in Heart Failure.","EXCITE","Active, not recruiting","No Results Available","Heart Failure","Behavioral: Exercise and Cognitive retraining|Behavioral: Exercise Only|Behavioral: Stretching and Flexibility","Neurocognitive performance|Cerebral oxygenation","Emory University|National Institute of Nursing Research (NINR)","All","40 Years to 75 Years   (Adult, Older Adult)","Not Applicable","67","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care","IRB00060752|P30NR014134","July 2013","December 30, 2018","December 30, 2018","May 30, 2014","null","January 4, 2018","Emory University Heart Failure Clinics, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02151266"
338,"NCT02147067","Microvascular Assessment of Ranolazine in Non-Obstructive Atherosclerosis (MARINA)","MARINA","Completed","No Results Available","Microvascular Angina","Drug: Ranolazine|Drug: Placebo","Change in Seattle Angina Questionnaire score regarding angina frequency|Change in Seattle Angina Questionnaire score regarding physical functioning, treatment satisfaction, angina stability, and quality of life|Change in peak rate of oxygen consumption|Change in time to angina|Change in exercise duration|Change in Coronary Flow Velocity Reserve (CFR)|Change in Hyperemic Microcirculatory Resistance (HMR)","Emory University|Gilead Sciences","All","18 Years and older   (Adult, Older Adult)","Phase 2","26","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRB00072996","September 2014","March 2018","June 2018","May 26, 2014","null","July 17, 2018","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02147067"
339,"NCT02139566","Improving Consent and Survey Procedures for Young MSM in Web-based HIV Prevention",,"Completed","No Results Available","Healthy","Behavioral: Video consent (high-tech)|Behavioral: Video consent (low-tech)|Behavioral: FAQ format consent|Behavioral: Standard consent|Behavioral: PDF informed consent document","Knowledge of Consent Information|Proportion of eligible men who consent|Engagement with Consent Information","Emory University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Male","18 Years to 34 Years   (Adult)","Not Applicable","2405","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","IRB00065333|1R21HD074502-01A1","July 2014","May 2015","September 2015","May 15, 2014","null","January 15, 2016","Rollins School of Public Health, Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02139566"
340,"NCT02137369","The ISLAND Study: InSuLa Assessed Needs for Depression","ISLAND","Recruiting","No Results Available","Depression","Drug: Escitalopram|Behavioral: Cognitive Behavioral Therapy|Other: Combination treatment (Escitalopram + CBT)","Remission from major depressive episode|Response to treatment","Emory University|National Institute of Mental Health (NIMH)","All","18 Years to 55 Years   (Adult)","Phase 4","150","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","IRB00073702|R01MH073719|00073702","September 2014","June 2019","June 2019","May 13, 2014","null","November 30, 2017","12 Executive Park Drive, 3rd floor, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02137369"
341,"NCT02133651","Mucosal Versus Fecal Microbiota in FMT",,"Completed","No Results Available","Clostridium Difficile","","The proportion of subjects who experience resolution of diarrhea associated with C. difficile infection without relapse 2 weeks and 10 weeks post Intestinal Microbiota Transplantation (IMT)","Emory University","All","18 Years and older   (Adult, Older Adult)","","10","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IRB00069524","April 2014","August 2015","August 2015","May 8, 2014","null","December 9, 2015","Emory University Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02133651"
342,"NCT02128594","Serosorting Intervention for HIV Negative MSM",,"Completed","No Results Available","STDs","Behavioral: Serosorting Intervention","Sexually Transmitted Disease","University of Connecticut|National Institute of Mental Health (NIMH)","Male","18 Years and older   (Adult, Older Adult)","Not Applicable","600","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","H10-299|R01MH094230","January 2012","April 2015","April 2015","May 1, 2014","null","May 28, 2015","SHARE Project, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02128594"
343,"NCT02124811","Minocycline Augmentation to Clozapine",,"Completed","Has Results","Schizophrenia|Schizoaffective Disorder","Drug: Minocycline","Positive Subscale Score of the Positive and Negative Syndrome Scale (PANSS)|Negative Subscale Score of the Positive and Negative Syndrome Scale (PANSS)|Brief Assessment of Cognition in Schizophrenia (BACS) Score|General Psychopathology Score of the Positive and Negative Syndrome Scale (PANSS)|Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF) Score|Global Assessment of Functioning (GAF) Score","Emory University","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","10","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRB00071195","February 2015","November 2016","November 2016","April 28, 2014","August 29, 2018","September 26, 2018","Grady Memorial Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02124811"
344,"NCT02124642","Folic Acid Supplementation in Pregnant Women: Dose Response","FAPREG","Completed","No Results Available","Pregnancy","Dietary Supplement: Folic acid, 400 mcg/day|Dietary Supplement: Folic acid 800 mcg/day","Serum folate|Red blood cell (RBC) folate|Serum folic acid|Gene-specific DNA methylation|Cell-type-specific DNA methylation|Infant birth weight|Infant length|Infant head circumference|Apgar score","University of Georgia|University of Florida|Emory University|Cornell University","Female","18 Years to 40 Years   (Adult)","Not Applicable","51","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","FASUPPPREG-2014","May 2014","December 2015","December 2017","April 28, 2014","null","March 5, 2018","Athens Regional Medical Center Midwifery Practice, Athens, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02124642"
345,"NCT02124135","Eat Out With KP: A Pilot to Improve the Impact of Dietary Advice for Families",,"Completed","No Results Available","Obesity","Behavioral: Diet/Nutrition Education","Change in Fruit and Vegetable Intake|Change in Whole Grain Intake|Change in Saturated Fat Intake|Change in Added Sugars Intake|Change in Nutritional Knowledge of Families|Self-efficacy around food purchasing and dietary decisions","Kaiser Permanente","All","8 Years to 64 Years   (Child, Adult)","Not Applicable","94","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","Pro00004774","May 2014","October 2014","December 2014","April 28, 2014","null","August 18, 2017","Kaiser Permanente Center for Health Research, Southeast, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02124135"
346,"NCT02122679","Tranexamic Acid Effect on Platelet Aggregation Following Infant Cardiopulmonary Bypass",,"Withdrawn","No Results Available","Heart Defect, Congenital","Drug: Tranexamic Acid|Drug: placebo","Platelet Aggregation|Postoperative bleeding","Emory University","All","up to 6 Months   (Child)","Phase 4","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","IRB00073642","December 2014","June 2015","June 2015","April 24, 2014","null","November 25, 2016","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02122679"
347,"NCT02121964","Capsulectomy vs Capsulotomy With Repair in Direct Anterior Total Hip Arthroplasty",,"Enrolling by invitation","No Results Available","Hip Arthrosis|Osteoarthritis|Arthritis","Procedure: Capsulectomy in Direct Anterior Total Hip Arthroplasty|Procedure: Capsulotomy in Direct Anterior Total Hip Arthroplasty","Range of Motion- Resisted Hip Flexion Strength|Change in Range of Motion - Maximum Hip Flexion|Change in Range of Motion - Maximum Hip Extension|Change in Range of Motion - Evidence of Flexion Contraction (Thomas Test)|Change in Pain Score with Resisted Hip Flexion|Change in Hip Disability and Osteoarthritis Outcome Score|Surgical Time|Transfusion Rate by Percent Hemoglobin Drop|Number of Adverse Events","Emory University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","IRB00054340|Capsulectomy in Anterior THA","August 2013","December 2018","December 2018","April 24, 2014","null","January 10, 2018","Emory University School of Medicine, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02121964"
348,"NCT02119910","Technology-supported Behavioral Feeding Intervention",,"Completed","No Results Available","Feeding and Eating Disorders of Childhood","Behavioral: Technology Supported Manual","Mealtime Behaviors|Parenting Stress Index- Short Form","Emory University","All","12 Months to 6 Years   (Child)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00072609","January 2014","December 2014","March 2015","April 22, 2014","null","March 17, 2015","The Marcus Autism Center, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02119910"
349,"NCT02118766","Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis",,"Completed","Has Results","Dermatitis, Atopic","Drug: AN2728 Topical Ointment, 2%|Drug: Matching vehicle control","Percentage of Participants Who Achieved Treatment Success Based on Investigator's Static Global Assessment (ISGA) at Day 29|Number of Participants With Treatment-Emergent Adverse Events (AEs) And Serious Adverse Events (SAEs)|Number of Participants With Clinically Significant Change From Baseline in Vital Signs at Day 29|Number of Participants With Clinically Significant Change From Baseline in Laboratory Values at Day 29|Percentage of Participants With an Investigator's Static Global Assessment (ISGA) Score of Clear (0) or Almost Clear (1) at Day 29|Time to Achieve Treatment Success Based on Investigator's Static Global Assessment (ISGA)|Change From Baseline in Signs of Atopic Dermatitis (AD) at Day 29","Pfizer","All","2 Years and older   (Child, Adult, Older Adult)","Phase 3","763","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AN2728-AD-301","March 2014","April 2015","April 2015","April 21, 2014","March 6, 2017","March 6, 2017","Anacor Investigational Site, Stockbridge, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02118766"
350,"NCT02116335","Endothelin Receptor Function and Acute Stress","End-Stress","Recruiting","No Results Available","Hypertension","Drug: Bosentan|Drug: Placebo","Flow-Mediated Dilation (FMD)|Arterial Stiffness Evaluation (PWV)|Physio Flow|Femoral blood flow|Blood Pressure","Augusta University|National Heart, Lung, and Blood Institute (NHLBI)","All","18 Years to 50 Years   (Adult)","Not Applicable","320","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","End-Stress|5P01HL069999","June 2015","April 2019","April 2020","April 16, 2014","null","July 11, 2018","Georgia Regents University, Augusta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02116335"
351,"NCT02115724","Nitric Oxide Bioavailability and Early Life Stress (NO-Stress)","NO-Stress","Recruiting","No Results Available","Cardiovascular Disease","Dietary Supplement: Antioxidant cocktail|Other: Biopsy|Other: Placebo|Drug: NMD; 0.4mg sub-lingual nitroglycerin spray","Acute Change in Flow mediated dilation|Acute Change in Biomarkers of oxidative stress|Acute Change in Arterial Stiffness|Acute change in Flow mediated dilation","Augusta University|National Heart, Lung, and Blood Institute (NHLBI)","All","18 Years to 40 Years   (Adult)","Not Applicable","340","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","NO-Stress Pro00001887|5P01HL069999","April 2014","April 2019","April 2020","April 16, 2014","null","November 9, 2017","Georgia Prevention Institute , Georgia Regents University, Augusta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02115724"
352,"NCT02114697","Accelerated Atherosclerosis in High Risk Population Groups: An Assessment by Magnetic Resonance Imaging",,"Terminated","Has Results","Atherosclerosis","Drug: Statin therapy|Behavioral: Lifestyle modification","Plaque Volume of Carotid Arteries","Emory University","All","22 Years and older   (Adult, Older Adult)","Phase 4","9","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","IRB00059784","April 2014","July 2017","July 2017","April 15, 2014","August 14, 2018","September 11, 2018","Emory University, Atlanta, Georgia, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/97/NCT02114697/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02114697"
353,"NCT02111369","Propranolol and Botulinum Toxin for Essential Vocal Tremor",,"Completed","Has Results","Essential Vocal Tremor|Essential Voice Tremor|Essential Tremor|Voice Tremor|Vocal Tremor","Drug: Propranolol|Procedure: Botulinum Toxin","Change in Quality of Life in Essential Tremor (QUEST) Questionnaire Score|Change in Voice-Related Quality Of Life (VRQOL) Questionnaire Score|Change in Consensus Auditory-Perceptual Evaluation of Voice (CAPE-V) Score|Change in Global Voice Rating|Change in Acoustic Spectrograms","Emory University","All","45 Years and older   (Adult, Older Adult)","Phase 4","18","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00072929","May 2014","October 2014","November 2014","April 11, 2014","April 27, 2016","April 27, 2016","Emory Voice Center, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02111369"
354,"NCT02103543","Comparison of the Order of Treatment in Lumbar Spinal Stenosis",,"Withdrawn","No Results Available","Lumbar Spinal Stenosis","Other: physical therapy|Procedure: lumbar interlaminar epidural steroid injection|Drug: epidural steroid injection","Oswestry disability Index|visual analog scale","Emory University","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","0","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00061868","January 2014","January 2017","December 2017","April 4, 2014","null","February 23, 2017","Atlanta Veterans Affairs Medical Center, Decatur, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02103543"
355,"NCT02101463","MOSTEGRA TRIAL:MO-(Dified) STE-(nt) GRA(-ft): Surgeon-modified Fenestrated-branched Stent-grafts","MOSTEGRA","Recruiting","No Results Available","Complex Aortic Aneurysms","Device: surgeon-modified fenestrated-branched stent-grafts (sm-FBSG)","Determine the safety and effectiveness of sm-FBSG for the treatment of complex aortic aneurysms in patients at high-risk for open surgical repair.|Evaluate postoperative all-cause morbidity after repair with sm-FBSG|Evaluate long-term survival and complications after repair of complex aortic aneurysms with sm-FBSG|Successful device delivery and deployment with patency of all branches|Procedural / In-Hospital Evaluations","Northside Hospital, Inc.","All","18 Years and older   (Adult, Older Adult)","Not Applicable","150","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NSH 997","March 2012","March 2022","December 2022","April 2, 2014","null","January 9, 2015","Northside Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02101463"
356,"NCT02100813","Safety and Efficacy of Doses of LEO 43204 Once Daily for Two Consecutive Days on Full Balding Scalp in Subjects With Actinic Keratosis",,"Completed","No Results Available","Actinic Keratosis","Drug: LEO 43204|Drug: Placebo","Part 1: Dose Limiting Toxicity up to and including Day 8|Part 2: Reduction in AK count|Part 2: Complete clearance of AKs|Part 2: Partial clearance of AKs","LEO Pharma","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","220","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","LP0084-1014|2014-000037-23","May 2014","March 2015","March 2015","April 1, 2014","null","June 14, 2016","Gwinnett Clinical Research Center, Inc., Snellville, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02100813"
357,"NCT02098876","Wall Shear Stress and Neointimal Healing Following PCI in Angulated Coronary Vessels","SHEAR-STENT","Recruiting","No Results Available","Coronary Artery Disease","Device: Resolute Integrity Zotarolimus eluting stent|Device: Xience Xpedition everolimus eluting stent","Coefficient of variance in neointimal hyperplasia|Percent area of low wall shear stress|N (%) uncovered and malopposed struts","Emory University|Medtronic","All","30 Years to 80 Years   (Adult, Older Adult)","Not Applicable","126","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","IRB00066353","May 2014","December 2018","December 2018","March 28, 2014","null","February 8, 2018","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02098876"
358,"NCT02092727","The Reducing Disparities in Access to kidNey Transplantation (RaDIANT) Community Study","RaDIANT","Completed","No Results Available","Kidney Disease","Behavioral: Behavioral Interventions for Dialysis Facilities","Referral for Kidney Transplantation|Reduction in Racial Disparity","Emory University|National Institute on Minority Health and Health Disparities (NIMHD)","All","18 Years to 69 Years   (Adult, Older Adult)","Not Applicable","134","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","IRB00056381|1R24MD008077-01","February 2014","December 2016","January 2018","March 20, 2014","null","February 21, 2018","Dialysis Facilities throughout the State of Georgia, ESRD Network 6, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02092727"
359,"NCT02092532","Intravitreal Aflibercept for Neovascular Polypoidal Choroidal Vasculopathy (RIVAL Trial)","RIVAL","Unknown status","No Results Available","Neovascular Polypoidal Choroidal Vasculopathy","Drug: Rescue Intravitreal Aflibercept Injection|Procedure: Rescue Therapy with PDT, Laser or Intravitreal Steroids","Incidence and Severity|Change in Best Corrected Visual Acuity (BCVA)|Photography Assessments","Southeast Retina Center, Georgia|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 4","20","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VGFTe-AMD-1401","March 2014","March 2015","March 2016","March 20, 2014","null","October 15, 2014","Southeast Retina Center, PC, Augusta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02092532"
360,"NCT02089672","RF Lesion Monitoring With 8mm IntellaTip MiFi XP",,"Completed","No Results Available","Atrial Flutter|Arrhythmia","Device: Catheter ablation","Total bipolar electrogram amplitude using tip to ring and pin to pin configurations|Total number of seconds per isthmus ablation spent in excess of the post-hoc identified complete lesion time.","Emory University|Boston Scientific Corporation","All","18 Years and older   (Adult, Older Adult)","","30","Other|Industry","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","IRB00069674|ISRCRM90003","April 2014","November 2015","November 2015","March 18, 2014","null","November 17, 2015","Emory University Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02089672"
361,"NCT02089555","African American Alzheimer's Progression Markers - CSF and Neuro-Imaging","A3PM","Completed","No Results Available","Mild Cognitive Impairment|Alzheimer's Disease","Procedure: Lumbar puncture|Procedure: Blood draw|Procedure: Magnetic Resonance Imaging (MRI)","CSF endothelial marker levels|CSF Alzheimer's biomarker levels|MRI evidence of small vessel disease|MRI evidence of brain atrophy","Emory University|National Institute on Aging (NIA)","All","60 Years to 85 Years   (Adult, Older Adult)","","135","Other|NIH","Observational","Observational Model: Case Control|Time Perspective: Prospective","IRB00066145|R21AG043885","September 2013","June 2016","June 2016","March 18, 2014","null","June 23, 2016","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02089555"
362,"NCT02088567","Amniotic Membrane in Total Knee Replacements to Reduce Scarring",,"Completed","No Results Available","Scarring","Procedure: Total Knee Arthroplasty|Other: Application of dHACM","Increased range of motion between both groups as measured by goniometer|Incidence of need for manual manipulation of affected knee","MiMedx Group, Inc.","All","18 Years and older   (Adult, Older Adult)","Not Applicable","52","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","AFTKR001","January 2014","October 2014","October 2014","March 17, 2014","null","September 23, 2015","Georgia Knee and Sports Medicine, Decatur, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02088567"
363,"NCT02084849","ADPKD Cohort Study",,"Completed","No Results Available","Autosomal Dominant Polycystic Kidney Disease","","Change in GFR as compared to change in renal volume over time|Differences in the ability to determine change in renal volume over time between MRI and ultrasound","Emory University|PKD Foundation","All","up to 60 Years   (Child, Adult)","","624","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IRB00041117|0247-1998","June 1998","May 2015","May 2015","March 12, 2014","null","June 24, 2015","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02084849"
364,"NCT02082912","NMDA Receptors in Motor Learning in Humans",,"Completed","Has Results","Stroke","Drug: D-cycloserine|Other: Placebo|Device: HandMentor Pro","Mean Change in Grip Strength of Affected Hand|Change in Stroke Impact Scale Score|Change in Depressive Symptoms|Change in Memory and Information Processing Speed|Change in Functional Motor Task Performance","Emory University","All","18 Years to 95 Years   (Adult, Older Adult)","Phase 2","14","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","IRB00035176","June 2010","April 2012","April 2012","March 10, 2014","April 22, 2015","April 22, 2015","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02082912"
365,"NCT02080507","rTMS in Treatment Resistant Depression","rTMSECT","Completed","Has Results","Depression","Device: Active Neuronetics rTMS stimulator|Device: Inactive Neuronetics rTMS stimulator","Depression Severity as Assessed by the Montgomery Åsberg Depression Rating Scale (MADRS) Score|Quality of Life Assessed by the Quality of Life Enjoyment and Satisfaction Questionnaire Short Form (Q-Les-SF) Score","Emory University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","12","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRB00068138","March 2014","December 2015","December 2015","March 6, 2014","May 30, 2017","May 30, 2017","Emory University at Wesley Woods Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02080507"
366,"NCT02078323","Investigation of Linaclotide's Effect on the Bi-directional Brain and Gut Axis in IBS-C Patients",,"Completed","No Results Available","Irritable Bowel Syndrome With Constipation (IBS-C)","Drug: Linaclotide|Drug: Placebo","1: Change from baseline in Prolongation and normalization of anal CEP and rectal CEP responses at 10 weeks.|Change from Baseline in Prolongation and normalization of rectal MEP and anal MEP at 10 weeks.","Augusta University|Forest Laboratories","All","18 Years to 64 Years   (Adult)","Not Applicable","39","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other","LNZ-IT-01","February 2014","October 4, 2017","July 20, 2018","March 5, 2014","null","July 23, 2018","Augusta University, Augusta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02078323"
367,"NCT02067039","Evaluation of Rapid HIV Self-testing Among MSM (eSTAMP)",,"Completed","No Results Available","HIV Infection","Device: OraQuick in home & Sure Check HIV tests","Frequency of HIV testing by internet-recruited MSM.|Performance of rapid HIV tests used by internet-recruited MSM|Linkage to HIV testing and care services following a positive rapid test result.|Changes in sexual behaviors following rapid HIV testing.|Distribution of rapid HIV test to social and sexual partners.","Centers for Disease Control and Prevention|Emory University|Northwestern University|Public Health Solutions","Male","18 Years and older   (Adult, Older Adult)","Not Applicable","2700","U.S. Fed|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening","CDC-eSTAMP-41989","March 25, 2015","October 21, 2016","October 21, 2016","February 20, 2014","null","February 2, 2017","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02067039"
368,"NCT02066857","Cast vs. Splints for Minimally Displaced Distal Radius Fractures in the Elderly",,"Completed","Has Results","Radius; Fracture, Lower or Distal End","Device: Cast made of generic plaster or fiberglass cast material|Device: Generic ""off the shelf"" removable splint","Change in Wrist Range of Motion (ROM)|Mean Mayo Wrist Score|Change in Grip Strength|Complication Rate|Mean Pain Score|Mean Disabilities of the Arm and Shoulder (DASH) Questionnaire Score|Change in SF-12 QOL","Emory University","All","60 Years and older   (Adult, Older Adult)","Not Applicable","5","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00071060","April 2014","April 2016","April 2016","February 20, 2014","May 24, 2017","May 24, 2017","Emory Orthopaedics and Spine Center, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02066857"
369,"NCT02064790","Comparison of Gabapentin and Pregabalin for Radicular Pain",,"Completed","No Results Available","Radicular; Neuropathic, Lumbar, Lumbosacral|Radicular; Neuropathic, Cervical","","Pain reduction with Visual Analogue Scale|To compare the efficacy of each of the two neuropathic agents to the other in treatment of cervical or lumbar radiculopathy","Emory University","All","18 Years and older   (Adult, Older Adult)","","6","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IRB00069871","April 2014","December 2015","December 2015","February 17, 2014","null","March 9, 2016","Emory Orthopaedics and Spine Center, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02064790"
370,"NCT02057458","Blood Flow and Vascular Function in Cystic Fibrosis","CF-FLOW","Active, not recruiting","No Results Available","Cystic Fibrosis","Drug: Acute (1 hour) Sildenafil|Drug: Sub-Chronic (4 weeks) Sildenafil|Drug: Placebo","Exercise Capacity|Flow-Mediated Dilation (FMD)|Arterial Stiffness Evaluation (PWV)|Physio Flow","Augusta University|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","18 Years and older   (Adult, Older Adult)","Phase 2","50","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","DK100783|R21DK100783","April 2014","July 2018","December 2018","February 7, 2014","null","June 27, 2018","Augusta University, Augusta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02057458"
371,"NCT02057068","Improving Sleep in Veterans and Their CGs","SLEEP-E Dyads","Completed","Has Results","Sleep Quality","Behavioral: SLEEP-E Dyads Intervention","Subjective Sleep Quality|Mean Sleep Efficiency|BEF-SHI Total Number of Negative Sleep Hygiene Behaviors","VA Office of Research and Development|Emory University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","102","U.S. Fed|Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","E7249-W","November 2014","June 2016","July 2016","February 6, 2014","December 5, 2017","January 23, 2018","Atlanta VA Medical and Rehab Center, Decatur, GA, Decatur, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02057068"
372,"NCT02048709","Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Advanced Solid Tumors",,"Completed","No Results Available","Solid Tumor","Drug: GDC-0919","Percentage of patients with dose-limiting toxicities|Number of dose-limiting toxicities|Percentage of patients with adverse events|Pharmacokinetics: Serum concentrations (Cmax/Steady State)","Genentech, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","22","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GO29753|NLG9191","April 2014","February 2016","February 2016","January 29, 2014","null","February 6, 2017","Georgia Regents University, Augusta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02048709"
373,"NCT02043041","Evaluation of the Quality of Self-collected Blood Spot Specimens for Laboratory HIV Testing - An InvolveMENt Sub Study",,"Completed","No Results Available","HIV","Other: Number of DBS Spots","Viable sample for HIV Testing","Emory University|National Institute of Allergy and Infectious Diseases (NIAID)","Male","18 Years and older   (Adult, Older Adult)","","45","Other|NIH","Observational","Time Perspective: Cross-Sectional","IRB00042405|P30AI050409","January 2014","May 2015","May 2015","January 23, 2014","null","June 25, 2015","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02043041"
374,"NCT02024074","Evaluation of Magnetic Resonance Imaging (MRI) vs Molecular Breast Imaging (Tc-MBI) in Breast Cancer Patients",,"Terminated","No Results Available","Breast Cancer","Other: Sestamibi (Tc-MBI) scan of the breast","Cancer detection rates by Sestambi imaging","Emory University","Female","18 Years and older   (Adult, Older Adult)","Phase 1","1","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","IRB00064317","November 2013","January 2015","January 2015","December 31, 2013","null","February 6, 2015","Emory University Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02024074"
375,"NCT02023645","The Effects of a Carotenoid Intervention on Cognitive Function",,"Unknown status","No Results Available","Mild Cognitive Impairment","Dietary Supplement: active supplement|Other: placebo","macular pigment optical density|serum carotenoid levels|reaction time|executive function|short-term memory|visual attention","University of Georgia|Abbott Nutrition|DSM Nutritional Products, Inc.","All","18 Years to 95 Years   (Adult, Older Adult)","Not Applicable","120","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","2012-10516","January 2012","September 2015","December 2015","December 30, 2013","null","May 27, 2015","The University of Georgia, Athens, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02023645"
376,"NCT02021565","Evaluating the CG ASSIST Program for Caregiving Dyads","CG ASSIST","Completed","Has Results","Transfer Impairment","Behavioral: Immediate Intervention Group|Other: Delayed Intervention Control Group","Caregiver Transfer Efficacy|Veteran Task Efficacy|Caregiver Burden","VA Office of Research and Development","All","18 Years and older   (Adult, Older Adult)","Not Applicable","126","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care","D7873-R|00050313","December 2013","June 2016","June 2016","December 27, 2013","March 1, 2018","March 1, 2018","Atlanta VA Medical and Rehab Center, Decatur, GA, Decatur, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02021565"
377,"NCT02017418","The Effects of a Zeaxanthin Intervention on Visuomotor Function",,"Completed","No Results Available","Behavior and Behavior Mechanisms","Dietary Supplement: zeaxanthin|Dietary Supplement: combinatory supplement","Macular pigment optical density|fixed reaction time|variable reaction time|coincidence anticipation","University of Georgia|ZeaVision, LLC","All","18 Years to 40 Years   (Adult)","Not Applicable","102","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","2012-10531","February 2012","July 2014","July 2014","December 20, 2013","null","May 27, 2015","Department of Psychology, UGA, Athens, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02017418"
378,"NCT02013414","Fusion Targeted Biopsy of the Prostate",,"Active, not recruiting","No Results Available","Prostate Cancer","Procedure: PET/Ultrasound Fusion Targeted Biopsy of the Prostate","The cancer detection rates by the targeted and standard biopsy approaches","Emory University","Male","18 Years to 99 Years   (Adult, Older Adult)","Not Applicable","9","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","IRB00045065","September 2013","June 30, 2019","June 30, 2019","December 17, 2013","null","October 13, 2017","Emory University Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT02013414"
379,"NCT01999712","Right Ventricular Failure After Implantation of Left Ventricular Assist Devices",,"Completed","No Results Available","Heart Failure","Procedure: Echocardiography","Right ventricular failure|Quality of life|Right ventricular recovery","Emory University|American Heart Association","All","18 Years to 75 Years   (Adult, Older Adult)","","83","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","IRB00058588|13SDG15960001","July 2013","December 31, 2017","December 31, 2017","December 3, 2013","null","May 31, 2018","Emory University Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01999712"
380,"NCT01998412","Iluvien Registry Safety Study","IRISS","Active, not recruiting","No Results Available","Chronic Diabetic Macular Oedema Considered Insufficiently Responsive to Available Therapies","","Number of participants with adverse events.","Alimera Sciences","All","Child, Adult, Older Adult","","559","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","M-01-12-001","December 2013","January 2020","January 2020","November 28, 2013","null","October 25, 2017","Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01998412"
381,"NCT01995045","Postoperative Pain Control Following Vitreoretinal Surgery",,"Completed","Has Results","Retinal Detachment|Proliferative Vitreoretinopathy|Retinoschisis","Drug: Triamcinolone|Drug: Bupivicaine Hydrochloride","Mean Pain Score|Mean Acetaminophen Intake|Mean Hydrocodone Intake|Mean Oxycodone Intake","Emory University","All","18 Years to 89 Years   (Adult, Older Adult)","Phase 4","58","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","IRB00053514","July 2012","December 2015","December 2015","November 26, 2013","February 16, 2017","March 21, 2017","Emory University Eye Center, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01995045"
382,"NCT01991236","Video-Based Education for Dermatology Patients on Systemic Corticosteroids",,"Completed","No Results Available","Chronic Inflammatory Skin Diseases","Behavioral: Video|Behavioral: Standard Script","Change in patient knowledge of systemic corticosteroids","Emory University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","75","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","IRB00059584","April 2013","July 2014","July 2014","November 25, 2013","null","March 6, 2015","Emory Dermatology Clinic, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01991236"
383,"NCT01989689","Etanercept and Vascular Function in Psoriasis","EVIP","Completed","Has Results","PSORIASIS","Drug: Etanercept|Drug: Placebo","Vascular Function as Measured by Brachial Artery Flow-mediated Dilation (FMD)|Vascular Function as Measured by Brachial Artery Flow Mediated Dilation (FMD)","Emory University|Amgen","All","21 Years to 70 Years   (Adult, Older Adult)","Phase 2","24","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","IRB00039574","August 2010","September 2013","September 2013","November 21, 2013","December 19, 2014","December 19, 2014","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01989689"
384,"NCT01988350","Pancreatic Insufficiency Secondary to Tobacco Exposure",,"Completed","No Results Available","Pancreatic Insufficiency","","pancreatic insufficency","Emory University","All","30 Years and older   (Adult, Older Adult)","","202","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IRB00064360","May 2013","August 2013","August 2013","November 20, 2013","null","November 20, 2013","The Emory Clinic, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01988350"
385,"NCT01986374","Injection of Hormone to Enhance Implantation in Embryo Transfer After IVF",,"Unknown status","No Results Available","Infertility","Drug: HCG is introduced","HCG enhances pregnancy rate|implantation rate|ongoing pregnancy rate","Servy Massey Fertility Insititute","Female","21 Years to 47 Years   (Adult)","Not Applicable","75","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HCG 2013","June 2013","December 2015","February 2016","November 18, 2013","null","November 26, 2014","Servy Massey Fertility Insititute, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01986374"
386,"NCT01985022","Changing Developmental Trajectories Through Early Treatment",,"Recruiting","No Results Available","Autism Spectrum Disorders","Behavioral: PII with IES|Behavioral: IES","Child's social communication|Child's Autism Symptoms|Child's Developmental Level|Child's Adaptive Behavior|Parent Report","Emory University|National Institute of Mental Health (NIMH)","All","9 Months to 24 Months   (Child)","Not Applicable","108","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","IRB00064779|P50MH100029-02","May 2013","December 2019","December 2019","November 15, 2013","null","January 5, 2018","Marcus Autism Center, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01985022"
387,"NCT01984710","DBS for TRD Medtronic Activa PC+S",,"Recruiting","No Results Available","Treatment Resistant Depression","Device: Medtronic Activa PC+S System","Activa PC+S LFP recordings","Emory University|Hope for Depression Research Foundation|The Dana Foundation","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00066843","September 2013","September 2023","September 2023","November 15, 2013","null","November 6, 2017","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01984710"
388,"NCT01984164","CAndesartan vs LIsinopril Effects on the BRain","CALIBREX","Active, not recruiting","No Results Available","Hypertension|Mild Cognitive Impairment","Drug: Candesartan|Drug: Lisinopril","Executive function (EXAMINER score)|Perfusion and Vasoreactivity (VR)|rs-fMRI","Ihab M. Hajjar|National Institute on Aging (NIA)|Emory University","All","55 Years and older   (Adult, Older Adult)","Phase 3","174","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","IRB00070087|R01AG042127","August 2014","December 15, 2018","December 15, 2018","November 14, 2013","null","October 10, 2018","Emory Univeristy, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01984164"
389,"NCT01982825","Innovative Web-Based Intervention for Smoking Cessation Among College Students",,"Completed","No Results Available","Tobacco Use Cessation|Cigarette Smoking","Behavioral: Online intervention arm|Behavioral: Online control arm","Intervention acceptability|Cessation|Cigarette consumption|Quit Attempts","Emory University|National Institutes of Health (NIH)|Georgia State University|Valdosta State University","All","18 Years to 30 Years   (Adult)","Phase 1","200","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","IRB00059657|1R43TR000358-01","January 2013","July 2013","July 2013","November 13, 2013","null","December 5, 2013","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01982825"
390,"NCT01977885","Exercise-Induced Epigenetic Modifications in Obese Aging Women","DIVAS2","Completed","No Results Available","Metabolic Syndrome","Behavioral: High Protein Diet|Behavioral: Exercise","Change in CD4+T Cells from Baseline to Post-Intervention|Change in Physical Function over 6 Months|Change in Psychological Well Being over 6 Months","University of Georgia","Female","50 Years to 64 Years   (Adult)","Not Applicable","21","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2013106780","June 2013","December 2014","December 2014","November 7, 2013","null","September 25, 2015","Body Composition and Metabolism Lab, UGA, Ramsey Student Center, Athens, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01977885"
391,"NCT01972113","Vitamin K and Glucose Metabolism in Children at Risk for Diabetes (Vita-K 'n' Kids Study)",,"Recruiting","No Results Available","Obesity|Insulin Resistance|Insulin Sensitivity|Prediabetes|Dyslipidemia|Diabetes","Dietary Supplement: Placebo-Control|Dietary Supplement: Low-Dose Vitamin K2 (menaquinone-7; 45 mcg/d)|Dietary Supplement: High-Dose Vitamin K2 (menaquinone-7; 90 mcg/d)","Change in serum lipid concentrations|Change in insulin sensitivity|Change in beta-cell function|Change in coagulation|Change in arterial stiffness (pulse wave velocity)|Change in endothelial function (Flow-mediated dilation)|Effects of sex, race, bone age, and pubertal stage on changes in glucosemetabolism (insulin sensitivity and beta-cell function)","Augusta University|University of Alabama at Birmingham|Yale University|Tufts University|Nattopharma ASA","All","8 Years to 17 Years   (Child)","Phase 1|Phase 2","30","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","611523 (Pro00000912)|16GRNT31090037","September 2013","August 2018","December 2018","October 30, 2013","null","July 12, 2018","Medical College of Georgia; Augusta University, Augusta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01972113"
392,"NCT01971047","Safety and Efficacy Study of Correcting Hyperglycemia in Patients With Diabetes Having Out-patient Surgery",,"Withdrawn","No Results Available","Type 1 Diabetes|Type 2 Diabetes","Drug: Regular Insulin|Drug: Humalog","BG concentration differences at 1 and 2 hours post intervention and post operatively|Number and percentage of target BG readings|Episodes of hypoglycemia|Episodes of hyperglycemia|Total dose of insulin|Change in glucose concentration from baseline to one, two and three hours post treatment|Number of perioperative complications","Emory University","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 4","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00067662","October 2013","September 2018","September 2018","October 28, 2013","null","March 15, 2017","Emory Healthcare Ambulatory Surgical Center, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01971047"
393,"NCT01969565","Study of Carfilzomib in Combination w/Dexamethasone in Patients w/Newly Diagnosed Multiple Myeloma",,"Terminated","Has Results","Multiple Myeloma","Drug: Carfilzomib|Drug: Dexamethasone","Tolerability and Safety of Increasing Doses of Carfilzomib in Combination With Dexamethasone.|Patients With ≥ VGPR (Very Good Partial Response)|Overall Response Rate (ORR), Defined as sCR, CR, Very Good Partial Response (VGPR), and PR at 4 Cycles","Emory University|Onyx Therapeutics, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","1","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00060113|ISTCAR511","August 2013","October 2014","October 2014","October 25, 2013","November 4, 2015","November 24, 2017","Winship Cancer Institute-Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01969565"
394,"NCT01966094","Observational Study of HIV-associated Neurocognitive Disorder","HAND2","Completed","No Results Available","HIV Associated Neurocognitive Disorder|Human Immunodeficiency Virus","","Difference in neurocognition change over 48 weeks as measured by a summary score (NPZ-8) that reflects an 8 test neurocognitive battery.","Emory University|National Institute of Mental Health (NIMH)","All","18 Years to 59 Years   (Adult)","","46","Other|NIH","Observational","Observational Model: Case-Control|Time Perspective: Prospective","IRB00065880|K23MH095679","October 2013","June 5, 2018","June 5, 2018","October 21, 2013","null","July 19, 2018","Emory University School of Medicine, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01966094"
395,"NCT01965366","Dexamethasone Plus Virtual Reality Exposure Therapy for PTSD","Dex","Completed","Has Results","PTSD","Behavioral: Virtual reality exposure therapy|Drug: 0.5 mg DEX","Change in The Clinician Administered PTSD Scale (CAPS)Scores|Change in The PTSD Symptom Scale Scores","Emory University","All","21 Years to 65 Years   (Adult, Older Adult)","Phase 4","27","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRB00068205","October 2013","March 2017","June 2017","October 18, 2013","July 12, 2018","July 12, 2018","Emory University, Atlanta, Georgia, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/66/NCT01965366/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT01965366"
396,"NCT01960062","Impact of Web-based Care Management for Poorly Controlled Type 2 Diabetes Mellitus: a Randomized, Controlled Trial",,"Withdrawn","No Results Available","Type 2 Diabetes Mellitus","Device: Diabetes software and device","Change in Hemoglobin A1c|Hemoglobin A1c<9|Office visit time","Kaiser Permanente","All","18 Years to 74 Years   (Adult, Older Adult)","Not Applicable","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GA-11NYate-01","October 2011","June 2012","June 2012","October 10, 2013","null","March 19, 2014","Kaiser Permanente Georgia Region, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01960062"
397,"NCT01959620","Optimal Dose of Early Intervention to Prevent PTSD",,"Completed","No Results Available","Posttraumatic Stress Disorder","Behavioral: 1-Session Exposure Therapy|Behavioral: 3-Session Exposure Therapy","Change in PTSD Symptom Scale-I (PSS)","Emory University","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","95","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","IRB00063758|NARSAD 19798","October 2013","December 2016","December 2016","October 10, 2013","null","July 21, 2017","Grady Memorial Hospital, Emergency Department, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01959620"
398,"NCT01954173","Adjuvant Radiation for High Risk Bladder Cancer",,"Recruiting","No Results Available","Bladder Cancer|Squamous Cell Carcinoma of the Bladder|Stage III Bladder Cancer|Stage IV Bladder Cancer|Transitional Cell Carcinoma of the Bladder","Radiation: 3D conformal radiation therapy","Gastrointestinal (GI) late effects, assessed using Radiation Therapy Oncology Group (RTOG) Late Effects in Normal Tissues (LENT)/Subjective, Objective, Management and Analytic (SOMA) scales|Acute adverse events greater than grade 2, graded by CTCAE version 4.0|Loco-regional failure, considered any failure in the treatment field of the pelvis|Rate of distant metastases|Rate of disease-free survival|Overall survival rate|Quality of life, assessed using FACT-BL","Emory University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","41","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00059097|NCI-2013-01381|RAD2271-12","July 2013","March 2019","March 2024","October 1, 2013","null","March 19, 2018","Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01954173"
399,"NCT01953614","Effects of Chiropractic Adjustments on Brain Function Using Quantitative Encephalography",,"Completed","No Results Available","Brain Function","Other: Chiropractic adjustment|Other: Sham adjustment","Changes in quantitative EEG values as compared to a normative database|Behavioral assessment questionaire","Life University","All","10 Years to 99 Years   (Child, Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Health Services Research","I-0010","June 2013","December 2015","December 2015","October 1, 2013","null","April 20, 2016","Life University, Marietta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01953614"
400,"NCT01952119","Effect of a Secure Message Reminder on Hypertension Follow-up at an Integrated Health Care System",,"Completed","No Results Available","Hypertension","Other: Secure message reminder","Appointment with new blood pressure reading|New appointment with new blood pressure reading|Existing appointment kept with new blood pressure reading|Change in antihypertensive regimen","Kaiser Permanente","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","182","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","GA-11AKuo-01","October 2011","December 2011","June 2012","September 27, 2013","null","September 27, 2013","Kaiser Permanente Georgia, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01952119"
401,"NCT01947673","Mechanisms of Intradialytic Hypertension","MID-H","Recruiting","No Results Available","Renal Failure Chronic Requiring Hemodialysis|Haemodialysis-induced Symptom|Hypertension","Other: Mindfulness Meditation|Other: Health Education","Blood Pressure during dialysis|Cardiopulmonary baroreflex Sensitivity|KDQOL Symptom Score","Emory University|Satellite Healthcare","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","IRB00066932|00025948","September 2013","August 2020","August 2020","September 20, 2013","null","October 5, 2018","Emory Dialysis Clinics, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01947673"
402,"NCT01946724","In-hospital and Long-term Outcomes for Percutaneous Chronic Total Coronary Occlusion Revascularization in a High-volume, Multi-operator Program","Perspective","Completed","No Results Available","Ischemic Heart Disease","","CTO procedural success|Major Adverse Cardiac Events (MACE)","Piedmont Healthcare","All","18 Years and older   (Adult, Older Adult)","","500","Other","Observational","Observational Model: Other|Time Perspective: Other","Perspective","August 2013","May 24, 2017","May 24, 2017","September 20, 2013","null","May 4, 2018","Piedmont Heart Institute, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01946724"
403,"NCT01930968","Definity for Ultrasound of Intraocular Tumors",,"Not yet recruiting","No Results Available","Ocular Melanoma","","Quantification of tumor perfusion and visualization of microvasculature using ultrasound enhanced images of intraocular tumors with microbubbles|Correlation between tumor vascularity by contrast enhanced ultrasoungraphy and histologically determined tumor vascular density|Correlation between tumor size by contrast enhanced ultrasoungraphy and histologically determined tumor size","Emory University","All","20 Years and older   (Adult, Older Adult)","","10","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IRB00039493","January 2019","December 2019","December 2019","August 29, 2013","null","February 28, 2018","Emory Eye Center, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01930968"
404,"NCT01926678","Efficacy of Swedish Massage Therapy on Cancer-related Fatigue in Cancer Survivors",,"Completed","No Results Available","Cancer Related Fatigue","Other: Swedish massage therapy|Other: Light touch therapy","Cancer-Related Fatigue|Inflammation","Emory University|National Center for Complementary and Integrative Health (NCCIH)|National Cancer Institute (NCI)","Female","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","66","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRB00062853|R21AT007090","November 2013","May 2016","May 2016","August 21, 2013","null","July 11, 2016","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01926678"
405,"NCT01924910","A Single Wintertime Dose of Vitamin D3 to Prevent Winter Decline in Vitamin D Status in Healthy Adults",,"Completed","No Results Available","Vitamin D Deficiency","Dietary Supplement: 250,000 IU cholecalciferol as single, oral dose|Dietary Supplement: Placebo","blood levels of 25(OH)D|Blood Calcium level|Blood pro-inflammatory cytokines|Blood hepcidin concentration|Blood markers of iron status","Emory University","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","28","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRB00061103|OnceYearlyD","October 2012","December 2013","July 2017","August 19, 2013","null","July 13, 2017","Emory University Campus, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01924910"
406,"NCT01923896","D-cycloserine and Treatment of Feeding Disorders",,"Completed","Has Results","Feeding Disorders|Specific Phobia","Behavioral: Behavioral Intervention|Drug: d-cycloserine (DCS)|Drug: Placebo","Rapid Swallowing|Disruptions","Emory University","All","18 Months to 6 Years   (Child)","Phase 1|Phase 2","16","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRB00061465|DCS-2012-Marcus","March 2013","September 2013","November 2013","August 16, 2013","October 23, 2014","October 23, 2014","Marcus Autism Center - Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01923896"
407,"NCT01922206","Maternal HIV: Trial to Assist Disclosure to Children","TRACK II","Active, not recruiting","No Results Available","HIV","Behavioral: TRACK Intervention","Disclosure of Maternal HIV status to child|Child Mental Health Functioning (Composite measure)","Georgia State University|University of California, Los Angeles","All","Child, Adult, Older Adult","Not Applicable","362","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care","MH094233|1R01MH094233","March 2013","August 2016","April 2018","August 14, 2013","null","August 11, 2017","Georgia State University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01922206"
408,"NCT01921270","Dysport for the Treatment of OMD",,"Completed","Has Results","Oral Dystonia|Tardive Dystonia","Drug: Low Dose - AbobotulinumtoxinA","Mean Global Dystonia Rating Scale Score as Measured by Blinded Rater|Change in Analogue Pain Scale Score|Mean Sialorrhea Clinical Scale for Parkinson's Disease (SCS-PD) Score|Change in Number of Tongue Bites Per Day|Mean Swallowing Disturbance Questionnaire (SDQ-20) Score|Mean Fahn-Marsden Part B ""Speech"" Question (BFM-q21) Rating|Mean Oromandibular Dystonia Quality of Life Questionnaire (OMDQ-25) Score|Mean Global Clinical Impression - Improvement Scale (CGI) Index Score|Mean Global Clinical Impression Scale (CGI-S) With Severity Index Score|Mean Global Clinical Impression- Efficacy Index Score|Mean Unified Dystonia Rating Scale (UDRS) Score as Measured by Un-blinded Rater|Mean Global Dystonia Rating Scale Score as Measured by Un-blinded Rater|Mean Unified Dystonia Rating Scale (UDRS) Score as Measured by Blinded Rater","Emory University|Ipsen","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","18","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00064292","August 2013","February 8, 2017","February 8, 2017","August 13, 2013","November 17, 2017","November 17, 2017","Wesley Woods Health Center; Emory University Hospital, Atlanta, Georgia, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/70/NCT01921270/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT01921270"
409,"NCT01921218","Belatacept Therapy for the Failing Renal Allograft","IM103-133","Active, not recruiting","No Results Available","Failing Renal Allograft","Drug: Belatacept|Drug: Calcineurin inhibitor therapy|Drug: Mycophenolate mofetil|Drug: prednisone","Comparison of development of donor-specific antibody between groups|Change of glomerular filtration rate between groups","Andrew B Adams, MD, PhD|Bristol-Myers Squibb|Emory University","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","72","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00060470|IM103-133","August 2013","August 2018","August 2019","August 13, 2013","null","December 15, 2017","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01921218"
410,"NCT01917708","BMT Abatacept for Non-Malignant Diseases",,"Recruiting","No Results Available","Hurler Syndrome|Fanconi Anemia|Glanzmann Thrombasthenia|Wiskott-Aldrich Syndrome|Chronic Granulomatous Disease|Severe Congenital Neutropenia|Leukocyte Adhesion Deficiency|Shwachman-Diamond Syndrome|Diamond-Blackfan Anemia|Dyskeratosis-congenita|Chediak-Higashi Syndrome|Severe Aplastic Anemia|Thalassemia Major|Hemophagocytic Lymphohistiocytosis|Sickle Cell Disease","Drug: Abatacept","Tolerability of abatacept|Proportion of Participants experiencing Immunological effects|Proportion of Participants experiencing Regimen-related toxicity|Proportion of Participants experiencing Engraftment failure|Proportion of Participants experiencing Graft versus Host Disease|Survival Rate|Pharmacokinetics of abatacept","Emory University","All","up to 21 Years   (Child, Adult)","Phase 1","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","IRB00069836","January 2014","September 2018","January 2020","August 7, 2013","null","May 17, 2018","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01917708"
411,"NCT01916824","Effects of Treatment on Decision-making in Major Depression",,"Completed","Has Results","Major Depressive Disorder|Healthy Controls","Drug: Any FDA Approved Antidepressant","Money Earned","Emory University","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","53","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","IRB00066705","August 2013","December 2015","December 2015","August 6, 2013","October 20, 2017","November 21, 2017","Emory Mood and Anxiety Disorders Program, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01916824"
412,"NCT01916096","Lancet Blood Volume Comparison Study",,"Completed","No Results Available","Diabetes","Device: Delica Device","Blood Volume Measurements","Facet Technologies","All","18 Years to 85 Years   (Adult, Older Adult)","","180","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","FT-837-068-BV","February 2012","February 2012","February 2012","August 5, 2013","null","August 5, 2013","Facet Technologies, Kennesaw, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01916096"
413,"NCT01914302","The Characterization of Blood Volumes of Commercially Available Lancing Devices",,"Completed","No Results Available","Diabetes","Device: Delica Lancing Device|Device: Flash Lancing Device|Device: Easy Touch Lancing Device|Device: Glucoject Lancing Device|Device: Microlet Lancing Device|Device: Multiclix Lancing Device|Device: Fastclix Lancing Device|Device: Reli-On Lancing Device","Blood Volumes measured in microliters|Pain rating measure on a 0-20 Gracely Scale","Facet Technologies|LifeScan","All","18 Years to 75 Years   (Adult, Older Adult)","","64","Other|Industry","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","FT6000682013","July 2013","July 2013","July 2013","August 2, 2013","null","August 2, 2013","Facet Technologies, Kennesaw, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01914302"
414,"NCT01913470","Study of Losartan in the Treatment of NAFLD in Children",,"Completed","Has Results","NAFLD","Drug: Losartan","Change in Alanine Aminotransferase (ALT) From Baseline to End of Treatment (8 Weeks of Treatment)|Change in Cholesterol Levels From Baseline to End of Treatment (8 Weeks of Treatment)|Change in Triglyceride Levels From Baseline to End of Treatment (8 Weeks of Treatment)|Change in Fatty Acid Levels From Baseline to End of Treatment (8 Weeks of Treatment)|Changes in Homeostasis Model of Assessment - Insulin Resistance (HOMA-IR) Between Baseline and End of Treatment (8 Weeks of Treatment)|Changes in Plasminogen Activator Inhibitor-1 (PAI-1) Concentrations Between Baseline and End of Treatment","Miriam Vos, MD|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Children's Healthcare of Atlanta|Emory University","All","11 Years to 19 Years   (Child, Adult)","Phase 2","12","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRB00062895|1R03DK096157-01A1|1R03DK096157-01","July 2013","December 2015","December 2015","August 1, 2013","May 15, 2017","May 15, 2017","Emory University / Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01913470"
415,"NCT01910519","Systems Biology of Influenza A (H5N1) Virus Monovalent Vaccine With and Without Adjuvant System 03 (AS03)",,"Completed","No Results Available","Influenza A Virus, H5N1 Subtype","Biological: Influenza A (H5N1) Virus Monovalent Vaccine with AS03 adjuvant|Biological: Influenza A (H5N1) Virus Monovalent Vaccine without AS03 adjuvant","Change in traditional immune parameters measurements using Luminex assays and gene expression measurement using microarray experiments from baseline with Influenza A Vaccine with and without AS03 adjuvant|Measurement of Hemagglutination Inhibition Assay (HAI) titers +/- microneutralization (MN) titers with Influenza A Vaccine with and without AS03 adjuvant|Correlation of innate immune signatures and adaptive immune responses using correlation coefficient and SAM with quantitative outcome|Frequency, severity and causality of all adverse events in participant receiving Influenza A Vaccine with and without AS03 adjuvant","National Institute of Allergy and Infectious Diseases (NIAID)|Emory University","All","21 Years to 45 Years   (Adult)","Phase 2","50","NIH|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","DAIT HIPC: VAX-010","July 2013","February 2015","November 2015","July 29, 2013","null","February 15, 2016","The Hope Clinic - Emory Vaccine Center, Decatur, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01910519"
416,"NCT01909115","Randomized Study of Two Vitamin D Dosing Strategies in Children With Chronic Kidney Disease",,"Active, not recruiting","No Results Available","Chronic Kidney Disease","Dietary Supplement: Vitamin D3","Vitamin D sufficiency","Emory University","All","9 Years to 19 Years   (Child, Adult)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRB00067067|EmoryPedNeph-001","September 2014","April 2020","June 2020","July 26, 2013","null","July 18, 2018","Childen's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01909115"
417,"NCT01903876","A Web-based Bystander Education Program","RealConsent","Completed","Has Results","Sexual Violence","Behavioral: Bystander & Sexual Violence Prevention|Behavioral: General Health Promotion","Prosocial Intervening Behavior|Sexual Violence Perpetration","Emory University|Centers for Disease Control and Prevention","Male","18 Years to 24 Years   (Adult)","Not Applicable","743","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","IRB00000472|R49CE000892|EmoryVAW","February 2010","May 2011","May 2011","July 19, 2013","July 23, 2014","July 23, 2014","Georgia State University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01903876"
418,"NCT01899521","Examination of Zinc, S-adenosylmethionine, and Combination Therapy Versus Placebo in Alcoholics","ExZACTO","Completed","No Results Available","Alcoholism","Procedure: Bronchoscopy|Dietary Supplement: Zinc sulfate 220 mg once daily|Dietary Supplement: S-adenosylmethionine 400 mg twice daily","Primary Endpoint|Secondary Endpoint","VA Office of Research and Development","All","18 Years to 60 Years   (Adult)","Not Applicable","113","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","PULM-038-12S|IRB00060773|IK2CX000643","May 1, 2013","July 31, 2017","July 31, 2017","July 15, 2013","null","November 8, 2017","Atlanta VA Medical and Rehab Center, Decatur, GA, Decatur, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01899521"
419,"NCT01896180","Study to Compare the Safety and Efficacy of ALZ-1101 to Latanoprost in Patients With Intraocular Pressure Inadequately Controlled by Latanoprost",,"Completed","No Results Available","Primary Open Angle Glaucoma|Ocular Hypertension|Elevated Intraocular Pressure","Drug: ALZ-1101|Drug: Latanoprost","Goldmann applanation tonometry|Safety","Alleanza Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","63","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","ALZ-1101-101","July 2013","January 2014","January 2014","July 11, 2013","null","September 30, 2014","Morrow, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01896180"
420,"NCT01893684","Dietary Intervention and Varying Physical Activity in Seniors","ugaDIVAS","Completed","No Results Available","Obesity","Behavioral: Exercise|Behavioral: Higher Protein Diet|Behavioral: Conventional Carbohydrate Diet","Change from Baseline in Body Composition at 3 Months and 6 Months|Change from Baseline in Strength & Muscle Quality at 3 Months and 6 Months|Change from Baseline in Energy & Fatigue Symptoms/Psychological Function at 3 Months and 6 Months|Physical Functional Performance|Biomarkers Related to Fatigue|Physical Activity|Acceptability","University of Georgia","Female","65 Years to 80 Years   (Older Adult)","Not Applicable","81","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCBA","January 1, 2013","December 31, 2014","July 1, 2015","July 9, 2013","null","September 7, 2017","University of Georgia, Athens, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01893684"
421,"NCT01890226","A Mobile Personal Health Record for Behavioral Health Homes","mPHR","Active, not recruiting","No Results Available","Hypertension|Hyperlipidemia|Diabetes","Behavioral: Mobile Personal Health Record App.","Quality of General Medical Care","Emory University|National Institute of Mental Health (NIMH)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","300","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","IRB00067447|1R01MH100467-01","November 2014","October 2018","December 2018","July 1, 2013","null","September 12, 2018","Viewpoint Health & Oakhurst Medical Center, Conyers, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01890226"
422,"NCT01889355","User Study for Enhanced Meter Feature",,"Completed","Has Results","Diabetes Mellitus","Device: AgaMatrix Blood Glucose Monitor","Enhanced Meter Feature Usability","AgaMatrix, Inc.","All","18 Years and older   (Adult, Older Adult)","Not Applicable","121","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","AGAFPGM01","January 2014","February 2014","March 2014","June 28, 2013","August 6, 2018","August 6, 2018","Atlanta Diabetes Associates, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01889355"
423,"NCT01880346","Comparison of Absorption of Vitamin D in Cystic Fibrosis",,"Completed","No Results Available","Cystic Fibrosis","Dietary Supplement: Vitamin D Powder|Dietary Supplement: Vitamin D Oil","Rate of Absorption of vitamin D3 to blood","Emory University","All","18 Years to 59 Years   (Adult)","Phase 4","17","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention","IRB00066261|Hermes vitamin D","October 2013","March 2015","October 2015","June 19, 2013","null","November 20, 2015","Emory University Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01880346"
424,"NCT01873495","Omacetaxine for Consolidation and Maintenance",,"Completed","No Results Available","Acute Myelogenous Leukemia (AML)","Drug: Omacetaxine","Disease status will be assessed by a bone marrow aspirate and biopsy prior to each of 3 consolidation cycles (to ensure that patients are still in remission).|Assessment of disease status|Bone marrow aspirate to confirm continuous remission will be obtained before starting maintenance and at 3 and 6 months from the start of maintenance.|Toxicities will be monitored by history, physical examination, and laboratory monitoring-during maintenance.|Toxicities will be monitored by history, physical examination, and laboratory monitoring-during consolidation.","Emory University|Teva Pharmaceuticals USA","All","55 Years and older   (Adult, Older Adult)","Phase 2","7","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00057844|Winship2176-11","May 2013","July 2018","July 2018","June 10, 2013","null","September 3, 2018","Emory University Winship Cancer Institute, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01873495"
425,"NCT01868958","DTI of the Brain and Cervical Spine: Evaluation in Normal Subjects and Patients With Cervical Spondylotic Myelopathy",,"Completed","No Results Available","Cervical Spondylosis With Myelopathy","","Diffusion properties of the spinal cord","Emory University|Siemens Medical Solutions","All","30 Years to 70 Years   (Adult, Older Adult)","","26","Other|Industry","Observational","Observational Model: Case Control|Time Perspective: Prospective","IRB00058267","January 2013","June 2015","June 2015","June 5, 2013","null","July 15, 2015","Center for Systems Imaging (CSI), Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01868958"
426,"NCT01865708","Pilot Study of the Safety of a Daily Ethanol Lock for Urinary Catheters in Critically Ill Children",,"Completed","Has Results","Complication of Urinary Catheter","Drug: Ethanol Lock","Blood Alcohol Level|Urine Analysis","Children's Healthcare of Atlanta","All","6 Months to 17 Years   (Child)","Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","Ethanol Lock, Safety","July 2013","November 2013","June 2015","May 31, 2013","April 2, 2018","June 28, 2018","Children's Helathcare of Atlanta at Egleston, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01865708"
427,"NCT01861210","Couples HIV Counseling and Testing for Male Couples in the United States","CVCT","Completed","No Results Available","HIV","Behavioral: Couples Voluntary HIV Counseling and Testing|Behavioral: Individual Counseling and Testing","Intimate partner violence|Relationship dissolution","Emory University|National Institute of Mental Health (NIMH)","Male","18 Years to 39 Years   (Adult)","Not Applicable","216","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","IRB00043714|R34MH086331|CVCTMSM","September 2010","May 2012","June 2012","May 23, 2013","null","May 22, 2015","AID Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01861210"
428,"NCT01848483","Living Well Project for Persons With AIDS",,"Completed","No Results Available","Acquired Immunodeficiency Syndrome (AIDS)","Behavioral: AIDS EPC Package plus MI|Other: Standard of Care (SOC)","Change in Quality of Life|Change in Clinical Indicators","Emory University|Grady Health System","All","18 Years and older   (Adult, Older Adult)","Not Applicable","121","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","IRB00059987|NIH/NINR-1R01NR014054-01","June 2014","June 2017","June 2017","May 7, 2013","null","July 31, 2017","Emory University, Nell Hodgson Woodruff School of Nursing, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01848483"
429,"NCT01848041","Safety and Efficacy Study of RVL-1201 in Acquired Blepharoptosis",,"Completed","No Results Available","Blepharoptosis","Drug: RVL-1201|Drug: RVL-1201 Vehicle Placebo","Humphrey Visual Field|Marginal Reflex Distance|Palpebral Fissure Distance Measurement|Contrast Sensitivity|Safety","RevitaLid Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","46","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RVL-1201-001","May 2013","January 2014","February 2014","May 7, 2013","null","January 13, 2016","Morrow, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01848041"
430,"NCT01845844","Ranibizumab For Persistent Diabetic Macular Edema After Bevacizumab","ROTATE","Unknown status","No Results Available","Diabetic Macular Edema","Drug: Ranibizumab 0.3mg/0.05cc","Incidence of ocular and systemic adverse events will be compared between experimental and active comparator groups|Severity of ocular and systemic adverse events will be compared between experimental and active comparator groups|Efficacy of monthly and monthly followed by PRN dosing of 0.3 mg ranibizumab after persistent DME despite previous bevacizumab therapy","Southeast Retina Center, Georgia|Genentech, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","30","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ML28713","April 2013","January 2015","January 2015","May 3, 2013","null","September 17, 2014","Southeast Retina Center, PC, Augusta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01845844"
431,"NCT01841658","Folic Acid Supplementation in Women of Child Bearing Age","FASUPP","Completed","No Results Available","Obesity","Dietary Supplement: Folic acid","Cell-type-specific DNA methylation|Gene-specific DNA methylation|Serum folate|Red Blood Cell (RBC) Folate|Body Composition","University of Georgia|University of Florida|Emory University","Female","18 Years to 40 Years   (Adult)","Not Applicable","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Basic Science","UGA_FASUPPLEMENT_EPIGEN","April 2013","August 2015","June 2016","April 26, 2013","null","July 4, 2016","University of Georgia, Athens, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01841658"
432,"NCT01840696","Phase Analysis and Obstructive CAD on Rubidium PET",,"Withdrawn","No Results Available","Coronary Artery Disease","Drug: Regadenoson","Stress/rest differences in global left ventricular mechanical contraction bandwidth.|Stress/rest differences in segmental left ventricular mechanical contraction bandwidth.","Emory University","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 2","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","IRB00062632|REGA12I11","October 2013","May 2014","May 2014","April 26, 2013","null","June 2, 2014","Emory University Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01840696"
433,"NCT01838057","Evaluation of the Clinical and Economic Impact of painPRIMER in the Treatment of Low Back Pain in a Primary Care Setting",,"Terminated","No Results Available","Low Back Pain","Device: painPREMIER cohort|Other: Control cohort","Roland Morris Disability Questionnaire: Change from baseline to month 3 in the Roland Morris Disability Questionnaire (RMDQ) total score in the painPRIMER cohort vs control cohort|Low back pain (LBP) Cost: LBP (specific and related) direct medical costs associated with utilization of healthcare incurred by each study patient from baseline to month 6|Change from baseline to month 6 in RMDQ total score|Change from baseline to month 3 and 6 in low back pain intensity (LBPI)|Change from baseline to month 3 and 6 daily sleep interference rating scale (DSIRS)|Response as defined as a the proportion of patients with at least 30% and 50% improvement in LBPI at 3 and 6 months|Response as defined as a the proportion of patients with at least 30% and 50% improvement in RMDQ at 3 and 6 months|Quality of Life in the painPRIMER cohort vs control cohort: Change from baseline to month 3 and 6 in the Short- Form.|psychosocial outcomes in the painPRIMER cohort and control cohort: Proportion of patients at risk for depression and/or anxiety (via Patient Health Questionnaire-4 [PHQ-4]) at baseline, 3 and 6 months|psychosocial outcomes in the painPRIMER cohort and control cohort: Changes from baseline to month 3 and 6 in patients at risk for depression (PHQ-8) and anxiety (GAD-7), among those receiving the instrument (NOTE: only given to those scoring >/=|3 on PHQ-4)|psychosocial outcomes in the painPRIMER cohort and control cohort: Change from baseline to month 3 and 6 in catastrophizing (Coping Strategies Questionnaire -Catastrophizing [CSQ-CAT])|productivity/indirect costs: Changes from baseline to month 3 and 6 in Work Productivity and Activity Impairment (WPAI): Specific Health Problem, LBP|Direct cost: Comparison of resource use/direct medical costs, in 6 months pre-enrollment/index date and 6 months post-enrollment/index date via insurance claims data for painPRIMER and control cohorts|Patient satisfaction with painPRIMER|Healthcare professional satisfaction with painPRIMER","Pfizer|Piedmont Healthcare System","All","18 Years and older   (Adult, Older Adult)","","103","Industry|Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","X9001010","June 2013","July 2014","July 2014","April 23, 2013","null","April 16, 2015","Pfizer Investigational Site, Fayetteville, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01838057"
434,"NCT01837524","The KP Personal Shopper: A Pilot to Improve the Impact of Dietary Advice",,"Completed","Has Results","Overweight|Obesity","Behavioral: KP Personal Shopper Visits|Behavioral: In-Office Dietitian Visits","Change in Dietary Quality Scores of Members as Measured Using the 2005 Healthy Eating Index (HEI).|Nutritional Knowledge of Members","Kaiser Permanente","All","18 Years to 64 Years   (Adult)","Not Applicable","55","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","Pro00003988","June 2013","October 2013","November 2013","April 23, 2013","April 12, 2017","April 12, 2017","Kaiser Permanente Center for Health Research, Southeast, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01837524"
435,"NCT01833962","A Retrospective Study of Actifuse Synthetic Bone Graft Versus Other Bone Graft Substitutes in Patients Requiring Lumbar Fusion",,"Unknown status","No Results Available","Lumbar Fusion","","Achievement of fusion prior to or at 12 months postoperatively","OrthoGeorgia|Baxter Healthcare Corporation","All","18 Years and older   (Adult, Older Adult)","","100","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","001-3708","January 2013","August 2015","December 2015","April 17, 2013","null","April 21, 2015","OrthoGeorgia, Macon, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01833962"
436,"NCT01824134","Aloe Vera on Irradiated Breast Tissue",,"Completed","No Results Available","Irradiated Breast Tissue","Other: Klean & Klear The Dandy Day Corp|Other: The Skin Gel Herbal Answers, Inc","erythema|itching","John D. Archbold Memorial Hospital","Female","18 Years and older   (Adult, Older Adult)","Phase 3","40","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care","12-09-008","October 2012","March 2014","March 2014","April 4, 2013","null","September 19, 2016","Lewis Hall Singletary Oncology Center at John D. Archbold Memorial Hospital, Thomasville, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01824134"
437,"NCT01823237","Effect of Increasing Motor Cortex Inhibition on Task Specific Dystonia",,"Recruiting","No Results Available","Dystonia","Device: Transcranial Magnetic Stimulation","Efficacy of TMS on task-specific focal hand dystonia","Emory University","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","15","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Diagnostic","IRB00062538|DYST","February 2013","December 2018","April 2019","April 4, 2013","null","February 1, 2018","Emory University School of Medicine, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01823237"
438,"NCT01815567","DETECT and Retinal Outcomes in Hypertension",,"Recruiting","No Results Available","Hypertension|Retinal Disorder|Cognitive Impairment","","DETECT neurocognitive outcome scores (Z-scores) in association with blood pressure measures and retinal pathology (isolated retinal hemorrhage, grade III/IV hemorrhagic retinopathy)|Variance of DETECT scores (Z-score) attributed to reading level","Emory University","All","18 Years to 65 Years   (Adult, Older Adult)","","300","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","IRB00060043","November 2012","December 2018","March 2019","March 21, 2013","null","January 18, 2018","Grady Memorial Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01815567"
439,"NCT01813409","Rheumatology Clinical Registry","RCR","Unknown status","No Results Available","Rheumatoid Arthritis","","Quality of the treatment of rheumatoid arthritis and other diseases|Submission to federal reporting programs","American College of Rheumatology","All","Child, Adult, Older Adult","","820","Other","Observational","","ACR-RCR","August 2009","December 2015","null","March 19, 2013","null","September 1, 2014","Registry Site, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01813409"
440,"NCT01808222","FACBC for Recurrent Prostate Cancer",,"Active, not recruiting","No Results Available","Recurrent Prostate Cancer","Drug: FACBC","The presence of cancer tissue inside and outside of the prostate bed.","David M. Schuster, MD|Emory University","Male","18 Years to 99 Years   (Adult, Older Adult)","Phase 2","25","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","IRB00061518|FACBC2","November 2013","October 2018","October 2018","March 11, 2013","null","November 6, 2017","Emory University Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01808222"
441,"NCT01807156","Phase II Trial of Tivozanib in Advanced Hepatocellular Cancer",,"Terminated","Has Results","Hepatocellular Cancer","Drug: Tivozanib","Number of Patients With Advanced Hepatocellular Cancer (HCC) Receiving Tivozanib Who Are Free From Progression|Response Rate Based on Response Evaluation Criteria in Solid Tumors (RECIST) Criteria","Emory University|AVEO Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","7","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00061422|WINSHIP2302-12","March 2013","February 2015","February 2015","March 8, 2013","April 22, 2016","April 22, 2016","Emory University, Winship Cancer Institute, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01807156"
442,"NCT01805895","A Pilot Study of Minocycline in Intracerebral Hemorrhage Patients","MACH","Completed","Has Results","Intracerebral Hemorrhage","Drug: Minocycline","Modified Rankin Scale|Safety Assessment","Augusta University|American Heart Association","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","16","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","Pro00000718","February 2013","December 2016","December 2016","March 6, 2013","April 26, 2018","April 26, 2018","Georgia Health Sciences University, Augusta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01805895"
443,"NCT01805622","Educational Program to Increase Colorectal Cancer Screening: a Cluster Trial","EPICS","Unknown status","No Results Available","Colorectal Cancer","Behavioral: Active Arm #1, #2, Passive Arm #1, #2","Reach (RE-AIM Framework)|Effectiveness (RE-AIM Framework)|Adoption (RE-AIM Framework)|Implementation (RE-AIM Framework)","Morehouse School of Medicine|National Cancer Institute (NCI)","All","50 Years to 74 Years   (Adult, Older Adult)","Not Applicable","7200","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening","EPICS cRCT|1R01CA166785","August 2012","March 2017","March 2017","March 6, 2013","null","March 6, 2013","Morehouse School of Medicine, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01805622"
444,"NCT01799837","Norepinephrine Transporter Availability in PTSD",,"Completed","No Results Available","Posttraumatic Stress Disorder","Drug: [C-11]MENET","Measurement of norepinephrine availability","Emory University","Male","30 Years to 70 Years   (Adult, Older Adult)","Phase 1","9","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","IRB00057641|URC-00025435","June 2012","April 2013","July 2013","February 27, 2013","null","September 11, 2013","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01799837"
445,"NCT01798550","Enoxaparin Dosing in Obesity",,"Completed","Has Results","Obesity","Drug: Enoxaparin","Proportion of Patients With an Initial Therapeutic Anti-Xa Level at Steady State in Each Group|Time to Therapeutic Anti-Xa Level for Both Groups","Emory University","All","18 Years and older   (Adult, Older Adult)","Phase 4","62","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00063210","March 2013","October 1, 2016","October 15, 2016","February 26, 2013","November 6, 2017","December 14, 2017","Grady Memorial Hospital, Atlanta, Georgia, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/50/NCT01798550/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT01798550"
446,"NCT01794949","Optical Frequency Domain Imaging (OFDI) and Vascular Healing After Stent Placement","OFDI-DM","Completed","Has Results","Coronary Artery Disease","Device: Resolute Integrity stent","Percent Stent Coverage","Emory University","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","8","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00057208","September 2013","March 2016","November 2016","February 20, 2013","May 15, 2017","May 15, 2017","Emory University Hospital Midtown, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01794949"
447,"NCT01787292","Effects of Exercise Intervention on Aging-related Motor Decline","EIAMD","Active, not recruiting","No Results Available","Aging|Exercise","Behavioral: Coordination training|Behavioral: Short Term exercise - supervised|Behavioral: Long Term Exercise","Motor Dexterity Score Improvement|Interhemispheric Inhibition Improvement after Exercise|Enhanced Interhemispheric Inhibition Improvement after Long Term Exercise","VA Office of Research and Development","All","60 Years to 85 Years   (Adult, Older Adult)","Not Applicable","40","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","E0956-W|2012-060697","January 14, 2013","July 7, 2018","November 1, 2019","February 8, 2013","null","October 11, 2018","Atlanta VA Medical and Rehab Center, Decatur, GA, Decatur, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01787292"
448,"NCT01786148","Music for Health Project","MFH","Completed","No Results Available","Human Immunodeficiency Virus","Behavioral: mobile phone application","Increased antiretroviral therapy (ART) adherence rates|Significantly higher mean levels of ART drug levels in hair sample analyses.|Mediators and Moderators","Emory University|National Institute of Nursing Research (NINR)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","149","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","IRB00055077|1R01NR012923","June 2014","April 19, 2017","June 30, 2017","February 7, 2013","null","July 31, 2017","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01786148"
449,"NCT01782092","Activator and Type II Diabetics",,"Completed","No Results Available","Type II Diabetes","Other: Chiropractic Adjustment","Lowered A1C Levels","Life University","All","30 Years to 60 Years   (Adult)","","5","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","I-009","August 2012","August 2014","August 2014","February 1, 2013","null","April 20, 2016","Life University, Marietta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01782092"
450,"NCT01776073","Evaluation of a Patient Navigation System to Reduce Time to Waitlisting for Potential Kidney Transplant Recipients",,"Completed","No Results Available","End-Stage Renal Disease","Behavioral: Patient Navigation","Time from evaluation to waitlisting in referred patients; Rate of pre-transplant evaluation completion|Time from referral to evaluation appointment|Time from referral to initial listing (active or inactive)|Time from referral to transplant","Emory University","All","18 Years to 95 Years   (Adult, Older Adult)","Not Applicable","401","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","IRB00060661|Mason-01","January 2013","October 2017","October 2017","January 25, 2013","null","February 22, 2018","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01776073"
451,"NCT01774708","Predict Near Future Initiation of Bed Exit","BEDEXIT","Unknown status","No Results Available","Sleep","Device: Pressure sensitive pad","Bed Exit|Movement in bed","Atlanta VA Medical Center|National Institute on Aging (NIA)","All","18 Years and older   (Adult, Older Adult)","","60","U.S. Fed|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","1R21EB015943-01|0664699330000|R43AG042237-01","December 2012","March 2014","March 2014","January 24, 2013","null","January 7, 2014","Budd Terrace, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01774708"
452,"NCT01773356","Effect of Dihydrocapsiate on Energy Expenditure in Women",,"Completed","No Results Available","Obesity","Dietary Supplement: Dihydrocapsiate","Resting Energy Expenditure|Thermic effect of feeding|Body Composition","Ellen Evans|Kellogg Company|University of Georgia","Female","25 Years to 45 Years   (Adult)","Not Applicable","126","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","WASABI","January 2011","March 2014","March 2014","January 23, 2013","null","September 25, 2015","University of Georgia, Department of Kinesiology, Athens, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01773356"
453,"NCT01772758","Cystic Fibrosis and Endothelial Function: At Rest and During Exercise",,"Completed","Has Results","Cystic Fibrosis","Drug: BH4 5mg|Drug: BH4 20mg|Dietary Supplement: Antioxidant Cocktail","Percentage Flow-Mediated Dilation (FMD)","Augusta University","All","7 Years and older   (Child, Adult, Older Adult)","Phase 2","64","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other","CFD Study","August 2011","June 21, 2016","June 21, 2016","January 21, 2013","January 10, 2018","January 10, 2018","Georgia Prevention Institute/ Laboratory of Integrative and Exercise Physiology, Augusta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01772758"
454,"NCT01772602","The National Amyotrophic Lateral Sclerosis Registry",,"Recruiting","No Results Available","Amyotrophic Lateral Sclerosis","","The National Amyotrophic Lateral Sclerosis (ALS) Registry|Risk factors of ALS","Centers for Disease Control and Prevention|VA Office of Research and Development|Centers for Medicare and Medicaid Services","All","18 Years and older   (Adult, Older Adult)","","16000","U.S. Fed","Observational","Observational Model: Other|Time Perspective: Other","CDC-NCEH/ATSDR-5768","October 2010","December 2022","December 2022","January 21, 2013","null","February 14, 2018","CDC, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01772602"
455,"NCT01752777","Behavioral Intervention to Enhance HIV Test/Treat",,"Completed","No Results Available","HIV/AIDS","Behavioral: Infectiousness Risk Reduction|Behavioral: General Health Improvement","HIV RNA Viral Load|Sexual Transmission Risk Behaviors","University of Connecticut","All","18 Years to 100 Years   (Adult, Older Adult)","Not Applicable","500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention","H11-159","February 1, 2012","February 1, 2018","February 1, 2018","December 19, 2012","null","May 9, 2018","Southeast HIV/AIDS Research and Evaluation Project, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01752777"
456,"NCT01752296","Psychological Concomitants of Morquio Syndrome (The MAP Study)","MAP","Completed","No Results Available","Morquio Disease|Mucopolysaccharidosis IV","","ASEBA Self-Report|Brief Pain Inventory|SF-36","Nadia Ali, PhD|BioMarin Pharmaceutical|Emory University","All","18 Years and older   (Adult, Older Adult)","","20","Other|Industry","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","IRB00058524|BioMarin-1","July 2012","October 2013","October 2013","December 19, 2012","null","December 4, 2013","Emory University, Decatur, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01752296"
457,"NCT01749566","Exploring HIV Entry Blockade as a Pre-exposure Prophylaxis Strategy in Women","MVC-PREP","Completed","No Results Available","HIV","Drug: maraviroc","Change in female genital tract maraviroc concentration|Female genital tract HIV target cells|Female genital tract T cell activation|Vaginal microbiome","Emory University","Female","18 Years and older   (Adult, Older Adult)","Phase 1","31","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","IRB00059752|KL2TR000455|ACTSIKL22012","December 2012","May 2015","May 2015","December 13, 2012","null","July 9, 2015","Grady Infectious Diseases Program, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01749566"
458,"NCT01743196","Folate Metabolism in Normal Weight and Obese Women of Child-bearing Age",,"Completed","No Results Available","Obesity|Neural Tube Defects","","Area under the serum concentration versus time curve (AUC) for folic acid|Peak Serum Concentration (Cmax) of Folate|Time to peak concentration (tmax) of folate","University of Georgia","Female","18 Years to 35 Years   (Adult)","","32","Other","Observational","","UGAFOLATEPILOT","May 2012","August 2012","December 2014","December 6, 2012","null","October 21, 2015","University of Georgia, Athens, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01743196"
459,"NCT01740726","Comparison of Behavioral Activation and Antidepressant Medication in the Treatment of Adolescents With Depression",,"Terminated","Has Results","Major Depressive Disorder","Behavioral: Behavioral Activation|Drug: Fluoxetine","Change in Depressive Symptoms From Baseline Based on Beck Depression Inventory, 2nd Edition (BDI-II)|Change in Depressive Symptoms From Baseline Based on Children's Depression Rating Scale - Revised (CDRS-R)|Overall Improvement and Change in Symptom Severity From Baseline Based on Clinical Global Impression - Improvement and Severity (CGI-I, CGI-S)|Change in Behaviors From Baseline Based on Behavioral Activation for Depression Scale (BADS)|Change in Anxiety From Baseline Based on Multidimensional Anxiety Scale for Children (MASC)|Change in Suicidal Ideation Based on Suicidal Ideation Questionnaire (SIQ)|Change in Hope Based on Children's Hope Scale (CHS)","Emory University","All","13 Years to 17 Years   (Child)","Not Applicable","3","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","IRB00061525|CAMP-61525","January 2013","March 2014","March 2014","December 4, 2012","April 7, 2015","December 20, 2017","Emory Executive Park, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01740726"
460,"NCT01740323","Phase II Study of Curcumin vs Placebo for Chemotherapy-Treated Breast Cancer Patients Undergoing Radiotherapy",,"Completed","No Results Available","Breast Cancer","Drug: Placebo|Drug: Curcumin","Plasma IL-6 measured in pg/ml|PBMC NF-kB DNA binding measured in ng/well|Plasma TNF-alpha measured in pg/ml|Plasma sTNF2 measured in pg/ml|Plasma IL-1ra measured in pg/ml|Fatigue","Andrew H Miller|Emory University","Female","18 Years and older   (Adult, Older Adult)","Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","IRB00055328|Winship2139-11","May 2015","July 27, 2018","July 27, 2018","December 4, 2012","null","October 10, 2018","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01740323"
461,"NCT01733641","Test-Retest Reliability in DETECT",,"Terminated","No Results Available","Reliability Properties of a Concussion Screening Tool","","Primary Objective is to assess the reliability of the DETECT cognitive assessment tool, as measured by changes in DETECT scores from baseline in non-injured athletes.","Emory University","All","16 Years and older   (Child, Adult, Older Adult)","","44","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IRB00052187","September 2011","April 2013","April 2013","November 27, 2012","null","December 12, 2014","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01733641"
462,"NCT01733615","Discovering New Biomarkers For Monitoring Disease Progression in Patients With Mucopolysaccharidosis IVA",,"Terminated","No Results Available","Mucopolysaccharidosis Type IVA","","Quantification of urinary oligosaccharides in urine from a first morning void in patients with Mucopolysaccharidosis IVA.|Quantification of urinary oligosaccharides in urine from a random collection in patients with Mucopolysaccharidosis IVA.","Emory University|BioMarin Pharmaceutical","All","Child, Adult, Older Adult","","3","Other|Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","IRB00058450","June 2012","February 2013","February 2013","November 27, 2012","null","September 4, 2014","Emory University, Dept of Human Genetics, Decatur, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01733615"
463,"NCT01730196","Lifestyle Change to Prevent Diabetes Via African-American Churches",,"Completed","No Results Available","Diabetes|Weight Loss","Behavioral: Fit Body and Soul|Behavioral: Wellness Education","Weight change|Fasting plasma glucose|physical activity level|quality of life measures|cost-effectiveness|hemoglobin A1C","Augusta University","All","20 Years to 64 Years   (Adult)","Not Applicable","604","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention","R18DK082401","September 2009","April 2012","April 2013","November 21, 2012","null","April 9, 2014","Georgia Health Sciences University, Augusta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01730196"
464,"NCT01728649","Reperfusion With Cooling in Cerebral Acute Ischemia II","ReCCLAIM II","Withdrawn","No Results Available","Ischemic Stroke|Hypothermia","Other: Mild Hypothermia","Number of participants with adverse events|Hyperintense Acute Reperfusion Marker (HARM)|Hemorrhagic Conversion|National Institutes of Health Stroke Scale (NIHSS)|Modified Rankin Scale (mRS)|Biomarkers","WellStar Health System","All","18 Years to 85 Years   (Adult, Older Adult)","Not Applicable","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MSNC 02","February 2013","February 2015","June 2015","November 20, 2012","null","September 13, 2018","Grady Memorial Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01728649"
465,"NCT01726218","Role of Ipsilateral Motor Cortex in Executing Movements With Increasing Demand on Precision","RIMC","Active, not recruiting","No Results Available","Stroke","","Define key parameters that contribute to contralesional M1 reorganization following stroke","Cathrin Buetefisch|National Institutes of Health (NIH)|National Institute of Neurological Disorders and Stroke (NINDS)|Emory University","All","18 Years to 80 Years   (Adult, Older Adult)","","50","Other|NIH","Observational","Observational Model: Case-Control|Time Perspective: Prospective","IRB00048694|R56NS070879-01|RIMCR56","May 2011","November 2016","December 2018","November 14, 2012","null","October 11, 2017","Emory University School of Medicine, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01726218"
466,"NCT01725815","The Health Access and Recovery Peer Program","HARP","Completed","No Results Available","Hypertension|Arthritis|Coronary Artery Disease|Hepatitis|Diabetes|Asthma|Hyperlipidemia|HIV","Behavioral: HARP Intervention","Health related quality of life|Patient Activation|Health Behaviors","Emory University|National Institute of Mental Health (NIMH)","All","18 Years and older   (Adult, Older Adult)","Phase 3","400","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","IRB00047631a|1R01MH090584-01A1","June 2011","June 1, 2016","March 31, 2017","November 14, 2012","null","July 13, 2017","Central Fulton Community Mental Health Center at Grady Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01725815"
467,"NCT01725061","Study of the Function of Cells Involved in Inflammation in the Lungs of Those With Acute Lung Injury and Sepsis","AMFAS","Completed","No Results Available","Sepsis","","Development of acute lung injury|mortality","Emory University","All","18 Years and older   (Adult, Older Adult)","","80","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IRB00014152","December 2009","September 2012","September 2012","November 12, 2012","null","December 18, 2014","Grady Memorial Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01725061"
468,"NCT01724125","An Electronic Personal Health Record for Mental Health Consumers",,"Completed","No Results Available","Chronic Comorbid Conditions","Other: personal electronic medical record","Quality of Care","Emory University|National Institute of Mental Health (NIMH)|Agency for Healthcare Research and Quality (AHRQ)","All","18 Years and older   (Adult, Older Adult)","Phase 3","170","Other|NIH|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research","IRB00012759|1R18HS017829","March 2009","September 2011","December 2011","November 9, 2012","null","August 5, 2016","Grady Health Systems, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01724125"
469,"NCT01713881","Effect of a Tracking Program on Colon Adenoma Surveillance and Adherence to Guideline Recommendations",,"Unknown status","No Results Available","Colon Polyp Surveillance","","Percentage completing follow up colonoscopy","United States Department of Defense","All","18 Years and older   (Adult, Older Adult)","","500","U.S. Fed","Observational","Observational Model: Cohort|Time Perspective: Retrospective","DDEAMC-Fincher 1","August 2012","December 2013","June 2014","October 25, 2012","null","March 20, 2014","D.D. Eisenhower Army Medical Center, Fort Gordon, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01713881"
470,"NCT01705548","Hypofractionated Stereotactic Radiosurgery in Treating Patients With Large Brain Metastasis",,"Recruiting","No Results Available","Metastatic Malignant Neoplasm to Brain|Unspecified Adult Solid Tumor, Protocol Specific","Radiation: Hypofractionated Radiosurgery","Maximum tolerated dose (MTD) of hypofractionated radiosurgery defined as the highest dose level where a grade 3 or greater with an attribution score of ≥ 3 develops in ≤ 2 of 6 patients in a dose group|Neurologic toxicity due to treatment, graded according to the CTCAE version 4.03|Local control; lack of progression of disease in resection cavity as defined by Response Evaluation Criteria In Solid Tumors (RECIST) criteria|Distant control: lack of progression of disease in surrounding brain as defined by RECIST criteria|Freedom from failure/progression free survival|Overall survival (OS): death from any cause|Long-term neurocognitive outcomes: using the Hopkins Verbal Learning Test-Revised (HVLT-R), Mini Mental Status Exam (MMSE) and Cognitive Functioning Subscale of the Medical Outcomes Scale (MOS)|Quality of life (QOL) outcomes: using the quality of life questionnaire for the Functional Assessment of Cancer Therapy-Brain (FACT-Br).","Emory University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","24","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00055063|NCI-2012-01933|RAD2156-11","September 2012","August 2020","July 2022","October 12, 2012","null","August 20, 2018","Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01705548"
471,"NCT01696929","An Open-Label Trial of Tocilizumab in Schizophrenia",,"Completed","Has Results","Schizophrenia","Drug: Tocilizumab","Change in Cognition|Change in Total Psychotic Symptoms","Brian Miller|Augusta University","All","18 Years to 50 Years   (Adult)","Phase 1","8","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00000405","September 2012","December 2014","December 2014","October 2, 2012","October 7, 2015","June 27, 2016","Georgia Health Sciences University, Augusta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01696929"
472,"NCT01696448","The BANGALORE Study; Combination of Berberine, Lipoic Acid, and Picrorhiza","CAR-191","Completed","No Results Available","Metabolic Syndrome","Dietary Supplement: CAR-191|Other: Placebo","appetite suppression|Endothelial function using noninvasive brachial artery reactivity (BAR) ultrasound|Weight control|Body Composition","Carmel Biosciences|Atlanta Vascular Research Foundation","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","28","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AVR-2012-01","August 2012","April 2013","April 2013","October 1, 2012","null","November 13, 2014","Atlanta Vascular Research Foundation, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01696448"
473,"NCT01693913","Cognitive-behavioral Weight Loss Treatment",,"Withdrawn","No Results Available","Weight","Behavioral: cognitive behavioral exercise and nutrition over|Behavioral: nutrition and exercise education","weight","YMCA of Metropolitan Atlanta","Female","21 Years to 60 Years   (Adult)","Not Applicable","0","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","YMCAAtlantaWeightLoss","October 2012","April 2014","April 2014","September 26, 2012","null","December 31, 2013","YMCA of Metro Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01693913"
474,"NCT01691352","Wick vs. No Wick: Does Method of Closure Affect Rate of Wound Infection?",,"Withdrawn","No Results Available","Postoperative Wound Infection","Procedure: Wick dressing|Procedure: No Wick","Wound infection","Children's Healthcare of Atlanta","All","up to 18 Years   (Child, Adult)","Not Applicable","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","Stoma Closure_Wound Infection","January 2012","June 2014","June 2014","September 24, 2012","null","December 17, 2014","Children's Healthcare of Atlanta at Egleston, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01691352"
475,"NCT01689727","Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Pituitary Tumors",,"Completed","No Results Available","Pituitary Tumors","Drug: Technetium Tc 99m EC20","","Endocyte","All","18 Years and older   (Adult, Older Adult)","Phase 2","40","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)","EC20.7","September 2002","September 2004","null","September 21, 2012","null","September 21, 2012","Emory Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01689727"
476,"NCT01682902","A Randomised Trial Evaluating Continuous Subcutaneous Infusion of Formulations of NN1218 and NovoLog® in Subjects With Type 1 Diabetes",,"Completed","No Results Available","Diabetes|Diabetes Mellitus, Type 1","Drug: Faster-acting insulin aspart|Drug: insulin aspart","Mean change in plasma glucose concentration|Self-measured plasma glucose (SMPG) 7-point profile|Self-measured plasma glucose (SMPG) 9-point profile|Number of adverse events (AEs) (including infusion site reactions/infections)|Number of hypoglycaemic episodes|Number of unexplained self-reported episodes of hypoglycaemia or hyperglycaemia (confirmed by SMPG)|Number of episodes of infusion set occlusions","Novo Nordisk A/S","All","18 Years and older   (Adult, Older Adult)","Phase 1","43","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","NN1218-3930|U1111-1121-5106","September 2012","March 2013","March 2013","September 11, 2012","null","January 9, 2017","Novo Nordisk Investigational Site, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01682902"
477,"NCT01681849","Neural Circuits in Women With Abuse and Posttraumatic Stress Disorder",,"Completed","Has Results","PTSD","Drug: Placebo|Drug: Paroxetine|Other: Positron Emission Tomography (PET) Imaging","Mean Clinical Administered PTSD Scale for DSM-IV (CAPS) Score|Change in Brain Blood Flow Assessed by Statistical Parametric Mapping (SPM)","Emory University|National Institute of Mental Health (NIMH)","Female","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","91","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRB00000857|R01MH056120","July 2009","July 2015","July 2015","September 10, 2012","June 28, 2017","June 28, 2017","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01681849"
478,"NCT01674179","Quantitative EEG During PSG in Patients With and Without Fibromyalgia","FMQEEG-10-26","Completed","No Results Available","Fibromyalgia","","Delta Event/Alpha Event Ratios in Non-REM sleep","SouthCoast Medical Group","All","18 Years to 80 Years   (Adult, Older Adult)","","560","Other","Observational","Observational Model: Case Control|Time Perspective: Retrospective","SM 10-26","July 2010","October 2012","October 2012","August 28, 2012","null","October 13, 2016","SouthCoast Medical Group, Savannah, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01674179"
479,"NCT01668602","Stroke Gait Rehabilitation Using Functional Electrical Stimulation",,"Recruiting","No Results Available","Cerebrovascular Accident","Device: Functional electrical stimulation (FES)|Other: Fast Treadmill Walking","Change in Motor evoked potentials (MEP) amplitude measure in milliVolt (mV) of FastFES versus Fast walking after 3 training sessions in Cohort 1|Change in H‐reflex /M‐wave (Hmax/Mmax) ratio among FastFES versus Fast walking after 3 training sessions in Cohort 1|Change in Motor evoked potentials (MEP) amplitude measure in milliVolt (mV) of FastFES versus Fast walking after 18 training sessions in Cohort 2|Change in H‐reflex /M‐wave (Hmax/Mmax) ratio among FastFES versus Fast walking after 18 training sessions in Cohort 2|Change in Peak anterior ground reaction force (AGRF) of FastFES versus Fast walking after 3 training sessions in Cohort 1|Change in Peak anterior ground reaction force (AGRF) of FastFES versus Fast walking after 18 training sessions in Cohort 2","Emory University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|American Heart Association","All","30 Years to 80 Years   (Adult, Older Adult)","Not Applicable","55","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","IRB00058363|5K01HD079584-02|13SDG13320000","August 2013","May 2019","May 2019","August 20, 2012","null","September 19, 2018","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01668602"
480,"NCT01668576","Properties of Mesenchymal Stem Cells in Lung Transplant",,"Terminated","No Results Available","Lung Transplantation","","Intrinsic variability of MSCs measured by time to third passage of confluent MSC|2-3 IDO production measured as ug/mL of passage 3 MSCs|Percent specific inhibition of CD4 and CD8 T cell proliferation toward donor target cells in one way mixed-lymphocyte reactions","Emory University","All","18 Years to 70 Years   (Adult, Older Adult)","","4","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","IRB00053075","August 2012","September 2014","September 2014","August 20, 2012","null","January 14, 2016","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01668576"
481,"NCT01666808","FACBC Outcomes for Post Prostatectomy",,"Recruiting","No Results Available","Prostate Cancer","Drug: FACBC|Radiation: Radiation therapy","Failure-free Survival","Emory University|National Cancer Institute (NCI)","Male","18 Years to 95 Years   (Adult, Older Adult)","Phase 2|Phase 3","162","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00057680|1R01CA169188-01","September 2012","December 2018","December 2018","August 16, 2012","null","July 13, 2018","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01666808"
482,"NCT01659762","A Phase I Study Evaluating Autologous Bone Marrow Derived Mesenchymal Stromal for Crohn's Disease.","EPIC/MSC/IBD","Completed","No Results Available","Crohn's Disease","Biological: autologous mesenchymal stromal cell","Number of adverse events|Crohn's disease activity Index (CDAI)","Emory University|Atlanta Clinical and Translational Science Institute","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","16","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00051454|EPIC001","July 2012","July 2015","null","August 8, 2012","null","October 17, 2016","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01659762"
483,"NCT01659749","Educational, Social Support, and Nutritional Interventions and Their Cumulative Effect on Pregnancy Outcomes and Quality of Life in Teen and Adult Women With Phenylketonuria",,"Recruiting","No Results Available","Pregnancy|Phenylketonuria","Behavioral: Metabolic camp","","Emory University","Female","11 Years and older   (Child, Adult, Older Adult)","Not Applicable","200","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","IRB00002447a|NIH NCRR M01-RR00039","June 1995","July 2035","July 2037","August 8, 2012","null","August 17, 2018","Emory University Department of Human Genetics, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01659749"
484,"NCT01659645","Anti-1-amino-3-[18F]Fluorocyclobutyl-1-carboxylic Acid (Anti-[18F](FACBC)Positron Emission Tomography (PET-CT) of the Breast",,"Completed","No Results Available","Breast Cancer","Drug: FACBC","Presence of FACBC radiotracer in breast carcinoma on FACBC PET scan","Emory University","Female","18 Years to 85 Years   (Adult, Older Adult)","Early Phase 1","12","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","IRB00052551|FACBCBr","August 2012","January 2015","January 2015","August 8, 2012","null","October 27, 2016","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01659645"
485,"NCT01655875","AMD3100 for Sensitizing in Allogeneic Blood or Marrow Transplant for Chemotherapy Resistant Pediatric Acute Leukemia","BMTAMD3100","Terminated","No Results Available","Pediatric Acute Myeloblastic Leukemia, Relapsed|Pediatric Acute Lymphoblastic Leukemia, Relapsed","Drug: AMD3100","AMD3100 safety|AMD3100 correlative biology analyses","Emory University","All","2 Years to 22 Years   (Child, Adult)","Phase 1","1","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00053638|CHOA AMD3100 Pilot","June 2012","April 2014","April 2014","August 2, 2012","null","April 7, 2014","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01655875"
486,"NCT01651793","Effect of Phytochemicals From Theobroma Cacao on Mental Energy",,"Completed","Has Results","Mental Fatigue","Other: Caffeinated cocoa|Other: Cocoa|Other: Caffeine|Other: Placebo","Correct Responses on Serial 7 Subtraction Task|Performance on Bakan Task|Vigor Symptoms (Profile of Mood State)","University of Georgia|The Hershey Company","All","18 Years to 34 Years   (Adult)","Not Applicable","24","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","Study of cocoa-like beverages","July 2012","June 2014","June 2014","July 27, 2012","June 25, 2018","June 25, 2018","University of Georgia, Athens, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01651793"
487,"NCT01647737","Green Tea Lozenges for the Management of Dry Mouth",,"Completed","Has Results","Xerostomia|Sjogren Syndrome|Dry Mouth","Dietary Supplement: MighTeaFlow|Dietary Supplement: Xylitol","Change in Salivary Flow From Baseline","Augusta University|GlaxoSmithKline","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","60","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","GHSU Lozenge Xerostomia Study","March 2011","June 2013","June 2013","July 24, 2012","March 18, 2015","March 18, 2015","GHSU Center for Oral Medicine, Augusta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01647737"
488,"NCT01636466","The Everolimus-Transplant Exit Strategy Trial (E-TEST)","E-TEST","Terminated","Has Results","Kidney Failure, Chronic","Drug: Everolimus","Mean Fluorescence Index (MFI) of Donor Specific Alloantibodies (DSA)|Incidence of Return to Dialysis Dependence","Ashtar Chami|Novartis Pharmaceuticals|Emory University","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","1","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00059278|CRAD001AUS191T","June 2013","May 2014","May 2014","July 10, 2012","June 8, 2015","February 5, 2018","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01636466"
489,"NCT01635881","Evaluation of Coronary Luminal Diameter Enlargement With Emerge™ 1.20 mm PTCA Dilatation Catheter",,"Completed","Has Results","Coronary Artery Disease","Device: Emerge™ 1.20 mm PTCA Dilatation Catheter","Device Procedural Success|In-hospital Major Adverse Cardiac Events (MACE)","Boston Scientific Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 3","60","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","S2228","July 2012","December 2012","December 2012","July 10, 2012","November 6, 2013","November 6, 2013","Piedmont Heart Institute, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01635881"
490,"NCT01632748","Validation Study in Healthy Female Volunteers: A Comparison of Two Neurotech Vital Devices Set up to Provide Different Types of Electrical Stimulation",,"Completed","No Results Available","Healthy Female Volunteers","Device: Neurotech Vital Device|Device: Modified Neurotech Vital Device","The primary objective of this validation study is to verify that the Modified Neurotech Vital Device does not elicit a pelvic floor contraction compared to the Neurotech Vital Device.|The secondary objective of this validation study is to verify that the Modified Neurotech Vital Device is perceived by the volunteers as a valid treatment option in terms of sensation.","Bio-Medical Research, Ltd.","Female","18 Years and older   (Adult, Older Adult)","Phase 1","20","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)","BMR-12-1004","June 2012","August 2012","August 2012","July 3, 2012","null","September 21, 2012","North Georgia College and State University, Dahlonega, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01632748"
491,"NCT01630265","Caregivers' Knowledge of Emergency Department Discharge Instructions Improves With the Use of Video",,"Completed","No Results Available","Evaluation of Video Discharge Instructions in Improving Understanding","Other: Standard written discharge instructions|Other: Video Discharge Instructions","Knowledge about the child's diagnosis, treatment and follow-up care.|Caregiver satisfaction with their discharge instructions","Augusta University","All","Child, Adult, Older Adult","Not Applicable","436","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","10-03-173","April 2010","June 2010","June 2010","June 28, 2012","null","June 28, 2012","Medical College of Georgia, Augusta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01630265"
492,"NCT01629121","Prevention of Traumatic Brain Injury in Youth and Adolescents",,"Completed","No Results Available","Focus of Study: Bicycle Helmet Wearing Compliance","Behavioral: education intervention","parental report of bicycle helmet use","Augusta University","All","5 Years to 18 Years   (Child, Adult)","Phase 1","120","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","GHSF11085","September 2010","August 2011","August 2011","June 27, 2012","null","June 21, 2013","Georgia Regents University, Children's Medical Center, Augusta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01629121"
493,"NCT01627301","Sympathetic Overactivity in Post-traumatic Stress Disorder","SO-PTSD","Recruiting","No Results Available","Post-traumatic Stress Disorder|Prehypertension","Device: Device-Guided Breathing using the RESPeRATE device","Sympathetic activity|Inflammatory markers|Ambulatory Blood Pressure","Emory University","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00054697","July 2012","December 2018","March 2019","June 25, 2012","null","January 4, 2018","Atlanta VA Medical Center, Decatur, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01627301"
494,"NCT01627184","Long-term Use: CGM System Assessment in Adult Athletes With Diabetes Mellitus","LUCID","Completed","No Results Available","Diabetes Mellitus","Device: Dexcom G4 CGM System","Glycemic Control during Exercise|System Utility and Usability","DexCom, Inc.","All","18 Years and older   (Adult, Older Adult)","","13","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","PTL-900905","May 2012","January 2013","June 2013","June 25, 2012","null","February 12, 2015","Atlanta Diabetes Association, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01627184"
495,"NCT01625468","Brief Interventions to Create Smoke-Free Home Policies in Low-Income Households",,"Completed","No Results Available","Chronic Diseases","Behavioral: Educational print materials and a coaching call","Presence of a total home smoking ban|Weekly secondhand smoke exposure for non-smokers|Cessation attempts (for smokers)|Number of cigarettes smokes (for smokers)|Stage of change to quit smoking (for smokers)|Successful cessation (for smokers)","Emory University|National Cancer Institute (NCI)|University of North Carolina, Chapel Hill|The University of Texas Health Science Center, Houston|Washington University School of Medicine","All","18 Years and older   (Adult, Older Adult)","Not Applicable","500","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","IRB00056797|U01CA154282-01","June 2012","July 2013","July 2013","June 21, 2012","null","March 10, 2015","Emory University Rollins School of Public Health, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01625468"
496,"NCT01623830","Targeting Reconsolidation to Prevent Return of Fear",,"Completed","Has Results","Fear of Flying","Behavioral: Virtual Reality Exposure Therapy","Fear of Flying Inventory (FFI)|The Questionnaire on Attitudes Toward Flying (QAF)|The Beck Depression Inventory (BDI)|State Trait Anxiety Inventory- State (STAI-State)|State Trait Anxiety Inventory- Trait (STAI-Trait)","Emory University|National Institute of Mental Health (NIMH)","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","89","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRB00056442|Reconsolidation_NIMH_2012","July 2012","June 2015","June 2016","June 20, 2012","February 2, 2017","February 2, 2017","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01623830"
497,"NCT01622634","Effect of a High-Protein Diet and/or High-Intensity Training on Metabolic Syndrome","EPHIT","Completed","No Results Available","Metabolic Syndrome","Behavioral: Sprint Interval Exercise|Other: Higher PRO Diet|Other: Higher CARB Diet","Metabolic Syndrome Risk Factors|Satiety","University of Georgia","Female","30 Years to 65 Years   (Adult, Older Adult)","Not Applicable","49","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","EPHIT","February 2012","March 2013","March 2013","June 19, 2012","null","September 25, 2015","Body Composition and Metabolism Lab, Ramsey Center, University of Georgia, Athens, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01622634"
498,"NCT01620892","Study of Patient Outcomes 5 Years After Partial Knee Replacement",,"Completed","No Results Available","Osteoarthritis, Knee","","Time to revision of the partial total knee prosthesis","Athens Orthopedic Clinic, P.A.|Arthrex, Inc.","All","18 Years and older   (Adult, Older Adult)","","159","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","AOC-OM-Arthrex-001","June 2012","April 2015","April 2015","June 15, 2012","null","December 19, 2017","Athens Orthopedic Clinic, P.A., Athens, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01620892"
499,"NCT01611779","FAST as a Treatment for Obstructive Sleep Apnea","FAST","Terminated","Has Results","Obstructive Sleep Apnea","Device: Encore Tongue Suspension System","Place the Implant and Stabilize the Tongue|Number of Participants Experiencing Complications|Apnea Hypopnea Index|Functional Outcomes and Sleep Questionnaire (FOSQ)|Snoring Scale (VAS)|Epworth Sleeping Scale (ESS)","Siesta Medical, Inc.","All","20 Years to 65 Years   (Adult, Older Adult)","Phase 4","5","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2011","May 2012","June 2013","June 2013","June 5, 2012","January 6, 2017","February 24, 2017","The Atlanta Snoring and Sleep Disorders Institute, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01611779"
500,"NCT01606085","Cost Effectiveness and Quality of Life in Heart Failure Patients With Diabetes","QUALITYHF-DM","Completed","No Results Available","Diabetes Mellitus|Heart Failure","Behavioral: HF DM self care|Behavioral: Usual Care","Heart failure health related quality of life measures|Diabetes health related quality of life measures|Heart Failure and Diabetes (HF-DM) physical outcomes|Heart Failure Knowledge|Health resource use|Heart Failure (HF) self-efficacy|Heart Failure and Diabetes(HF-DM) self-care behaviors|Diabetes (DM) Knowledge|Diabetes (DM) self efficacy","Emory University|Atlanta VA Medical Center|Atlanta Clinical and Translational Science Institute|National Institute of Nursing Research (NINR)","All","21 Years to 80 Years   (Adult, Older Adult)","Not Applicable","141","Other|U.S. Fed|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","IRB00026671|1R01NR011888-01","September 2009","September 2013","April 2014","May 25, 2012","null","April 24, 2014","Emory University School of Nursing, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01606085"
501,"NCT01598545","Hydromorphone and C-section",,"Completed","Has Results","Postoperative Pain","Drug: Hydromorphone","Pain Scores, Visual Analogue Pain Scale","Emory University","Female","18 Years to 40 Years   (Adult)","Phase 2","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","IRB00058097","February 2013","June 2014","September 2014","May 15, 2012","December 17, 2014","December 17, 2014","Grady Memorial Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01598545"
502,"NCT01598506","Intrathecal Hydromorphone for Labor Analgesia",,"Completed","Has Results","Labor Pain","Drug: Hydromorphone","Pain Score, Visual Analogue Pain Scores|Pain Scores, Visual Analogue Pain Scale","Emory University","Female","18 Years to 40 Years   (Adult)","Phase 2","22","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","IRB00054701","September 2013","February 2014","February 2014","May 15, 2012","November 10, 2014","January 12, 2018","Grady Memorial Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01598506"
503,"NCT01592188","Cognitively-Based Compassion Training and Mindfulness Attention Training Program",,"Completed","No Results Available","Behavioral Resilience|Biological Resilience","Behavioral: Cognitively-Based Compassion Training (CBCT)|Behavioral: Mindfulness training","Interpersonal behaviors assessed using standardized protocols of social behavior, social cognition, and empathy.|Concentrations of stress system biomarkers in saliva","Emory University","All","7 Years to 12 Years   (Child)","Phase 3","53","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)","IRB00054782|CBCT-Paideia","January 2012","November 2013","November 2013","May 7, 2012","null","November 14, 2013","Paideia School, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01592188"
504,"NCT01585597","Reperfusion With Cooling in Cerebral Acute Ischemia","ReCCLAIM","Completed","Has Results","Stroke, Acute","Device: Zoll- Coolgaurd 3000","Number of Participants With Reperfusion Injury \ Hemorrhagic Transformation|Modified Rankin Scale 0-2","Emory University","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 1","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00056889|MSNC 01","May 2012","August 2012","August 2012","April 26, 2012","August 1, 2014","August 1, 2014","Marcus Stroke and Neuroscience Center at Grady Memorial Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01585597"
505,"NCT01583621","Vitamin D Supplementation in Overweight/Obese African American Adults and Youth (D-SUNNY)","D-SUNNY","Completed","No Results Available","Vitamin D Deficiency","Dietary Supplement: Cholecalciferol","Cardiovascular phenotypes|Primary outcome 1 dose-responsive effects of vitamin D3 supplementations|Primary Outcome 2 dose-responsive effects of vitamin D3 supplementations","Augusta University","All","13 Years to 45 Years   (Child, Adult)","Not Applicable","74","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Health Services Research","pro#00000051","November 2011","November 2012","August 2015","April 24, 2012","null","February 9, 2017","Georgia Prevention Institute, Augusta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01583621"
506,"NCT01574287","Anti-3-[18F]FACBC Imaging of Parathyroid Adenomas",,"Recruiting","No Results Available","Parathyroid Disease","Drug: FACBC","Correlate uptake of anti-3-[18F]FACBC to surgical findings of parathyroid adenomas|Measure uptake mechanisms of anti-3-[18F]FACBC in parathyroid adenomas","David M. Schuster, MD|Emory University","All","18 Years to 99 Years   (Adult, Older Adult)","Not Applicable","12","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","IRB00051415","August 2012","May 2019","May 2019","April 10, 2012","null","November 6, 2017","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01574287"
507,"NCT01569607","Structurally Reorganizing Motor Cortex in Stroke Patients Through Hebbian-type Stimulation",,"Completed","Has Results","Stroke","Device: Repetitive Transcranial Magnetic Stimulation (rTMS)|Device: Sham stimulation","Primary Motor Cortex (M1) Excitability Derived From Stimulus Response Curve|Mean Time to Completion for Jebsen Hand Function Test (JTT)|Mean Peak Acceleration of Wrist Extension Movements|Mean Reaction Time of Wrist Extension Movements|Mean Motor Activity Log (MAL) Score: Amount Subtest|Mean Motor Activity Log (MAL): How Well Subtest|Mean Wolf Motor Function Test (WMFT) Total Time|Mean Wolf Motor Function Test Functional Ability (WMFT-FS) Scale Score|Mean Wolf Motor Function Test (WMFT) Grip Strength","Cathrin Buetefisch|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Emory University","All","18 Years to 85 Years   (Adult, Older Adult)","Not Applicable","48","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","IRB00052053|R21HD067906-01A1|SRMC21","March 8, 2012","August 26, 2016","August 26, 2016","April 3, 2012","January 16, 2018","January 16, 2018","Emory University School of Medicine, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01569607"
508,"NCT01568944","Role of Infected Blood Dendritic Cells in Heart Disease Risk",,"Completed","No Results Available","Chronic Periodontitis","Drug: Oral Antibiotic and Oral Rinse|Procedure: Standard Treatment","Change in frequency of blood dendritic cells from baseline|probing attachment levels|serum response|probing depths|plaque index|gingival index","Augusta University|National Institute of Dental and Craniofacial Research (NIDCR)","All","40 Years and older   (Adult, Older Adult)","Not Applicable","19","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)","R21DE020916|Pro00000394","March 2012","September 2014","September 2014","April 2, 2012","null","January 28, 2015","GHSU-CDM Clinical Research Center, Augusta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01568944"
509,"NCT01568528","Oxytocin as Adjunctive Treatment of Schizophrenia",,"Active, not recruiting","No Results Available","Schizophrenia","Drug: Oxytocin|Drug: Placebo","eye tracking|Social reward ball-tossing task","Emory University|Atlanta VA Medical Center","Male","18 Years to 55 Years   (Adult)","Not Applicable","40","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","IRB00052127","March 2013","June 2019","January 2020","April 2, 2012","null","September 10, 2018","Atlanta VA Medical Center, Decatur, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01568528"
510,"NCT01567462","PlasmaKinetic (PK) Button Vaporization Electrode for Treatment of Bladder Tumors","PK Button","Completed","Has Results","Bladder Cancer","Device: Monopolar electrocautery loop in Transurethral resection of bladder tumors|Device: PK Button Vaporization Electrode in transurethral resection of bladder tumors","Number of Procedural Complications|Mean Operative Time|Mean Catheterization Time|Number of Participants With Disease Recurrence","Emory University|Olympus","All","18 Years to 89 Years   (Adult, Older Adult)","Not Applicable","95","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","IRB00053735|PK Button and Bladder Tumors","September 2012","March 28, 2017","March 28, 2017","March 30, 2012","December 8, 2017","December 8, 2017","Emory University Department of Urology, Atlanta, Georgia, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/62/NCT01567462/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT01567462"
511,"NCT01567384","A Phase I Study of OSI-906 in Combination With Pemetrexed in Advanced Solid Tumor Malignancies",,"Withdrawn","No Results Available","Cancer|Neoplasms|Tumors","Drug: OSI-906 and Pemetrexed","Assessment of dose-limiting toxicity|Progression-free survival","Emory University|OSI Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 1","0","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00047570|WCI1895-10","May 2012","October 2013","October 2013","March 30, 2012","null","November 20, 2013","Winship Cancer Institute of Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01567384"
512,"NCT01563679","Analysis of Percutaneous Ablations for Cancer Treatment",,"Completed","No Results Available","Cancer","","Effect of percutaneous and transarterial treatments for cancer in quality of life|response rate to percutaneous and transarterial treatment for cancer","Emory University","All","18 Years and older   (Adult, Older Adult)","","26","Other","Observational","Time Perspective: Prospective","IRB00054905|RAD2160-11","February 2012","January 2014","January 2014","March 27, 2012","null","May 28, 2014","Emory University Hospital, Altanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01563679"
513,"NCT01556282","TheraSpheres Treatment for Unresectable Hepatocarcinoma and Portal Vein Thrombosis",,"Completed","No Results Available","Liver Cancer|Portal Vein Thrombosis","Device: TheraSphere","Response rate to the administration of Therasphere|Progression free survival for patients with unresectable liver cancer.","Emory University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","35","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00015167","March 2009","January 2014","January 2014","March 16, 2012","null","May 28, 2014","Emory University Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01556282"
514,"NCT01554969","Phase I Trial of Ganetespib, Capecitabine, and Radiation in Rectal Cancer",,"Completed","No Results Available","Rectal Cancer","Drug: capecitabine + ganetespib","Tumor response and disease progression will be evaluated in this study using the international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST).","Emory University|Synta Pharmaceuticals Corp.","All","18 Years and older   (Adult, Older Adult)","Phase 1","16","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00054181|STA 9090","May 2012","March 2015","June 2015","March 15, 2012","null","February 22, 2016","Emory University Winship Cancer Institute, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01554969"
515,"NCT01553682","Project N-Liten- HIV Prevention for African American Women",,"Completed","No Results Available","Sexually Transmitted Diseases","Behavioral: Horizons+General Health Promotion (GHP)|Behavioral: Horizons+Motivational Enhancement Therapy (GMET)","Incident STD infection confirmed by laboratory PRC testing over a 12-month follow-up.|Proportion of condom-protected vaginal or anal sex acts over a 12-month follow-up.","Emory University","Female","18 Years to 24 Years   (Adult)","Not Applicable","560","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","IRB00048502|5R01AA018096","December 2011","March 2015","March 2015","March 14, 2012","null","June 25, 2015","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01553682"
516,"NCT01544816","Evaluating the Effects of Snack Products on Energy",,"Completed","No Results Available","Energy","Other: Snack Product","Energy questionnaire OR Rating of perceived energy OR Subjective feeling of energy (visual analog scale)","Mondelēz International, Inc.|Cognitive Research Corporation|Mercer University","All","20 Years to 45 Years   (Adult)","Not Applicable","49","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","KFG-123X-01","February 2012","August 2012","August 2012","March 6, 2012","null","May 8, 2013","Mercer University Center for Clinical Research, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01544816"
517,"NCT01542320","Effect of Probiotic Supplementation on Immune Function in Healthy Infants","ProBoost","Completed","No Results Available","Inflammation","Dietary Supplement: Lactobacillus reuteri DSM 17938|Other: Placebo","Biomarkers of immune response","Emory University|The Gerber Foundation","All","6 Weeks to 32 Weeks   (Child)","Not Applicable","15","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","IRB00055040|ProBoost","March 2012","December 2014","December 2014","March 2, 2012","null","March 6, 2015","Emory Children's Center, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01542320"
518,"NCT01539993","Prospective Liver Study",,"Completed","No Results Available","Liver Cancer","","Assess efficacy of percutaneous and transarterial treatments for liver cancer.|long term follow up","Emory University","All","18 Years and older   (Adult, Older Adult)","","400","Other","Observational","Time Perspective: Prospective","IRB00014768","November 2008","January 2014","January 2014","February 28, 2012","null","May 28, 2014","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01539993"
519,"NCT01536457","Reflux Disease Therapy in the Management of Childhood Asthma-data Entry and Analysis Only",,"Completed","No Results Available","Asthma|Gastroesophageal Reflux Disease","","Asthma exacerbations in the treatment group","Children's Center for Digestive Health Care|Takeda Pharmaceuticals North America, Inc.","All","4 Years to 11 Years   (Child)","","59","Other|Industry","Observational","Time Perspective: Retrospective","BG-LAN-2011","July 2011","September 2012","January 2013","February 22, 2012","null","February 11, 2015","Children's Center for Digestive Health Care, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01536457"
520,"NCT01529138","Study of Axitinib and Temsirolimus in Solid Tumors",,"Completed","No Results Available","Cancer","Drug: Axitinib|Drug: Temsirolimus","Changes in the largest diameter (unidimensional measurement) of the tumor lesions and the shortest diameter in the case of malignant lymph nodes are used in the Response Evaluation Criteria in Solid Tumors (RECIST) criteria for evaluation.","Emory University|Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 1","13","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00048705|WCI1939-10","October 2011","March 2014","March 2014","February 8, 2012","null","April 13, 2015","Emory University Winship Cancer Institute, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01529138"
521,"NCT01526486","Videoscopic Versus Open Inguinal Lymphadenectomy for Cancer",,"Completed","No Results Available","Melanoma|Merkel Cell Carcinoma|Squamous Cell Carcinoma|Penile Carcinoma|Urethral Carcinoma|Extramammary Paget's Disease|Scrotal Carcinoma|Anal Cancer|Vulvar Cancer|Skin Cancer|Lymphadenopathy","Procedure: Videoscopic procedure|Procedure: Open, traditional approach","Complication profile|Length of stay|Lymphedema|Nodal yield|Readmission|Oncologic outcomes--survival","Emory University","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","29","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00012329|WCI1585-08","June 2009","February 2013","February 2013","February 6, 2012","null","May 6, 2015","Emory University Hospital-Winship Cancer Institute, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01526486"
522,"NCT01522404","Effects of Atomoxetine in Mild Cognitive Impairment","ATX-001","Completed","No Results Available","Mild Cognitive Impairment","Drug: Atomoxetine|Drug: Placebo","Change in Interleukin1 (IL1-alpha) in Cerebrospinal fluid (CSF) in subjects with Mild Cognitive Impairment MCI treated with Atomoxetine compared to subjects treated with Placebo|Change in Thymus-Expressed Chemokine (TECK) in Cerebrospinal fluid (CSF) in subjects with Mild Cognitive Impairment MCI treated with Atomoxetine compared to subjects treated with Placebo|Number of adverse events with Mild Cognitive Impairment MCI treated with Atomoxetine compared to subjects treated with Placebo|Percentage of subject drop out rate that are treated with Atomoxetine|Change in rate of cerebral blood flow in subjects with Mild Cognitive Impairment MCI treated with Atomoxetine compared to subjects treated with Placebo|Change in Fluoro Deoxy Glucose [FDG] uptake in subjects with Mild Cognitive Impairment MCI treated with Atomoxetine compared to subjects treated with Placebo","Emory University|National Institute on Aging (NIA)","All","50 Years to 90 Years   (Adult, Older Adult)","Phase 2","39","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","IRB00054397|5U01AG010483|ATX-001","March 2012","October 31, 2017","June 30, 2018","January 31, 2012","null","August 6, 2018","Emory University School of Medicine, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01522404"
523,"NCT01522196","A Study of Varespladib Infusion in Subjects With Sickle Cell Disease.","IMPACTS-2","Terminated","No Results Available","Sickle Cell Disease|Vaso-occlusive Crisis","Drug: Varespladib|Other: Placebo (Normal Saline)","Efficacy of A 001 infusion in preventing acute chest syndrome in sickle cell disease (SCD) subjects with the combination of vaso-occlusive crisis, fever, and elevated serum C-reactive protein (CRP).|Safety and tolerability of A 001 therapy when administered as a 48-hour continuous infusion to SCD subjects at-risk for acute chest syndrome.|Impact of A-001 treatment on sPLA2 levels and CRP.|Impact of A-001 treatment on the signs and symptoms of vaso-occlusive crisis.|Impact of A-001 treatment on opioid use for pain in the treatment of vaso-occlusive crisis.","Anthera Pharmaceuticals","All","5 Years and older   (Child, Adult, Older Adult)","Phase 2","2","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","AN-SCD1122","February 2012","March 2012","March 2012","January 31, 2012","null","March 4, 2014","Investigator Site 101, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01522196"
524,"NCT01507246","Adult Patients Undergoing Open Colectomy MA402S23B303","IMPROVE-Open","Completed","Has Results","Bowel Obstruction","Drug: IV morphine sulfate|Drug: EXPAREL (bupivacaine liposome injectable suspension)","Total Opioid Burden|Health Economic Benefits - Total Cost of Hospitalization|Health Economic Benefits - Length of Stay|Incidence of Predefined Opioid-related Adverse Events","Pacira Pharmaceuticals, Inc|Registrat-Mapi","All","18 Years and older   (Adult, Older Adult)","Phase 4","42","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","MA402S23B303","December 2011","July 2012","August 2012","January 10, 2012","May 8, 2013","May 8, 2013","Atlanta Colon and Rectal Surgery, Riverdale, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01507246"
525,"NCT01505049","Immune Memory After Papillomavirus Vaccination","IMAP-1","Completed","No Results Available","Healthy Volunteers","Drug: quadrivalent HPV vaccine","To examine markers of immune memory in women receiving quadrivalent HPV vaccine including antibody levels and memory B cells","Emory University|National Institute of Allergy and Infectious Diseases (NIAID)","Female","18 Years to 30 Years   (Adult)","","203","Other|NIH","Observational","Time Perspective: Prospective","IRB00046117|DMID 10-0014","January 2012","January 2015","January 2015","January 6, 2012","null","July 21, 2015","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01505049"
526,"NCT01504776","Phase I Study of Panobinostat + Bortezomib for Relapsed and/or Refractory Mantle Cell Lymphoma (MCL)","BUS48T","Completed","No Results Available","Mantle Cell Lymphoma","Drug: Panobinostat|Drug: Bortezomib","Dose-Limiting Toxicity (DLT) and Maximum Tolerated Dose (MTD)|Observe the activity of the combination against Mantle Cell Lymphoma (MCL) in patients treated in this Phase I study.","Anand Jillella|Novartis Pharmaceuticals|Augusta University","All","18 Years and older   (Adult, Older Adult)","Phase 1","3","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CLBH589BUS48T","April 2011","September 2014","September 2014","January 5, 2012","null","September 19, 2014","Georgia Regents University, Augusta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01504776"
527,"NCT01502683","Stroke Study: Operative Strategies to Reduce Cerebral Embolic Events During Coronary Artery Bypass Surgery",,"Completed","No Results Available","Stroke","Procedure: No aortic clamping|Procedure: partial occluding clamp|Procedure: single cross clamp|Procedure: cross clamp and partial occluding clamp","Cerebral embolic events measured via transcranial doppler ultrasound|Neurocognitive dysfunction","Emory University|National Heart, Lung, and Blood Institute (NHLBI)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","193","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","IRB00046608|1K23HL105892-01A1","December 2011","December 2016","December 2016","January 2, 2012","null","January 24, 2017","Emory University Hospital Midtown, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01502683"
528,"NCT01502670","Amino Acid Tracer (FACBC) Positron Emission Tomography for Lung Nodule","SPN","Completed","No Results Available","Lung Cancer","Drug: 18F-FACBC Radiotracer","Correlation of Radiotracer Uptake with Histology","Emory University|NIHON MEDI-PHYSICS CO.,LTD.","All","18 Years and older   (Adult, Older Adult)","Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","IRB00006621|14701","May 2009","June 2012","January 2013","January 2, 2012","null","November 19, 2013","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01502670"
529,"NCT01502449","Delivery of Self Training and Education for Stressful Situations-Telephone Version","DESTRESS-T","Unknown status","No Results Available","PTSD","Behavioral: DESTRESS-T|Other: Optimized Usual Care (OUC)","Posttraumatic Stress Disorder Checklist - Civilian Version (PCL)|Medical Outcomes Survey Short-Form-12 (SF-12)|World Health Organization Health & Work Performance Questionnaire (HPQ)|Patient Health Questionnaire (PHQ)|Generalized Anxiety Symptom Severity (GAD-7)|Sheehan Disability Scale (SDS)|Alcohol Use Disorders Identification Test-Civilian version (AUDIT-C)|Numeric Rating Scale for Pain (NRS).","Uniformed Services University of the Health Sciences|Walter Reed National Military Medical Center|United States Department of Defense|US Department of Veterans Affairs","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","91","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","D10-I-AR-J5-786","January 2012","January 2014","January 2014","December 30, 2011","null","January 12, 2012","Fort Benning - Martin Army Community Hospital, Columbus, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01502449"
530,"NCT01498406","Vitamin D Status, Disease Specific and Quality of Life Outcomes in Patients With Cutaneous Lupus",,"Terminated","No Results Available","Cutaneous Lupus Erythematosus","Dietary Supplement: vitamin D","cutaneous lupus severity as measured by the CLASI instrument(Cutaneous Lupus Erythematosus Disease Area and Severity Index)|Quality of life as measured by the Skindex 29|serum 25-hydroxy vitamin D","Emory University|Dermatology Foundation","All","18 Years and older   (Adult, Older Adult)","Phase 2","3","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","IRB00051622","December 2011","June 2013","June 2013","December 23, 2011","null","November 20, 2013","Emory Dermatology Clinics, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01498406"
531,"NCT01495728","Thoracic Manipulation in Patients With Cervical Radiculopathy",,"Unknown status","No Results Available","Cervical Radiculopathy","Procedure: Thrust Manipulation - Thoracic Spine|Procedure: Sham Manipulation","Global Rating of Change|Numeric Pain Rating Scale (Neck & Upper Extremity)|Neck Disability Index|Cervical Range of Motion|Deep Neck Flexor Endurance|Numbness and Tingling Scale","Spine and Sport, Georgia|Virginia Commonwealth University","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","jacki2006","September 2011","July 2012","August 2012","December 20, 2011","null","December 20, 2011","Spine and Sport, Savannah, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01495728"
532,"NCT01477762","Cortisol Suppression and Startle Responses in Posttraumatic Stress Disorder (PTSD)","CSS","Completed","Has Results","Post Traumatic Stress Disorder","Drug: Dexamethasone|Drug: Placebo","Mean Baseline Startle Magnitude During Fear Conditioning|Mean Startle Magnitude to Danger Signal During Fear Conditioning|Mean Fear-potentiated Startle to Danger Signal During Early Extinction|Mean Fear-potentiated Startle to Danger Signal During Late Extinction","Emory University|National Institute of Mental Health (NIMH)","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","165","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","IRB00051911|1R21MH092576-01A1","November 2011","July 2015","July 2015","November 23, 2011","April 18, 2017","April 18, 2017","Grady Health System, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01477762"
533,"NCT01470248","Study of Arsenic Trioxide in Small Cell Lung Cancer",,"Completed","Has Results","Lung Cancer|Cancer of Lung|Pulmonary Cancer|Pulmonary Neoplasms|Carcinoma, Small Cell","Drug: Arsenic Trioxide","Response Rate (RR)|Clinical Benefit Rate (CBR)|Progression-free Survival|Overall Survival","Emory University|Cephalon|Teva Pharmaceuticals USA|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","20","Other|Industry|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00050301|WCI1988-11|K23CA164015","August 2011","January 2016","January 2016","November 11, 2011","March 8, 2017","April 5, 2017","Emory University Winship Cancer Institute, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01470248"
534,"NCT01470209","A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies",,"Completed","No Results Available","Solid Tumors|Lung Cancer","Drug: BKM120|Drug: Everolimus","Dose limiting toxicity|Clinical benefit rate","Emory University|Novartis Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 1","43","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00048549|WCI1925-10","January 2012","May 2017","May 2017","November 11, 2011","null","March 19, 2018","Winship Cancer Institute of Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01470209"
535,"NCT01469572","Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases",,"Active, not recruiting","No Results Available","Neuroendocrine Tumors","Drug: Pasireotide|Procedure: Sir-sphere Radioembolization|Drug: Everolimus","Evaluate the number of patients who develop side effects from combination therapy.|Compare the size of the tumor before and three months after treatment using cross sectional imaging (CT ro MRI)","Emory University|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 1","13","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00051599|WCI2031-11","December 2011","December 2018","March 2019","November 10, 2011","null","November 22, 2017","Emory University Winship Cancer Institute, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01469572"
536,"NCT01469156","Safety Study of 2.0mg Lucentis to Treat Polypoidal Choroidal Vasculopathy",,"Unknown status","No Results Available","Polypoidal Choroidal Vasculopathy","Drug: ranibizumab 0.5 or 2.0 mg/0.05 cc","Incidence and severity of ocular and systemic adverse events will be compared between the 2.0mg and 0.5 mg groups.","Southeast Retina Center, Georgia|Genentech, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","20","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","FVF4916s","September 2011","February 2015","February 2015","November 10, 2011","null","February 20, 2014","Southeast Retina Center, Augusta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01469156"
537,"NCT01463111","Decision-Making in Bipolar Disorder",,"Completed","Has Results","Bipolar Disorder","Drug: Lithium|Drug: Valproate|Drug: Lamotrigine","Change in Vigilance Assessed by the Melbourne Decision Making Questionnaire (MDMQ)|Change in Hypervigilance Assessed by the Melbourne Decision Making Questionnaire (MDMQ)|Change in Buckpassing Assessed by the Melbourne Decision Making Questionnaire (MDMQ)|Change in Procrastination Assessed by the Melbourne Decision Making Questionnaire (MDMQ)|Mean Difference in Barratt Impulsiveness Scale, Version 11 (BIS-11) Score","Emory University","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","37","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","IRB00050442|BDDM","May 2011","April 2016","April 2016","November 1, 2011","May 31, 2017","May 31, 2017","Emory University Mood and Anxiety Disorders Program, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01463111"
538,"NCT01455740","A Commitment Device for Medication Adherence Among HIV Patients",,"Completed","No Results Available","Acquired Immunodeficiency Syndrome|HIV","Behavioral: Provider Visit Incentive (PVI)|Behavioral: Incentive Choice (IC)","Virologic Suppression (pVL =< 200 copies/mL) at Fifth Study Visit|Virologic Suppression (pVL =< 200 copies/mL) at Unanticipated Sixth Study Visit","National Bureau of Economic Research, Inc.|Emory University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","110","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","0005","October 2011","June 2013","October 2014","October 20, 2011","null","December 18, 2017","Emory University Ponce Clinic, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01455740"
539,"NCT01447173","Vitamin and Asthma Study",,"Completed","No Results Available","Asthma","Drug: Vitamin D","Change in Pulmonary Function Test (PFT) after vitamin D supplementation|Change in Asthma Control Test (ACT) scores after vitamin D supplementation","Augusta University","All","7 Years to 17 Years   (Child)","Phase 4","10","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VDAS","December 2010","September 2011","September 2011","October 6, 2011","null","October 23, 2012","Pediatrics Allergy Clinic at Georgia Health Sciences University, Augusta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01447173"
540,"NCT01442103","Clinical Utility of a New Silver Gel for Use on Chronic Wounds",,"Completed","Has Results","Chronic Wounds","Device: Normlgel Ag","Resolution of Signs and Symptoms of Local Wound Infection/Inflammation.|Infection Assessment|Pain Upon Application of Investigational Product.","Molnlycke Health Care AB","All","18 Years and older   (Adult, Older Adult)","Not Applicable","10","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Ngel Ag 01","September 2011","April 2012","May 2012","September 28, 2011","November 8, 2013","April 14, 2016","Joseph M. Still Research Foundation, Inc., Augusta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01442103"
541,"NCT01434459","Study of Gemcitabine With TheraSphere® (Yttrium-90)in Patients With Hepatic Tumors of Pancreatobiliary Origin",,"Terminated","No Results Available","Pancreatic Neoplasms|Cholangiocarcinoma","Drug: Gemcitabine with TheraSphere","The maximum tolerated dose of gemcitabine when given in combination with therasphere|Toxicities (side effects) experienced by patients on the trial|Tumor response rate when treated with gemcitabine and Therasphere using CT scan and F18-FDG-PET scan .|The progression free of patients treated on the trial","Emory University","All","18 Years and older   (Adult, Older Adult)","Phase 1","9","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00047233a|WCI1907-10","September 2011","January 2014","September 2014","September 15, 2011","null","May 4, 2015","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01434459"
542,"NCT01431742","Longterm Safety Study of BEMA Buprenorphine in Subjects With Chronic Low Back Pain",,"Withdrawn","No Results Available","Pain|Low Back Pain","Drug: BEMA Buprenorphine","Mean change in pain intensity","BioDelivery Sciences International","All","18 Years and older   (Adult, Older Adult)","Phase 3","0","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BUP-306","July 2012","July 2013","July 2013","September 12, 2011","null","April 17, 2012","Marietta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01431742"
543,"NCT01426997","Phenotype Depression Study",,"Completed","No Results Available","Major Depressive Disorder","","We are using clinician administered and self report psychiatric measurements to compare relevant symptom domains in patients with major depression and increased inflammation versus patients with major depression without increased inflammation.|We are measuring immune markers for the identification of relevant immunologic patterns of activation in patients with major depression and increased inflammation versus patients with major depression without increased inflammation.","Emory University|National Institute of Mental Health (NIMH)","All","21 Years to 65 Years   (Adult, Older Adult)","","279","Other|NIH","Observational","Observational Model: Case Control|Time Perspective: Cross-Sectional","IRB00039107|1R01MH087604-01A1","July 2010","May 2016","May 2016","September 1, 2011","null","June 22, 2016","Emory University Department of Psychiatry and Behavioral Sciences, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01426997"
544,"NCT01420965","Sipuleucel-T, CT-011, and Cyclophosphamide for Advanced Prostate Cancer",,"Terminated","No Results Available","Prostatic Neoplasms","Drug: CT-011 (Anti-PD1 Antibody)|Other: Sipuleucel-T (Provenge)|Drug: Cyclophosphamide","Determine feasibility of Provenge plus low-dose Cyclophosphamide as well as the immune efficacy of Provenge alone versus Provenge plus low-dose Cyclophosphamide and anti PD1 monoclonal antibodies (CT011) on the change in specific immune response...|Determine whether the combination of low dose-Cyclophosphamide and anti PD1 monoclonal antibodies (CT-011) with Provenge(tm) lead to improvement in increase progression free survival (PFS) and Overall Survival (OS) in patients with advanced, min...","Augusta University","Male","18 Years and older   (Adult, Older Adult)","Phase 2","7","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","11C0231","September 2012","December 2016","December 2016","August 22, 2011","null","September 18, 2017","Georgia Regents University, Augusta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01420965"
545,"NCT01398943","Nitric Oxide Bioavailability in Chronic Obstructive Pulmonary Disease (COPD)",,"Completed","Has Results","Pulmonary Disease, Chronic Obstructive","Drug: Tetrahydrobiopterin (BH4)|Dietary Supplement: Antioxidant Cocktail","Flow-Mediated Dilation (FMD)|Pulse Wave Velocity","Augusta University|American Heart Association","All","18 Years and older   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","AHA00115CS","September 2010","June 2015","June 2015","July 21, 2011","July 25, 2017","December 11, 2017","Augusta University, Augusta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01398943"
546,"NCT01396694","An Evaluation of Psychological Parameters That May Influence the Outcome Following Arthroscopy and Arthroplasty for Temporomandibular Joint Surgery",,"Completed","No Results Available","Psychological Predictors","Other: Questionnaire","Pain|Function","Emory University","All","18 Years to 90 Years   (Adult, Older Adult)","","105","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IRB00061869","June 2009","December 2012","December 2015","July 19, 2011","null","February 17, 2016","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01396694"
547,"NCT01395836","Management of New-Onset Postoperative Atrial Fibrillation","Monitor-AF","Completed","No Results Available","Atrial Fibrillation|Coronary Artery Disease|Post Operative Arrythmia","","The presence of AF at any post-operative points in time.","Emory University|Medtronic","All","Child, Adult, Older Adult","","23","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","IRB00047554a|EPEUHM","October 2011","March 2016","March 2016","July 18, 2011","null","November 4, 2016","Emory University Hospital Midtown, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01395836"
548,"NCT01395394","Phenylketonuria, Oxidative Stress, and BH4",,"Terminated","Has Results","Phenylketonuria","Drug: Kuvan|Other: Meal Challenge","Lipid Peroxidation|C-Reactive Protein (CRP)","Emory University","All","10 Years to 45 Years   (Child, Adult)","Phase 2","12","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","IRB00046153","June 2011","June 2013","June 2013","July 15, 2011","August 28, 2014","August 28, 2014","Emory University, Decatur, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01395394"
549,"NCT01382290","Magnetic Resonance Imaging of the Spine","MRIS","Withdrawn","No Results Available","Tethered Cord|Chiari I Malformation","Procedure: MRI","","Children's Healthcare of Atlanta","All","up to 18 Years   (Child, Adult)","Not Applicable","0","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","MRI DIffusion Spine","March 2008","December 2009","December 2009","June 27, 2011","null","August 9, 2016","Childrens Healthcare at Scottish Rite, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01382290"
550,"NCT01380197","Choosing Opioid Management for Pain and Analyzing Acute Chest Syndrome (ACS) Rates Equally","COMPARE","Completed","Has Results","Pain|Sickle Cell Disease","Drug: Morphine|Drug: Nubain","Acute Chest Syndrome|Number of Participants Who Experienced Pain Relief","Children's Healthcare of Atlanta|Atlanta Clinical and Translational Science Institute","All","6 Years to 19 Years   (Child, Adult)","Phase 3","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","09-076","May 26, 2010","January 14, 2014","October 18, 2016","June 27, 2011","February 16, 2015","February 20, 2018","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01380197"
551,"NCT01380171","Primary Palatoplasty in Pediatric Patients - A Retrospective Review of Surgical Outcomes",,"Completed","No Results Available","Cleft Lip|Cleft Palate","","","Children's Healthcare of Atlanta","All","Child, Adult, Older Adult","","1295","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","06-196","February 2007","November 2009","December 2009","June 27, 2011","null","June 27, 2011","Children's Healthcare of Atlanta at Scottish Rite, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01380171"
552,"NCT01371695","Serum IGF-II and Cancer: Can IGF II Levels be Used to Monitor and Screen Patients Specifically for Cervical Cancer",,"Unknown status","No Results Available","Cervical Cancer|Cervical Intraepithelial Neoplasia II|Cervical Intraepithelial Neoplasia III","","","Onconix, Inc","All","18 Years to 75 Years   (Adult, Older Adult)","","60","Industry","Observational","Observational Model: Case Control|Time Perspective: Prospective","onc11-03-164","May 2011","September 2011","September 2013","June 13, 2011","null","June 13, 2011","Georgia Health Sciences, Augusta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01371695"
553,"NCT01370408","Palonosetron, Ondansetron, and Dexamethasone for Delayed Nausea and Vomiting in Autologous Transplant Patients",,"Completed","Has Results","Chemotherapy-induced Nausea and Vomiting","Drug: Palonosetron|Drug: ondansetron|Drug: Dexamethasone","Complete Response Rate for Delayed Chemotherapy Induced Nausea & Vomiting|Complete Remission During Acute Phase Post-chemotherapy|Complete Remission During Overall Chemotherapy Time Period|Complete Control Rate for Nausea & Vomiting|Emetic Episodes|Patients Who Experience First Emetic Episode Within 24 Hours|Number of Patients That Required First Administration of Rescue Medication Within 24 Hours|Number of Patients That Experience Treatment Failure Within the First 24 Hours","Northside Hospital, Inc.|Blood and Marrow Transplant Group of Georgia","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2","85","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","NSH 940","February 2012","March 2016","March 2016","June 9, 2011","February 6, 2017","April 17, 2017","Northside Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01370408"
554,"NCT01369147","The Energy Dose Study",,"Suspended","No Results Available","Critical Illness","Drug: Parenteral nutrition energy dose at 0.6 x measured REE|Drug: Parenteral nutrition energy dose at 1.0 x measured REE|Drug: Parenteral nutrition energy dose at 1.3 X measured REE","To compare the effect of three specific energy doses [0.6, 1.0 and 1.3 x measured Resting Energy Expenditure, respectively], on total hospital acquired infection incidence rates in patients in the ICU over a 28 day period.|To examine the impact of cumulative and mean daily 28-day energy deficits on nosocomial infection incidence rates","Emory University|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 2","60","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","IRB00049495|1R21DK089369","July 2011","October 2019","October 2019","June 8, 2011","null","October 12, 2018","Emory University Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01369147"
555,"NCT01366469","Inflammatory Biomarkers Predict Pulmonary Outcomes in Coronary Artery Bypass Grafting","CABG BALF","Completed","No Results Available","Coronary Artery Disease|Chronic Obstructive Pulmonary Disease","","Primary outcome measure|Secondary outcome measure","Emory University","All","18 Years to 89 Years   (Adult, Older Adult)","","10","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IRB00046469|CABG BALF","April 2011","December 2012","December 2013","June 6, 2011","null","February 19, 2014","Emory University Hospital Midtown, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01366469"
556,"NCT01362309","D-Cycloserine to Enhance Extinction to Alcohol Cues",,"Completed","No Results Available","Alcohol Use Disorders.","Drug: d-cycloserine.","Change in Craving for alcohol.|Change in Tolerability","University of Georgia|National Institute on Alcohol Abuse and Alcoholism (NIAAA)|Boston University|Brown University","All","21 Years to 65 Years   (Adult, Older Adult)","Not Applicable","37","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Basic Science","R21AA017696","November 2010","October 2012","October 2012","May 30, 2011","null","February 19, 2014","Experimental and Clinical Psychopharmacology Laboratory, Dept. of Psychology, University of Georgia, Athens, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01362309"
557,"NCT01361594","Intensive Insulin Therapy in Patients Undergoing Coronary Artery Bypass Surgery","CABG","Completed","Has Results","Diabetes","Other: Regular insulin (intensive treatment)|Other: Regular Insulin (conventional treatment)","Number of Subjects That Were Diagnosed for Peri-operative Complications|Hospital Mortality|Glycemic Control|Major Cardiovascular Events|Acute Renal Failure|Respiratory Failure, Defined as PaO2 Value < 60 mm Hg While Breathing Air or a PaCO2 > 50 mm Hg.|ICU and Hospital Length of Stay, and ICU Readmissions|Surgical Wound Infection|Pneumonia (CDC Criteria)|Cerebrovascular Events|Duration of Ventilatory Support and ICU Readmission|Thirty Day Mortality|Number of Hospital Readmissions and Emergency Room Visits|Incidence of Organ Failures Assessed by the Daily SOFA Score|Measures of Inflammation","Emory University|American Diabetes Association","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","338","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00048356|00048356-2010","June 2011","December 2013","December 2013","May 27, 2011","December 31, 2014","December 31, 2014","Emory University Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01361594"
558,"NCT01352143","Thrombin Generation in Neonatal Plasma After Cardiopulmonary Bypass",,"Completed","No Results Available","Cardiopulmonary Bypass","Drug: Recombinant activated factor VII|Drug: Prothrombin Complex Concentrate","Peak thrombin Generation","Emory University|Children's Research Oversight Committee Funds","All","up to 30 Days   (Child)","","24","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","IRB00048151","March 2011","June 2012","June 2012","May 11, 2011","null","November 20, 2013","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01352143"
559,"NCT01349621","Clinical Evaluation of Polarized Light Assisted Colposcopy",,"Completed","No Results Available","Cervical Intraepithelial Neoplasia","","To determine whether polarized light increases the sensitivity and specificity over unpolarized light, the area under a receiver operating characteristic curve (AROC) will be calculated.|We will determine the differences in the severity of cervical neoplasia between biopsies taken using polarized and unpolarized light using a Bowker's test of symmetry.","Augusta University|National Institutes of Health (NIH)|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Older Adult)","","330","Other|NIH","Observational","Time Perspective: Prospective","CA156166|1R21CA156166-01A1","April 2011","February 2014","February 2014","May 6, 2011","null","March 10, 2015","Georgia Health Sciences University, Augusta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01349621"
560,"NCT01348451","Human Spinal Cord Derived Neural Stem Cell Transplantation for the Treatment of Amyotrophic Lateral Sclerosis","ALS","Unknown status","No Results Available","Amyotrophic Lateral Sclerosis","Device: surgical implantation","The primary objective of this study is to determine the safety of human spinal cord-derived neural stem cell transplantation for the treatment of amyotrophic lateral sclerosis.|The Secondary Objectives of the study are to evaluate spinal stem cell transplantation therapy in this patient population.","Neuralstem Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","18","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NS2008-1","January 2009","December 2015","December 2016","May 5, 2011","null","March 10, 2016","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01348451"
561,"NCT01342757","Magnetic Resonance Spectroscopy Imaging in Predicting Response to Vorinostat and Temozolomide in Patients With Recurrent or Progressive Glioblastoma",,"Completed","Has Results","Adult Glioblastoma|Depression|Recurrent Adult Brain Tumor","Drug: vorinostat|Drug: temozolomide|Procedure: magnetic resonance spectroscopic imaging|Other: survey administration","Proportion of Patients With Magnetic Resonance Spectroscopy (MRS) Response to Initial Vorinostat by MRI and MRS Scans as Determined by Spectroscopic Index|Proportion of Patients Who Experience Metabolic Restoration Between the Responders and Non-responder Groups by MRS Scans|Measurable Change on Magnetic Resonance Spectroscopy Imaging After Vorinostat Administration|Mean Change in Metabolite Levels","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","12","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","NCI-2011-02569|EMORY IRB #00044064|WCI-44064|R21CA141836","December 2010","May 2012","May 2012","April 27, 2011","June 11, 2014","January 29, 2018","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01342757"
562,"NCT01340378","A Pilot Study of Thrombin Generation Changes in Neonates Undergoing Placement of a Blalock-Taussig Shunt",,"Completed","No Results Available","Aortic Coarctation","","Thrombin generation - peak amount|Thrombin Generation Curve validation in neonates","Emory University|Children's healthcare of Atlanta: Cardiac Research Donor Funds","All","up to 30 Days   (Child)","","20","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","IRB00034496","January 2010","January 2013","December 2014","April 22, 2011","null","December 12, 2014","Children's Healthcare of Atlanta at Egleston, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01340378"
563,"NCT01337713","Efficacy of Massage Therapy in the Treatment of Generalized Anxiety Disorder (GAD)","GAD","Completed","No Results Available","Generalized Anxiety Disorder","Other: Swedish Massage|Other: Light Touch","Hamilton Anxiety Scale","Emory University|National Center for Complementary and Integrative Health (NCCIH)","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","40","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRB00052054|7R21AT004208-02","September 2010","January 2014","July 2014","April 19, 2011","null","July 27, 2017","Emory University, Department of Psychiatry, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01337713"
564,"NCT01336712","Total Body Irradiation/Fludarabine Based Ablative Haploidentical Transplant for Hematologic Diseases",,"Completed","Has Results","Chronic Leukemia|Acute Leukemia|Hodgkin's Disease|Non-Hodgkin's Lymphoma|Myelodysplastic Syndrome","Procedure: Peripheral Blood Stem Cell Transplant","Percentage of Patients Experiencing Hemorrhagic Cystitis Post Transplant|Survival|Percentage of Participatns With Donor Chimerism Post-transplant|Disease Free Survival (DFS) Percentage|Non-relapsed Mortality (NRM) Percentage|Relapse Rate|Cumulative Incidence of Chronic Graft-versus-host Disease","Northside Hospital, Inc.|Blood and Marrow Transplant Group of Georgia","All","18 Years to 60 Years   (Adult)","Phase 2","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NSH 922","April 2011","December 2014","July 2015","April 18, 2011","January 14, 2016","January 14, 2016","Northside Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01336712"
565,"NCT01331148","Vitamin D for Sickle Cell","SCD Vitamin D","Unknown status","No Results Available","Sickle Cell Disease","Drug: Vitamin D|Other: Placebo","Rate and extent of vitamin D deficiency|clinical outcomes associated with vitamin D deficiency|Vitamin D deficiency correction|serum markers of inflammation and oxidant stress versus vitamin D status|Vitamin D receptor polymorphisms versus vitamin D and chronic pain status","Emory University|Children's Healthcare of Atlanta","All","7 Years to 21 Years   (Child, Adult)","Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","SCD Vitamin D","February 2009","December 2011","December 2013","April 7, 2011","null","March 29, 2012","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01331148"
566,"NCT01331135","Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors","Aflac ST0901","Active, not recruiting","No Results Available","Ewing's Sarcoma|Osteosarcoma|Astrocytoma|Atypical Teratoid/Rhabdoid Tumor|Ependymoma|Germ Cell Tumor|Glioma|Medulloblastoma|Rhabdoid Tumor|Retinoblastoma|Clear Cell Sarcoma|Renal Cell Carcinoma|Wilms Tumor|Hepatoblastoma|Neuroblastoma|Rhabdomyosarcoma","Drug: sirolimus","Maximum tolerated dose (MTD)|define and describe toxicities of sirolimus|anti-tumor activity of sirolimus|evaluate correlation of p70S6 kinase activity|evaluate risk of infection","Emory University|Children's Healthcare of Atlanta","All","up to 30 Years   (Child, Adult)","Phase 1","24","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00047016|Aflac ST0901 CHOANOME","April 2011","August 2014","April 2021","April 7, 2011","null","May 16, 2018","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01331135"
567,"NCT01328873","FOB in HSCT and Leukemia Patients With Acute Respiratory Symptoms and Pulmonary Infiltrates",,"Completed","Has Results","Pulmonary Infiltrate New","Other: Microbiological analysis","Number of Patients With Positive Culture or Molecular Results After Brochoscopy|Number of Patients With Positive CT Result|Number of Participants With Positive Bacterial Results by PCR|Number of Patients With Positive Fungal Results by PCR|Number of Participants With Positive Viral Results by PCR|Number of Participants With Positive Myocbacteria Results by Culture","Northside Hospital, Inc.|Blood and Marrow Transplant Group of Georgia","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","49","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NSH 909","March 2011","October 2015","April 2017","April 5, 2011","April 26, 2017","July 11, 2017","Northside Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01328873"
568,"NCT01319851","Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation",,"Terminated","Has Results","Thalassemia|Sickle Cell Disease|Glanzmann Thrombasthenia|Wiskott-Aldrich Syndrome|Chronic-granulomatous Disease|Severe Congenital Neutropenia|Leukocyte Adhesion Deficiency|Schwachman-Diamond Syndrome|Diamond-Blackfan Anemia|Fanconi Anemia|Dyskeratosis-congenita|Chediak-Higashi Syndrome|Severe Aplastic Anemia","Drug: Alefacept","Feasibility of Alefacept Pre-conditioning, Measured by Number of Subjects With Full Donor Engraftment|Number of Participants That Expressed Grade 2 or 3 Regimen-Related Toxicity|Number of Participants That Expressed Successful Neutrophil Engraftment|Incidence of Greater Than or Equal to 85% CD3 Donor Chimerism|Incidence of 100% CD33 Donor Chimerism|Number of Participants Who Experienced Acute Graft-versus-host Disease (aGVHD), Measured by NIH Consensus Criteria (NCC) Score: Grade II-IV|Number of Participants Who Experienced Chronic Graft-versus-host Disease (cGVHD), Measured by the NIH Criteria Consensus (NCC)","Emory University|Children's Healthcare of Atlanta","All","up to 21 Years   (Child, Adult)","Not Applicable","3","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00039680|BMT Alefacept","September 2010","September 2013","September 2013","March 22, 2011","March 9, 2015","July 27, 2017","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01319851"
569,"NCT01319838","Aflac ST1001 Prolonged Isotretinoin","Aflac ST1001","Withdrawn","No Results Available","Neuroblastoma","Drug: Isotretinoin","Progression free survival|Isotretinoin toxicity|Bone growth effect|Isotretinoin pharmacokinetic profile|Neurologic or psychologic sequelae","Emory University|Children's Healthcare of Atlanta","All","up to 30 Years   (Child, Adult)","Phase 1","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00047148|Aflac ST1001","March 2011","December 2013","December 2013","March 22, 2011","null","December 10, 2013","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01319838"
570,"NCT01317537","Using an Electronic Personal Health Record to Empower Patients With Hypertension",,"Completed","No Results Available","Hypertension","Other: Electronic personal health record","Systolic blood pressure|Diastolic blood pressure|patient activation|Patient satisfaction with care|adherence to guidelines","Augusta University|Agency for Healthcare Research and Quality (AHRQ)|Cerner Corporation|The Institute for Patient- and Family-Centered Care","All","21 Years to 80 Years   (Adult, Older Adult)","Not Applicable","445","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Investigator)","HS017234","September 2007","July 2010","July 2010","March 17, 2011","null","March 17, 2011","Georgia Health Sciences University, Augusta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01317537"
571,"NCT01313416","Gemcitabine and CT-011 for Resected Pancreatic Cancer",,"Terminated","No Results Available","Pancreatic Neoplasms|Cancer of the Pancreas|Neoplasms Pancreatic|Pancreatic Cancer|Pancreas Cancer","Biological: CT-011|Drug: Gemcitabine","Toxicity Evaluation: From time of first treatment with CT-011 (pidilizumab, MDV9300)|Disease Response: Evaluated using the revised Response Evaluation Criteria in Solid Tumors (RECIST) guidelines (v1.1)","Augusta University","All","18 Years and older   (Adult, Older Adult)","Phase 2","2","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","11-C-0100","September 2012","January 2017","January 2017","March 11, 2011","null","September 18, 2017","Georgia Regents University, Augusta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01313416"
572,"NCT01308983","Study of Amiloride on Vascular Phenotypes in Young Adults With Prehypertension","SAPHA","Unknown status","No Results Available","Prehypertension","Drug: Amiloride","Vascular phenotypes","Augusta University","All","18 Years to 35 Years   (Adult)","Phase 4","32","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1000","September 2010","December 2012","null","March 4, 2011","null","October 23, 2012","Georgia Prevention Institute, Augusta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01308983"
573,"NCT01305590","Understanding Medication Adherence Among HIV Patients",,"Completed","No Results Available","Patient Commitment Preferences for Medication Adherence","Other: Survey to Understand Medication Adherence among HIV Patients","Commitment Preferences for Increasing Medication Adherence|Medication Adherence and Commitment Preference","National Bureau of Economic Research, Inc.|National Institute on Aging (NIA)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","200","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","0004|P01AG005842","July 2011","July 2011","July 2011","February 28, 2011","null","April 3, 2018","Ponce Clinic, Emory University School of Medicine, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01305590"
574,"NCT01304706","Fluocinolone Acetonide in Diabetic Macular Edema (FAME) Extension Study",,"Completed","Has Results","Diabetic Macular Edema","Drug: Fluocinolone Acetonide","Number of Participants With Adverse Events","Alimera Sciences","All","Child, Adult, Older Adult","Phase 3","120","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","C-01-11-008","April 2011","November 2013","null","February 25, 2011","May 4, 2015","May 4, 2015","Alpharetta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01304706"
575,"NCT01301417","Data Collection of Patients Treated With the ColonRing™ for the Creation of Circular Compression Anastomosis","RETROPRESS","Completed","No Results Available","Diverticulum, Colon|Colorectal Neoplasms|Crohn Disease|Colitis, Ulcerative|Colostomy|Ileostomy - Stoma|Rectal Prolapse|Intestinal Polyposis|Lymphoma|Endometriosis|Intestinal Volvulus","Device: ColonRing™","Rate of anastomotic leakage|Rate of other device related complications and measures during hospitalization and post procedure:","novoGI","All","18 Years and older   (Adult, Older Adult)","","171","Industry","Observational","Time Perspective: Retrospective","RETROPRESS","February 2011","August 2011","August 2011","February 23, 2011","null","June 5, 2013","Southern Regional Medical Center, Riverdale, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01301417"
576,"NCT01300585","MRI Evaluation of the Breast Areolar Margin and Paryenchyma","Breast MRI","Terminated","No Results Available","Breast Cancer","Other: MRI","Patterns of Breast Gland Attachment","Piedmont Healthcare","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","68","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","Breast MRI","February 2011","May 2014","May 2014","February 21, 2011","null","May 5, 2014","Piedmont Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01300585"
577,"NCT01295541","Early Progressive Mobility in the CVICU: Assessing Current Status",,"Completed","No Results Available","Immobility and Weakness Associated With Long Intensive Care Unit Stays","","First OOB|ICU LOS|Type and Frequency of PM orders","Hill-Rom","All","18 Years and older   (Adult, Older Adult)","","10","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","CR-2009-05a","July 2010","December 2010","December 2010","February 14, 2011","null","February 14, 2011","Medical College of Central Georgia, Macon, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01295541"
578,"NCT01293526","Acute Optimization of Cardiac Resynchronization Therapy (CRT)Using Echocardiography and SonR","SonR Access","Completed","No Results Available","Heart Failure","Device: Control|Device: Experimental|Device: Experimental 2","Percent of responding patients|Comparison of echocardiography and SonR signals","Piedmont Healthcare|LivaNova","All","18 Years and older   (Adult, Older Adult)","Not Applicable","39","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","SonR Access","February 2011","June 2014","June 2014","February 10, 2011","null","November 20, 2017","Piedmont Heart Institute, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01293526"
579,"NCT01292746","Study of the Effect of Low Level Laser Light on Hair Growth on the Female Human Scalp",,"Terminated","Has Results","Female Pattern Alopecia","Device: Erchonia MLS","Change in Non-vellus Terminal Hair Count Across a 3 cm Diameter Scalp Area","Erchonia Corporation","Female","18 Years to 60 Years   (Adult)","Not Applicable","14","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EC_FA001","February 2011","October 2012","October 2012","February 9, 2011","December 11, 2015","December 11, 2015","Advanced Gynecology Specialists of Georgia, Evans, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01292746"
580,"NCT01290055","Turnover of Antigen Specific Lymphocytes After Immunization With the Yellow Fever Vaccine",,"Active, not recruiting","No Results Available","Yellow Fever","Biological: Yellow fever vaccine|Biological: Yellow fever vaccine and D20 water","To evaluate the life span and decay curve of effector CD8 T cells after immunization with 17D yellow fever vaccine|To evaluate the rate of homeostatic turnover of memory CD8 T cells after immunization with 17D yellow fever vaccine","Sri Edupuganti, MD MPH|University of California, Berkeley|National Institutes of Health (NIH)|Emory University","All","18 Years to 45 Years   (Adult)","Not Applicable","40","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","IRB00046406|YFV heavy water study|5U19AI057266","February 2011","January 2020","January 2020","February 4, 2011","null","October 1, 2018","The Hope clinic of Emory Vaccine Center, Decatur, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01290055"
581,"NCT01287910","Transmyocardial Laser Revascularization and Cardiovascular Magnetic Resonance Imaging","Amsterdam","Terminated","No Results Available","Angina|Chest Pain","Other: Cardiac MRI","Number of coronary arteries with blood flow defects evaluated by magnetic resonance imaging (MRI) or computed tomography (CT)","Piedmont Healthcare|Cardiogenesis Corporation, a wholly-owned subsidiary of CryoLife, Inc.","All","18 Years and older   (Adult, Older Adult)","Not Applicable","2","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)","Amsterdam","January 2011","August 2013","August 2013","February 2, 2011","null","September 5, 2013","Piedmont Heart Institute, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01287910"
582,"NCT01287234","Atrio-Ventricular (AV) Delay Optimization Using Echocardiography Versus the SonR Signal","SonR Pilot","Completed","No Results Available","Heart Failure","Other: Echocardiogram/SonR","Optimal blood flow method","Piedmont Healthcare|LivaNova","All","18 Years and older   (Adult, Older Adult)","Not Applicable","15","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)","SonR Pilot","January 2011","July 2012","July 2012","February 1, 2011","null","December 20, 2012","Piedmont Heart Institute, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01287234"
583,"NCT01284023","Use of Near Infrared Spectroscopy to Detect Muscle Perfusion in the Lower Extremity of Uninjured Subjects",,"Completed","No Results Available","Acute Compartment Syndrome","Other: Shaving","Near infrared spectroscopy|Skin pigmentation|fat depth","J&M Shuler|Nonin Medical, Inc","All","18 Years and older   (Adult, Older Adult)","","44","Industry","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","NIRS-02","January 2011","December 2011","August 2012","January 26, 2011","null","August 15, 2018","Athens Orthopedic Clinic, PA, Athens, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01284023"
584,"NCT01283451","Ability of Near Infrared Spectroscopy to Isolate Compartments of the Extremity",,"Completed","No Results Available","Acute Compartment Syndrome","Behavioral: Muscle contraction","Near infrared spectroscopy","J&M Shuler","All","18 Years to 75 Years   (Adult, Older Adult)","","63","Industry","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","NIRS-01","January 2010","December 2016","December 2016","January 26, 2011","null","August 15, 2018","Athens Orthopedic Clinic, PA, Athens, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01283451"
585,"NCT01283334","A Study of Carboplatin, Cetuximab and RAD001 in Advanced Head and Neck Cancer",,"Completed","Has Results","Head and Neck Neoplasms|Cancer of the Head and Neck","Drug: Carboplatin|Drug: Cetuximab|Drug: RAD001","To Measure the Safety and Clinical Effectiveness of the Combination of Carboplatin, Cetuximab and RAD001 in Patients With Advanced (Recurrent or Metastatic) Head and Neck Cancer|Progression-free Survival (PFS)","Emory University|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","20","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00040298|WCI1761-09","January 2011","November 2013","November 2014","January 25, 2011","December 4, 2014","December 4, 2014","Emory University Winship Cancer Institute, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01283334"
586,"NCT01283321","RiaSTAP vs. Conventional Transfusion in Patients Having Heart Valve Surgery","RiaCT","Terminated","Has Results","Heart Valve Disease|Coronary Artery Disease","Drug: Human fibrinogen concentrate|Other: apheresis platelets","Bleeding Scores|Number of Participants in Whom Transfusion of Platelet Concentrate is Required During or After Surgery.|Volume (mL) of Fresh-frozen Plasma (FFP) Transfused-during Surgery and up to 24 Hours After Surgery|Volume (mL) of Platelets Transfused- During Surgery and up to 24 Hours After Surgery|Median Blood Loss (mL) at 12 Hours After Surgery","Emory University|CSL Behring","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2","26","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00036062|RiaCT 2010","January 2011","May 2013","May 2013","January 25, 2011","February 16, 2015","June 21, 2018","Emory University Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01283321"
587,"NCT01283282","Investigation of the Athero-Protective Effects of Clopidogrel","APECS","Completed","Has Results","Coronary Artery Disease","Drug: Clopidogrel|Drug: Placebo","Flow-mediated Dilation (FMD)|Nitroglycerin-mediated Vasodilation|Endothelial Progenitor Cells (EPCs)|Pulse Wave Velocity (PWV)|Oxidative Stress Markers|Inflammatory Marker High-sensitivity C-reactive Protein (hsCRP)|Inflammatory Marker CD40 Ligand","Emory University","All","21 Years to 80 Years   (Adult, Older Adult)","Phase 4","48","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","IRB00005145|APECS","January 2008","December 2010","December 2010","January 25, 2011","May 1, 2015","May 1, 2015","Emory University Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01283282"
588,"NCT01280604","Effect of Fenofibrate Conversion on Triglyceride Levels in Patients on Statin Therapy",,"Completed","Has Results","Hyperlipidemias","Drug: Fenofibrate 54mg","Triglyceride Levels|Low-density Lipoprotein (LDL)|High-density Lipoprotein,(HDL)|Alanine Aminotransferase(ALT)|Aspartate Aminotransferase (AST)|Serum Creatinine(SCr)","Kaiser Permanente","All","18 Years and older   (Adult, Older Adult)","Not Applicable","66","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KPGA-10KMani-01","October 2010","January 2013","January 2013","January 21, 2011","June 8, 2015","June 8, 2015","Kaiser Permanente of Georgia, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01280604"
589,"NCT01272336","Study Effects of Intermittent Hypoxia on Restoring Hand Function Following SCI",,"Completed","No Results Available","Spinal Cord Injury","Drug: Acute Intermittent Hypoxia (AIH)|Other: SHAM-Intermittent Room Air","Hand grasp|Grip strength","Emory University|University of Saskatchewan|University of Wisconsin, Madison","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","53","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRB00035986|163907","December 2010","August 2013","October 2015","January 7, 2011","null","January 26, 2016","Emory Center for Rehabilitation Medicine, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01272336"
590,"NCT01271738","Evaluating and Comparing Two Surgical Methods for Treatment of Early Stage Breast Cancer",,"Completed","No Results Available","Breast Neoplasms|Breast Cancer|Breast Tumors|Cancer of Breast|Cancer of the Breast|Human Mammary Carcinoma|Neoplasms, Breast","Procedure: Remove tumor only|Procedure: Removal of tumor and tissue","Comparing 2 surgical methods for treatment of early stage breast cancer","Emory University","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","79","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","IRB00013658|WCI1659-09","September 2009","February 2015","February 2015","January 7, 2011","null","August 17, 2015","Emory University Winship Cancer Institute, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01271738"
591,"NCT01271374","Changes in Endothelial Function and Biomarkers in African Americans (AA) With Metabolic Syndrome","AMORE","Unknown status","No Results Available","Hypertension","Drug: amlodipine and olmesartan|Drug: losartan and HCTZ","Change in Central Aortic Pressure (CAP)|Blood pressure control","InVasc Therapeutics, Inc.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","80","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AVR-2010-001","April 2010","June 2011","December 2011","January 6, 2011","null","May 5, 2011","Atlanta Clinical Research Center, Tucker, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01271374"
592,"NCT01264471","Mechanisms of Mitochondrial Defects in Gulf War Syndrome",,"Completed","No Results Available","Gulf War Syndrome|Mitochondrial Disease","Procedure: Skin biopsy|Procedure: Blood Collection","Characterize mitochondrial cellular energetics in Gulf War Syndrome patients|Mitochondrial DNA","Medical Neurogenetics, LLC|United States Department of Defense","All","18 Years and older   (Adult, Older Adult)","","26","Other|U.S. Fed","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","H09378|GW080138","May 2009","June 2013","June 2013","December 21, 2010","null","April 13, 2015","Medical Neurogenetics, LLC, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01264471"
593,"NCT01251341","The Compassion and Attention Longitudinal Meditation Study","CALM","Completed","No Results Available","Immune System Processes|Inflammatory Activation and Modulation|ANS Function","Behavioral: Cognitive-Based Compassion Training|Behavioral: Mindful Attention Training|Behavioral: Adult Health Education Curriculum","Effects of compassion meditation on inflammatory and behavioral responses to psychosocial stress using a longitudinal design.","University of Arizona|Emory University","All","25 Years to 55 Years   (Adult)","Not Applicable","226","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","5R01AT004698","September 2009","May 2014","May 2014","December 1, 2010","null","December 5, 2014","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01251341"
594,"NCT01245179","Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease","LBH589","Active, not recruiting","No Results Available","Sickle Cell Disease","Drug: panobinostat","Primary Outcome Measure|Secondary Outcome Measure|Define mechanisms of effect of panobinostat (Hb F induction and anti-inflammatory effects) and discover biomarkers of treatment response","Abdullah Kutlar|Novartis Pharmaceuticals|Augusta University","All","18 Years and older   (Adult, Older Adult)","Phase 1","12","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CLBH589BUS43T","November 2010","July 2022","July 2023","November 22, 2010","null","June 5, 2018","Augusta University, Augusta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01245179"
595,"NCT01244906","Post-transplant Cyclophosphamide and Sirolimus Following Reduced Intensity Conditioning (RIC) Transplant",,"Completed","Has Results","Hematologic Neoplasms","Procedure: Allogeneic Hematopoietic Stem Cell Transplantation","Incidence of GVHD|Incidence of Absolute Neutrophil Count (ANC)/Platelet Engraftment|Number of Participants With Non-Relapse Mortality|Number of Patients With Disease Free Survival at 2 Years|Number of Patients to Achieve Full Donor Chimerism|Number of Patients With Overall Survival at 2 Years.","Northside Hospital, Inc.|Blood and Marrow Transplant Group of Georgia","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","26","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NSH 911","December 2010","April 2014","December 2014","November 19, 2010","March 17, 2015","May 1, 2015","Northside Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01244906"
596,"NCT01244802","Immune Responses to Yellow Fever Vaccine",,"Recruiting","No Results Available","Yellow Fever Vaccine","","Determine the phenotypic and functional characterization of memory T cell responses to YF vaccination","Emory University|National Institutes of Health (NIH)","All","18 Years and older   (Adult, Older Adult)","","150","Other|NIH","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","IRB00002834|YFV-2 Cross sectional|5U19AI057266","November 2010","August 2020","August 2020","November 19, 2010","null","September 28, 2018","The Hope clinic of Emory Vaccine Center, Decatur, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01244802"
597,"NCT01240200","Satisfaction of Treatment Among Elderly Patients With Insulin Therapy",,"Completed","Has Results","Diabetes Mellitus","Drug: Glargine|Device: glargine via insulin pen","Diabetes Treatment Satisfaction Questionnaire: Status (DTSQs) Score|Diabetes Treatment Satisfaction Questionnaire: Change (DTSQc) Score|Hemoglobin A1c (HbA1c)|Fasting Blood Glucose|Percent of Participants With Dosing Errors|Number of Hypoglycemic Events","Emory University|Sanofi","All","60 Years and older   (Adult, Older Adult)","Phase 4","49","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00046366","January 2011","August 2012","December 2012","November 15, 2010","October 30, 2014","September 26, 2018","Grady Memorial Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01240200"
598,"NCT01235702","Metro Atlanta Heart Disease Study - II (MAHDS II)",,"Completed","No Results Available","African Americans With Hypertension.","Behavioral: 12-week lifestyle modification","blood pressure|body weight","Morehouse School of Medicine","All","21 Years to 65 Years   (Adult, Older Adult)","Phase 1","210","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","TS-0724","September 2002","October 2003","October 2003","November 5, 2010","null","November 5, 2010","Morehouse School of Medicine, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01235702"
599,"NCT01233999","Botulinum Toxin in the Treatment of Raynaud's",,"Completed","Has Results","Raynaud's Syndrome","Drug: botulinum toxin A","Mean Digital Temperature Difference From Baseline","Emory University","All","18 Years to 89 Years   (Adult, Older Adult)","Not Applicable","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","IRB00015510","October 2010","October 2011","March 2012","November 4, 2010","April 21, 2014","April 21, 2014","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01233999"
600,"NCT01232868","Systems Biology of Trivalent Influenza Vaccine (TIV) in Young and Elderly",,"Completed","Has Results","Influenza","Biological: trivalent Influenza vaccine (TIV)","Efficacy, Measured by the Number of Subjects With a Change in Innate Immune Signatures|Number of Participants With Specific B Cell Responses That Correlate With the Innate Immune Signatures","Emory University","All","25 Years and older   (Adult, Older Adult)","Not Applicable","66","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","IRB00046787|NIH|VAX-001","October 2010","October 2011","October 2011","November 2, 2010","November 30, 2015","November 30, 2015","Hope Clinic of the Emory Vaccine Center, Decatur, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01232868"
601,"NCT01230892","Evaluation of The Effects of Nebivolol in Comparison to Atenolol on Wall Shear Stress and Rupture Prone Coronary Plaques",,"Completed","Has Results","Atherosclerosis|Endothelial Function","Drug: Nebivolol|Drug: Atenolol","Number of Participants With Reduction of Thin-cap Fibroatheromas (TCFA) as Defined by VH-IVUS","Emory University|Georgia Institute of Technology","All","21 Years to 79 Years   (Adult, Older Adult)","Phase 4","29","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRB00027953|Emory #00000681","February 2010","September 2013","September 2013","October 29, 2010","February 27, 2015","February 27, 2015","Emory University Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01230892"
602,"NCT01229969","A Pilot Study of the Wii Fit as a Low-Cost Virtual Reality System to Evaluate Balance Ability in Older Adults","WiiFit","Completed","No Results Available","Falls, Accidental","Other: Wii Fit Balance Games|Other: NeuroCom EquiTest® System","Feasibility and validity of the Wii Fit gaming system in detect balance problems in older adults","Atlanta VA Medical Center|Emory University","All","60 Years and older   (Adult, Older Adult)","Not Applicable","20","U.S. Fed|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2009-060390","August 2009","October 2011","March 2012","October 28, 2010","null","January 24, 2013","Atlanta VA Medical Center, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01229969"
603,"NCT01228344","Surveillance of Effectiveness/Safety of Artemether-lumefantrine in Patients With Malaria",,"Completed","No Results Available","Malaria","Other: Artemether-lumefantrine","Effectiveness: Resolution of clinical signs and symptoms after artemether-lumefantrine treatment start|Adverse event, serious adverse event after artemether-lumefantrine treatment start|Pregnancies after artemether-lumefantrine treatment start","Novartis Pharmaceuticals|Centers for Disease Control and Prevention|Novartis","All","Child, Adult, Older Adult","","324","Industry|U.S. Fed","Observational","Observational Model: Other|Time Perspective: Other","CCOA566A2424","May 1, 2010","September 30, 2015","September 30, 2015","October 26, 2010","null","April 7, 2017","Centers for Disease Control and Prevention,GA, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01228344"
604,"NCT01228318","Bone Loss and Immune Reconstitution in HIV/AIDS (BLIR-HIV)","BLIR-HIV","Completed","Has Results","HIV Infection|Bone Loss|Osteopenia|Osteoporosis","Drug: Zoledronic acid","Baseline-Adjusted Means for C-terminal Telopeptide of Collagen (CTx) Levels|Baseline-Adjusted Means of Osteocalcin","Emory University","All","30 Years to 50 Years   (Adult)","Phase 2","63","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","IRB00038739|BLIR-HIV","January 2011","April 13, 2017","April 13, 2017","October 26, 2010","June 25, 2018","June 25, 2018","Grady Infectious Diseases Clinic (Ponce Center), Atlanta, Georgia, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/18/NCT01228318/ICF_000.pdf|""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/18/NCT01228318/Prot_SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01228318"
605,"NCT01228032","The Health Outcomes Management and Evaluation (HOME) Study","HOME","Completed","No Results Available","Diabetes|Hyperlipidemia|Heart Disease|High Blood Pressure","Other: Care team","Quality of healthcare services received","Emory University|National Institute of Mental Health (NIMH)","All","18 Years and older   (Adult, Older Adult)","Phase 3","447","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","IRB00027782|2R01MH070437-06A1","April 2010","July 2015","December 2015","October 25, 2010","null","February 26, 2016","Cobb County Community Service Board, Marietta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01228032"
606,"NCT01203618","Exploratory Study of Farletuzumab to Treat Resectable, Non-functioning Pituitary Adenomas",,"Withdrawn","No Results Available","Resectable, Non-functioning Pituitary Adenoma","Drug: Farletuzumab","Efficacy of farletuzumab in subjects with resectable, non-functioning pituitary macroadenomas as measured by objective response in the tumor size.|Safety and tolerability of farletuzumab in this patient population.","Morphotek","All","18 Years and older   (Adult, Older Adult)","Phase 2","0","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MORAb-003-007","February 2011","June 2013","August 2013","September 16, 2010","null","November 4, 2013","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01203618"
607,"NCT01198470","TRIUMPH Lumbar Artificial Disc IDE: A Pilot Study",,"Completed","Has Results","Lumbar Degenerative Disc Disease","Device: TRIUMPH® Lumbar Artificial Disc","Number of Participants With a Change of at Least 15 Points in Pain/Disability Using the Oswestry Disability Index (ODI) Score at 24 Months Compared With the Score at Baseline|Number of Participants With No Device Failures|Number of Participants With Major Complications Defined as Major Vessel Injury or Neurological Damage|Number of Participants Determined to Have a Normal Neurological Status","Globus Medical Inc","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","20","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","G090143","September 2010","December 2016","December 2016","September 10, 2010","October 2, 2018","October 2, 2018","Memorial Health University Medical Center, Savannah, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01198470"
608,"NCT01194908","Re-expression of ER in Triple Negative Breast Cancers",,"Terminated","Has Results","Breast Cancer|Breast Tumors|Breast Neoplasms","Drug: Decitabine, LBH589, Tamoxifen","To Determine the Maximum Tolerated Dose of Decitabine and LBH589 Given in Combination in Patients With Metastatic or Locally Advanced Metastatic Breast Cancers|To Determine the Safety of Tamoxifen in Combination With Decitabine and LBH589","Emory University|Novartis|Eisai Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","5","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00029718|WCI1696-09","July 2010","January 2014","January 2014","September 3, 2010","January 26, 2015","January 26, 2015","Emory University Winship Cancer Institute, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01194908"
609,"NCT01188161","Postural Effects of Being Rotated in a Whole Body Gyroscope","Gyro","Completed","No Results Available","Falls|Balance|Movement Disorders","Device: Rotating Chair","Computerized Dynamic Posturography","Carrick Institute for Graduate Studies","All","18 Years to 60 Years   (Adult)","","25","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","1-2010-06","July 2010","August 2010","August 2010","August 25, 2010","null","August 25, 2010","Life University, Marietta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01188161"
610,"NCT01188083","Effects of Dietary Fructose Reduction in Children With Hepatic Steatosis","Sweet Bev","Completed","No Results Available","Non-alcoholic Fatty-liver Disease","Dietary Supplement: Fructose Drink|Dietary Supplement: Glucose Drink","Hepatic Fat|Plasma Triglycerides","Emory University","All","11 Years to 18 Years   (Child, Adult)","Not Applicable","53","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","IRB00007471|Emory-Vos-SweetBev","June 2009","November 2012","November 2012","August 25, 2010","null","November 21, 2013","Emory Children's Center, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01188083"
611,"NCT01188070","Caregiver Stress: Interventions to Promote Health and Wellbeing",,"Completed","No Results Available","Health Promotion","Behavioral: Usual Care|Behavioral: Psycho-education|Behavioral: Psycho-education plus physical exercise","Emotional outcomes|Behavioral Outcomes|Health Status|Neuroendocrine|Cardiovascular Risk Outcomes","Emory University|National Institute of Nursing Research (NINR)","All","21 Years and older   (Adult, Older Adult)","Not Applicable","354","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","IRB00032005|P01NR011587","January 2010","April 2014","May 2014","August 25, 2010","null","February 23, 2017","Emory Universtiy, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01188070"
612,"NCT01183364","A Dose Escalation Study of STA-9090 and Docetaxel in Patients With Solid Tumors",,"Completed","No Results Available","Solid Tumor Malignancies","Drug: STA-9090 (ganetespib) with Docetaxel","Safety of STA-9090 (ganetespib) and docetaxel combination|Pharmacokinetics","Synta Pharmaceuticals Corp.","All","18 Years and older   (Adult, Older Adult)","Phase 1","27","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","9090-07","July 2010","March 2013","May 2013","August 17, 2010","null","September 19, 2014","Emory University School of Medicine, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01183364"
613,"NCT01183312","Flumazenil for the Treatment of Primary Hypersomnia",,"Completed","Has Results","Hypersomnia|Primary Hypersomnia|Idiopathic Hypersomnia|Narcolepsy Without Cataplexy","Drug: Flumazenil","Change in Psychomotor Vigilance Task (PVT) Median Reaction Time|PVT Additional Measure #1, Change in Lapse Frequency|PVT Additional Measure #2, Change in Duration of Lapse Domain|PVT Additional Measure #3, Change in Optimum Response Times|PVT Additional Measure #4, Change in False Response Frequency|PVT Additional Measure #5, Change in Visual Analog Scale Rating of Sleepiness at the Completion of PVT|Change in Stanford Sleepiness Scale|Electroencephalogram (EEG) Power","Lynn Marie Trotti|Georgia Research Alliance|Emory University","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","10","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRB00044836","September 2010","January 2012","January 2012","August 17, 2010","March 27, 2013","December 12, 2017","Emory Sleep Center, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01183312"
614,"NCT01170676","Promoting Asthma Wellness in Rural Communities",,"Completed","No Results Available","Asthma","Behavioral: Puff City GA|Behavioral: General Asthma Education","Days of asthma symptoms; personal cigarette smoking and cessation; and days of school missed because of asthma, measured by self report|Change in exhaled nitric oxide and active and passive smoke exposure, measured by salivary cotinine.","Augusta University|Henry Ford Health System|University of Michigan","All","14 Years to 21 Years   (Child, Adult)","Not Applicable","700","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","R01HL092412","August 2009","May 2012","May 2014","July 27, 2010","null","February 2, 2015","Georgia Health Sciences University, Augusta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01170676"
615,"NCT01169077","EP1300 Polyepitope DNA Vaccine Against Plasmodium Falciparum Malaria",,"Completed","No Results Available","Plasmodium Falciparum Malaria","Drug: Placebo|Biological: EP-1300","The number of serious adverse events considered associated with the vaccine.|The number of subjects reporting solicited systemic adverse events of severity (grade 3) or higher.|The number of subjects experiencing spontaneous adverse events of severity (grade 3) or higher and considered associated with the vaccine.|The number of subjects reporting local reactogenicity of severity (grade 3) or higher.|Responses to tolerability questionnaire used to document subject feedback of electroporation mediated DNA vaccine delivery; proportion of subjects judging the procedure to be suitable for use in context of a prophylactic malaria vaccine.|Antibody titers in serum measured against malaria circumsporozoite protein [Geometric Mean Titer and individual log Enzyme-Linked Immunosorbent Assay (ELISA) units] for subjects in groups II and III.|Sample number showing positive falciparum-specific responses, Geometric Mean Titer spot-forming cells/million peripheral blood mononuclear cell per cohort, subject frequency per cohort with at least 1 positive response.|Interferon-gamma Enzyme-Linked Immunospot Assay (ELISPOT) assay.","National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years to 40 Years   (Adult)","Phase 1","39","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","08-0008|N01AI80005C","August 2010","July 2012","July 2012","July 23, 2010","null","November 16, 2012","Emory Children's Center - Pediatric Infectious Diseases, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01169077"
616,"NCT01164306","The Impact of a Tobacco Control Intervention in African-American Families",,"Completed","No Results Available","Tobacco Prevention|Environmental Tobacco Smoke Exposure|Tobacco Cessation","Behavioral: LifeSkills Training|Behavioral: Healthy Lifestyle Behavior Choices|Behavioral: NRT and Motivational Interviewing (MI)","Primary prevention of tobacco use in youth|Smoking cessation in parents/guardians","Augusta University|National Cancer Institute (NCI)","All","8 Years and older   (Child, Adult, Older Adult)","Not Applicable","688","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","R01CA118066","September 2007","May 2012","May 2014","July 16, 2010","null","February 2, 2015","Georgia Health Sciences University, Augusta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01164306"
617,"NCT01162317","AcuSleep in Mild Traumatic Brain Injury (TBI)","AcuTBI","Completed","Has Results","Brain Injuries, Traumatic|Sleeplessness","Other: Acupuncture|Other: Sham Acupuncture","PSQI Change|Wrist Actigraphy (an Objective Sleep Measure) Sleep Efficiency","VA Office of Research and Development","All","18 Years to 55 Years   (Adult)","Not Applicable","60","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","B6924-W","July 5, 2011","September 30, 2015","December 18, 2017","July 14, 2010","April 5, 2017","January 19, 2018","Atlanta VA Medical and Rehab Center, Decatur, GA, Decatur, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01162317"
618,"NCT01161628","Rituximab for the Primary Treatment of Denovo Extensive Chronic Graft Versus Host Disease (GVHD)",,"Completed","Has Results","Chronic Graft-versus-host Disease","Drug: Rituximab","Rate of Complete Response of cGVHD to Treatment.|Rate of Overall Response of cGVHD to Treatment|Rate of Partial Response of cGVHD to Treatment|Requirement for Systemic Corticosteroid Use|Time to Immunosuppression Withdrawal|Incidence of Overall Survival|Duration of Systemic Corticosteroid Use|Incidence of Disease-free Survival|Incidence of Non-relapse Mortality","Northside Hospital, Inc.|Blood and Marrow Transplant Group of Georgia","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","25","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NSH 893","April 2011","January 2014","July 2015","July 13, 2010","February 24, 2016","April 20, 2016","Northside Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01161628"
619,"NCT01149863","Alteration in Timing of Plerixafor Administration",,"Completed","Has Results","Autologous Transplantation","Drug: Plerixafor","Number of Patients Who Collected ≥ 6 x 10^6 CD34+ Cells by Day 5 (4 Apheresis Sessions) With Plerixafor Administration at 1500.|Number of Patients Who on Day 1 Collected > 10 x 10^6 CD34+ Cells/kg Following Plerixafor Dosing at 1500 Hrs","Emory University|Genzyme, a Sanofi Company","All","18 Years and older   (Adult, Older Adult)","Phase 2","34","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00034057|WCI1680-09","June 2010","December 2011","null","June 24, 2010","July 8, 2013","December 13, 2013","Emory University Winship Cancer Institute, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01149863"
620,"NCT01147497","Misoprostol Prior to Intrauterine Device (IUD) Insertion in Nulliparous Women","miso","Completed","Has Results","Contraception","Drug: Misoprostol|Drug: Placebo","Provider Perceived Ease of Insertion on a 100 Point Visual Analogue Scale|Patient Perceived Pain on a 100 Point Visual Analogue Scale|The Use of Adjunctive Measures Including Ultrasound Guidance or Cervical Dilation to Insert the IUD|Time for Insertion Procedure|Acceptability of Discomfort Associated With Insertion|Ease of Insertion and Presence of Pain in Nulliparous Women Versus Nulligravid Women|Need for Additional Pain Medications After Insertion of the IUD","Emory University","Female","18 Years to 45 Years   (Adult)","Not Applicable","78","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","IRB00021303|MISO Emory","June 2010","September 2011","September 2011","June 22, 2010","March 24, 2014","January 12, 2018","The Emory Clinic, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01147497"
621,"NCT01146600","Clarithromycin for the Treatment of Hypersomnia",,"Completed","Has Results","Hypersomnia|Idiopathic Hypersomnia|Narcolepsy","Drug: Clarithromycin followed by placebo|Drug: Placebo then Clarithromycin","Psychomotor Vigilance Task (PVT) Reaction Time|PVT Median Reaction Time at Week 1|PVT Number of Lapses|Epworth Sleepiness Scale|FOSQ|SF-36, Vitality Subscale|PSQI","Lynn Marie Trotti|Emory University","All","18 Years and older   (Adult, Older Adult)","Phase 2","26","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRB00044170","July 2010","September 2012","September 2012","June 17, 2010","June 12, 2014","November 6, 2017","Emory Sleep Center, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01146600"
622,"NCT01141192","The Effect of Vitamin D Supplementation on Glucose Metabolism in Non-Diabetic African American Adults","AVIS","Completed","No Results Available","Type 2 Diabetes","Dietary Supplement: vitamin D3, cholecalciferol|Dietary Supplement: Inactive comparator","Fasting glucose level before, mid-way through, and after the vitamin D3 supplement or placebo trial.|Serum 25-OH D levels in response to vitamin D3 supplement or placebo across a range of adiposity","Augusta University","All","19 Years to 60 Years   (Adult)","Not Applicable","48","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","0910091","January 2010","May 2010","May 2010","June 10, 2010","null","June 10, 2010","Medical College of Georgia, Augusta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01141192"
623,"NCT01139996","Use of Transdermal Clonidine in Trauma Patients",,"Terminated","Has Results","Delirium","Drug: Clonidine|Drug: Placebo","Duration of Mechanical Ventilation Following Administration of the First Dose of Clonidine or Placebo|Incidence and Duration in Hours of Delirium Currently Used|Time to Pass First SBT Following Administration of the First Dose of Clonidine or Placebo|Mean Incidence and Duration of Delirium","Memorial Health University Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 4","22","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","MHUMC-2010-04-02","May 2010","August 2012","August 2012","June 9, 2010","June 14, 2017","June 14, 2017","Memorial Health University Medical Center, Savannah, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01139996"
624,"NCT01138371","Effects of Low-density Lipoprotein (LDL) Apheresis on Inflammatory and Lipid Markers","INFLAME","Completed","No Results Available","Familial Hypercholesterolemia","Procedure: LDL Apheresis","Lipid Marker Change|Inflammatory Marker Change|Inflammatory Marker Rebound","Emory University|Kaneka Pharma America LLC","All","3 Years to 70 Years   (Child, Adult, Older Adult)","","8","Other|Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","IRB00044778|INFLAME_EUH","March 2011","February 2012","March 2012","June 7, 2010","null","December 17, 2013","Emory University Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01138371"
625,"NCT01131052","Diabetes in the Elderly: Prospective Study","DMElderly","Completed","Has Results","Diabetes|Hyperglycemia","Drug: Insulin Glargine|Drug: Insulin|Drug: Insulin glulisine","Percent of Participants With a Mean Blood Glucose Concentration of Less Than 70 mg/dL|Percent of Participants With a Mean Blood Glucose Concentration of Less Than 40 mg/dL|Mean of Weekly Fasting Blood Glucose Concentration|Mean Blood Glucose Concentration|Mean of Glycosylated Hemoglobin (hbA1c)|Mean of Daily Blood Glucose Concentration","Guillermo Umpierrez|Emory University","All","60 Years and older   (Adult, Older Adult)","Phase 4","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00038789","March 2011","December 2013","December 2013","May 26, 2010","December 31, 2014","December 31, 2014","Guillermo Umpierrez, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01131052"
626,"NCT01129635","Optimal Coronary Sinus Lead Implantation Using Intracardiac Impedography and Magnetic Resonance Imaging",,"Completed","No Results Available","Heart Failure, Systolic|Left Bundle Branch Block","Procedure: Cardiac Resynchronization Therapy (CRT) implantation","Anatomic correlation between largest Ts (see description) and site of longest delay among probed locations in the CMR dyssynchrony map.|Differential correlation of Ts, Tp, and Td (see description) to the CMR dyssynchrony map.","Emory University","All","Child, Adult, Older Adult","Not Applicable","38","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00036655|ACTSI-EP-001","June 2010","August 2014","December 2014","May 24, 2010","null","January 21, 2015","Emory University Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01129635"
627,"NCT01121874","Suture Fixation System Versus Tendonous Reconstruction in Carpometacarpal (CMC) Arthroplasty",,"Completed","No Results Available","Thumb Carpometacarpal Arthritis","Procedure: Ligament reconstruction with suture fixation system|Procedure: Ligament Reconstruction with Tendon Interposition (LRTI)","Overall functionality|Overall Functionality|Analog pain scale|Strength measures|Range of motion|Operative time|Scaphometacarpal distance","J&M Shuler","All","18 Years and older   (Adult, Older Adult)","Not Applicable","53","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","CMC-101","April 12, 2010","May 21, 2012","July 25, 2012","May 12, 2010","null","August 15, 2018","Athens Orthopedic Clinic, Athens, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01121874"
628,"NCT01118715","Use of Compression Glove to Prevent Complications After Distal Radius Fractures: a Randomized Controlled Trial",,"Unknown status","No Results Available","Post-traumatic Carpal Tunnel Syndrome|Complex Regional Pain Syndrome|Edema","Device: Compression glove","Incidence of Post-traumatic Carpal Tunnel Syndrome (CTS)|Incidence of Complex Regional Pain Syndrome|Edema|Grip strength|Disabilities of the Arm, Shoulder, & Hand questionnaire|Pain|Time-to-recovery","J&M Shuler","All","18 Years to 85 Years   (Adult, Older Adult)","Not Applicable","139","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","DRF-001","April 2010","December 2015","December 2017","May 7, 2010","null","February 24, 2016","Athens Orthopedic Clinic, Athens, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01118715"
629,"NCT01116752","Pediatric Intensive Care Units (ICUs) at Emory-Children's Center Glycemic Control: The PedETrol Trial","PedETrol","Completed","No Results Available","Pediatric Patient (1m-21y)|ICU Admission|Hyperglycemia","Other: Active Glycemic Control Strict (80-140mg/dL) vs. Conservative (190-220mg/dL) (with or without Continuous Glucose Monitoring)","Determine recovery of organ function in critically ill children subject to either strict or conservative glycemic control.|Adverse effect rates|Glycemic control compared to conservative control on care cost","Indiana University|National Heart, Lung, and Blood Institute (NHLBI)|Children's Healthcare of Atlanta","All","1 Month to 18 Years   (Child, Adult)","Phase 3","153","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00005792|RO1|Pedetrol5792","August 2010","December 2013","August 2015","May 5, 2010","null","August 31, 2015","Children's Healthcare of Atlanta at Egleston, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01116752"
630,"NCT01114373","Melatonin and Nighttime Blood Pressure in African Americans--24 mg Study",,"Completed","Has Results","Hypertension","Drug: Melatonin|Drug: Placebo","Mean Nighttime Systolic Blood Pressure (SBP)|Mean Nighttime Diastolic Blood Pressure (DBP)|Mean Nighttime Mean Arterial Pressure (MAP)|Mean Nighttime Heart Rate (HR)|Mean Daytime Systolic Blood Pressure (SBP)|Mean Daytime Diastolic Blood Pressure (DBP)|Mean Daytime Mean Arterial Pressure (MAP)|Mean Daytime Heart Rate (HR)|Urinary Dopamine Excretion Rate|Urinary Noradrenaline Excretion Rate|Urinary Adrenaline Excretion Rate|Plasma E-Selectin|Plasma P-Selectin|Total Sleep Time","Emory University|National Center for Complementary and Integrative Health (NCCIH)","All","18 Years to 64 Years   (Adult)","Phase 2","40","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","IRB00021300a|3R21AT004509-01A2S1","June 2010","September 2013","September 2014","May 3, 2010","December 18, 2015","February 26, 2016","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01114373"
631,"NCT01114360","Melatonin and Nighttime Blood Pressure in African Americans-8 mg Study",,"Completed","Has Results","Hypertension","Drug: Melatonin|Drug: Placebo","Mean Nighttime Systolic Blood Pressure (SBP)|Mean Nighttime Diastolic Blood Pressure (DBP)|Mean Nighttime Mean Arterial Pressure (MAP)|Mean Nighttime Heart Rate (HR)|Mean Daytime Systolic Blood Pressure (SBP)|Mean Daytime Diastolic Blood Pressure (DBP)|Mean Daytime Mean Arterial Pressure (MAP)|Mean Daytime Heart Rate (HR)|Urinary Dopamine Excretion Rate|Urinary Noradrenaline Excretion Rate|Urinary Adrenaline Excretion Rate|Plasma E-Selectin|Plasma P-Selectin|Total Sleep Time|Nocturnal Dipping of Blood Pressure|Percentage of Participants With Melatonin-related Side Effect.","Emory University|National Center for Complementary and Integrative Health (NCCIH)","All","18 Years to 64 Years   (Adult)","Phase 2","37","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","IRB00021300|1R21AT004509-01A2","March 2010","September 2013","September 2014","May 3, 2010","December 18, 2015","December 18, 2015","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01114360"
632,"NCT01105767","Methicillin-resistant Staphylococcus Aureus (MRSA) Skin and Soft Tissue Infection (SSTI) Prevention in Military Trainees",,"Completed","Has Results","Staphylococcus Aureus|MRSA Skin Infections|Staphylococcal Skin Infections","Drug: Chlorhexidine gluconate|Other: Supplemental training, education and hygiene","Incidence of Skin and Soft Tissue Infection (SSTI)|Incidence of Methicillin-resistant Staphylococcus Aureus (MRSA)-Associated SSTI","Uniformed Services University of the Health Sciences|Centers for Disease Control and Prevention","Male","18 Years to 42 Years   (Adult)","Not Applicable","30209","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","IDCRP-055","May 2010","January 2012","January 2012","April 16, 2010","November 4, 2014","November 4, 2014","Usa Meddac Mach, Columbus, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01105767"
633,"NCT01099618","Ketosis-Prone Diabetes Mellitus (KPDM): Metformin Versus Sitagliptin Treatment",,"Completed","Has Results","Ketosis Prone Diabetes|Diabetes Ketoacidosis|Hyperglycemia","Drug: metformin|Drug: placebo|Drug: Sitagliptin","Length of Remission","Dawn Smiley MD|Emory University","All","19 Years to 65 Years   (Adult, Older Adult)","Phase 4","48","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","IRB00026272","March 2010","February 2014","August 2014","April 7, 2010","June 18, 2015","June 18, 2015","Grady Memorial Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01099618"
634,"NCT01095757","Evaluation of the Drug Plerixafor in Combination With Chemotherapy and G-CSF for Stem Cell Collection",,"Completed","Has Results","Myeloma|Lymphoma","Drug: Plerixafor","Patients Achieving Greater Than or Equal to 5 x 10^6 of CD34+ Cells/kg in a Single Day of Apheresis|Patients Achieving >= 3 X 10^6 CD34+ Cell/Kg|Average Number of Days for Engraftment (Engraftment Defined as Absolute Neutrophil Count>500)","Emory University|Genzyme, a Sanofi Company","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","45","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00027735|WCI1671-09","March 2010","May 2012","February 2014","March 30, 2010","September 12, 2014","September 29, 2014","Emory University Winship Cancer Institute, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01095757"
635,"NCT01084941","Lifestyle Intervention to Limit Excessive Weight Gain During Pregnancy in Minority Women",,"Completed","No Results Available","Pregnancy|Weight Gain","Behavioral: Lifestyle Intervention group|Behavioral: Standard of Care","The primary outcome is whether a woman's weight gain follows the Institute of Medicine's recommendations for pregnancy weight gain.|To compare the occurrence of carbohydrate intolerance and GDM at 24-28 weeks gestation and after delivery between women in the lifestyle intervention group and women receiving standard care.|To explore the impact of the lifestyle intervention in preventing maternal and fetal complications between women in the lifestyle intervention group and women receiving standard care.","Guillermo Umpierrez|Emory University","Female","18 Years to 45 Years   (Adult)","Phase 4","57","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","IRB00030742","April 2010","December 2012","December 2012","March 11, 2010","null","November 21, 2013","Grady Memorial Hospital, Atlant, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01084941"
636,"NCT01084928","A Culturally Tailored Lifestyle Intervention to Prevent Diabetes in South Asians","SHAPE","Completed","No Results Available","Diabetes|Obesity","Behavioral: Lifestyle Intervention Classes","body weight|percent body fat|body mass index|waist-to-hip ratio|fasting glucose|blood pressure|plasma lipids|self-reported physical activity|Percent of Total Calories from Fat","Emory University|American Diabetes Association|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","25 Years and older   (Adult, Older Adult)","Not Applicable","16","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","IRB00035893|1R34DK081723-01A1","April 2010","July 2012","July 2012","March 11, 2010","null","September 25, 2013","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01084928"
637,"NCT01084694","Caregiver Burden and Distress in Hematopoeitic Stem Cell Transplant",,"Active, not recruiting","No Results Available","Depression|Anxiety|Fatigue|Distress","","Level of distress & Feelings of Burden|Impact of patient distress, fatigue & pain on the level of caregiver distress & burden|Impact of caregiver distress and burden on overall patient survival and length of patient hospitalization|Common characteristics of caregivers","Northside Hospital, Inc.","All","Child, Adult, Older Adult","","100","Other","Observational","Observational Model: Other|Time Perspective: Prospective","NSH 888","April 19, 2010","September 29, 2017","April 2018","March 10, 2010","null","March 29, 2018","Northside Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01084694"
638,"NCT01077934","Assessment of Near Infrared Spectroscopy as a Diagnostic Tool in Acute Compartment Syndrome",,"Completed","No Results Available","Compartment Syndrome","Device: near-infrared spectroscopy","NIRS values in lower leg extremity injury","J&M Shuler|Emory University","All","13 Years to 85 Years   (Child, Adult, Older Adult)","","8","Industry|Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","01-10-14b","November 2011","March 2012","March 2012","March 1, 2010","null","April 27, 2015","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01077934"
639,"NCT01072370","Safety and Effectiveness of Cord Blood Stem Cell Infusion for the Treatment of Cerebral Palsy in Children",,"Recruiting","No Results Available","Cerebral Palsy","Biological: Cord Blood Infusion|Biological: Intravenous Sham","Confirm the safety of autologous cord blood infusion in children with cerebral palsy by repeated follow-up over one year with clinical and laboratory evaluations.|Confirm the efficacy of autologous cord blood infusion in children with cerebral palsy using patient questionnaire and standardized Gross Motor Function Measure evaluation.","Augusta University","All","1 Year to 12 Years   (Child)","Phase 1|Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ACBSC09","January 2010","June 2019","July 2019","February 22, 2010","null","June 29, 2018","Augusta University, Augusta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01072370"
640,"NCT01068119","Same-Day Discharge After Coronary Percutaneous Transluminal Coronary Angioplasty (PTCA)","GREECE","Terminated","No Results Available","Acute Coronary Syndrome","Procedure: Same-day discharge","Number of cardiac MACE, major cerebral events, and groin complications|Rate of compliance with dual antiplatelet therapy","Piedmont Healthcare|Medtronic","All","18 Years and older   (Adult, Older Adult)","Phase 4","57","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GREECE","February 2010","August 2011","March 2012","February 12, 2010","null","September 23, 2013","Piedmont Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01068119"
641,"NCT01061762","Adherence Intervention for People With Low-literacy",,"Completed","No Results Available","HIV Infections","Behavioral: Stick To It|Behavioral: Standard medication adherence counseling|Behavioral: Health Counseling","Unannounced Phone Based Pill Counts for Medication Adherence|Theoretical Constructs derived from the Information-Motivation-Behavioral Skills Model assessed by psychometric scales of AIDS knowledge, behavioral intentions, adherence self-efficacy, adherence strategies/skills","University of Connecticut|National Institute of Mental Health (NIMH)","All","18 Years and older   (Adult, Older Adult)","Phase 2","450","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention","H07-266|R01MH082633-01","February 2008","February 2013","February 2013","February 3, 2010","null","June 17, 2013","Southeast HIV/AIDS Research and Evaluation Project, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01061762"
642,"NCT01061021","HIV Prevention Intervention for People Living With HIV/AIDS",,"Completed","No Results Available","HIV Infections","Behavioral: In The Mix|Behavioral: Information Support Group","Computerized Interview or Sexual Transmission Risk Behavior|Unannounced Phone Based Pill Counts for Medication Adherence|Infectiousness Beliefs","University of Connecticut|National Institute of Mental Health (NIMH)","All","18 Years and older   (Adult, Older Adult)","Phase 2","490","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention","H06-113|R01MH071164-04","March 2005","October 2009","August 2010","February 2, 2010","null","November 17, 2010","Southeast HIV/AIDS Research and Evaluation Project, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01061021"
643,"NCT01060449","Stimulus Intensity in Left Ventricular Leads","SILVeR-CRT","Completed","No Results Available","Congestive Heart Failure","Other: LV stimulus intensity","Ejection Fraction|Quality of Life|Six minute hall walk|End diastolic dimension","Emory University|Medtronic","All","18 Years and older   (Adult, Older Adult)","Not Applicable","60","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRB00016194|Medtronic-639130","August 2008","June 2011","February 2012","February 2, 2010","null","December 17, 2013","Emory University Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01060449"
644,"NCT01058031","Neural Correlates of PTSD Prevention With Mindfulness Based Stress Reduction (MBSR) in Iraqi Veterans",,"Completed","No Results Available","Stress Disorders, Posttraumatic|PTSD","Behavioral: MBSR","PTSD symptom level measured with the CAPS","US Department of Veterans Affairs|Emory University|VA Office of Research and Development","Male","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","30","U.S. Fed|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Bremner Merit 007","January 2007","April 2010","November 2010","January 28, 2010","null","November 5, 2013","Atlanta VA Medical and Rehab Center, Decatur, Decatur, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01058031"
645,"NCT01054703","Clinical Evaluation of the Ethmoid Sinus Spacer","SPACER","Terminated","Has Results","Sinusitis, Chronic Rhinosinusitis","Device: Ethmoid Sinus Spacer","Occurrence of Adverse Events at the Time of the Procedure and Cumulatively up to 6 Weeks Post-implant|Efficacy: Improvement in Ethmoid Sinus Health as Demonstrated by CT Scan and Quality-of-life Measures","Acclarent","All","21 Years and older   (Adult, Older Adult)","Not Applicable","14","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CPR02082","April 1, 2007","November 1, 2007","November 1, 2007","January 22, 2010","February 24, 2010","August 7, 2017","Georgia Nasal and Sinus Institute, Savannah, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01054703"
646,"NCT01052207","Pilot Study Assessing Oxidative Stress in Children","OxStress","Completed","Has Results","Adrenal Insufficiency|Critical Illness","","Pediatric Logistic Organ Dysfunction Score in Critically Ill Children|Establish the OS Profile of Healthy Children to Act as Controls and Help Establish the Normal Pediatric Baseline.|Analysis of Clinical Data to Determine Correlation of OS With AI and Evaluation of OS as a Potential Biomarker.","Emory University|Children's Healthcare of Atlanta","All","up to 18 Years   (Child, Adult)","","102","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IRB00034236","February 2010","June 2011","June 2011","January 20, 2010","September 22, 2014","June 4, 2015","Children's Healthcare of Atlanta at Egleston, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01052207"
647,"NCT01051999","Glutamine Supplementation in Cystic Fibrosis","CFG","Completed","No Results Available","Cystic Fibrosis|Immune Function","Dietary Supplement: Glutamine|Dietary Supplement: L-alanine","Percent increase in plasma glutamine and glutathione redox levels measured at weeks 0, 4, 8, and 12.","Emory University|Emmaus Medical, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","17","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","IRB00025564","February 2010","February 2011","February 2011","January 20, 2010","null","January 14, 2015","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01051999"
648,"NCT01049009","The Effect of Nebivolol on Endothelial Dysfunction in African Americans With Hypertension",,"Completed","Has Results","High Blood Pressure","Drug: Nebivolol|Drug: Metoprolol XL","Endothelial Function Measured by Forearm Blood Flow (FBF) at 12 Weeks|Endothelial Function Measured by Forearm Blood Flow (FBF) at 24 Weeks","Emory University|Forest Laboratories","All","21 Years to 80 Years   (Adult, Older Adult)","Phase 4","91","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","IRB00017946","December 2009","June 2012","June 2012","January 14, 2010","December 19, 2014","April 11, 2017","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01049009"
649,"NCT01047150","The Comparison of the Necessity of Repeat Myocardial Perfusion SPECT Studies Between Tc-99m Tetro and Tc-99m Mibi",,"Unknown status","No Results Available","Myocardial Ischemia","","Number of studies repeated.|Number of studies that should have been repeated","Cardiac Imaging of Augusta|GE Healthcare","All","Child, Adult, Older Adult","","250","Other|Industry","Observational","Observational Model: Case Control|Time Perspective: Cross-Sectional","DB1","January 2010","February 2010","February 2010","January 12, 2010","null","January 12, 2010","Cardiac Imaging of Augusta, Augusta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01047150"
650,"NCT01044199","Study of Intradermal Administration of PCEC Rabies Vaccine","Rabies-ID","Completed","No Results Available","Rabies Prevention|Rabies Exposure","Biological: PCEC rabies vaccine given intradermally|Biological: PCEC rabies vaccine administered intramuscularly","Proportion of subjects who have virus-neutralizing antibody titers of at least 1:5 serum dilution by the RFFIT, 14 days after receipt of the last dose of the vaccine.|Adverse event (AE) or serious adverse event (SAE) information (solicited in-clinic and via memory aids, concomitant medications, and periodic targeted physical assessment).|Proportion of subjects who have virus-neutralizing antibody titers of at least 1:5 serum dilution by the RFFIT in each group.|Distribution GMTs of virus-neutralizing antibody titers in each group.","Centers for Disease Control and Prevention","All","18 Years and older   (Adult, Older Adult)","Not Applicable","130","U.S. Fed","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","CDC-NCEZID-5506|IND-13814|CDC-IRB 5506","February 2009","September 2009","August 2013","January 7, 2010","null","January 29, 2014","CDC Occupational Clinic, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01044199"
651,"NCT01041417","Granulocyte-Macrophage Stimulating Factor in the Treatment of Peripheral Arterial Disease","GPAD-2","Completed","Has Results","Peripheral Arterial Disease","Drug: Granulocyte-Macrophage Stimulating Factor (GM-CSF)|Drug: Placebo","Change in Peak Walking Time During Treadmill Exercise Tolerance Test From Baseline to 3 Months|Change in Peak Walking Time During Treadmill Exercise Tolerance Test From Baseline to 6 Months|Change in Claudication Onset Time (COT) From Baseline to 3 Months|Change in Claudication Onset Time (COT) From Baseline to 6 Months|Change in Walking Distance Scores on Walking Impairment Questionnaire (WIQ) From Baseline to 3 Months|Change in Walking Distance Scores on Walking Impairment Questionnaire (WIQ) From Baseline to 6 Months|Change in Walking Speed Score on Walking Impairment Questionnaire (WIQ) From Baseline to 3 Months|Change in Walking Speed Score on Walking Impairment Questionnaire (WIQ) From Baseline to 6 Months|Change in Stair Climbing Score on Walking Impairment Questionnaire (WIQ) From Baseline to 3 Months|Change in Stair Climbing Score on Walking Impairment Questionnaire (WIQ) From Baseline to 6 Months|Change in Score on Physical Composite Score (PCS) Subscale of the Short Form 36 Health Survey (SF-36) From Baseline to 3 Months|Change in Score on Physical Composite Score (PCS) Subscale of the Short Form 36 Health Survey (SF-36) From Baseline to 6 Months|Change in Score on Mental Composite Score (MCS) Subscale of the Short Form 36 Health Survey (SF-36) From Baseline to 3 Months|Change in Score on Mental Composite Score (MCS) Subscale of the Short Form 36 Health Survey (SF-36) From Baseline to 6 Months|Change in Score on Physical Functioning Subscale of the Short Form 36 Health Survey (SF-36) From Baseline to 3 Months|Change in Score on Physical Functioning Subscale of the Short Form 36 Health Survey (SF-36) From Baseline to 6 Months","Emory University|National Institutes of Health (NIH)|National Heart, Lung, and Blood Institute (NHLBI)","All","21 Years to 80 Years   (Adult, Older Adult)","Phase 2","159","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","IRB00030362|1RC2HL101515-01","September 2009","March 2014","null","December 31, 2009","December 23, 2014","December 23, 2014","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01041417"
652,"NCT01041287","Effect of Nebivolol on Oxidative Stress and Endothelial Progenitor Cells",,"Completed","Has Results","Hypertension","Drug: Nebivolol|Drug: Metoprolol succinate","Pulse Wave Velocity (Measure of Arterial Stiffness)","Emory University|Forest Laboratories","All","21 Years to 80 Years   (Adult, Older Adult)","Phase 4","96","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","IRB00013262|BYD-MD-20","December 2009","December 2013","December 2013","December 31, 2009","December 19, 2014","December 19, 2014","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01041287"
653,"NCT01038388","A Study of the Combination Vorinostat With Lenalidomide, Bortezomib and Dexamethasone for Patients With Newly Diagnosed Multiple Myeloma",,"Active, not recruiting","No Results Available","Multiple Myeloma","Drug: Bortezomib|Drug: Lenalidomide|Drug: Dexamethasone|Drug: Vorinostat","To determine the maximum tolerated dose (MTD) and recommended phase II doses (RP2D) of vorinostat in combination with lenalidomide, bortezomib, and dexamethasone.|Efficacy by standard myeloma measurements (SPEP, UPEP [urine protein electrophoresis], bone marrow)","Emory University|Merck Sharp & Dohme Corp.|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1","30","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00017528|1591|RV-MM-PI-0420","January 15, 2010","January 2019","January 2019","December 24, 2009","null","February 8, 2018","Emory University Winship Cancer Institute, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01038388"
654,"NCT01035580","Trial on Safety and Pharmacokinetics of Intravaginal Curcumin",,"Completed","No Results Available","Uterine Cervical Dysplasia","Drug: Curcumin|Drug: curcumin","The primary endpoint is to reach the maximum selected dose (MSD) or maximum tolerated dose (MTD) of intravaginal curcumin among Pap test negative women without causing a dose-limiting toxicity.","Emory University","Female","18 Years to 45 Years   (Adult)","Phase 1","13","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00020139","January 2010","April 2011","January 2012","December 18, 2009","null","November 28, 2013","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01035580"
655,"NCT01031043","Topical Bethanechol for Improvement of Esophageal Dysmotility",,"Completed","Has Results","Esophageal Dysmotility","Drug: Bethanechol","Distal Contractile Integral","Augusta University","All","18 Years and older   (Adult, Older Adult)","Phase 1","5","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","09-03-244","November 2009","April 2012","April 2012","December 14, 2009","January 29, 2015","January 29, 2015","Medical College of Georgia, Augusta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01031043"
656,"NCT01030328","AFRICA: Atorvastatin Plus Fenofibric Acid (TriLipix) in the Reduction of Intermediate Coronary Atherosclerosis","AFRICA","Terminated","No Results Available","Coronary Atherosclerosis","Drug: Placebo|Drug: TriLipix","Change in calcified plaque volume/percent, non-calcified high-density plaque volume/percent, and low-density plaque volume/percent|The secondary endpoint of the study will be the change in PAV of the ""Study Lesion"" from baseline to follow-up. PAV will be expressed as a ratio of the plaque volume/total vessel volume.","Piedmont Healthcare","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 3","18","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Diagnostic","PH09001","November 2009","July 2011","July 2011","December 11, 2009","null","April 15, 2014","Piedmont Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01030328"
657,"NCT01028157","S.T.A.R.S.: Sistas Talking About Real Solutions","STARS","Completed","No Results Available","HIV Prevention","Behavioral: STARS: Sistas Talking About Real Solutions|Behavioral: General Health & Nutrition","To evaluate the efficacy of a HIV risk-reduction condition relative to general health control condition in reducing HIV-associated sexual behaviors and incident STDs.|To evaluate the efficacy of a HIV risk-reduction condition relative to general health control condition in enhancing theoretically-derived mediators of HIV-preventive behaviors.","Emory University|National Institute of Mental Health (NIMH)","Female","18 Years to 29 Years   (Adult)","Phase 1","855","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","0524-2002|5R01MH062717","October 2002","March 2006","March 2006","December 9, 2009","null","December 17, 2013","Emory University, Rollins School of Public Health, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01028157"
658,"NCT01027897","Pharmacokinetic and Pharmacodynamic Evaluation of Doripenem in Critically Ill Trauma Patients",,"Completed","Has Results","Sepsis","Drug: Doripenem","Volume of Distribution (Vd)|Clearance (CL)|Elimination Constant (ke)","Emory University|Ortho-McNeil Janssen Scientific Affairs, LLC","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 4","30","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00016181a|DORICPK4003","April 2010","December 2011","December 2011","December 9, 2009","September 25, 2012","January 27, 2014","Grady Memorial Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01027897"
659,"NCT01024647","Optimizing Cimzia in Crohn's Patients",,"Unknown status","No Results Available","Crohn's Disease","Biological: certolizumab pegol","Crohn's Disease Activity Index","Atlanta Gastroenterology Associates|UCB Pharma","All","18 Years and older   (Adult, Older Adult)","Phase 4","50","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CMZ-2010","December 2009","May 2013","May 2013","December 3, 2009","null","November 5, 2012","Atlanta Gastroenterology Associates, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01024647"
660,"NCT01020045","Effect of HIV Infection and Highly Active Antiretroviral Treatment (HAART) on Bone Homeostasis","OPG-2","Completed","No Results Available","HIV Infection|Osteopenia|Osteoporosis","","To correlate serum and B cell and T cell OPG and/or RANKL production in treatment-naïve HIV-infected patients, with indices of bone turnover and structure and with viral load.","Emory University|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)","All","18 Years to 50 Years   (Adult)","","120","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","IRB00027210|R01AR059364-01","October 2010","May 2013","October 2015","November 25, 2009","null","October 19, 2015","Grady Infectious Diseases Program Clinic, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01020045"
661,"NCT01005979","A Phase I Trial Using Cyclophosphamide, Rituximab and Revlimid (CR2) for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Small Lymphocytic Lymphoma (SLL)",,"Terminated","No Results Available","Leukemia, Lymphocytic, Chronic, B-Cell|Chronic Lymphocytic Leukemia|Lymphoma, Small Lymphocytic","Drug: Lenalidomide, Rituximab, and Cyclophosphamide","The primary endpoint is to determine the maximum tolerated dose of lenalidomide in combination with cyclophosphamide and rituximab for the treatment of CLL or SLL.|Assess response criteria, including complete response rate, survival at 1 year, time to progression, duration of response, and eradication of minimal residual disease.","Emory University|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1","6","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00024085|WCI1642-09","July 2010","October 2012","null","November 2, 2009","null","August 13, 2014","Emory University Winship Cancer Institute, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01005979"
662,"NCT01000363","Diabetes Group Visits",,"Completed","No Results Available","Diabetes","","Patients who participate in the diabetes group visits should achieve improvement in Clinical outcomes - better A1C levels, reduced blood pressure, reduced cholesterol levels|keeping appointments and scheduling eye exams, foot checks|goal setting, achievement of goals, problem solving; access|attendance at educational sessions; and satisfaction among patients and health professionals|behavioral outcomes","Emory University|Johnson & Johnson|American Association of Diabetes Educators","All","18 Years to 80 Years   (Adult, Older Adult)","","92","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","IRB00029165","November 2009","December 2013","December 2013","October 23, 2009","null","July 9, 2014","Grady North DeKalb Clinic, Chamblee, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01000363"
663,"NCT00999752","Study to Determine the Effects of Nebivolol and Hydrochlorothiazide in African Americans With Hypertension","NASAA","Completed","No Results Available","Hypertension","Drug: Nebivolol|Drug: Hydrochlorothiazide","Changes in systolic and diastolic blood pressure after treatment with nebivolol and reaching normal blood pressure <140/90|Differences after nebivolol treatment on diastolic function as measured by tissue doppler imaging (ECHO), arterial compliance and stiffness and vascular nitric oxide availability determined by neutrophil function","InVasc Therapeutics, Inc.","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","AVR-2009-02 (BYS-MD-27)","October 2009","February 2010","May 2010","October 22, 2009","null","May 5, 2011","Atlanta Vascular Research Foundation, Tucker, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00999752"
664,"NCT00974597","Comparison of AWBAT™-D and MEPILEX® AG for Treatment of Donor Sites in Burn Surgery",,"Terminated","No Results Available","Burn Surgery","Device: AWBAT™-D and Mepilex® Ag dressings","Compare rate of healing of donor sites|Compare complication rates|Compare patient reported perception of pain|Compare clinical outcome (scarring)","Aubrey Inc.","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","#AW-101008DS","September 2009","September 2010","null","September 10, 2009","null","June 22, 2010","Doctors Hospital of Augusta, Augusta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00974597"
665,"NCT00969865","Individualized Comprehensive Atherosclerosis Risk-reduction Evaluation Program","iCARE","Completed","No Results Available","Atherosclerosis","","To determine the proportion of subjects and patients who are diagnosed with subclinical and clinically significant coronary atherosclerosis with the PHI-ACE-iCARE approach, compared to the current guideline-driven approach.|To determine the proportion of patients who receive appropriate revascularization procedures for clinically significant coronary atherosclerosis with the PHI-ACE-iCARE approach, compared to the current guideline-driven approach.","Piedmont Healthcare|Abbott","All","18 Years and older   (Adult, Older Adult)","","170","Other|Industry","Observational","Observational Model: Case-Control|Time Perspective: Prospective","iCARE","October 2011","December 2016","December 2016","September 1, 2009","null","November 20, 2017","Piedmont Heart Institute, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00969865"
666,"NCT00969501","Three Injections of EUFLEXXA (Sodium Hyaluronate) for Treatment of Chronic Shoulder Pain Associated With Osteoarthritis (OA)",,"Completed","Has Results","Osteoarthritis","Drug: EUFLEXXA","Number of Participants With a Reduction in Pain by the Scores.","Georgia Institute for Clinical Research, LLC|Ferring Pharmaceuticals","All","30 Years to 79 Years   (Adult, Older Adult)","Not Applicable","32","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EUF-SHO-0001","August 2009","August 2010","August 2010","September 1, 2009","May 7, 2013","May 7, 2013","Georgia Institute for Clinical Research, LLC, Marietta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00969501"
667,"NCT00962819","Measles, Mumps, and Rubella (MMR) Immunity in College Students",,"Completed","No Results Available","Measles|Mumps|Rubella","Biological: MMR vaccine","Levels of mumps antibody and levels of memory B and T cell responses|Determine proportion of college-aged students who are seronegative for mumps","Sri Edupuganti, MD MPH|Merck Sharp & Dohme Corp.|Emory University","All","18 Years to 24 Years   (Adult)","","74","Other|Industry","Observational","Time Perspective: Cross-Sectional","IRB00007373","March 2010","December 2012","December 2012","August 20, 2009","null","March 5, 2014","The Hope Clinic of the Emory Vaccine Center, Decatur, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00962819"
668,"NCT00961688","The Impact of Polycystic Ovary Syndrome (PCOS) on Quality of Life and Healthcare Beliefs","PCOS","Completed","No Results Available","Polycystic Ovary Syndrome","","","Georgia Reproductive Specialists","Female","18 Years to 55 Years   (Adult)","","600","Other","Observational","","GRS-3296","August 2009","January 2010","January 2010","August 19, 2009","null","February 3, 2010","Georgia Reproductive Specialists, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00961688"
669,"NCT00957567","Comparison Study of Breast Tomosynthesis Slice Thicknesses",,"Completed","No Results Available","Breast Cancer","","Equivalence in diagnostic accuracy","Emory University|Hologic, Inc.","Female","35 Years and older   (Adult, Older Adult)","","182","Other|Industry","Observational","Observational Model: Case Control|Time Perspective: Retrospective","IRB00008667","April 2009","September 2011","December 2012","August 12, 2009","null","November 21, 2013","Emory University Hospital Breast Imaging Center, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00957567"
670,"NCT00957320","Study of Sirolimus With PEG-Asparaginase in Acute Lymphoblastic Leukemia (ALL)",,"Withdrawn","No Results Available","Acute Lymphoblastic Leukemia","Drug: Sirolimus|Drug: PEG-asparaginase","To estimate the maximum tolerated dose (MTD) of sirolimus in children with refractory or recurrent acute lymphoblastic leukemia (ALL) who are concurrently receiving PEG-asparaginase.|To determine the dose limiting toxicities of sirolimus in combination with PEG-asparaginase in this Phase I Study.|To use phospho-flow to measure the degree of phosphorylation of signaling pathway proteins in response to specific stimulating events in bone marrow derived leukemia cells obtained at the time of study entry and at day 15 and 29.|To correlate the signal pathway phosphorylation to clinical response to the chemotherapy regimen used in this study.","Emory University","All","up to 21 Years   (Child, Adult)","Phase 1","0","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00015324|Sirolimus","June 2009","August 2012","August 2012","August 12, 2009","null","December 3, 2013","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00957320"
671,"NCT00957307","Breast Computed Tomography (CT) as a Diagnostic Tool",,"Completed","No Results Available","Breast Cancer","","Reduction in negative biopsies","Emory University","Female","35 Years and older   (Adult, Older Adult)","","16","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","IRB00014006","May 2009","January 2010","January 2015","August 12, 2009","null","July 23, 2015","Emory University Hospital Breast Imaging Center, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00957307"
672,"NCT00957099","Comparison Study of Breast Computed Tomography (CT) With Magnetic Resonance Imaging (MRI)",,"Completed","No Results Available","Breast Cancer","","Comparison of staging accuracy","Emory University","Female","35 Years and older   (Adult, Older Adult)","","2","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IRB00014357","June 2009","September 2011","January 2012","August 12, 2009","null","September 12, 2013","Emory University Hospital Breast Imaging Center, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00957099"
673,"NCT00956800","Remote Management of Diabetic Patients Via Data Transmission by Accu-Chek 360 Software",,"Completed","No Results Available","Diabetes","Other: Accu-Chek 360 software|Other: Normal care","Columbus Research Foundation will take the objective data that constitutes the defined end-points of the study and enter it for each patient into an Access data base, using the established data base management system of Columbus Research Foundation.","Columbus Research Foundation|Hoffmann-La Roche","All","19 Years to 65 Years   (Adult, Older Adult)","Not Applicable","100","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Roche 360","September 2009","June 2011","June 2011","August 11, 2009","null","June 27, 2011","Columbus Research Foundation, Columbus, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00956800"
674,"NCT00953654","Exercise Training for the Treatment of Generalized Anxiety Disorder",,"Completed","Has Results","Generalized Anxiety Disorder","Other: Strength Training|Other: Endurance Training","Generalized Anxiety Disorder (GAD) Remission as Measured by Anxiety Disorders Interview Schedule-Adult Version (ADIS-IV) Severity Ratings|Worry Symptoms","University of Georgia","Female","18 Years to 39 Years   (Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","UGA-2009-01913-1","August 2009","May 2010","May 2010","August 6, 2009","September 29, 2010","September 9, 2016","The University of Georgia, Athens, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00953654"
675,"NCT00949026","Assessment of Systemically Administered Torisel Delivery to Brain Tumors by Intratumoral Microdialysis",,"Withdrawn","No Results Available","Brain Neoplasms","Drug: Temsirolimus (Torisel)","Microdialysate torisel concentration|Toxicity assessment","Emory University|Wyeth is now a wholly owned subsidiary of Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 1","0","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","IRB00008256|WCI1388-07","July 2009","May 2010","May 2010","July 30, 2009","null","November 21, 2013","Emory University Winship Cancer Institute, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00949026"
676,"NCT00937287","Human Papilloma Virus (HPV) Vaccination Among Rural African American Primary Caregivers and Daughters",,"Completed","No Results Available","Human Papillomavirus","Other: There is no intervention in this study.","HPV vaccination compliance","University of Georgia","Female","13 Years to 17 Years   (Child)","","410","Other","Observational","Time Perspective: Prospective","MISP 36701","July 2009","April 2011","July 2012","July 10, 2009","null","August 14, 2013","The Center for Family Research, Athens, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00937287"
677,"NCT00932633","Magnetic Resonance Imaging (MRI) to Evaluate Brain Injury in Congenital Heart Disease","CHD Brain","Completed","No Results Available","Neonatal Congenital Heart Disease","","The primary outcome will be a measure of the association of pro-inflammatory cytokines with WMI score|Association between inflammatory response and neurodevelopmental testing|Association of neuroimaging abnormalities with neurodevelopmental testing","Emory University|Children's Healthcare of Atlanta","All","up to 30 Days   (Child)","","92","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IRB00017965|17965","August 2009","January 2016","January 2016","July 3, 2009","null","February 10, 2016","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00932633"
678,"NCT00927355","Effect of Thiazolidinediones on Human Bone",,"Completed","Has Results","Osteoblast|Adipocytes|Bone Density|Osteocalcin|Adiponectin|Mesenchymal Stem Cells","Drug: Pioglitazone|Drug: Placebo","Percent Change in Number of Osteoblast and Adipocyte Colony Forming Units Cultured From Bone Marrow Stem Cells Harvested 6 Months After Treatment With Study Drug Compared to Baseline|βCTX (Carboxy Terminal Collagen Crosslinks), Osteocalcin, and Adiponectin.|Bone Mineral Density","Emory University","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","10","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)","IRB00014509|08006","April 2009","October 2010","July 2011","June 25, 2009","June 2, 2014","March 29, 2016","Grady Diabetes Clinic, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00927355"
679,"NCT00919100","Buzzy Versus Vapocoolant Spray: Pediatric Needle Pain Relief",,"Completed","Has Results","Pain","Device: Buzzy|Other: vapocoolant","Faces Pain Scale-Revised (FPS-R)|OSBD-R Observational Pain/Distress Scale|Number of Participants With Venipuncture Success in One Attempt","Georgia State University|Mayday Fund","All","4 Years to 18 Years   (Child, Adult)","Not Applicable","81","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care","08007","April 2008","August 2008","August 2008","June 12, 2009","September 18, 2018","September 18, 2018","Children's Healthcare of Atlanta, Scottish Rite, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00919100"
680,"NCT00917865","FACBC Positron Emission Tomography/Computed Tomography(PET/CT) Used in the Diagnosis of Primary Prostate Cancer",,"Terminated","Has Results","Prostate Cancers","Drug: anti [18F]FACBC","Diagnostic Performance Per Sextant at Each Time Point by Visual Analysis|Mean SUVmax of Low Versus High Gleason Groups","David M. Schuster, MD|Emory University","Male","18 Years and older   (Adult, Older Adult)","Phase 2","11","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","IRB00008094|FACBC","April 2008","April 2011","January 2013","June 10, 2009","January 7, 2014","January 7, 2014","Emory University Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00917865"
681,"NCT00912782","Vitamin D and Arteriovenous Fistulae",,"Completed","Has Results","End-stage Renal Disease","Drug: Vitamin D3|Drug: Placebo","Arteriovenous Fistulae Maturation|25-hydroxyvitamin D and Serum Calcium","Emory University","All","18 Years to 85 Years   (Adult, Older Adult)","Not Applicable","52","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRB00014859","January 2009","June 2011","June 2011","June 3, 2009","July 2, 2014","July 2, 2014","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00912782"
682,"NCT00910611","A Test of the Effectiveness of a Device for Pediatric Immunization Pain","Buzzy","Unknown status","No Results Available","Pain","Device: Buzzy","FLACC observational pain/distress scale|Self report using Faces Pain Scale - Revised","MMJ Labs LLC|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","4 Years to 6 Years   (Child)","Not Applicable","60","Industry|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care","08-028|1R44HD056647-01A2","January 2009","June 2009","July 2010","June 1, 2009","null","June 25, 2010","Sandy Springs Pediatrics and Adolescent Medicine, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00910611"
683,"NCT00909454","Vitamin D Supplement Study for Adolescents","VIP","Completed","No Results Available","Vitamin D Deficiency|Overweight|Obesity","Dietary Supplement: 2000 IU Vitamin D3 daily supplement|Dietary Supplement: 400 IU Vitamin D3 supplement","Plasma 25-OH D level|Blood pressure","Augusta University","All","14 Years to 19 Years   (Child, Adult)","Not Applicable","45","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Basic Science","0901159","February 2009","March 2009","June 2009","May 28, 2009","null","October 17, 2011","Georgia Prevention Institute at Medical College of Georgia, Augusta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00909454"
684,"NCT00909090","Macular Pigment and Glare Disability","MP-GD","Unknown status","No Results Available","Glare Disability in Healthy Subjects","Dietary Supplement: lutein and zeaxanthin supplements|Drug: Placebo","Disability glare and contrast enhancement thresholds, photostress recovery times","University of Georgia","All","20 Years to 40 Years   (Adult)","Phase 2|Phase 3","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","UGA-2009-10141-1","May 2009","December 2011","December 2011","May 27, 2009","null","August 11, 2011","Vision Sciences Laboratory, UGA, Athens, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00909090"
685,"NCT00897039","Laboratory Study in Predicting Tumor Response to Chemotherapy in Patients With Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer",,"Unknown status","No Results Available","Fallopian Tube Cancer|Ovarian Cancer|Primary Peritoneal Cavity Cancer","Other: flow cytometry|Other: immunohistochemistry staining method","Correlation of a statistically significant discriminator of sensitivity with complete response rate","Southeastern Gynecologic Oncology|National Cancer Institute (NCI)","Female","Child, Adult, Older Adult","","60","Other","Observational","","CDR0000491440|SEG-20060042|SEG-IRB-1075624","March 2006","null","null","May 12, 2009","null","September 20, 2013","Southeastern Gynecologic Oncology, LLP - Northside, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00897039"
686,"NCT00895518","Examining the Effectiveness of an Early Psychological Intervention to Prevent Post-Traumatic Stress Disorder",,"Completed","No Results Available","Post-Traumatic Stress Disorder","Behavioral: Prolonged Exposure (PE) Therapy","PTSD Symptom Scale- I (PSS)","Emory University|National Institute of Mental Health (NIMH)","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","139","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","IRB00009260|DATR AD-TS|R34MH083078","April 2008","January 2012","January 2012","May 8, 2009","null","September 8, 2016","Grady Memorial Hospital, Emergency Department, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00895518"
687,"NCT00892554","The Effect of Supplemental Docosahexaenoic Acid (DHA) on Neurocognitive Outcomes in Teen and Adult Women With Phenylketonuria(PKU)","PKU&DHA","Completed","No Results Available","Phenylketonuria","Dietary Supplement: Docosahexaenoic Acid|Dietary Supplement: Corn/soy oil","Cognitive processing speed|Executive function|Plasma and red blood cell DHA concentrations","Emory University|Atlanta Clinical and Translational Science Institute","Female","12 Years to 50 Years   (Child, Adult)","Not Applicable","33","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","IRB00002447","June 2007","January 2010","January 2010","May 4, 2009","null","December 11, 2015","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00892554"
688,"NCT00873613","Digital Ocular Fundus Photography in the Emergency Department: A New Application for Telemedicine?",,"Completed","No Results Available","Headache|Acute, Focal Neurologic Disease|Severely Elevated Blood Pressure|Acute Visual Loss","Procedure: Use of Non-dilated retinal photography","Difference in detection rate of papilledema by emergency department physicians using non-dilated retinal photography vs. direct ophthalmoscopy.","Emory University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","705","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Screening","IRB00006900","April 2009","August 2011","July 2012","April 1, 2009","null","November 8, 2013","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00873613"
689,"NCT00870818","Protege Extension Trial - Long Term Follow Up Trial for Subjects Who Completed the Protege Study (CP-MGA031-01)",,"Terminated","No Results Available","Type 1 Diabetes Mellitus","Drug: Teplizumab","Primary outcome measures will include the number and percentage of subjects who experience a SAE, Adverse Event of Special Interest (including Opportunistic Infection, Lymphopoliferative disease), or other Immediately Reportable Event.|A secondary endpoint will be determining the efficacy of teplizumab by measuring the subject's total daily insulin usage and HbA1c levels.|C-peptide secretory response will be analyzed in terms of basal levels of C-peptide produced before a mixed meal and stimulated levels after a mixed meal, measured as AUC and peak post-meal production.|Immunophenotyping of blood mononuclear cells will be summarized by visit and graphed over time, as appropriate.|A secondary efficacy endpoint will be assessing Heath Related Quality of Life Questionnaires filled out by subjects at different timepoints in the study.","MacroGenics|Eli Lilly and Company","All","10 Years to 37 Years   (Child, Adult)","Phase 2|Phase 3","219","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CP-MGA031-02","February 2009","February 2011","May 2011","March 27, 2009","null","March 8, 2012","Atlanta Diabetes Associates, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00870818"
690,"NCT00866710","Behavioral Therapy to Treat Urinary Incontinence in Parkinson's Disease","BETTUR PD","Completed","No Results Available","Urinary Incontinence|Parkinson's Disease","Other: Exercise-based behavioral therapy","Bladder diary|Quality of Life Questionnaire","Atlanta VA Medical Center|The John A. Hartford Foundation","All","50 Years and older   (Adult, Older Adult)","Not Applicable","28","U.S. Fed|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","6-38941","October 2008","October 2011","October 2011","March 20, 2009","null","January 12, 2012","Atlanta VA Medical Center, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00866710"
691,"NCT00864370","Bipolar Disorder (BPD) in Pregnancy: Predictors of Morbidity",,"Completed","No Results Available","Pregnancy|Bipolar Disorder","","To determine if psychiatric morbidity among pregnant women with BPD is greatest for those who receive suboptimal pharmacotherapy, have a more severe past illness-course, or have experienced recent psychosocial stressors.","Emory University|Massachusetts General Hospital|The Cleveland Clinic","Female","18 Years to 45 Years   (Adult)","","237","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IRB00046058|R01MH071531|Bipolar Disorder in Pregnancy","May 2005","January 2011","June 2013","March 18, 2009","null","November 13, 2013","Emory University Department of Psychiatry & Behavioral Sciences, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00864370"
692,"NCT00863889","Steroid Injection for the Treatment of Greater Trochanteric Pain Syndrome",,"Withdrawn","No Results Available","Bursitis","Drug: Depomedrol injection|Drug: Lidocaine, Marcaine","WOMAC hip score","Emory University","All","17 Years and older   (Child, Adult, Older Adult)","Phase 4","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","IRB00010776","March 2009","February 2010","February 2010","March 18, 2009","null","September 23, 2013","Dr. Tom Bradbury, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00863889"
693,"NCT00862056","Detection of Subclinical Atherosclerosis in Asymptomatic Individuals","Decide CTA","Completed","No Results Available","Coronary Artery Disease","Procedure: Cardiac CT","The primary endpoint of the study is identifying the prevalence of coronary artery disease (CAD) in an asymptomatic population of patients without prior history of, but with high likelihood of CAD.","Piedmont Healthcare","All","35 Years to 90 Years   (Adult, Older Adult)","","73","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","PH08012","January 2009","July 2013","July 2013","March 16, 2009","null","November 20, 2017","Piedmont Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00862056"
694,"NCT00861653","Atherosclerotic Plaque Characterization","APC","Completed","No Results Available","Atherosclerosis","","Characterization of plaque that is found in the carotid walls of patients who have atherosclerosis|To evaluate the effectiveness of MR imaging in identifying these plaque characteristics","Piedmont Healthcare","All","18 Years and older   (Adult, Older Adult)","","50","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Prospective","P06-31","October 2006","August 2011","July 2013","March 13, 2009","null","April 15, 2014","Piedmont Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00861653"
695,"NCT00861575","Cardiogenomics Registry","CGR","Completed","No Results Available","Cardiovascular Disease","","To assess the relationship of multiple phenotypes and genotypes with cardiovascular disease|To assess the impact of phenotypes and genotypes of specific patient subgroups (gender, ethnic, family history) on cardiovascular disease","Piedmont Healthcare","All","18 Years to 99 Years   (Adult, Older Adult)","","2601","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","PH05005","February 2006","February 2012","February 2012","March 13, 2009","null","November 20, 2017","Piedmont Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00861575"
696,"NCT00860327","Examining Developmental Changes in Heart Contractions of Children With Congenital Heart Defects",,"Terminated","No Results Available","Hypoplastic Left Heart Syndrome|Tetralogy of Fallot","","Calcium handling assay","Emory University|National Heart, Lung, and Blood Institute (NHLBI)","All","up to 1 Year   (Child)","","375","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","IRB00007244|R01HL088488","December 2007","June 2016","June 2016","March 12, 2009","null","August 22, 2016","Emory University, Department of Pediatrics, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00860327"
697,"NCT00851162","Using Mesenchymal Stem Cells to Fill Bone Void Defects in Patients With Benign Bone Lesions",,"Withdrawn","No Results Available","Bone Neoplasms","Biological: Trinity multipotent stem cells|Biological: Demineralized bone matrix(DBM)","Time to fill bony defect|Adverse reaction from bone graft","Emory University","All","11 Years and older   (Child, Adult, Older Adult)","Phase 2|Phase 3","0","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","IRB00009762","March 2009","March 2010","March 2010","February 25, 2009","null","November 28, 2012","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00851162"
698,"NCT00850720","Study of Possible Brain Hormone Problems After Open Heart Surgery in Infants",,"Terminated","Has Results","Congenital Heart Disease","Other: Blood draws","NO Outcomes - Study Terminated Without Data.","Emory University|Children's Healthcare of Atlanta","All","up to 1 Year   (Child)","","3","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","IRB00007443","March 2009","October 2009","October 2009","February 25, 2009","January 7, 2014","January 7, 2014","Children's Healthcare of Atlanta at Egleston, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00850720"
699,"NCT00846404","Markers of Oxidative Stress Diastolic Dysfunction","ODDS","Unknown status","No Results Available","Diastolic Heart Failure|Diastolic Dysfunction","","Evidence of diastolic dysfuntion documented by echocardiography with six months before the time of enrollment.|This study is observational. It entails measurement products from a blood draw.","Emory University","All","18 Years to 65 Years   (Adult, Older Adult)","","50","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","730-2006","July 2006","May 2007","July 2010","February 18, 2009","null","February 18, 2009","Atlanta VAMC, Decatur, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00846404"
700,"NCT00838331","Adverse Effects of RBC Transfusions: A Unifying Hypothesis","INOBA","Completed","Has Results","Healthy Volunteers","Biological: Fresh blood|Biological: Aged blood","The Effects of Storage-related RBC Changes on Acetylcholine-stimulated (NO-mediated) Forearm Blood Flow.","Emory University","All","21 Years to 80 Years   (Adult, Older Adult)","Phase 2","24","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00015316","April 2009","May 2013","October 2013","February 6, 2009","March 6, 2015","March 6, 2015","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00838331"
701,"NCT00837512","Insulin Delivery Using Microneedles in Type 1 Diabetes",,"Completed","Has Results","Type 1 Diabetes Mellitus","Device: Microneedle|Device: Subcutaneous insulin catheter","Onset Time (Tmax)","Emory University|Thrasher Research Fund","All","8 Years to 18 Years   (Child, Adult)","Phase 2|Phase 3","16","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1348-2005|FWA00005792","September 2008","December 2012","July 2013","February 5, 2009","January 8, 2014","January 8, 2014","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00837512"
702,"NCT00837330","Ranibizumab (Lucentis) for Polypoidal Choroidal Vasculopathy",,"Completed","Has Results","Polypoidal Choroidal Vasculopathy","Drug: ranibizumab 0.5 or 0.3 mg/0.05 cc","Commonly Reported and Notable Adverse Events","Southeast Retina Center, Georgia|Genentech, Inc.","All","35 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","20","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FVF3761s","May 2006","December 2010","December 2010","February 5, 2009","June 23, 2014","December 3, 2014","Southeast Retina Center, Augusta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00837330"
703,"NCT00833651","Protective Immunity Project 02","PIP-02","Completed","No Results Available","Kidney Transplant|Immunology|Immunosuppression","","To determine the effect of immunosuppressive regimens on the magnitude and character of the adaptive immune response to flu vaccine|To determine the effects of chronic immunosuppressive therapies on innate immunity during response to flu vaccine|To define the transcriptional and protein signatures of the response to flu vaccination in patients on conventional immunosuppressive regimens compared to healthy volunteers","Emory University","All","18 Years to 59 Years   (Adult)","","97","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IRB00024793|PIP-02","November 2006","February 2010","October 2011","February 2, 2009","null","November 25, 2013","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00833651"
704,"NCT00833430","Avascular Necrosis (AVN) Long-Term Follow-up",,"Terminated","No Results Available","Avascular Necrosis|Femoral Head Collapse","","Safety, Efficacy and longevity of device with patient as opposed to conventional total hip replacement","Zimmer Biomet","All","18 Years to 75 Years   (Adult, Older Adult)","","35","Industry","Observational","","IC006-99","June 2006","February 2013","February 2013","February 2, 2009","null","February 19, 2016","Emory Orthopedic Clinic, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00833430"
705,"NCT00833144","Bedside Ultrasound Identifies Congestive Heart Failure",,"Completed","No Results Available","Heart Failure|Dyspnea","","sensitivity and specificity of the ultrasound lung rockets to predict congestive heart failure|comparison of the BNP with the thoracic ultrasound findings","Emory University","All","18 Years and older   (Adult, Older Adult)","","375","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","IRB00015895|2008125","February 2009","February 2010","February 2011","January 30, 2009","null","December 13, 2013","Grady Memorial Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00833144"
706,"NCT00829036","Wayfinding Information Access System for People With Vision Loss",,"Completed","Has Results","Blindness","Device: Wayfinding Prototype","Mean Percent (Prototype / Baseline) Time","US Department of Veterans Affairs|VA Office of Research and Development","All","18 Years and older   (Adult, Older Adult)","Not Applicable","24","U.S. Fed","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)","C6690-R","October 2012","December 2012","December 2012","January 26, 2009","April 2, 2014","April 2, 2014","Atlanta VA Medical and Rehab Center, Decatur, Decatur, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00829036"
707,"NCT00827099","Umbilical Cord Blood (UCB) Transplant, Fludarabine, Melphalan, and Anti-thymocyte Globulin (ATG) in Treating Patients With Hematologic Cancer",,"Terminated","Has Results","Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes","Biological: anti-thymocyte globulin|Drug: fludarabine phosphate|Drug: Melphalan|Drug: mycophenolate mofetil|Drug: tacrolimus|Procedure: umbilical cord blood transplantation","Number of Participants With 100 Day Transplant-related Mortality (TRM)|Number of Patients That Engrafted Blood Counts by 30 Days After Transplant|Percentage of Donor and Host Chimerism of Each Cord Blood Unit|Number of Patients Who Experience Acute and Chronic Graft-vs-host Disease After Transplant.|Number of Patients Who Experience Disease Relapse Post-transplant|Number of Patients Who Survive Following Treatment on This Protocol","Northside Hospital, Inc.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","5","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CDR0000632453|BMTGG-NSH-801","June 2006","November 2009","November 2009","January 22, 2009","August 3, 2011","March 23, 2012","Blood and Marrow Transplant Group of Georgia, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00827099"
708,"NCT00823264","Phenytoin and Multidose Activated Charcoal",,"Completed","Has Results","Phenytoin Toxicity","Drug: Activated Charcoal","Time of Elimination of Phenytoin in Patients With Elevated Phenytoin Levels","Emory University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","17","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00008017","August 2008","July 2010","January 2012","January 15, 2009","September 11, 2014","September 11, 2014","Grady Memorial Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00823264"
709,"NCT00818961","Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer",,"Terminated","Has Results","Leukemia|Lymphoma|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases","Biological: alemtuzumab|Biological: graft-versus-tumor induction therapy|Biological: rituximab|Drug: busulfan|Drug: cyclophosphamide|Drug: fludarabine phosphate|Drug: methotrexate|Drug: tacrolimus|Procedure: allogeneic bone marrow transplantation","Survival at Day 100|Overall Survival at 1 Year|Non-relapse Mortality at Day 100|Non-relapse Mortality at 1 Year Post-transplant|Complete Donor Chimerism|Neutrophil Recovery|Platelet Engraftment|Number of Patients Requiring the Use of Donor Leukocyte Infusion (DLI) for Early Mixed T-cell Chimerism|Number of Patients Experiencing Grade 2-4 Acute Graft-versus-host Disease Post-transplant|Number of Patients Experiencing Chronic Graft Versus Host Disease|Number of Patients Experiencing Veno-occlusive Disease (VOD) Post-transplant","Northside Hospital, Inc.|Blood and Marrow Transplant Group of Georgia","All","40 Years to 72 Years   (Adult, Older Adult)","Phase 2","36","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CDR0000630617|BMTGG-NSH-756","May 2005","March 2011","March 2012","January 8, 2009","December 18, 2013","December 18, 2013","Blood and Marrow Transplant Group of Georgia, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00818961"
710,"NCT00817102","Validation of Stenosis Assessment by Coronary Artery Computed Tomography Against Invasive Measurements of Fractional Flow Reserve in Patients With Significant Coronary Artery Stenoses",,"Completed","No Results Available","Coronary Artery Stenosis","Procedure: FFR, IVUS, VH, or combination of the three","The CT-derived endpoints: Study lesion %DS predicting FFR<0.75; %AS predicting FFR<0.75; MLD predicting FFR<0.75; Study lesion MLA predicting FFR<0.75; IVUS-derived endpoints: Study lesion MLD predicting FFR<0.75; MLA predicting FFR<0.75","Piedmont Healthcare","All","21 Years to 85 Years   (Adult, Older Adult)","Not Applicable","25","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","ATLANTA II","November 2008","November 2011","April 2013","January 6, 2009","null","April 15, 2014","Piedmont Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00817102"
711,"NCT00808041","Chemotherapy Monitoring With Breast Computed Tomography (CT)",,"Completed","No Results Available","Breast Cancer","Device: Dedicated breast computed tomography imaging","Tumor response","Emory University|National Institutes of Health (NIH)","Female","18 Years and older   (Adult, Older Adult)","","3","Other|NIH","Observational","Observational Model: Case-Only|Time Perspective: Prospective","IRB00012068|1P50CA128301-01A1","July 2009","September 2012","July 2015","December 15, 2008","null","July 23, 2015","Emory University Winship Cancer Institute, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00808041"
712,"NCT00795262","Effects of Quinapril 40 mg With Alpha Lipoic Acid or Placebo on Diabetes and Hypertension","QUALITY","Completed","No Results Available","Diabetes|Hypertension","Drug: Quinapril (Accupril) plus Alpha Lipoic Acid|Drug: accupril, placebo|Drug: accupril, alpha lipoic acid","Comparison of relative change of systolic BP/diastolic BP and urinary albumin excretion from baseline in diabetic patients treated with quinapril plus lipoic acid versus quinapril and placebo.|Comparison of patients treated with quinapril plus lipoic acid versus quinapril plus placebo in the following areas: a) Changes from baseline in high sensitivity C-reactive protein, adiponectin, and leptin","InVasc Therapeutics, Inc.","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","23","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","INV-064 QUALITY","July 2008","July 2009","July 2009","November 21, 2008","null","May 5, 2011","Atlanta Vascular Research Foundation, Tucker, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00795262"
713,"NCT00793884","Emory Latino Diabetes Education Program","ELDEP","Recruiting","No Results Available","Diabetes","","To describe the social and demographic characteristics of the Latino population with diabetes mellitus in Georgia|To examine barriers to health care among Latinos with Diabetes in the population we serve|To determine differences in clinical outcomes (hemoglobin A1C, waist circumference, BMI, blood pressure) and diabetes self-management behaviors between initial and follow-up data","Emory University|Sanofi|Eli Lilly and Company|Takeda|Novo Nordisk A/S","All","18 Years and older   (Adult, Older Adult)","","800","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","IRB00013340","October 2008","December 2018","December 2018","November 19, 2008","null","October 12, 2017","Emory University School of Medicine, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00793884"
714,"NCT00793650","Combination High Dose Melphalan and Autologous Peripheral Blood Stem Cell (PBSC) Transplant With Bortezomib for Multiple Myeloma: A Dose and Schedule Finding Study",,"Terminated","Has Results","Cancer|Multiple Myeloma","Drug: Bortezomib|Drug: Melphalan|Procedure: Autologous PBSC Transplant","Safety and Engraftment|Response Rate Using EBMT(European Group for Blood and Bone Marrow Transplan) Criteria at Day +100 After Transplant.","Emory University|Millennium Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","39","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","080-2005","May 2005","October 2009","September 2011","November 19, 2008","June 18, 2012","August 30, 2012","Emory University Winship Cancer Institute, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00793650"
715,"NCT00788320","Vitamin D in Active Tuberculosis (TB) Study",,"Withdrawn","No Results Available","Tuberculosis","Drug: Vitamin D3|Drug: Placebo","LL-37 level|Sputum Conversion|25-hydroxyvitamin D and serum calcium","Atlanta VA Medical Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","0","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Vitamin D in TB","October 2008","February 2010","February 2010","November 10, 2008","null","January 20, 2012","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00788320"
716,"NCT00788138","Effects of Vitamin D Supplementation on Lung Function in an Acute Pulmonary Exacerbation of Cystic Fibrosis",,"Completed","No Results Available","Cystic Fibrosis","Dietary Supplement: Vitamin D3|Dietary Supplement: Placebo","Vitamin D status measured by serum 25-hydroxyvitamin D|Antimicrobial peptide levels of LL-37, an endogenous anti-microbial peptide in humans|Markers of pulmonary function measured by FEV1 % predicted|Length of hospitalization measured in days|Number of days on antibiotic therapy","Emory University|Atlanta VA Medical Center","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Inpatient Vitamin D in CF","October 2008","September 2010","September 2010","November 10, 2008","null","October 11, 2010","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00788138"
717,"NCT00788021","Protective Immunity Project 01","PIP-01","Completed","No Results Available","Kidney Transplantation|Immunity|Immunosuppression","","To determine the effects of chronic immunosuppressive therapies on adaptive immunity|To determine the effects of chronic immunosuppressive therapies on innate immunity, dendritic cell phenotype and function and TLR signaling|To define the transcriptional signatures associated with specific immunosuppressive regimens","Emory University","All","18 Years to 59 Years   (Adult)","","124","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IRB00000709|PIP-01","September 2006","January 2011","October 2011","November 10, 2008","null","November 25, 2013","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00788021"
718,"NCT00787904","Role of T-cells in Post-Menopausal Osteoporosis",,"Completed","Has Results","Osteoporosis","","Changes in T-cell Activation Measured by Flow Cytometry, Specifically the Percentage of CD3+CD69+ T-cells|Percent Change in Thymus Size Measured by CT Scan|Bone Mineral Density","Atlanta VA Medical Center|Emory University","All","18 Years to 55 Years   (Adult)","","19","U.S. Fed|Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","T-cells in osteoporosis","December 2006","June 2011","December 2012","November 10, 2008","December 13, 2016","December 13, 2016","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00787904"
719,"NCT00787839","Opportunistic Screening for Prediabetes and Early Diabetes in Primary Care",,"Completed","Has Results","Type 2 Diabetes Mellitus|Prediabetic State","Other: Glucose challenge test|Other: Glucose tolerance test","Ability of Different Screening Tests Which Can be Performed Opportunistically (During Outpatient Visits -- at Any Time of Day, Regardless of Meal Status) to Predict Findings With the Oral Glucose Tolerance Test (in the Morning, After an Overnight Fast)|Cost to Identify a Single Case of High-risk Dysglycemia or Previously Unrecognized Diabetes","US Department of Veterans Affairs|Emory University|VA Office of Research and Development","All","18 Years and older   (Adult, Older Adult)","","1939","U.S. Fed|Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","IIR 07-138","June 2009","December 2012","December 2012","November 10, 2008","December 23, 2014","April 27, 2015","Atlanta VA Medical and Rehab Center, Decatur, GA, Decatur, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00787839"
720,"NCT00787761","Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer",,"Completed","Has Results","Myeloproliferative Disorders|Kidney Cancer|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases","Biological: anti-thymocyte globulin|Drug: busulfan|Drug: cyclophosphamide|Drug: fludarabine phosphate|Drug: methotrexate|Drug: tacrolimus|Procedure: nonmyeloablative allogeneic HSCT","Achievement of > 90% (Full) Donor Chimerism in the T-cell Lineage as Measured by PCR at Day 30 Post-transplantation|T-cell and Myeloid Chimerism at Days 90 Post-transplantation (>90% Chimerism)|T-cell and Myeloid Chimerism at Days 180 Post-transplantation (>90%)|Number of Patients Who Experience Severe (Grade 3 or 4) Acute Graft-versus-host Disease|Number of Patients Experiencing Extensive Chronic Graft Versus Host Disease (GVHD)|Non-relapse Mortality (NRM) at Day 180 Post-transplantation|Disease-free Survival (DFS) at 24 Months|Overall Survival (OS) at 24 Months","Northside Hospital, Inc.|Blood and Marrow Transplant Group of Georgia","All","up to 75 Years   (Child, Adult, Older Adult)","Phase 2","24","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CDR0000618483|BMTGG-NSH-807","April 2007","July 2010","May 2012","November 10, 2008","October 1, 2012","October 1, 2012","Blood and Marrow Transplant Group of Georgia, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00787761"
721,"NCT00782379","Combination Chemotherapy, Donor Stem Cell Transplant, Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide in Treating Patients With Hematologic Cancer",,"Completed","Has Results","Leukemia|Lymphoma|Myelodysplastic Syndromes","Drug: busulfan|Drug: cyclophosphamide|Drug: fludarabine phosphate|Drug: mycophenolate mofetil|Drug: tacrolimus|Procedure: allogeneic hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation","Incidence of Graft Rejection for Patients at Day 100|Number of Patients Who Experienced Severe Graft-versus-host Disease (GVHD)(Grade 3 or 4)|Overall Survival at Day 100|Non-relapse Mortality at 1 Year After Peripheral Blood Stem Cell Transplantation (PBSCT)|Achievement of >90% (Full) Donor Chimerism in the T-Cell Lineage as Measured by PCR at Day 30 Post-transplantation|Non-relapse Mortality at Day 100 After Peripheral Blood Stem Cell Transplantation (PBSCT)|Achievement of >90% (Full) Donor Chimerism in the T-Cell Lineage as Measured by PCR at Day 60 Post-transplantation|Achievement of >90% (Full) Donor Chimerism in the T-Cell Lineage as Measured by PCR at Day 90 Post-transplantation|Overall Survival at 12 Months|Disease Free Survival at 12 Months|Disease Free Survival at Day 100","Northside Hospital, Inc.","All","18 Years to 60 Years   (Adult)","Phase 2","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CDR0000617648|BMTGG-NSH-864","October 2008","April 2011","April 2012","October 31, 2008","May 3, 2013","November 21, 2013","Blood and Marrow Transplant Group of Georgia, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00782379"
722,"NCT00781417","Prevention of Secondary Hyperparathyroidism With Vitamin D in Stage II/III Chronic Kidney Disease","POSH-D","Completed","No Results Available","Kidney Disease","Dietary Supplement: Vitamin D|Other: Placebo","25(OH)D|Parathyroid Hormone|24 hour urine calcium|Markers of bone turnover","Atlanta VA Medical Center|Emory University","All","18 Years to 85 Years   (Adult, Older Adult)","Not Applicable","48","U.S. Fed|Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Atlanta VAMC","October 2008","October 2011","December 2011","October 29, 2008","null","February 7, 2012","Atlanta VAMC, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00781417"
723,"NCT00771134","Efficacy and Safety of Lu AA39959 in Patients With Bipolar Depression",,"Terminated","No Results Available","Bipolar Disorder","Drug: Lu AA39959|Drug: Placebo|Drug: Quetiapine","Depressive symptoms as measured by the change from baseline in total MADRS score|Global impression (Clinical Global Impression; CGI-BP-Severity/Improvement), depression/anxiety symptoms (Hamilton Depression/Anxiety scale; HAM-D/A), mania symptoms (Young Mania Rating Scale; YMRS), adverse events","H. Lundbeck A/S","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","105","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","12601A","December 2008","June 2009","August 2009","October 13, 2008","null","May 28, 2014","US024, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00771134"
724,"NCT00761436","Pilot Study of Safety and Efficacy of Spheramine",,"Terminated","No Results Available","Parkinson's Disease","Biological: Spheramine (BAY86-5280)","The primary outcome measure for evaluating efficacy will be the motor subscore of the Unified Parkinson's Disease Rating Scale (UPDRS) (version 3.0) in the practically defined ""off"" state. During the Screening and at Baseline Evaluations.|Involuntary Movements, time Motor Tests|Motor Fluctuation and Percent OFF Time Evaluation|Quality of Life and Physician's and Patients Global Evaluations|Neuropsychological Evaluations","Bayer|Titan Pharmaceuticals","All","40 Years to 70 Years   (Adult, Older Adult)","Phase 2","6","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","91677|311361","February 2000","May 2012","May 2012","September 29, 2008","null","December 2, 2014","Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00761436"
725,"NCT00757510","Congenital Heart Disease Research Registry","CHDRR","Terminated","No Results Available","Congenital Heart Disease","","There is no outcome measure. This is a data, blood and serum collection only to provide a base for future studies","Emory University","All","Child, Adult, Older Adult","","861","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IRB00006304","January 2008","February 2010","February 2010","September 23, 2008","null","December 9, 2014","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00757510"
726,"NCT00755599","Eisenhower's Alternative Speculum Examination","EASE","Unknown status","No Results Available","Papanicolaou Smear","Procedure: no-stirrup vaginal examination|Procedure: Vaginal speculum examination done with stirrups.","physical discomfort|Provider satisfaction|sense of loss of control|sense of vulnerability","HamesNet Research Network|Eisenhower Army Medical Center|Pearl Network","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","1200","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)","DDEAMC 07-15|JGAP G0806","September 2008","January 2010","January 2010","September 19, 2008","null","September 19, 2008","Eisenhower Army Medical Center, Fort Gordon, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00755599"
727,"NCT00753142","Mechanism Underlying Beta-cell Failure in Obese African Americans With History of Hyperglycemic Crises",,"Completed","Has Results","Diabetes Mellitus, Type 2","Drug: Intralipid 20%|Drug: Glucose infusion","First-Phase Insulin Release (FPIR)|Number of Participants With Beta-cell Failure","Emory University|American Diabetes Association","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","28","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","898-2003","March 2004","December 2009","December 2009","September 16, 2008","August 1, 2014","October 12, 2018","Grady Memorial Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00753142"
728,"NCT00747162","Muscle Oxygenation and Skin Pigmentation",,"Withdrawn","No Results Available","Muscle Oxygenation|Skin Pigmentation","Device: Measure of muscle oxygenation|Device: Skin pigmentation determination","Measure from The INVOS cerebral oximeter and DermaSpectrometer","Emory University","All","18 Years and older   (Adult, Older Adult)","Phase 4","0","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","IRB00009004","August 2008","January 2009","February 2009","September 4, 2008","null","November 27, 2013","Grady Healthcare System, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00747162"
729,"NCT00746369","IMARA, Adapting SiHLE for Detained African American Adolescent Females","IMARA","Completed","No Results Available","HIV Infections","Behavioral: IMARA HIV Prevention Intervention","Proportion of condom protected vaginal sex acts over the last 90 days|Incident infection of chlamydia or gonorrhea as confirmed by laboratory PCR testing","Emory University|Centers for Disease Control and Prevention","Female","13 Years to 17 Years   (Child)","Not Applicable","188","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","IRB00005355|5UR6PS000679","October 2008","August 2012","August 2012","September 4, 2008","null","November 19, 2013","Metro Regional Youth Detention Center, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00746369"
730,"NCT00744003","An Observational Study of Early Coagulopathy, or Clotting Disorder, in Injured Patients",,"Withdrawn","No Results Available","Trauma-induced Coagulopathy","","Development of coagulopathy as defined by abnormal PT/INR","Emory University","All","18 Years and older   (Adult, Older Adult)","","0","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IRB00006685|ETIC Study","July 2008","June 2009","July 2009","August 29, 2008","null","November 18, 2013","Grady Memorial Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00744003"
731,"NCT00743756","Study of a Home Delivered Meal Program on Obese Elderly African American Subjects With Type 2 Diabetes Mellitus (DM)",,"Terminated","No Results Available","Obesity|Diabetes","Dietary Supplement: home-delivered meals|Behavioral: diabetes education for 12 months","Weight Loss in the elderly african american population|Endothelial Function (assessed by pulse-wave analysis); sympathetic activity; insulin sensitivity","Emory University","All","65 Years to 85 Years   (Older Adult)","Not Applicable","38","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","1404-2005","April 2006","February 2009","December 2009","August 29, 2008","null","June 10, 2014","Grady Health System, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00743756"
732,"NCT00741117","Conjugated Hyperbilirubinemia and Pulse Oximetry",,"Terminated","No Results Available","Liver Disease|Hyperbilirubinemia","Procedure: Arterial Blood Gas|Procedure: Pulse Oximetry Machine|Procedure: Direct and Indirect Serum Bilirubin Measurement","Comparison of pulse oximetric saturation and calculated oxygen saturation.","Emory University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","4","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","IRB00008493","October 2011","October 2011","October 2011","August 26, 2008","null","March 6, 2013","Emory University Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00741117"
733,"NCT00738114","Diabetes in the Perioperative Period",,"Completed","No Results Available","Hyperglycemia|Diabetes","","assess impact of hyperglycemia and diabetes during the periop period on clinical outcome(mortality and morbidity)in patients undergoing general and non-cardiac surgery.|determine the scope of clinical inertia in patients with diabetes and untreated hyperglycemia in patients undergoing non-cardiac surgery","Emory University","All","18 Years and older   (Adult, Older Adult)","","3184","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","IRB00011938","August 2008","December 2009","December 2009","August 20, 2008","null","November 21, 2013","Emory Universiy Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00738114"
734,"NCT00738023","Free Fatty Acid-Induced Hypertension in Obese Subjects With Type 2 Diabetes",,"Completed","Has Results","Type 2 Diabetes|Hypertension","Drug: Rosiglitazone|Drug: Normal saline 0.9%|Drug: Intralipid 20%","Changes in Systolic Blood Pressure During Initial Intralipid Infusion|Changes in Systolic Blood Pressure During Saline Infusions|Changes in Systolic Blood Pressure During Intralipid Infusion Post-rosiglitazone Intervention","Emory University|GlaxoSmithKline","All","18 Years and older   (Adult, Older Adult)","Phase 4","36","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","967-2003","March 2004","December 2009","December 2009","August 20, 2008","December 30, 2014","December 30, 2014","Grady Memorial Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00738023"
735,"NCT00726076","Managing Epilepsy Well- WebEase Project",,"Completed","No Results Available","Epilepsy","Behavioral: WebEase","Epilepsy self-management: medication adherence, stress level, and sleep quality|Seizure frequency","Emory University|Centers for Disease Control and Prevention","All","18 Years and older   (Adult, Older Adult)","Not Applicable","194","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","IRB00006628|5 U48 DP00004304","July 2008","October 2010","November 2010","July 31, 2008","null","December 11, 2013","Rollins School of Public Health, Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00726076"
736,"NCT00721617","FFA Hypertension and Inflammation in Lean and Obese Subjects","FFAADA","Completed","Has Results","Diabetes|Hypertension|Obesity","Other: Intralipid 20%|Other: Normal Saline|Other: Oral fat load","Change in Flow-mediated Dilation From Baseline to 4 Hours|Change in Systolic Blood Pressure From Baseline to 4 Hours|Change in Systolic Blood Pressure From Baseline to 8 Hours|Change in Diastolic Blood Pressure From Baseline to 4 Hours|Change in Diastolic Blood Pressure From Baseline to 8 Hours|Change in FFA (Free Fatty Acid) Levels From Baseline to 4 Hours|Changes in FFA (Free Fatty Acid) Levels From Baseline to 8 Hours|Change in Triglyceride Levels From Baseline to 4 Hours|Change in Triglyceride Levels From Baseline to 8 Hours|Plasma Glucose Levels for Saline Infusion|Plasma Glucose Levels for Intralipid Infusion|Plasma Glucose Levels for Dextrose Infusion|Plasma Glucose Levels for Intralipid/Dextrose Infusion|Insulin Levels for Saline Infusion|Insulin Levels for Intralipid Infusion|Insulin Levels for Dextrose Infusion|Insulin Levels for Intralipid/Dextrose Infusion|C-peptides Levels for Saline Infusion|C-peptides Levels for Intralipid Infusion|C-peptides Levels for Dextrose Infusion|C-peptides Levels for Intralipid/Dextrose Infusion","Emory University|American Diabetes Association","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","12","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Basic Science","IRB00009277","April 2009","June 2011","June 2011","July 24, 2008","July 27, 2015","July 27, 2015","Grady Memorial Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00721617"
737,"NCT00720395","Identifying Predictors of Bipolar Disorder Relapse During Pregnancy and the Postpartum Period",,"Withdrawn","No Results Available","Bipolar Disorder","","Preconception, predelivery, and postpartum predictors of postpartum bipolar disorder relapse and burden of illness|Impact of predelivery expectations, the role of breastfeeding, and self-reported sleep disturbance in the risk for postpartum bipolar disorder relapse","National Institute of Mental Health (NIMH)","Female","18 Years to 45 Years   (Adult)","","0","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","R01 MH085026|DATR A2-AIE","August 2005","July 2011","July 2011","July 22, 2008","null","May 8, 2015","Emory University Department of Psychaitry and Behavioral Sciences, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00720395"
738,"NCT00720148","A Phase I Trial of Bortezomib and Sunitinib",,"Completed","No Results Available","Solid Tumors","Drug: Sunitinib and Bortezomib","Safety and toxicity of combination therapy with sunitinib and bortezomib|Tumor shrinkage","Emory University|Millennium Pharmaceuticals, Inc.|Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 1","30","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00003549|3549","February 2008","July 2010","July 2010","July 22, 2008","null","August 26, 2014","Emory University Winship Cancer Institute, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00720148"
739,"NCT00716508","Surgical Treatment for Acute Patella Tendon Rupture",,"Terminated","No Results Available","Acute Patella Tendon Rupture","Procedure: Repair with transpatellar tunnels|Procedure: Repair with suture anchors.","Outcome measures will include SF 36, Tegner and Lysholm scores, as well as IKDC scores.","Emory University","All","18 Years and older   (Adult, Older Adult)","Phase 4","3","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00010200","September 2008","December 2009","December 2009","July 16, 2008","null","September 19, 2013","Grady Healthcare System, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00716508"
740,"NCT00715520","Neurobiological Principles Applied to the Rehabilitation of Stroke Patients",,"Completed","Has Results","Stroke","Other: Transcranial Magnetic Stimulation (TMS)|Drug: Carbidopa-Levodopa|Drug: Methylphenidate|Drug: Amphetamine Sulfate|Drug: Placebo|Other: Sham Transcranial Magnetic Stimulation (TMS)|Other: Transcranial Magnetic Stimulation (TMS) Training","Aim 1: Mean Parameter Estimate for Maximal Motor Evoked Potential (MEPmax) Derived From Stimulus Response Curves (SRC)|Aim 1: Mean Peak Acceleration of Wrist Extension Movements|Aim 2: Mean Sum of Normalized Motor Evoked Potentials (MEPs) With Respect to Pulse|Aim 2: Mean Peak Acceleration of Wrist Extension Movements With Respect to Pulse|Aim 2: Mean Sum of Normalized Motor Evoked Potentials (MEPs) for rTMS Treatment With Respect to Frequency|Aim 2: Mean Peak Acceleration for rTMS Treatment With Respect to Frequency|Aim 3: Mean Parameter Estimate for Maximal Motor Evoked Potential (MEPmax) Derived From Stimulus Response Curves (SRC)|Aim 3: Mean Peak Acceleration of Wrist Extension Movements","Emory University|National Institutes of Health (NIH)|National Institute of Neurological Disorders and Stroke (NINDS)","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","33","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","IRB00046953|R01NS060830-01A1|NPARR01","April 2007","September 2016","September 2016","July 15, 2008","October 16, 2017","October 16, 2017","Emory University School of Medicine, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00715520"
741,"NCT00714571","Behavioral and Neuroimaging Changes After Cognitive Rehab in Traumatic Brain Injuries (TBI) and Mild Cognitive Impairment (MCI)",,"Completed","Has Results","Mild Cognitive Impairment|Alzheimer's Disease|Traumatic Brain Injury","Behavioral: Mnemonic strategy training (MST)|Behavioral: Repeated exposure (XP)|Behavioral: Subtracting Cues training","Memory Test Accuracy on Trained Stimuli","VA Office of Research and Development|Emory University","All","18 Years to 88 Years   (Adult, Older Adult)","Phase 1","82","U.S. Fed|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Treatment","B6366-W","July 2008","September 2014","September 2014","July 14, 2008","January 4, 2017","January 4, 2017","Atlanta VA Medical and Rehab Center, Decatur, Decatur, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00714571"
742,"NCT00700115","Kaletra-isentress Treatment Evaluation","KITE","Completed","Has Results","HIV Infections","Drug: Kaletra + Isentress|Drug: Pre-study antiretroviral regimen","Plasma Viral Loads (HIV-1 RNA PCR)|To Compare Plasma Triglyceride Levels at 48 Weeks Between LPV/r + RAL and Standard HAART Treated Subjects","Emory University|Abbott|Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Older Adult)","Phase 4","60","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00006876|KITE-6876","June 2008","January 2011","January 2011","June 18, 2008","October 22, 2013","December 12, 2014","Grady Infectious Diseases Program (Ponce Clinic), Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00700115"
743,"NCT00694655","Human Immune Responses to The Yellow Fever Virus Vaccine",,"Active, not recruiting","No Results Available","Yellow Fever","Biological: Yellow fever vaccine","1. Isolation and characterization of yellow fever vaccine (YFV-17D) specific adaptive immune responses: characterize the magnitude and quality of YFV specific T cell responses, antibody secreting cells and memory B cells.|Determine the signatures of innate immune responses: cytokines, chemokines, dendritic cells and microarray analyses on peripheral blood mononuclear cells","Emory University|National Institutes of Health (NIH)|National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","200","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","IRB00009560|YFV/Human Immune Responses|5U19AI057266","May 2008","December 2020","December 2020","June 10, 2008","null","October 1, 2018","The Hope Clinic of the Emory Vaccine Center, Decatur, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00694655"
744,"NCT00694447","Acupuncture for Pain and Sleep Disturbance in Knee Osteoarthritis",,"Completed","No Results Available","Sleep|Pain","Procedure: Acupuncture","Sleep disturbances as recorded by wrist actigraph, including sleep duration and sleep efficiency. Pain as measured by 0-10 VAS and WOMAC pain scores.|WOMAC disability scores, IDEEA gait patterns and activity levels, medication type and amount consumed, side effects, and medical care utilization.","Emory University|Southeast Center of Excellence in Geriatric Medicine|The John A. Hartford Foundation","All","55 Years and older   (Adult, Older Adult)","Not Applicable","null","Other","Interventional","","IRB00000143|Grant #97333-G","February 2007","April 2008","null","June 10, 2008","null","November 21, 2013","Wesley Woods Geriatric Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00694447"
745,"NCT00689026","Efficacy of Lubiprostone in Combination With Standard PEG Preparation",,"Terminated","Has Results","Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2","Drug: Lubiprostone|Other: Polyethylene glycol with electrolytes","The Percentage of Patients That Received a Quality of Colonoscopy Preparation Rating of <=2 on a 5 Point Likert Scale.","Augusta University|Takeda Pharmaceuticals North America, Inc.","All","50 Years and older   (Adult, Older Adult)","Not Applicable","60","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Diagnostic","MCG 08-02-186","May 2008","March 2010","March 2010","June 3, 2008","October 20, 2014","October 20, 2014","Medical College of Georgia, Augusta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00689026"
746,"NCT00688597","Study to Evaluate the Safety of AT2220 (Duvoglustat) in Pompe Disease",,"Terminated","Has Results","Pompe Disease","Drug: Duvoglustat","Proportion Of Participants Experiencing Severe Treatment-emergent Adverse Events (TEAEs)|Change In 6-minute Walk Test (6MWT) From Baseline To End Of Study","Amicus Therapeutics","All","18 Years to 74 Years   (Adult, Older Adult)","Phase 2","3","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","POM-CL-201","December 8, 2008","December 14, 2009","December 14, 2009","June 3, 2008","August 17, 2018","August 17, 2018","Decatur, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00688597"
747,"NCT00681148","Botulinum Toxin Injection With Prostate Brachytherapy",,"Withdrawn","No Results Available","Prostate Cancer|Lower Urinary Tract Symptoms|Radioactive Seed Implantation","Drug: Botox injection|Drug: Saline injection","Urinary symptoms|PSA","Emory University","Male","18 Years and older   (Adult, Older Adult)","Phase 2","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","IRB00009836","null","July 2012","July 2012","May 21, 2008","null","November 21, 2013","Emory Clinic, Emory University Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00681148"
748,"NCT00676104","Discrete Hypothermia in the Management of Traumatic Brain Injury",,"Completed","No Results Available","Severe Traumatic Brain Injury","Device: CoolSystems Discrete Cerebral Hypothermia System","Perform a comparative analysis of outcome (Glasgow Outcome Score)|The effectiveness of the Discrete Cerebral Hypothermia System by CoolSystems in maintaining a significant gradient between the core and brain temperatures in study population.|Functional Independence Measure|Mortality|Confirm the effectiveness of the Discrete Cerebral System in reducing internal brain temperature","Emory University","All","18 Years and older   (Adult, Older Adult)","Phase 3","25","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0584-2005","July 2006","August 2007","October 2008","May 12, 2008","null","December 20, 2013","Emory University School of Medicine, Grady Health System campus, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00676104"
749,"NCT00675311","Remote Monitoring in Diabetes Disease Management",,"Completed","No Results Available","Type 1 Diabetes|Type 2 Diabetes","Behavioral: DM-Standard|Behavioral: Disease Management Plus","The primary study measures for this study include glycemic control and LDL levels, satisfaction with diabetes care, and adherence to diabetes medications and self-monitoring recommendations|Secondary measures include diabetes-related health-care utilization and physiologic data.","LifeScan","All","18 Years to 64 Years   (Adult)","Not Applicable","300","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","7021","March 2008","December 2009","December 2009","May 9, 2008","null","December 18, 2009","Marietta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00675311"
750,"NCT00674336","Infectivity of Norovirus in Shellfish Treated With High Hydrostatic Pressure Processing-Human Challenge Study","Shellfish","Completed","No Results Available","Healthy","Procedure: High Hydrostatic Pressure Processing","Infection with norovirus","Emory University|Virginia Polytechnic Institute and State University","All","18 Years to 50 Years   (Adult)","Not Applicable","51","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","0551-2006|RSPHGH-CLM-2007-NoVSHELLFISH","September 2007","October 2009","March 2010","May 7, 2008","null","November 19, 2013","Emory University General Clinical Research Center, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00674336"
751,"NCT00674206","A Phase II Trial of Gemcitabine and Oxaliplatin for Triple Negative Metastatic Breast Cancer",,"Terminated","Has Results","Breast Cancer","Drug: Gemcitabine|Drug: Oxaliplatin","Number of Participants With Complete Response, Partial Response, Progressive Disease and Stable Disease.|Overall Survival From Time of Study Entry","Emory University|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 2","6","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00007792|7792","October 2008","August 2009","October 2009","May 7, 2008","July 26, 2012","December 12, 2013","Emory University Winship Cancer Institute, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00674206"
752,"NCT00665678","Neural Correlates of Early Intervention for Posttraumatic Stress Disorder (PTSD)",,"Terminated","No Results Available","Posttraumatic Stress Disorder (PTSD)","Drug: paroxetine|Drug: placebo","PTSD symptoms as measured with the CAPS|Assess the effects of paroxetine versus placebo on amygdala metabolism and medial prefrontal response to stress in OIF veterans with PTSD.","Atlanta Research and Education Foundation|Emory University","All","18 Years to 50 Years   (Adult)","Phase 4","160","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CDMRP PT074585","April 2008","March 2012","March 2012","April 24, 2008","null","July 11, 2012","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00665678"
753,"NCT00663507","Kidney Transplantation in Patients With Sickle Cell Disease",,"Terminated","No Results Available","Sickle Cell Disease","","No measure applied","Emory University","All","18 Years to 65 Years   (Adult, Older Adult)","","2","Other","Observational","Time Perspective: Prospective","IRB00004914","March 2008","December 2010","December 2010","April 22, 2008","null","February 27, 2013","Mason Outpatient Tranplant Clinic Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00663507"
754,"NCT00653432","Safety and Effectiveness Study of Hyaluronic Acid for Osteoarthritis of the Knee",,"Completed","No Results Available","Osteoarthritis","Device: MONOVISC","WOMAC Pain|Global Assessment","Anika Therapeutics, Inc.","All","35 Years to 75 Years   (Adult, Older Adult)","Not Applicable","350","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","AM-0702","January 2008","December 2009","February 2010","April 7, 2008","null","June 22, 2010","Resurgens Orthopedics, Cumming, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00653432"
755,"NCT00652483","Safety and Efficacy Study of Brimonidine in Patients With Glaucoma or Ocular Hypertension",,"Completed","No Results Available","Glaucoma|Ocular Hypertension","Drug: Brimonidine ophthalmic solution 0.1%|Drug: Brimonidine ophthalmic solution 0.2%","Intraocular pressure (IOP)|IOP","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 3","433","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","190342-021","May 2003","December 2003","September 2004","April 3, 2008","null","April 3, 2008","Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00652483"
756,"NCT00646763","A Randomized Study of the Site for Growth Factor Injection for Patients Undergoing Autologous Stem Cell Transplantation",,"Terminated","Has Results","Cytokines","Drug: G-CSF, GM-CSF administered at extremities|Drug: G-CSF and GMCSF administered at abdomen","The Total Number of CD34+ Cells Collected.|Number of Participants for Whom Target Number of CD34+ Cells Were Collected.|Total Number of Days of Apheresis","Emory University","All","18 Years and older   (Adult, Older Adult)","Phase 2","35","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00007445|7445","April 2008","September 2009","February 2011","March 28, 2008","May 11, 2012","December 20, 2013","Emory University Winship Cancer Institute, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00646763"
757,"NCT00646282","Mineral Metabolism and Vascular Effects of Vitamin D Therapy in Kidney Transplant Patients","PAD","Terminated","Has Results","Hyperparathyroidism, Secondary","Drug: doxercalciferol","Number of Subjects With 50% Reduction of Intact Parathyroid Hormone (iPTH) Levels","Emory University","All","18 Years and older   (Adult, Older Adult)","Phase 4","12","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00006614","April 2008","January 2010","January 2010","March 28, 2008","January 26, 2015","January 26, 2015","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00646282"
758,"NCT00645957","A Comparison of Redrubber Versus Penrose Drains","redrubber","Completed","No Results Available","Odontogenic Infection","Procedure: penrose drain|Procedure: red rubber drain","Resolution of infection","Emory University","All","16 Years and older   (Child, Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00006249","February 2008","June 2011","June 2011","March 28, 2008","null","November 21, 2013","Grady Memorial Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00645957"
759,"NCT00645827","Use of an Insulin Infusion Conversion Equation (IICE) to Control Blood Glucose in Hospitalized Patients","IICE","Completed","Has Results","Glucose, Blood","Other: IICE Dosing|Other: Healthcare Provider dosing","Percentage of Blood Glucose Values Within 80-140 mg/dL|Hypoglycemia (Serum Blood Glucose < 70 mg/dL)","Emory University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","78","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00006564","January 2008","March 2009","March 2009","March 28, 2008","September 15, 2014","September 15, 2014","Emory Crawford Long Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00645827"
760,"NCT00638885","Memory and the Hippocampus in Twins",,"Completed","Has Results","PTSD|Stress Disorders, Post-Traumatic","","Neuropsychological Testing of Memory","US Department of Veterans Affairs|VA Office of Research and Development","Male","50 Years to 70 Years   (Adult, Older Adult)","","142","U.S. Fed","Observational","Observational Model: Cohort|Time Perspective: Prospective","MHBA-008-07S","April 2010","June 2012","June 2013","March 19, 2008","January 15, 2015","January 15, 2015","Atlanta VA Medical and Rehab Center, Decatur, Decatur, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00638885"
761,"NCT00636727","A Comparison of Arthrocentesis, Arthroscopy and Arthroplasty in the Treatment of Temporomandibular Joint Dysfunction","TMJ","Completed","No Results Available","Temporomandibular Joint Dysfunction","Procedure: arthrocentesis|Procedure: arthroscopy|Procedure: arthroplasty","Reduction in pain","Emory University","All","18 Years to 89 Years   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00000450","January 2007","December 2009","February 2010","March 14, 2008","null","November 21, 2013","Emory Clinic, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00636727"
762,"NCT00636701","Improving Rehabilitation by Magnetic Brain Stimulation",,"Completed","Has Results","Stroke","Device: Repetitive Transcranial Magnetic Stimulation","Percentage BOLD (Blood-oxygen-level Dependent Contrast Imaging) Signal From Baseline at 2 Weeks","US Department of Veterans Affairs|VA Office of Research and Development","All","18 Years and older   (Adult, Older Adult)","Phase 1","4","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","B4657-P","September 2007","March 2009","May 2009","March 14, 2008","May 1, 2015","May 1, 2015","Atlanta VA Medical and Rehab Center, Decatur, Decatur, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00636701"
763,"NCT00634179","A Phase I/II Trial of VR-CHOP in Lymphoma Patients",,"Completed","Has Results","Lymphoma, B-Cell|Follicular Lymphoma","Drug: Bortezomib|Biological: Rituximab|Drug: Doxorubicin|Drug: Cyclophosphamide|Drug: Vincristine|Drug: Prednisone","Maximal Tolerated Doses of Bortezomib and Vincristine When Used in Combination of Bortezomib, Rituximab and the CHOP Chemotherapy Regimen (Phase I)|An Estimate of the Overall Response Rate (ORR)(Complete Response [CR] + CR Unconfirmed [CRu] + Partial Response [PR]) to Bortezomib and Rituximab (VR)-CHOP According to International Workshop to Standardize Response Criteria (IWRC) Criteria","Emory University|Millennium Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","37","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00002996|X05215","February 2008","November 2015","November 2015","March 12, 2008","March 15, 2016","October 27, 2016","Emory University Winship Cancer Institute, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00634179"
764,"NCT00628849","Champy Versus AO for Mandible Fractures","Mand","Completed","No Results Available","Mandibular Injuries","","fracture healing|malocclusion","Emory University","All","11 Years to 89 Years   (Child, Adult, Older Adult)","","126","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IRB00000444","February 2007","June 2009","June 2009","March 5, 2008","null","November 21, 2013","Grady Memorial Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00628849"
765,"NCT00628589","Staccato Loxapine in Agitated Patients With Schizophrenia",,"Completed","Has Results","Patients With Schizophrenia and Acute Agitation","Drug: Inhaled loxapine 5 mg|Drug: Inhaled loxapine 10 mg|Drug: Inhaled placebo","Change in PANSS-EC From Baseline|Clinical Global Impression-Improvement (CGI-I) Score|CGI-I Responders","Alexza Pharmaceuticals, Inc.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","344","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AMDC-004-301","February 2008","May 2008","May 2008","March 5, 2008","June 29, 2017","July 26, 2017","Atlanta Center for Medical Research, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00628589"
766,"NCT00615706","Study to Evaluate the Impact of Obesity on Airway Inflammation and Mechanics in Asthmatics","ABI/BALA","Completed","No Results Available","Asthma","Other: No intervention","","Emory University|Critical Therapeutics","All","18 Years to 70 Years   (Adult, Older Adult)","","300","Other|Industry","Observational","Time Perspective: Cross-Sectional","345-2004|Emory IRB ID 345-2004","January 2005","September 2008","September 2008","February 14, 2008","null","September 23, 2008","Emory University, Emory Crawford Long Hospital, Clinical Research Center, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00615706"
767,"NCT00615498","Study to Evaluate the Effects of Weight Loss on Airway Inflammation and Mechanics in Subjects With Asthma (Asthma-Bariatric Surgery Study)",,"Completed","No Results Available","Asthma","","To measure levels of exhaled nitric oxide, reactive nitrogen species, exhaled biomarkers of lipid peroxidation, asthma quality of life, airway function (spirometry and response to methacholine), and degree of asthma control|To measure systemic markers of redox stress and inflammation, including plasma levels of adipokines, adiposity-related cytokines (IL-6, TNF-α), GSH/GSSG, 8-isoprostanes, and leukotrienes","Emory University|National Institutes of Health (NIH)","All","18 Years to 70 Years   (Adult, Older Adult)","","80","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","IRB00000064","July 2006","September 2008","September 2008","February 14, 2008","null","July 31, 2013","Emory University, Emory Crawford Long Hospital, Clinical Research Center, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00615498"
768,"NCT00614341","Effect of Pulsing Electrical Fields on Lower Extremity Diabetic Neuropathy: A Pilot, Open-Label Study","DPN","Completed","No Results Available","Diabetic Peripheral Neuropathy","Device: MedRelief SE 55","Pain reduction in diabetic patients with chronic diabetic neuropathy|Improvement in sensation and overall foot condition","MedRelief","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","23","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","600-001","May 2006","December 2007","January 2008","February 13, 2008","null","February 13, 2008","Nephrology and Rheumatology Associates, Augusta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00614341"
769,"NCT00605007","Study on COPD Corticosteroid-induced Hyperglycemia on Clinical Outcome in Patients With COPD",,"Completed","No Results Available","COPD","","The primary outcome of the study is to determine the mortality rate of COPD patients with corticosteroid-induce hyperglycemia.","Emory University","All","18 Years to 80 Years   (Adult, Older Adult)","","450","Other","Observational","Time Perspective: Retrospective","IRB00001392|e1392","February 2006","June 2009","December 2009","January 30, 2008","null","November 21, 2013","Grady Memorial Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00605007"
770,"NCT00604669","TPN-Induced Hyperglycemia: Impact on Clinical Outcome in Intensive Care Unit (ICU) and Non-ICU Patients",,"Completed","Has Results","Hyperglycemia","","Mortality","Emory University","All","18 Years and older   (Adult, Older Adult)","","170","Other","Observational","Time Perspective: Retrospective","IRB00004573|e4573","June 2007","August 2009","August 2009","January 30, 2008","April 7, 2010","December 13, 2013","Grady Memorial Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00604669"
771,"NCT00601939","Effectiveness of Empowerment Group Sessions for Treating Suicidal African American Women in Abusive Relationships",,"Recruiting","No Results Available","Battered Women|Suicide, Attempted","Behavioral: Psychoeducational intervention (PEI)|Behavioral: Enhanced treatment as usual (ETAU)","Beck Scale for Suicidal Ideation; Suicide Attempt Index; Index of Spouse Abuse|Beck Depression Inventory - II; Beck Hopelessness Scale; Self Efficacy Scale for Battered Women","Emory University|National Institute of Mental Health (NIMH)","Female","18 Years to 64 Years   (Adult)","Not Applicable","397","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","IRB00045774|R01MH078002","March 2008","December 2028","December 2028","January 28, 2008","null","August 8, 2018","Grady Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00601939"
772,"NCT00601029","Rhabdomyolysis in Basic Training",,"Completed","No Results Available","Exertional Rhabdomyolysis","","Exertional Rhabdomyolysis","Martin Army Community Hospital","Male","18 Years to 45 Years   (Adult)","","499","U.S. Fed","Observational","Observational Model: Cohort|Time Perspective: Prospective","DDEAMC 07-25|USUHS G192FP|CIRO 2007522","January 2008","September 2009","September 2010","January 25, 2008","null","April 20, 2012","Martin Army Community Hospital, Ft. Benning, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00601029"
773,"NCT00598780","Evaluation of Safety of Levocetirizine in Routine Clinical Practice-non- Interventional Study",,"Completed","No Results Available","Rhinitis Allergic, Persistent","","Number of patients with adverse events Number and type of serious adverse events Number of patients withdrawing levocetirizine treatment due to adverse events|To evaluate the global clinical improvement on levocetirizine compared to baseline at each follow up visit.|To evaluate the treating physician's perception of patient satisfaction of levocetirizine tolerability at each follow up visit|To evaluate symptoms (nasal pruritus, rhinorrhea, nasal congestion, sneezing, ocular pruritus) at each follow up visit|To evaluate the impact of co-morbidities (asthma, urticaria and inflammation of upper airways) at each follow up visit|To evaluate the treating physician's perception of patient satisfaction of treatment regimen effectiveness at each follow up visit|To evaluate the treating physician's prescription practice in the treatment of Persistent Allergic Rhinitis|To evaluate concomitant medications prescribed with levocetirizine at each follow up visit|The evaluate reason for discontinuation at last follow up visit|To evaluate the overall physician´s treatment satisfaction in comparison with previously used antihistamines in patient population previously treated by antihistamines at last follow up visit|To evaluate the dose prescribed by the treating physician at each follow up visit","UCB Pharma","All","2 Years and older   (Child, Adult, Older Adult)","","7870","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","A00421","September 2007","September 2008","September 2008","January 23, 2008","null","May 28, 2012","UCB Pharma, Smyrna, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00598780"
774,"NCT00598689","GenTeal in Perioperative Treatment of Laser Assisted in Situ Keratomileusis LASIK Patients",,"Completed","Has Results","Corneal Epithelium Defect","Drug: 0.3% hypromellose","Epithelial Healing After Laser Assisted in Situ Keratomileusis (LASIK) Surgery|Post Operative Pain Level|Tolerability and Alleviation of Post-operative Pain in LASIK Surgery","Augusta University|Novartis","All","18 Years to 60 Years   (Adult)","Phase 4","80","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","07-09-052","October 2007","October 2009","October 2009","January 22, 2008","March 7, 2016","March 7, 2016","EyeCare One, Augusta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00598689"
775,"NCT00596375","Lidocaine Lubricant in Pediatric Urethral Catheterization",,"Completed","No Results Available","Fevers|Pain","Procedure: Lubricant Instillation|Drug: Lidocaine Lubricant","Modified Behavior Pain Scale|Lidocaine Concentration|Visual Analog Scale","Children's Healthcare of Atlanta|Emory University","All","2 Months to 2 Years   (Child)","Not Applicable","47","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","06693","August 2006","null","March 2007","January 17, 2008","null","January 17, 2008","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00596375"
776,"NCT00590005","Redox Determinants of Severe Asthma (a Substudy of the Severe Asthma Research Program)","SARP","Completed","Has Results","Asthma","","Exhaled Nitric Oxide at Baseline and Over the Observational Period|Reduction in Breath pH","Emory University|The Cleveland Clinic","All","6 Years to 21 Years   (Child, Adult)","","225","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IRB00024906|2R01HL069170-07","January 2003","June 2011","June 2011","January 10, 2008","January 13, 2014","February 10, 2014","Emory Childrens Center, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00590005"
777,"NCT00589888","FFA-Induced Hypertension and Endothelial Dysfunction",,"Completed","Has Results","Endothelial Dysfunction|Hypertension","Drug: Intralipid 20%|Drug: Normal Saline|Dietary Supplement: 32-gram oral fat load|Dietary Supplement: 64-gram oral fat load","Change in Systolic Blood Pressure|Changes in Systolic Blood Pressure|Changes in Systolic Blood Pressure From Baseline|The Secondary Outcomes of Interest Are the Effects of Increased FFAs on BP, Endothelial Function and Inflammatory Markers After Oral Fat Load (Chylomicron Pathway) Versus IV Administration of Intralipid Infusion in Obese Normotensive Subjects.","Emory University|American Heart Association","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","13","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","IRB00041116|IRB 668-2006","August 2006","April 2008","August 2008","January 10, 2008","July 9, 2014","July 9, 2014","Grady Memorial Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00589888"
778,"NCT00576576","Evaluation of Atorvastatin on Atherosclerosis Composition",,"Completed","Has Results","Atherosclerosis","Drug: Atorvastatin","Change in Necrotic Core Volume|Change in Atheroma Volume|Change in Fibrous Plaque Volume","Emory University|Pfizer","All","18 Years and older   (Adult, Older Adult)","Not Applicable","27","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00000701|GA2580TT|Emory #07052168","July 2007","March 2010","March 2010","December 19, 2007","October 18, 2013","December 24, 2013","Emory University Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00576576"
779,"NCT00576329","Topical 0.4% Ketorolac and Vitreoretinal Surgery",,"Completed","No Results Available","Surgery","Drug: Ketorolac","Change in pupil size during vitreoretinal surgery|Postoperative pain and inflammation","Emory University","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","76","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","IRB00000517","November 2006","null","October 2007","December 19, 2007","null","May 14, 2014","Emory Eye Clinic, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00576329"
780,"NCT00573638","Effects of Xal-Ease on Patient Compliance With Xalatan","Xal-Ease","Unknown status","No Results Available","Glaucoma","Device: Xal-Ease device to be used with Xalatan eye drops","The primary outcome measure is compliance with the medication XALATAN using and not using the Xal-Ease delivery aid for their glaucoma treatment.|To determine if any of the other factors mentioned in the survey affect compliance to their medical regimen|To see whether or not the Xal-Ease device helps patients conserve medication. ie - aids in drops not distilled in the eye.","Augusta University|Pfizer","All","40 Years to 80 Years   (Adult, Older Adult)","Not Applicable","50","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","05-02-266|Guarantor or CPI # 002533552","February 2005","null","December 2009","December 14, 2007","null","August 8, 2008","Medical College of Georgia Health Inc, Augusta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00573638"
781,"NCT00571285","Clinical Effects of Vitamin D Repletion in Patients With Parkinson's Disease","VIDIP PILOT","Terminated","No Results Available","Parkinson's Disease","Dietary Supplement: Vitamin D3|Dietary Supplement: Vitamin D3 - high dose|Dietary Supplement: Placebo","Change from Baseline Visit to 3 month (Treatment Visit #1) in the TUG, timed walking task (8-meters) and UPDRS III subscore|Change from Baseline Visit to 3 month (Visit #1) and 6 month (Visit #2) in the UPDRS II, BAI-II and BDI-II score.","Emory University","All","18 Years to 89 Years   (Adult, Older Adult)","Phase 4","31","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRB00004539|VIDIP PILOT","June 2007","January 2011","September 2015","December 11, 2007","null","January 24, 2017","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00571285"
782,"NCT00567671","Corneal Collagen Cross-Linking for the Treatment of Progressive Keratoconus and Corneal Ectasia","CL","Completed","No Results Available","Progressive Keratoconus|Corneal Ectasia","Procedure: Corneal collagen|Procedure: Sham comparator","Change in keratometry|Best spectacle-corrected visual acuity","Emory University","All","14 Years and older   (Child, Adult, Older Adult)","Phase 2|Phase 3","160","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UVX-001","December 2007","June 2010","June 2010","December 5, 2007","null","September 2, 2010","Woolfson Eye Institute, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00567671"
783,"NCT00565201","Evaluation of BOTOX® With Rehabilitation Therapy for the Treatment of Wrist and Hand Spasticity in Post-Stroke Patients","Botox/Rehab","Completed","No Results Available","Stroke","Drug: Botox and rehab|Drug: Placebo and rehab","Wolf Motor Function Test|Arm Motor Ability Test|Stroke Impact Scale|Modified Ashworth Scale|Upper Extremity range of motion measurements|Caregiver questionnaire","Emory University|Allergan","All","18 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","25","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","IRB00002727","October 2007","December 2009","December 2011","November 29, 2007","null","August 13, 2013","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00565201"
784,"NCT00562315","FACBC PET/CT for Recurrent Prostate Cancer",,"Completed","Has Results","Prostate Cancer","Drug: FACBC|Other: ProstaScinct","Number of Participants With True Positive Scans Within the Prostate Bed|Number of Participants With False Positive Scans Within the Prostate Bed|Number of Participants With True Negative Scans Within the Prostate Bed|Number of Participants With False Negative Scans Within the Prostate Bed|Number of Participants With True Positive Scans Outside the Prostate Bed|Number of Participants With True Negative Scans Outside the Prostate Bed|Number of Participants With False Positive Scans Outside the Prostate Bed|Number of Participants With False Negative Scans Outside the Prostate Bed|Diagnostic Performance of Anti-[18F]FACBC PET-CT Imaging in Detection of Extra-prostatic Recurrence of Prostate Carcinoma|Diagnostic Performance of Anti-[18F]FACBC PET-CT Imaging in Detection of Recurrent Prostate Carcinoma in the Prostate Bed|Diagnostic Performance of ProstaScint Imaging in Detection of Recurrent Prostate Carcinoma in the Prostate Bed|Diagnostic Performance of ProstaScint Imaging in Detection of Extra-prostatic Recurrence of Prostate Carcinoma","David M. Schuster, MD|National Cancer Institute (NCI)|Emory University","Male","18 Years and older   (Adult, Older Adult)","Phase 2","128","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Single (Investigator)|Primary Purpose: Diagnostic","IRB00006468|R01CA129356-01","October 2007","July 2015","July 2015","November 22, 2007","August 18, 2015","June 21, 2016","Emory University Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00562315"
785,"NCT00561561","Sensorimotor Gating in Schizophrenia",,"Active, not recruiting","No Results Available","Schizophrenia","Procedure: acoustic startle testing","prepulse inhibition of acoustic startle","Emory University","All","18 Years to 80 Years   (Adult, Older Adult)","","500","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","IRB00021861","June 2001","July 2013","December 2018","November 21, 2007","null","November 6, 2017","Atlanta VA Medical Center, Decatur, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00561561"
786,"NCT00555412","Staccato Loxapine Multidose PK",,"Completed","No Results Available","Volunteers on Chronic, Stable Antipsychotic Regimens","Drug: A - 10 mg loxapine q 4 h x 3 (30 mg total)|Drug: B - 10 mg x 1, 5 mg x 2 loxapine q 4 h (20 mg total)|Drug: C - 5 mg loxapine q 4 h x 3 (15 mg total)|Drug: D - inhaled placebo q 4 h x 3","PK parameters: tmax, Cmax, AUClast, AUCinf, ke, t1/2 and clearance will be estimated for each subject and for the population using noncompartmental methods.|Plasma concentration-time (PK) profiles will be produced for each subject and a mean PK profile for subjects completing for each dose group|Tolerability will be assessed based on treatment emergent adverse events, vital signs, ECG and a visual-analog sedation scale.","Alexza Pharmaceuticals, Inc.|Atlanta Center for Medical Research","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","40","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AMDC-004-102","October 2007","December 2007","December 2007","November 8, 2007","null","March 15, 2017","Atlanta Center for Medical Research, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00555412"
787,"NCT00552838","The Impact of an Antimicrobial Utilization Program on Antimicrobial Use",,"Completed","No Results Available","Antimicrobial Prescribing Practices","Behavioral: Academic Detailing by the Antimicrobial Utilization Team (AUT)","Proportion of Appropriateness of Antimicrobial Prescriptions in each group.|Clinical Cure Rate, Mortality Rate between the two groups","Washington University School of Medicine|Emory University","All","18 Years to 85 Years   (Adult, Older Adult)","Not Applicable","785","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)","579-2002 Emory IRB","October 2002","null","August 2003","November 2, 2007","null","November 2, 2007","Grady Memorial Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00552838"
788,"NCT00549289","Study of Cyclosporine in the Treatment of Dry Eye Syndrome (ST-603-006)",,"Completed","No Results Available","Dry Eye Syndromes","Drug: cyclosporine A","","Sirion Therapeutics, Inc.","All","2 Years and older   (Child, Adult, Older Adult)","Phase 3","null","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)","ST-603-006","null","null","null","October 25, 2007","null","October 25, 2007","Clayton Eye Center, Morrow, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00549289"
789,"NCT00548886","Low-dose Epinephrine Infusion Tests in Adolescent and Pediatric Patients","LEAP","Terminated","Has Results","Congenital Disorders","Drug: Epinephrine","Percentage of Subjects With a Positive Result in Absolute QT Interval|Determine Interobserver Variability When Measuring QT Intervals","Emory University|Children's Healthcare of Atlanta","All","3 Years to 18 Years   (Child, Adult)","Not Applicable","7","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","IRB00008105","February 2008","January 2012","June 2012","October 24, 2007","March 6, 2015","December 6, 2017","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00548886"
790,"NCT00548847","Immunotherapy for Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Blast Phase Chronic Myelogenous Leukemia (BP CML), and Myelodysplastic Syndrome (MDS) Relapse After Allogeneic Transplantation",,"Completed","Has Results","Leukemia","Biological: GM-CSF|Biological: Interferon-α-2b","Efficacy of GM-CSF and Pegylated Interferon-alpha 2b When Administered to Patients With AML, ALL, Blast Phase CML, and MDS Relapse After Allogeneic Transplantation, Defined as Progression-free Survival of > 33% at 3 Months|Overall Survival at 6 Months (Evaluate Overall Responses; Perform Lab Experiments to Test Hypothesis That Exposure to Interferon-alpha and GM-CSF Up-regulates Co-stimulatory Molecule Expression on Relapsed Acute Leukemia Cells)","Emory University|Bayer","All","1 Year and older   (Child, Adult, Older Adult)","Phase 2","15","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00002219|WCI1228-06","January 2007","March 2015","March 2015","October 24, 2007","August 18, 2016","October 26, 2016","Emory University Winship Cancer Institute, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00548847"
791,"NCT00538304","A Study of the Safety and Efficacy of Bimatoprost in Patients With Glaucoma or Ocular Hypertension",,"Completed","Has Results","Glaucoma|Ocular Hypertension","Drug: bimatoprost eye drops|Drug: placebo","Change From Baseline in Mean Peak Macroscopic Conjunctival Hyperemia at Month 1|Percentage of Patients With an Increase in Macroscopic Conjunctival Hyperemia in Either Eye at Month 1|Change From Baseline in Mean Intraocular Pressure (IOP) at Month 1|Percentage of Physicians Who Were Very or Extremely Willing to Continue Patient on Drug, if Drug Were Marketed at Month 1|Percentage of Patients Who Were Very or Extremely Willing to Use This Glaucoma Medication at Month 1|Percentage of Patients Who Reported No Change in the Appearance of Their Eyes Since the Beginning of the Study at Month 1","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 2","222","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","192024-035","November 2007","May 2008","May 2008","October 2, 2007","October 27, 2011","October 27, 2011","Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00538304"
792,"NCT00535704","Preventing Substance Use and Risky Behavior Among Rural African American Youth",,"Completed","No Results Available","Risky Sexual Behavior","Behavioral: Strong African American Families-Teen Program|Behavioral: FUEL","Sexual behavior|Substance Use","National Institute on Drug Abuse (NIDA)","All","14 Years to 17 Years   (Child)","Not Applicable","502","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","1R01DA021736-01","November 2007","December 2012","December 2012","September 26, 2007","null","January 11, 2017","Center for Family Research, Athens, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00535704"
793,"NCT00535223","Group Based Exposure Therapy for Combat-Related PTSD",,"Completed","Has Results","Posttraumatic Stress Disorder","Behavioral: Group Based Exposure Therapy|Behavioral: Present Centered Group Therapy","Clinician Administered PTSD Scale (CAPS)|Posttraumatic Cognitions Inventory (PTCI)","US Department of Veterans Affairs|VA Office of Research and Development","Male","Child, Adult, Older Adult","Not Applicable","81","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","MHBA-010-06F","July 2007","July 2010","August 2012","September 26, 2007","March 26, 2015","March 26, 2015","VA Medical Center, Decatur, Decatur, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00535223"
794,"NCT00531661","CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Heart Failure Patients","CHAMPION","Completed","Has Results","Heart Failure, Congestive","Device: HF Pressure Measurement System","Rate of Heart Failure Related (HFR) Hospitalizations|Freedom From a Device/System-related Complication (DSRC).|Freedom From Pressure Sensor Failure|Change From Baseline in Pulmonary Artery Mean Pressure|Proportion of Patients Hospitalized for Heart Failure|Days Alive Outside of the Hospital|Quality of Life - Minnesota Living With Heart Failure Questionnaire (MLHFQ)","CardioMEMS","All","18 Years and older   (Adult, Older Adult)","Not Applicable","550","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","CM-06-04","September 2007","May 2010","November 2014","September 19, 2007","April 9, 2013","January 28, 2015","CardioMEMS Investigational Sites, Nationwide, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00531661"
795,"NCT00525226","Evaluating the Effects of Stress in Pregnancy",,"Completed","No Results Available","Depression|Panic Disorder|Generalized Anxiety Disorder|Post-Traumatic Stress Disorder|Obsessive Compulsive Disorder (OCD)","","Social and emotional development of infants who have mothers with depression and anxiety, during or soon after pregnancy","Emory University|National Institute of Mental Health (NIMH)","Female","18 Years to 45 Years   (Adult)","","1431","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","IRB00004249|P50MH077928|DDTR B3-PDB","September 2007","July 2012","July 2012","September 5, 2007","null","November 20, 2013","Emory University Women's Mental Health Program, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00525226"
796,"NCT00523146","Treatment of Primary Menstrual Pain With Kanion Capsule",,"Completed","No Results Available","Primary Dysmenorrhea","Drug: Kanion Capsule","pain reduction|accompanying symptoms improvement","Lianyungang Kanion Group, Ltd.","Female","18 Years to 45 Years   (Adult)","Phase 2","null","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GF-2006-001","April 2007","December 2008","February 2009","August 31, 2007","null","February 3, 2010","Mount Vernon Clinical Research, LLC, Sandy Springs, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00523146"
797,"NCT00522522","Naturalistic Study to Evaluate the Utilization of Care Services Associated to the Diagnostic Process of Any Kind of Epilepsy",,"Completed","No Results Available","Epilepsy","","","UCB Pharma","All","16 Years and older   (Child, Adult, Older Adult)","","400","Industry","Observational","Time Perspective: Retrospective","N01292|EPILIVE","February 2008","July 2008","July 2008","August 29, 2007","null","May 30, 2012","UCB Pharma, Smyrna, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00522522"
798,"NCT00519623","Transdermal Basal Insulin Patch Study in Type 1 Diabetes",,"Completed","Has Results","Type 1 Diabetes","Other: PassPort(R) Transdermal Insulin Delivery System","Pharmacokinetics of the PassPort(R) Transdermal Insulin Delivery System in Type 1 Diabetes Patients (Cmax)|Pharmacodynamics of the PassPort(R) Transdermal Insulin Delivery System in Type 1 Diabetes Patients (GIRmax)|Skin Response to the Application of the PassPort(R) Transdermal Insulin Delivery System in Type 1 Diabetes Patients","Altea Therapeutics","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","9","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IN2007001","August 2007","November 2007","December 2007","August 22, 2007","December 30, 2010","December 30, 2010","Altea Therapeutics Clinical Research Center, 387 Technology Circle, NW, Suite 100, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00519623"
799,"NCT00514865","Placebo-Controlled Study of ONO-2333Ms in Patients With Recurrent Major Depressive Disorder",,"Completed","No Results Available","Major Depressive Disorder","Drug: ONO-2333Ms","Change from baseline to treatment endpoint in the MADRS total score|Change from baseline to treatment endpoint in the HAM-D17, QIDS-SR16, CGI-S, CGI-I, PGI score","Ono Pharma USA Inc|Ono Pharmaceutical Co. Ltd","All","18 Years to 55 Years   (Adult)","Phase 2","278","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ONO-2333POU007","June 2007","April 2008","June 2008","August 10, 2007","null","December 25, 2013","Ono Pharma Investigtional Site, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00514865"
800,"NCT00510783","IV Keppra in the Emergency Department for Prevention of Early Recurrent Seizures",,"Completed","Has Results","Tonic-clonic Seizure","Drug: Keppra|Drug: Fosphenytoin|Drug: Dilantin","Number of Participants Who Experienced a Recurrent Seizure After Treatment.","Emory University|UCB Pharma","All","18 Years and older   (Adult, Older Adult)","Phase 4","158","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00002266","July 2007","December 2008","December 2008","August 2, 2007","August 5, 2013","December 12, 2013","Grady Memorial Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00510783"
801,"NCT00506272","Inpatient Self Monitoring and Administration Study (ISMAS)","ISMAS","Unknown status","No Results Available","Diabetes Mellitus|Hyperglycemia|Hypoglycemia","Procedure: Self blood glucose monitoring and insulin administration|Procedure: Standard care","number of blood glucose measurements obtained/number of blood glucose measurements ordered|number of insulin doses administered/number of insulin doses prescribed|average blood glucose","Atlanta VA Medical Center","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","1","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","Emory IRB: 805-2006","December 2007","December 2016","null","July 25, 2007","null","December 14, 2015","Atlanta VA Medical Center, Decatur, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00506272"
802,"NCT00501189","Gardasil Vaccination as Therapy in Low Grade Cervical Abnormalities",,"Unknown status","No Results Available","Papillomavirus Infections","Biological: human papillomavirus vaccine L1, type 6,11,16,18","","Eisenhower Army Medical Center","Female","18 Years to 26 Years   (Adult)","","300","U.S. Fed","Observational","Observational Model: Cohort|Time Perspective: Prospective","DDEAMC 07-43X","August 2007","null","July 2009","July 16, 2007","null","August 4, 2008","Eisenhower Army Medical Center, Fort Gordon, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00501189"
803,"NCT00490295","Biomarkers for Detection of Brain Ischemia",,"Completed","No Results Available","Congenital Disorders","","Diagnose brain ischemia in infants using a biomarker blood test.","Emory University|Children's Healthcare of Atlanta","All","up to 30 Days   (Child)","","10","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IRB00002572","March 2008","January 2010","January 2010","June 22, 2007","null","November 27, 2013","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00490295"
804,"NCT00490256","Modified Perfusion for Neonatal Aortic Arch Reconstruction",,"Completed","Has Results","Aortic Arch Hypoplasia or Atresia","Procedure: Modified Selective Cerebral Perfusion","Intestinal Fatty Acid Binding Protein and C-reactive Protein|iFAB Post-op|Cerebral and Lower Body Near Infra-red Spectroscopy Measures","Emory University|Children's Healthcare of Atlanta","All","up to 1 Year   (Child)","Not Applicable","14","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00002654","June 2007","April 2010","June 2010","June 22, 2007","August 5, 2011","June 3, 2014","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00490256"
805,"NCT00489957","Speckle Tracking in Pediatric Patients",,"Completed","No Results Available","Cardiomyopathy","","The investigators wish to study a new technology called Speckle Tracking and compare it to other technologies currently being used.","Emory University","All","up to 17 Years   (Child)","","70","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","IRB00001930","March 2007","May 2008","December 2009","June 22, 2007","null","November 27, 2013","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00489957"
806,"NCT00487006","Study of High Blood Sugars and Insulin in Hospitalized, Critically Ill Children","CIH","Completed","No Results Available","Critical Illness|Hyperglycemia","Other: Serum Lab testing","We hypothesize that the hyperglycemic response to critical illness will be associated with abnormally low levels of endogenous insulin as compared to patients without critical illness hyperglycemia.","Children's Healthcare of Atlanta","All","2 Years to 12 Years   (Child)","Not Applicable","209","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CIH","October 2006","July 2011","February 2015","June 15, 2007","null","June 16, 2015","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00487006"
807,"NCT00486096","Femoral Arterial Cannulation",,"Terminated","No Results Available","Congenital Disorders","","","Children's Healthcare of Atlanta","All","up to 3 Months   (Child)","","1","Other","Observational","Time Perspective: Retrospective","07-012","February 2007","null","August 2007","June 13, 2007","null","March 16, 2012","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00486096"
808,"NCT00486070","Review of Descending Aortic Flow Reversal in Total Anomalous Pulmonary Venous Connection",,"Terminated","No Results Available","Congenital Disorders","","","Children's Healthcare of Atlanta","All","up to 21 Years   (Child, Adult)","","40","Other","Observational","Time Perspective: Retrospective","06-197","December 2006","null","September 2007","June 13, 2007","null","March 16, 2012","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00486070"
809,"NCT00486057","Daclizumab Experience in Pediatric Heart Transplant",,"Terminated","No Results Available","Congenital Disorders","","","Children's Healthcare of Atlanta","All","up to 21 Years   (Child, Adult)","","30","Other","Observational","Time Perspective: Retrospective","06-199","August 2004","null","November 2007","June 13, 2007","null","November 21, 2011","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00486057"
810,"NCT00485992","Chlorhexidine Swabs Effectiveness in Reducing Blood Stream Infections",,"Terminated","No Results Available","Congenital Disorders","","","Children's Healthcare of Atlanta","All","up to 18 Years   (Child, Adult)","","352","Other","Observational","Time Perspective: Retrospective","06-201","August 2006","December 2006","December 2007","June 13, 2007","null","November 21, 2011","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00485992"
811,"NCT00485654","Racial Distribution of Heterotaxy Syndrome",,"Terminated","No Results Available","Congenital Disorders","","","Children's Healthcare of Atlanta","All","up to 21 Years   (Child, Adult)","","65","Other","Observational","Time Perspective: Retrospective","06-198","January 1990","January 2005","February 2008","June 13, 2007","null","March 16, 2012","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00485654"
812,"NCT00485524","Comparison of NIRS and Serum Lactate to Predict Poor Post-operative Outcomes",,"Completed","No Results Available","Congenital Disorders","","Evaluate the relationship of serum lactate levels with cardiac diagnosis, operation performed, post-operative course and outcome.|Compare the predictive values of NIRS score and serum lactate levels in the above setting to assess their respective efficacies in post-operative cardiac intensive care.","Children's Healthcare of Atlanta","All","up to 1 Month   (Child)","","12","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","06-177","January 2002","July 2008","July 2008","June 13, 2007","null","March 16, 2012","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00485524"
813,"NCT00478296","Pulmonary Hypertension in Trisomy 21 Patients",,"Completed","No Results Available","Congenital Disorders","","","Children's Healthcare of Atlanta","All","up to 8 Days   (Child)","","1","Other","Observational","Time Perspective: Retrospective","07-021","October 2004","February 2007","March 2008","May 24, 2007","null","March 16, 2012","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00478296"
814,"NCT00477932","Genes Mutation Pentalogy of Cantrell",,"Withdrawn","No Results Available","Pentalogy of Cantrell|Mutations in Non-muscle Genes","","•Those patients who have Pentalogy of Cantrell (as defined under STUDY DESIGN) or other diseases that could involve mutation of any of the nonmuscle myosin genes that will be defined in future amendments","Children's Healthcare of Atlanta|Emory University|University of Texas Southwestern Medical Center|University of California, San Francisco|Ben-Gurion University of the Negev|Brigham and Women's Hospital|Children's Hospital Medical Center, Cincinnati|Children's Hospital and Health System Foundation, Wisconsin|University of Puerto Rico","All","2 Years and older   (Child, Adult, Older Adult)","","0","Other","Observational","Time Perspective: Prospective","182-2006","March 2006","January 2012","January 2012","May 24, 2007","null","December 17, 2014","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00477932"
815,"NCT00472082","Early Conversion From Tacrolimus to Efalizumab Maintenance Therapy in Kidney Transplant Recipients",,"Terminated","Has Results","Kidney Transplantation|Chronic Kidney Failure","Drug: efalizumab","Efficacy Will be Determined by Change in Renal Function as Measured by Cold Iothalamate Glomerular Filtration Rate(GFR)3 Months After Enrollment, and Acute Rejection Episodes Within the First 6 Months Post Enrollment.|Safety, Including Incidence of Post- Transplant Infections, Malignancies, Morbidities, Hypertension, Glucose Intolerance, Serum Cholesterol and Triglycerides Profile Over Time, Development of New Anti-donor Antibodies.","Emory University|Genentech, Inc.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","5","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00003005|ACD4056s","May 2007","April 2009","April 2009","May 11, 2007","December 6, 2012","January 27, 2014","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00472082"
816,"NCT00469742","Aprotinin in Neonates Undergoing Cardiopulmonary Bypass",,"Completed","No Results Available","Cardiopulmonary Bypass|Congenital Defects|Hemostasis","","","Children's Healthcare of Atlanta","All","up to 1 Month   (Child)","","290","Other","Observational","Time Perspective: Retrospective","07-020","April 2007","null","December 2008","May 4, 2007","null","March 16, 2012","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00469742"
817,"NCT00466986","Abraxane Plus Carboplatin for Recurrent Platinum-Sensitive Ovarian Cancer",,"Completed","No Results Available","Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Cancer","Drug: Abraxane","Response Rate|Time to Response|Duration of Response|Overall Survival|Progression Free Survival|Safety|Tolerability","Southeastern Gynecologic Oncology|Celgene Corporation","Female","Child, Adult, Older Adult","Phase 2","40","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","WIRB#20051730","November 2005","October 2011","October 2011","April 27, 2007","null","October 12, 2011","Southeastern Gynecologic Oncology, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00466986"
818,"NCT00465621","Dose Response Study of AL-37807 Ophthalmic Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension",,"Completed","No Results Available","Open-Angle Glaucoma|Ocular Hypertension","Drug: Xalatan","Mean IP Change from Baseline","Alcon Research","All","18 Years and older   (Adult, Older Adult)","Phase 2","150","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment","C-06-10","March 2007","July 2007","null","April 25, 2007","null","July 29, 2008","Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00465621"
819,"NCT00460863","Effects of Hemodialysis on the Sleep/Wake Cycle",,"Completed","No Results Available","End Stage Renal Disease","Procedure: using cool versus warm dialysate during hemodialysis","Polysomnographic measures of sleep|Polysomnographic measures of daytime sleepiness|Distal/proximal skin temperature gradient|Subjective measure of sleep quality|Subjective measure of daytime sleepiness|Subjective measure of mood|Subjective measure of quality of life|Subjective measure of functional health status","Emory University|National Institute of Nursing Research (NINR)","All","21 Years to 75 Years   (Adult, Older Adult)","Phase 1","58","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","0602-2002|R01NR004340|72728732","April 2003","December 2007","December 2007","April 17, 2007","null","April 24, 2014","Nell Hodgson Woodruff School of Nursing, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00460863"
820,"NCT00460824","A Retrospective Review - Anti-HLA Antibodies",,"Withdrawn","No Results Available","Congenital Disorders","","","Emory University","All","up to 18 Years   (Child, Adult)","","0","Other","Observational","Time Perspective: Retrospective","IRB00003541","July 1988","null","null","April 17, 2007","null","December 31, 2013","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00460824"
821,"NCT00459563","Vitamin D and Blood Pressure",,"Withdrawn","No Results Available","Hypertension","Drug: Vitamin D|Drug: calcitriol|Drug: Placebo","Blood pressure|25(OH)D|Parathyroid hormone|Renin|Aldosterone|Angiotensin II","Atlanta VA Medical Center|Emory University","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","0","U.S. Fed|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","648-2006|VAMC Atlanta R&D AREF 283001","March 2007","December 2011","December 2011","April 12, 2007","null","January 8, 2014","VAMC, Decatur, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00459563"
822,"NCT00459225","Iron Prophylaxis for Anemia in Infants With Cyanotic Congenital Heart Disease",,"Withdrawn","No Results Available","Anemia","Drug: Iron (ferrous sulfate)","Complete blood count, Iron study labs (ferritin, Total Iron Binding Capacity, and Iron lab) 72 hours prior to discharge following neonatal surgery|Hemoglobin and Hematocrit at pre-Glenn catheterization|Complete Blood count, Iron study labs, and Reticulocyte count at pre-glenn screening|feeding regimen and transfusion history at 72 hours prior to discharge from neonatal surgery, at pre-Glenn catheterization, and at pre-Glenn screening","Emory University|Children's Healthcare of Atlanta","All","up to 2 Months   (Child)","Not Applicable","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","IRB00002287","April 2007","June 2013","June 2013","April 11, 2007","null","December 9, 2014","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00459225"
823,"NCT00453583","Evaluation of Treatment Satisfaction in Children With an Allergy and Who Received an Antihistamine",,"Completed","No Results Available","Allergies","","Parent satisfaction on a 11-point scale|Physician satisfaction on an 11-point scale|Efficacy, tolerability and global satisfaction","UCB Pharma","All","2 Years to 12 Years   (Child)","","4581","Industry","Observational","Time Perspective: Retrospective","A00420","March 2007","January 2008","January 2008","March 29, 2007","null","December 16, 2013","UCB Pharma, Smyrna, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00453583"
824,"NCT00453453","BNP Therapy Observation Unit Outcomes STudy (BOOST)","BOOST","Terminated","No Results Available","Congestive Heart Failure","Drug: Nesiritide","Number of subjects that return to the emergency department in 90 days|Correlation between BNP levels at admission and number of subjects who return to the emergency department","Emory University|Scios, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 4","17","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","IRB00038961|0009-2006","March 2007","September 2007","September 2007","March 29, 2007","null","February 9, 2015","Grady Memorial Hosptial, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00453453"
825,"NCT00453219","FHA: Characterization of Metabolic Status, Brain Circuitry, and Stress-Reactivity",,"Withdrawn","No Results Available","Anovulation|FHA|Eumenorrhea|Polycystic Ovary Syndrome","Procedure: Screening evaluation|Procedure: Meal Response|Genetic: Blood Collection|Procedure: Functional MRI|Procedure: Endocrine Assessment","","Emory University","Female","18 Years to 35 Years   (Adult)","","0","Other","Observational","Time Perspective: Prospective","IRB00024918","July 2011","null","null","March 28, 2007","null","October 30, 2013","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00453219"
826,"NCT00450073","Improving Vitamin D Status In Cystic Fibrosis",,"Completed","Has Results","Cystic Fibrosis","Drug: ergocalciferol (vitamin D2)|Device: Sperti Del Sol Lamp|Drug: Vitamin D3","25-hydroxyvitamin D|Parathyroid Hormone, Serum C-telopeptide, Osteocalcin","Atlanta VA Medical Center|Emory University","All","18 Years to 60 Years   (Adult)","Not Applicable","30","U.S. Fed|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Cystic Fibrosis Vitamin D","November 2006","May 2011","May 2011","March 21, 2007","February 21, 2014","February 21, 2014","Emory CF Center, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00450073"
827,"NCT00446927","SPY Imaging System: Its Role in Pediatric Cardiac Surgery",,"Completed","No Results Available","Cardiopulmonary Bypass|Congenital Heart Defects","","","Emory University|Children's Healthcare of Atlanta","All","up to 18 Years   (Child, Adult)","","40","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","IRB00001298","April 2007","January 2012","January 2012","March 13, 2007","null","May 24, 2012","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00446927"
828,"NCT00446160","Adult Congenital Heart Disease Surgery",,"Active, not recruiting","No Results Available","Congenital Disorders","","The primary interest of the study is to look at the breakdown of our adult congenital program in regards to location, personnel, and case type.","Emory University","All","19 Years to 65 Years   (Adult, Older Adult)","","350","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","IRB00002790","January 2000","December 2018","December 2019","March 12, 2007","null","February 23, 2018","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00446160"
829,"NCT00444912","The Effect of Rituximab on Mobilization With AMD3100 (Plerixafor) Plus G-CSF in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) or Hodgkin Disease (HD)",,"Completed","Has Results","Non-Hodgkin Lymphoma|Hodgkin Disease","Drug: G-CSF plus plerixafor|Biological: rituximab","Summary of Adverse Events (AEs)|Median Cumulative Number of CD34+ Cells Collected During Apheresis|Median Fold Increase in the Number of CD34+ Cells After Plerixafor Administration|Median Number of Apheresis Days Required to Reach a Minimum of 3*10^6 CD34+ Cells/kg|Median Number of Apheresis Days Required to Reach the Target of 5*10^6 CD34+ Cells/kg|Median Number of Days to Polymorphonuclear Leukocyte (PMN) Engraftment|Median Number of Days to Platelet (PLT) Engraftment|Median Number of Days to Lymphocyte Engraftment|Median Level of CD19+CD2-CD14- B-cells Six Months Post-Transplant|Median Level of CD19+CD2-CD14- B-cells Twelve Months Post-Transplant|The Percentage of CD19+CD3-CD14- B-cells of the Total Cells on the First Apheresis Day|Number of Participants With Durable Engraftment 12 Months After Transplantation","Genzyme, a Sanofi Company|Sanofi","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","30","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AMD31002113","February 2006","June 2009","June 2009","March 8, 2007","July 29, 2010","March 13, 2014","Winship Cancer Institute, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00444912"
830,"NCT00443196","Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas",,"Completed","No Results Available","Adenocarcinoma|Ovarian Neoplasms|Fallopian Tube Neoplasms|Peritoneal Neoplasms","Procedure: MiCK Assay","Complete Response, No Response","Pierian Biosciences","Female","Child, Adult, Older Adult","Phase 2|Phase 3","150","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","WIRB 20060042","March 2006","null","September 2010","March 5, 2007","null","March 12, 2018","Southeastern Gynecologic Oncology, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00443196"
831,"NCT00440141","Brimonidine 0.1% Versus Brinzolamide 1% as Adjunctive Therapy to Latanoprost 0.005%",,"Completed","No Results Available","Glaucoma|Ocular Hypertension","Drug: latanoprost 0.005% eye drops and brimonidine 0.1% eye drops|Drug: latanoprost 0.005% eye drops and brinzolamide 1.0% eye drops","IOP|Tolerability","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 4","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","MA-AP01","July 2006","March 2007","March 2007","February 26, 2007","null","January 2, 2008","Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00440141"
832,"NCT00431379","Treatment of Acute Respiratory Distress Syndrome With Tenecteplase: A Dose Escalation Pilot Study",,"Withdrawn","No Results Available","Acute Respiratory Distress Syndrome","Drug: Tenecteplase","Survival to Discharge|Safety Analysis of Bleeding Complications|Improved Pa02/Fi02 ratio|Improved cardiac profile|Incidence of organ failure|Decreased ventilator days|Decreased ICU days","Medical Center of Central Georgia|Genentech, Inc.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","0","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","H0605329","February 2007","November 2008","December 2008","February 5, 2007","null","November 6, 2013","Medical Center of Central GA, Macon, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00431379"
833,"NCT00430690","Acoustic Startle Reduction In Cocaine Dependence",,"Active, not recruiting","No Results Available","Cocaine-Related Disorders","Procedure: acoustic startle testing","acoustic startle magnitude","Emory University|National Institute on Drug Abuse (NIDA)","All","18 Years to 80 Years   (Adult, Older Adult)","","135","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","IRB00002489|R01DA018294-01A2","September 2006","August 2012","December 2018","February 2, 2007","null","January 23, 2018","Atlanta Veterans Adminstration Medical Center, Decatur, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00430690"
834,"NCT00427804","Tumor Necrosis Factor Decreases Vitamin D Dependant Calcium Absorption",,"Completed","Has Results","Rheumatoid Arthritis|Crohn's Disease","Drug: calcitriol","Intestinal Absorption of Calcium|Fractional Absorption of Calcium","Atlanta VA Medical Center|Emory University","Male","18 Years to 50 Years   (Adult)","Not Applicable","9","U.S. Fed|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Vitamin D-2007","January 2007","August 2009","November 2009","January 29, 2007","September 2, 2011","February 4, 2013","Atlanta VAMC, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00427804"
835,"NCT00427037","Cholecalciferol (Vitamin D3) Therapy in Chronic Kidney Disease (CKD) Subjects",,"Completed","Has Results","Chronic Kidney Disease|Vitamin D Deficiency","Drug: Cholecalciferol|Drug: Placebo","25-hydroxyvitamin D|Bone Turnover Marker-CTX","Atlanta VA Medical Center","All","18 Years to 85 Years   (Adult, Older Adult)","Not Applicable","34","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Vitamin D-2006","December 2005","July 2006","March 2013","January 26, 2007","March 12, 2009","July 22, 2015","Emory Clinic, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00427037"
836,"NCT00426413","Ketosis Prone Diabetes in African-Americans",,"Completed","No Results Available","Ketosis Prone Diabetes|Diabetic Ketoacidosis|Severe Hyperglycemia","Drug: pioglitazone","","Emory University","All","19 Years to 65 Years   (Adult, Older Adult)","","44","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IRB00024857|GCRC 1703|897-2003","May 2007","August 2010","August 2010","January 24, 2007","null","November 13, 2013","Grady Memorial Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00426413"
837,"NCT00422279","A Study of Dental Implants Coated With Bone Morphogenetic Protein",,"Completed","Has Results","Alveolar Ridge Abnormality","Device: Nobel Replace Tapered Groovy","Primary Endpoint Was to Assess Implant Stability of the Implants( 4 Patients in Two Groups With a Total of 8 Implants) at Baseline and After 3 Months of Submerged Healing and After 6 Months of Prosthetic Loading|Number of Participants Showing Bone Growth With rhBMP-2 (15 and 30 µg Per Implant)","Nobel Biocare","All","18 Years and older   (Adult, Older Adult)","Not Applicable","4","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)","CR06:3393","November 2006","November 2009","November 2009","January 15, 2007","May 29, 2015","April 20, 2016","Medical College of Georgia, Augusta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00422279"
838,"NCT00417560","Inactivated Influenza A/H5N1 Vaccine in Adult Subjects at Risk of Occupational Exposure to Live H5N1 Viruses",,"Unknown status","No Results Available","Influenza","Biological: inactivated influenza A/H5N1 vaccine","The primary outcome measures will be the frequencies and severities of AEs and the GMTS and proportions of subjects who achieve 4-fold rises in serum neutralizing and HAI titers against the influenza A/H5N1 virus.","Centers for Disease Control and Prevention","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","55","U.S. Fed","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","CDC-NCIRD-5000","January 2007","December 2007","January 2013","January 1, 2007","null","September 7, 2012","Centers for Disease Control and Prevention, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00417560"
839,"NCT00412386","Abnormal 3-D MRI Flow Patterns in Adolescents Patients With Bicuspid Aortic Valve",,"Completed","No Results Available","Congenital Heart Disease|Bicuspid Aortic Valve","","","Emory University|Children's Healthcare of Atlanta","All","10 Years to 18 Years   (Child, Adult)","","45","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","IRB00000134","December 2006","null","March 2012","December 18, 2006","null","December 3, 2013","Childrens Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00412386"
840,"NCT00412347","Insulin Infusion in the Hospital Wards",,"Completed","No Results Available","Hyperglycemia","Drug: Insulin Drip Therapy","","Emory University","All","19 Years and older   (Adult, Older Adult)","","200","Other","Observational","Time Perspective: Retrospective","1203-2005","August 2006","null","December 2006","December 18, 2006","null","February 11, 2014","University Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00412347"
841,"NCT00411216","Recovery of Visual Acuity in People With Vestibular Deficits",,"Completed","Has Results","Vestibular Neuronitis|Vestibular Neuronitis, Bilateral|Vestibular Schwannoma","Other: Control exercises|Other: gaze stabilization exercises","Change in Visual Acuity During Head Movement From Baseline to Discharge|Subjective Complaints: (All Pre- and Post-intervention):|Disability Scale|Activities Specific Balance Confidence Scale|Symptoms Intensity for Dizziness, Oscillopsia, Disequilibrium|Balance and Gait|Fall Risk (Dynamic Gait Index)|Eye Movements: Scleral Search Coil","Emory University|National Institute on Deafness and Other Communication Disorders (NIDCD)","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","23","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","IRB00000336|R01DC003196","August 2000","December 2004","December 2004","December 13, 2006","July 21, 2014","August 7, 2015","Center for Rehabilitation Medicine, Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00411216"
842,"NCT00406276","Phase I/II Trial of RAD001 Plus Docetaxel in Patients With Metastatic or Recurrent Non-Small Cell Lung Cancer",,"Terminated","Has Results","Lung Cancer","Drug: RAD001|Drug: Docetaxel","Number of Subjects Showing Partial Response and Stable Disease With the Combination of RAD001 and Docetaxel.|Time to Progression:Time Period (in Months) From Study Entry Until Disease Progression, Death, or Last Date of Contact.","Emory University","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","28","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1342-2004","November 2006","December 2010","February 2013","December 4, 2006","May 28, 2012","August 23, 2013","Emory University Winship Cancer Institute, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00406276"
843,"NCT00401778","Trial of RAD001 in Patients With Operable Non-Small Cell Lung Cancer (NSCLC)",,"Completed","Has Results","Lung Cancer","Drug: RAD001","Clinical Response as Assessed Metabolically by Changes in Positron Emission Tomography (PET) Scan Between Baseline and Immediately Prior to Surgery.|Effects of RAD001 on the Regulation of Key Proteins Involved With the Mammalian Target of Rapamycin (mTOR) Axis in Tumor Specimens and Buccal Mucosa in Patients With Operable Non-small Cell Lung Cancer (NSCLC).|Inhibition of Proliferation (Ki67) and Induction of Apoptosis (TUNEL Assay) in Tumor Specimens and Buccal Mucosa.|Safety and Tolerability of RAD001 as Pre-operative Therapy.|Duration of Hospital Stay Following Surgery.","Emory University","All","18 Years and older   (Adult, Older Adult)","Phase 1","33","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00024810","November 2006","December 2013","December 2013","November 22, 2006","July 14, 2015","December 21, 2016","Emory University Winship Cancer Institute, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00401778"
844,"NCT00400374","Secondary Primary Tumor Prevention With EGFR, OSI-774, and Cyclooxygenase-2",,"Completed","No Results Available","Head and Neck Cancer","Drug: Erlotinib|Drug: Celecoxib","Define biologic dose of Erlotinib and Celecoxib in Erlotinib plus Celecoxib in patients with early stage (I/II) SCCHN. Improve overall survival rate by reducing SPTs and recurrence with combination of Erlotinib and Celecoxib.|Assess tolerability and toxicity associated with combination of Erlotinib and toxicity associated with combination of Erlotinib and Celecoxib for patients with early stage (I/II) SCCHN.","Emory University|Genentech, Inc.|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1","10","Other|Industry|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","IRB00021851|5R01CA112643","August 2007","December 2012","November 2016","November 16, 2006","null","March 15, 2018","Emory University Winship Cancer Institute, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00400374"
845,"NCT00400205","Study of Induction Docetaxel, Cisplatin and 5-Fluorouracil",,"Terminated","Has Results","Squamous Cell Carcinoma|Oral Cancer","Drug: Docetaxel|Drug: Cisplatin|Drug: 5-fluorouracil","Number of Patients Who Had Response by RECIST Criteria (Response Evaluation Criteria in Solid Tumors)|Tumor Change by Baseline Acetylated Tubulin Expression Score","Emory University|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 2","14","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0414-2006","August 2006","September 2009","September 2009","November 16, 2006","January 4, 2011","November 6, 2017","Emory University Winship Cancer Institute, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00400205"
846,"NCT00399880","Improving Medication Adherence Through Graphically Enhanced Interventions in Acute Coronary Syndromes","IMAGE-ACS","Completed","Has Results","Acute Coronary Syndrome (ACS)","Behavioral: Health literacy intervention","Adherence to Refills and Medications Scale (ARMS)|Self-Efficacy for Appropriate Medication Use Scale (SEAMS)","Vanderbilt University Medical Center|National Heart, Lung, and Blood Institute (NHLBI)|American Society of Health-System Pharmacists Research and Education Foundation","All","18 Years and older   (Adult, Older Adult)","Not Applicable","130","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","00000116|K23HL077597","November 2006","August 2008","August 2008","November 15, 2006","September 25, 2017","September 25, 2017","Grady Memorial Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00399880"
847,"NCT00399555","Neurodevelopmental Outcomes in Hypoplastic Left Heart Syndrome",,"Completed","No Results Available","Congenital Heart Disease","","To describe the developmental outcome of school-age children with HLHS who have undergone the Norwood procedure at our institution after January 1, 2001|Determine whether there is a correlation between cerebral oxygen levels as measured by NIRS and subsequent developmental outcome","Emory University","All","29 Months to 6 Years   (Child)","","28","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","IRB00000275","November 2006","July 2009","July 2009","November 15, 2006","null","November 27, 2013","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00399555"
848,"NCT00385151","To Compare the Ischemic Pre-conditioning and Post-conditioning on Reperfusion Injury in Humans.",,"Completed","No Results Available","Endothelial Dysfunction","","","Emory University","All","15 Years to 35 Years   (Child, Adult)","","20","Other","Observational","Time Perspective: Prospective","0920-2004","May 2006","null","August 2006","October 6, 2006","null","November 18, 2013","Emory University Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00385151"
849,"NCT00385112","Follow Up on Freestyle Valves in Children",,"Completed","No Results Available","Right Ventricle|Pulmonary Valve Stenosis|Pulmonary Valve Atresia","Procedure: Echocardiogram","We hypothesize that this Medtronic Freestyle® porcine aortic root valve has good long term hemodynamic performance and longevity.","Emory University","All","8 Years to 40 Years   (Child, Adult)","","98","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IRB00000124|06-138","November 2006","December 2016","December 2016","October 6, 2006","null","January 26, 2017","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00385112"
850,"NCT00384761","Predictive Medicine Research",,"Completed","No Results Available","Atherosclerosis, Endothelial Dysfunction","","Oxidative Stress","Emory University|The Robert W. Woodruff Foundation","All","20 Years to 90 Years   (Adult, Older Adult)","","223","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","IRB00024767a|PreMed 6012|1190-2005","March 2006","October 2010","October 2010","October 6, 2006","null","November 18, 2013","Emory University Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00384761"
851,"NCT00384241","Evaluating the Relationship Between Inflammation, Genetics, and Stress in the Development of High Blood Pressure",,"Completed","Has Results","Hypertension","Behavioral: Induced Stress|Procedure: Buccal Swab","Change in Urinary Sodium Excretion (UNaV)|The Effect of Change in Stress Induced IL-6 on Systolic Blood Pressure","Augusta University|National Heart, Lung, and Blood Institute (NHLBI)","All","15 Years to 19 Years   (Child, Adult)","","1099","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Retrospective","1359|R21HL085817|1R21HL085817-01","August 2006","July 2009","July 2009","October 6, 2006","June 3, 2015","June 3, 2015","Medical College of Georgia, Georgia Regents University, Augusta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00384241"
852,"NCT00384163","Adult Pulmonary Valve Replacement: A Simple and Reproducible Technique",,"Terminated","No Results Available","Congenital Disorders","","","Emory University","All","18 Years and older   (Adult, Older Adult)","","50","Other","Observational","Time Perspective: Retrospective","0453-2006","August 2007","August 2007","August 2007","October 5, 2006","null","November 26, 2013","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00384163"
853,"NCT00382928","Automatic External Defibrillation Monitoring in Cardiac Arrest",,"Completed","Has Results","Death, Sudden, Cardiac|Ventricular Fibrillation|Tachycardia, Ventricular","Device: Defibrillation of pulseless VT/VF by AECD","Number of Participants Without Defibrillation|Frequency of Abnormal Rhythms Monitored by the AECD|Survival to Discharge|Cerebral Performance at Discharge","Atlanta Research and Education Foundation|Emory University","All","18 Years and older   (Adult, Older Adult)","Phase 1","192","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1216-2004","October 2006","September 2009","September 2009","October 2, 2006","July 1, 2014","July 15, 2015","Atlanta Veterans Adminstration Medical Center, Decatur, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00382928"
854,"NCT00379392","Mental Imagery to Reduce Motor Deficits in Stroke",,"Completed","No Results Available","Stroke","Behavioral: Mental Imagery only|Procedure: Mental Imagery and Constraint induced therapy","Wolf Motor Function Test|Fugl-Meyer Motor Assessment Test|Movement Imagery Questionnaire|Vividness of Movement Imagery Questionnaire|Center for Epidemiologic Studies Depression scale|Stroke Impact Scale|Sirigu's break test","Emory University","All","21 Years and older   (Adult, Older Adult)","Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","338-2003|R21AT002138-03","January 2003","July 2008","August 2011","September 21, 2006","null","April 14, 2015","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00379392"
855,"NCT00378924","Cardiology Biobank Registry",,"Recruiting","No Results Available","Cardiovascular Disease","","All cause death|Cardiovascular death|Re-hospitalization for heart failure","Emory University","All","20 Years and older   (Adult, Older Adult)","","12000","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional","IRB00000343|950-2003","December 2003","March 2020","April 2020","September 21, 2006","null","August 1, 2018","Emory School Of Medicine, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00378924"
856,"NCT00374608","Exercise in Chronically Paced Children",,"Completed","No Results Available","Congenital Diseases|Complete Heart Block|Pacemaker","","","Emory University|Children's Healthcare of Atlanta","All","10 Years to 21 Years   (Child, Adult)","","25","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","291-2006","January 2007","July 2009","July 2009","September 11, 2006","null","June 1, 2012","Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00374608"
857,"NCT00372606","An Evaluation of a Culturally- and Linguistically-Appropriate Online Diet Program for U.S Hispanics",,"Completed","No Results Available","Obesity","Behavioral: Online MiDieta Diet and Weight Management Program for Hispanics","Weight loss|Dietary behaviors|Fitness activities|Program acceptability by users","Robert Wood Johnson Foundation","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","1000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Prevention","51759","September 2004","February 2009","February 2009","September 7, 2006","null","October 7, 2009","DrTango, Inc., Roswell, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00372606"
858,"NCT00367354","Respiratory Motion Analysis in Children With MRI",,"Terminated","No Results Available","Congenital Disorders","","cardiac motion reduction in cardiac MRI images","Emory University","All","Child, Adult, Older Adult","","6","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","IRB00041134","August 2006","June 2010","July 2011","August 22, 2006","null","December 9, 2014","Emory University Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00367354"
859,"NCT00367341","Imaging Predictors of Treatment Response in Depression",,"Completed","Has Results","Major Depressive Disorder","Drug: escitalopram|Behavioral: Cognitive Behavioral Therapy (CBT)","Remission Defined as Hamilton Depression Rating Scale-17 Score of Less Than or Equal to 7 at 12 Weeks|Response Defined as 50% Change in Hamilton Depression Rating Scale-17 Score at 12 Weeks","Emory University|National Institute of Mental Health (NIMH)","All","21 Years to 60 Years   (Adult)","Not Applicable","82","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00026176","August 2006","August 2011","July 2013","August 22, 2006","January 9, 2014","January 9, 2014","Emory University School of Medicine, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00367341"
860,"NCT00367003","Deep Brain Stimulation for Treatment Resistant Depression",,"Recruiting","No Results Available","Major Depressive Disorder","Device: Deep Brain Stimulator, implantable","decrease in Hamilton Depression Rating Scale-24 score of at least 50% at 6 months open treatment","Emory University|The Dana Foundation","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00024883","September 2006","September 2018","September 2018","August 22, 2006","null","November 6, 2017","Emory University School of Medicine, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00367003"
861,"NCT00366886","Patients With NMDA Biomarker Data Following Cardiac Surgery",,"Terminated","No Results Available","Congenital Disorders","","","Children's Healthcare of Atlanta","All","up to 18 Years   (Child, Adult)","","22","Other","Observational","Observational Model: Defined Population|Observational Model: Natural History|Time Perspective: Longitudinal|Time Perspective: Retrospective","06-140","null","null","July 2006","August 21, 2006","null","June 13, 2007","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00366886"
862,"NCT00366847","Computer Modeling of Congenital Heart Disease",,"Completed","No Results Available","Congenital Disorders","","RV Function","Children's Healthcare of Atlanta","All","up to 18 Years   (Child, Adult)","","50","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","06-149","June 2001","April 2012","April 2012","August 21, 2006","null","May 8, 2014","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00366847"
863,"NCT00366821","Retrospective Review of the Outcomes of Newborns With Genetic Abnormalities",,"Completed","No Results Available","Congenital Disorders","","We wish to examine the outcomes following cardiac surgery in newborns with genetic abnormalities compared to those newborns without genetic abnormalities.","Children's Healthcare of Atlanta","All","up to 30 Days   (Child)","","1000","Other","Observational","Time Perspective: Retrospective","06-141","January 2002","November 2014","November 2014","August 21, 2006","null","December 2, 2014","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00366821"
864,"NCT00366561","Neonates With Neurological Complications",,"Completed","No Results Available","Congenital Disorders","","The purpose of this study was to examine short term outcomes following cardiac surgery in premature neonates.","Children's Healthcare of Atlanta","All","up to 30 Days   (Child)","","810","Other","Observational","Time Perspective: Retrospective","06-139","January 2002","April 2010","April 2010","August 21, 2006","null","December 2, 2014","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00366561"
865,"NCT00366314","Frequency of Accessing Central Lines for Blood Samples",,"Terminated","No Results Available","Congenital Disorders","","","Children's Healthcare of Atlanta","All","up to 18 Years   (Child, Adult)","","320","Other","Observational","Observational Model: Defined Population|Observational Model: Natural History|Time Perspective: Longitudinal|Time Perspective: Retrospective","06-142","June 2003","null","null","August 21, 2006","null","June 13, 2007","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00366314"
866,"NCT00362375","Evaluation of the Healthy Love Workshop, an HIV Prevention Intervention for African American Women",,"Completed","Has Results","HIV Infections|Sexually Transmitted Infections","Behavioral: Healthy Love Workshop|Behavioral: HIV/AIDS 101 Workshop","Condom Use During Vaginal Sex With Any Male Partner|HIV Testing and Receipt of Results|HIV Knowledge|Condom Use Self-efficacy|Knowledge of HIV Test","Centers for Disease Control and Prevention|SisterLove, Inc.","Female","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","313","U.S. Fed|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","CDC-NCHSTP-1927-4768|U65/CCU424514-02","May 2006","April 2008","April 2008","August 10, 2006","May 14, 2010","May 14, 2010","SisterLove, Inc., Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00362375"
867,"NCT00360256","Genetic Study of Liver Enzymes in Patients With Side Effects From Antidepressants",,"Completed","No Results Available","Major Depressive Disorder","","Cytochrome P450 2D6 and 2C19 genotype|Drug tolerability","Augusta University|Hoffmann-La Roche","All","18 Years to 65 Years   (Adult, Older Adult)","","46","Other|Industry","Observational","Time Perspective: Retrospective","CYP450 Antidepressant study|HAC File #: 06-04-278","June 2006","December 2007","December 2007","August 4, 2006","null","April 19, 2012","Medical College of Georgia, Dept. of Psychiatry and Health Behavior, Augusta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00360256"
868,"NCT00359099","Hepatitis C in Adults Who Underwent Congenital Heart Surgery Before Screening",,"Terminated","No Results Available","Congenital Heart Disease","","","Emory University","All","18 Years and older   (Adult, Older Adult)","","1000","Other","Observational","Time Perspective: Retrospective","0762-2006","January 1980","null","July 2006","August 1, 2006","null","November 27, 2013","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00359099"
869,"NCT00356278","D-cycloserine and Virtual Reality Exposure to Treat Iraq War Veterans With PTSD",,"Completed","Has Results","Stress Disorder, Post Traumatic","Drug: D-Cycloserine|Drug: Alprazolam|Behavioral: Virtual Reality Exposure Therapy|Drug: Placebo","Clinician-Administered PTSD Scale (CAPS)|PTSD Symptom Scale Self-Report","Emory University|National Institute of Mental Health (NIMH)","All","21 Years to 65 Years   (Adult, Older Adult)","Phase 2|Phase 3","156","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRB00024846|DATR AD-TS|R01MH070880","September 2006","June 2014","June 2014","July 25, 2006","November 19, 2014","January 8, 2016","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00356278"
870,"NCT00352885","Effectiveness of Escitalopram in Preventing or Reducing Depressive Symptoms in People Receiving Interleukin-2 Treatment",,"Completed","Has Results","Depression","Drug: Escitalopram|Drug: Placebo|Drug: IL-2","Number of IL-2 Treatments Tolerated|Plasma Concentrations of Adrenocorticotropic Hormone (ACTH)|Plasma Concentrations of Interleukin 6 (IL-6)|Plasma Concentrations of Cortisol|Hamilton Depression Rating Scale (HAM-D) Score|Genetic Polymorphisms","Emory University|National Institute of Mental Health (NIMH)","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","20","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","IRB00024759|R01MH071580|DATR A3-NSS","October 6, 2006","May 17, 2010","May 17, 2010","July 17, 2006","June 27, 2014","September 14, 2018","Winship Cancer Institute, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00352885"
871,"NCT00352196","Janssen Asperger's MRS (Magnetic Resonance Spectroscopy Risperidone Study",,"Completed","No Results Available","Asperger's Disorder","Drug: Risperidone|Other: Magnetic Resonance Spectroscopy","Chang in the Scale for the Assessment of Negative Symptoms (SANS)|Change in Positive and Negative Symptom Scale (PANNS)|Change in Brief Psychiatric Rating Scale (BPRS)|Change in Montgomery Asberg Rating Scale (MADRS)|Change in Global Assessment Scale (GAS)|Change in Abnormal Involuntary Movement Scale (AIMS)|Change in Neurocognitive test battery","Augusta University|Ortho-McNeil Janssen Scientific Affairs, LLC","All","6 Years and older   (Child, Adult, Older Adult)","Phase 4","23","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RIS-EMR-4026|MCG HAC File #01-09-063","November 2001","May 2007","May 2007","July 14, 2006","null","January 14, 2015","Medical College of Georgia, Dept. of Psychiatry, Augusta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00352196"
872,"NCT00348439","Study to Evaluate Plasmin for the Creation of a Posterior Vitreous Detachment",,"Terminated","No Results Available","Disorders Caused by Vitreo-retinal Traction.","Drug: Plasmin|Drug: Vehicle","Presence of a Grade A Posterior Vitreous Detachment (PVD)","Bausch & Lomb Incorporated","All","18 Years and older   (Adult, Older Adult)","Phase 2","29","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","437","April 2006","August 2007","August 2007","July 4, 2006","null","December 8, 2011","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00348439"
873,"NCT00344994","SWITCH:Restless Legs Patients Switched to Ropinirole From Pramipexole",,"Completed","No Results Available","Restless Legs Syndrome","Drug: pramipexole","CGI-S/CGI-I: (Visits 1, 2, and 4)|IRLS: (Visits 1, 2, and 4)|Epworth Sleepiness Scale: (Visits 1, 2, and 4)|ECG: An ""ECG"" or ""electrocardiogram"" is a test that measures the electrical activity of the heart. (Visits 1, 2, and 4)","Augusta University|GlaxoSmithKline","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 4","20","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","gskswitch","May 2006","September 2007","April 2010","June 27, 2006","null","May 13, 2011","Medical College of Georgia, Augusta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00344994"
874,"NCT00344968","Fluocinolone Acetonide Implant Compared to Sham Injection in Patients With Diabetic Macular Edema","FAME","Completed","Has Results","Diabetic Macular Edema","Drug: fluocinolone acetonide|Drug: Fluocinolone Acetonide|Procedure: Standard of care laser photocoagulation","Visual Acuity|Retinal Thickness","Alimera Sciences","All","18 Years and older   (Adult, Older Adult)","Phase 3","956","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","C-01-05-001","September 2007","December 2009","December 2010","June 27, 2006","May 7, 2014","May 7, 2014","Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00344968"
875,"NCT00342394","Fungicide Exposure Assessment Among Apple and Peach Farmers in the Argicultural Health Study",,"Completed","No Results Available","Pesticides|Occupational Exposure","","","National Cancer Institute (NCI)|Centers for Disease Control and Prevention|National Institute for Occupational Safety and Health (NIOSH/CDC)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult","","75","NIH|U.S. Fed","Observational","","999902049|02-C-N049","November 14, 2001","null","May 1, 2013","June 21, 2006","null","April 5, 2018","National Institute for Occupational Safety and Health, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00342394"
876,"NCT00336570","Predictive Medicine Research. (PRE MED)",,"Completed","No Results Available","Cardiovascular Diseases","","","Emory University|The Robert W. Woodruff Foundation","All","30 Years to 90 Years   (Adult, Older Adult)","","288","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional","IRB00024767|6012","February 2006","null","October 2010","June 14, 2006","null","November 18, 2013","Emory University Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00336570"
877,"NCT00333879","Virtual Reality Mobility Training System for Veterans With Vision Loss",,"Completed","Has Results","Blindness","Device: Virtual Sound System","Accuracy in Judging Direction of Traffic at Traffic Intersection|Accuracy in Selecting Appropriate Time to Cross Street","US Department of Veterans Affairs|VA Office of Research and Development","All","18 Years and older   (Adult, Older Adult)","Not Applicable","4","U.S. Fed","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)","C4188-R","March 2009","March 2009","April 2009","June 6, 2006","November 19, 2013","December 16, 2013","Atlanta VA Medical and Rehab Center, Decatur, Decatur, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00333879"
878,"NCT00330811","B-type Natriuretic Peptide in the Non-Cardiac Pediatric Patient",,"Completed","No Results Available","Heart Diseases","","","Emory University","All","up to 5 Years   (Child)","","87","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","1409-2005","April 2006","January 2007","May 2007","May 29, 2006","null","December 2, 2016","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00330811"
879,"NCT00328185","Allograft Fibrosis Following Pediatric Cardiac Transplantation",,"Terminated","No Results Available","Children Who Underwent Heart Transplantation Prior to Age 18|Received Care at Children's Healthcare of Atlanta","","","Children's Healthcare of Atlanta","All","up to 18 Years   (Child, Adult)","","100","Other","Observational","Time Perspective: Retrospective","05-217","January 2006","null","December 2006","May 19, 2006","null","March 16, 2012","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00328185"
880,"NCT00328146","Re-operative Surgery in Children:A Technique for Sternal Re-Entry",,"Completed","No Results Available","Congenital Disorders","Other: Observation of sternal reentry","Present an effective techniqe for sternal re-entry in children.","Children's Healthcare of Atlanta","All","up to 18 Years   (Child, Adult)","","802","Other","Observational","Observational Model: Other|Time Perspective: Retrospective","06-105","February 2001","October 2009","October 2009","May 19, 2006","null","March 1, 2017","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00328146"
881,"NCT00327977","Hypoxemia in Infants After Palliative Surgery",,"Completed","No Results Available","Congenital Disorders","","Analyze the growth and development of infants with post-surgical palliation in infancy and assess variations in oxygenation saturations and hemodynamics as they relate to weight gain, linear growth and increases in head circumference.","Children's Healthcare of Atlanta","All","up to 3 Years   (Child)","","375","Other","Observational","Time Perspective: Retrospective","06-128","January 2001","February 2011","February 2011","May 19, 2006","null","December 2, 2014","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00327977"
882,"NCT00327951","Infant Weight Gain With Trisomy 21 and CAVC",,"Terminated","No Results Available","Congenital Disorders","","","Children's Healthcare of Atlanta","All","up to 1 Year   (Child)","","46","Other","Observational","Time Perspective: Retrospective","06-109","January 2001","March 2006","February 2008","May 19, 2006","null","March 16, 2012","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00327951"
883,"NCT00327899","Home Inotropic Therapy in Children",,"Terminated","No Results Available","Congenital Disorders","","","Children's Healthcare of Atlanta","All","up to 18 Years   (Child, Adult)","","13","Other","Observational","Time Perspective: Retrospective","06-129","March 2006","null","May 2007","May 19, 2006","null","November 21, 2011","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00327899"
884,"NCT00327886","Managing Cyanosis Following Bidirectional Glenn Operation",,"Terminated","No Results Available","Congenital Disorders","","","Children's Healthcare of Atlanta","All","up to 1 Year   (Child)","","150","Other","Observational","Observational Model: Defined Population|Observational Model: Natural History|Time Perspective: Longitudinal|Time Perspective: Retrospective","06-029","February 2006","null","February 2006","May 19, 2006","null","June 13, 2007","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00327886"
885,"NCT00327795","Surgical Outcomes in Pediatric Patients With Coarctation and VSD",,"Terminated","No Results Available","Diagnosis of Coarctation of the Aorta and VSD|Surgical Repair at CHOA|Between January 1, 2002 and December 31, 2005","","","Children's Healthcare of Atlanta","All","Child, Adult, Older Adult","","32","Other","Observational","Observational Model: Case Control|Time Perspective: Retrospective","06-010","January 2006","null","November 2007","May 19, 2006","null","March 16, 2012","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00327795"
886,"NCT00327782","Palliative Care of Children With End-Stage Heart Failure",,"Terminated","No Results Available","Congenital Disorders","","","Children's Healthcare of Atlanta","All","1 Year to 18 Years   (Child, Adult)","","null","Other","Observational","Observational Model: Defined Population|Observational Model: Natural History|Time Perspective: Longitudinal|Time Perspective: Retrospective","06-114","January 1995","null","April 2006","May 19, 2006","null","May 4, 2007","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00327782"
887,"NCT00321503","Study of an Oropharyngeal Aerosolized pH Probe for Diagnosing Laryngopharyngeal Reflux (LPR)",,"Completed","No Results Available","Laryngopharyngeal Reflux","","","Emory University|AstraZeneca|Respiratory Technology Corporation","All","18 Years and older   (Adult, Older Adult)","","45","Other|Industry","Observational","Time Perspective: Prospective","1345-2005|DX-1 for LPR","May 2006","May 2007","May 2007","May 3, 2006","null","December 9, 2013","Emory Voice Center, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00321503"
888,"NCT00321139","Assessment of Translesional Markers and Metabolomics",,"Completed","No Results Available","Coronary Artery Disease","","A comparison of the markers of oxidation, inflammation, and leucocyte activation in the following:|A comparison will be made between the translesional marker gradients (distal level - proximal level) of samples from the culprit lesion and non-culprit lesion.|A comparison will be made between levels (distal level - proximal level) to the culprit lesion before and after angioplasty/stenting.|3. A|A comparison of the markers of oxidation, inflammation, and leucocyte activation with plaque morphologic indices as assessed by intravascular ultrasound.|comparison of 1H-NMR metabolomic spectra from culprit and non-culprit lesions as well as plaques that have high-risk and low-risk plaque morphologies.","Emory University|Boston Scientific Corporation","All","21 Years and older   (Adult, Older Adult)","","50","Other|Industry","Observational","Time Perspective: Prospective","1189-2005","April 2006","January 2007","null","May 3, 2006","null","December 15, 2014","Emory University Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00321139"
889,"NCT00314262","Phase I/II Study of Chemoprevention With EGFR and COX-2 Inhibitor",,"Completed","Has Results","Precancerous Conditions","Drug: Erlotinib & Celecoxib","Dose Escalation and Toxicity: Toxicities Including Grades 1 to 4|Clinical Outcome: Documented Progression|Clinical Outcome: Progression to a Higher-grade Dysplasia or Carcinoma","Emory University|National Institutes of Health (NIH)","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","17","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","IRB00024922","October 2006","November 2012","November 2012","April 13, 2006","October 24, 2014","October 24, 2014","Emory University Winship Cancer Institute, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00314262"
890,"NCT00313404","Infectivity of Norovirus in Groundwater-Human Challenge Study",,"Completed","No Results Available","Healthy","Biological: Safety tested norovirus inoculum","Infection with norovirus","Emory University|Johns Hopkins University","All","18 Years to 50 Years   (Adult)","Not Applicable","13","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","0584-2002|EPA-5 R01 AI056351-03|82911601-1|RSPHGH-CLM-2005-EPANoV","February 2006","January 2007","April 2011","April 12, 2006","null","November 19, 2013","Emory University General Clinical Research Center, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00313404"
891,"NCT00313391","Risperdal Consta and Health Care Utilization in Patients With Schizophrenia",,"Completed","No Results Available","Schizophrenia|Schizoaffective Disorder","Drug: Risperdal Consta","","Emory University|Janssen, L.P. - Investigator Initiated Studies Program","All","18 Years to 55 Years   (Adult)","Phase 4","null","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)","731-2005","December 2005","December 2007","null","April 12, 2006","null","September 25, 2014","Grady Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00313391"
892,"NCT00313365","Surgical Lavage vs Serial Needle Aspiration for Infected Joints",,"Withdrawn","No Results Available","Arthritis|Septic","Procedure: Surgical Lavage (Arthrotomy)|Procedure: Arthrocentesis (Serial needle aspiration)","Eradication of infection at 2 months","Emory University","All","18 Years and older   (Adult, Older Adult)","Phase 3","0","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","218-2006","April 2006","July 2013","July 2013","April 12, 2006","null","September 24, 2013","Grady Memorial Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00313365"
893,"NCT00313352","Effects of Beta-adrenergic in Adults w/Transposition of Great Arteries on Systemic Ventricular Function",,"Completed","No Results Available","Congenital Disorders","","functional class","Emory University","All","18 Years and older   (Adult, Older Adult)","","110","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","0293-2006","January 1997","March 2007","March 2007","April 12, 2006","null","November 13, 2013","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00313352"
894,"NCT00313339","Intra-coronary Infusion of Bone Marrow Derived Autologous CD34+ Selected Cells in Patients With Acute Myocardial Infarction","AMR-1","Completed","No Results Available","Myocardial Infarction|Coronary Artery Disease","Drug: Intra-coronary infusion","Cardiac function at 3 and 6 months follow-up will be compared to baseline measures obtained the day(s) before CD34+ cell product infusion.|Perfusion of the infarct region at 6 months follow-up will be compared to baseline measures obtained the day(s) before CD34+ cell product infusion|An assessment will be performed to determine if a correlation exist between clinical outcome and cell content (CD34+) and/or in vitro colony growth (CFU-GM, CFU-GEMM, BFU-E) CXCR-4 mobility and CXCR-4 and/or VEGF surface antigen expression.","Emory University|Texas Heart Institute","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","31","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0076-2006|FDA IND 12584","March 2006","March 2009","March 2013","April 12, 2006","null","November 18, 2013","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00313339"
895,"NCT00309764","CHF Management Using Telemedicine",,"Completed","No Results Available","Congestive Heart Failure (CHF)","Behavioral: Telemedicine","Change between study entry and exit (6-months later) in frequency of recommended CHF self-care practices (maintain CHF diary, check weight daily, check ankles and feet for swelling daily)|Knowledge of signs of worsening CHF (sudden weight gain, increase in shortness of breath)|Quality of life|Rate of acute CHF exacerbations (ED visits or hospital admissions for CHF or CHF-related conditions) in the 6-month intervention period compared with the 6-month period preceding study entry.","Kaiser Permanente|Robert Wood Johnson Foundation","All","30 Years and older   (Adult, Older Adult)","Not Applicable","106","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Project # 041873","November 2001","null","August 2002","April 3, 2006","null","April 3, 2006","Kaiser Permanente - Georgia, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00309764"
896,"NCT00308217","Single Ventricle Outcome",,"Completed","No Results Available","Heart Disease, Congenital|Single Ventricle|Hypoplastic Left Heart Syndrome","","","Emory University","All","Child, Adult, Older Adult","","30","Other","Observational","Time Perspective: Prospective","0604-2005","June 2005","null","June 2005","March 29, 2006","null","December 12, 2013","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00308217"
897,"NCT00303511","Pacemaker Therapy in Adults With Congenital Heart Defects",,"Completed","Has Results","Congenital Disorder","","Feasibility of Pacemaker Implant With Total Thoracoscopic Approach to Epicardial Pacing Lead","Emory University","All","19 Years and older   (Adult, Older Adult)","","10","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","0103-2006","January 1996","August 2006","August 2006","March 17, 2006","August 8, 2014","August 8, 2014","Emory University SOM Adult Cardiac Clinic, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00303511"
898,"NCT00299052","Efficacy of DBM on Fractures of the Shinbone (Tibia)",,"Completed","No Results Available","Closed Fracture|Open Fracture","Device: Grafton DBM|Biological: Reamings","Fracture healing","Emory University","All","18 Years and older   (Adult, Older Adult)","Phase 4","16","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1272-2005|3006","March 2006","December 2007","September 2008","March 6, 2006","null","September 24, 2013","Grady Memorial Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00299052"
899,"NCT00295178","Study Comparing CUBICIN® (Daptomycin for Injection) With Vancomycin in Cellulitis or Erysipelas",,"Completed","No Results Available","Cellulitis","Drug: Daptomycin|Drug: Vancomycin","investigating the differences in speed and degree of symptom resolution between CUBICIN and vancomycin|frequency of Serious Adverse Events between daptomycin and vancomycin will be described","Cubist Pharmaceuticals LLC","All","18 Years and older   (Adult, Older Adult)","Phase 4","80","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Treatment","3009-008|DAP-4CELL-05-02","February 20, 2006","August 9, 2006","August 9, 2006","February 23, 2006","null","September 7, 2017","Joseph Still Research Foundation, Augusta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00295178"
900,"NCT00289146","Comparison of Immune Response Following Surgical Management of Renal Tumors",,"Terminated","No Results Available","Kidney Cancer","","","Emory University","All","18 Years and older   (Adult, Older Adult)","","50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","0021-2005","November 2005","August 2006","August 2006","February 9, 2006","null","September 24, 2013","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00289146"
901,"NCT00289120","Effect of Cola on Urinary Stone Risk Factors",,"Completed","Has Results","Kidney Stone","Drug: Cola beverage|Drug: Deionized water","The Plasma and Urine Parameters|The Plasma Osmolarity|Total Urine Volume|Urinary pH","Emory University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","13","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","0133-2003|GCRC#2403","November 2003","October 2011","October 2011","February 9, 2006","July 8, 2014","June 8, 2016","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00289120"
902,"NCT00288444","Interaction of Docetaxel and Lonafarnib in Patients With Advanced Cancer",,"Terminated","No Results Available","Lung Cancer|Soft Tissue Sarcoma|Colorectal Carcinoma|Breast Cancer|Prostate Cancer","Drug: Lonafarnib|Drug: Docetaxel","Determine the molecular interaction|Determine safety and efficacy","Emory University|Aventis Pharmaceuticals|Schering-Plough","All","Child, Adult, Older Adult","Phase 1","38","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","174-2004|EU841-03","January 2006","May 2008","March 2009","February 8, 2006","null","December 18, 2012","Emory University Winship Cancer Institute, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00288444"
903,"NCT00284570","Pro-Calcitonin Levels Following Pediatric Cardiac Surgery",,"Completed","No Results Available","Congenital Heart Disease|Sepsis|Infection","","","Emory University|Children's Healthcare of Atlanta","All","up to 5 Years   (Child)","","49","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","IRB00002022","January 2006","null","March 2007","February 1, 2006","null","November 27, 2013","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00284570"
904,"NCT00283998","Comparing Surgical to Conservative Management in the Treatment of Type II Odontoid Fractures Among the Elderly",,"Completed","No Results Available","Odontoid Fractures Type II","Procedure: surgical versus conservative treatment","Quality of life using the Neck disability Index|Quality of life using the SF-36|Proportion of bony fusion between the two treatments|Proportion rate of non-union between the two treatments|Rate of complications|Cervical range of motion|Identify the risk factors for a poor outcome independent of treatment intervention","AO Clinical Investigation and Documentation|AOSpine North America","All","65 Years and older   (Older Adult)","Phase 4","166","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","06-Odont-02","January 2006","October 2010","March 2012","January 31, 2006","null","March 26, 2014","Emory University SOM: Orthopedics, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00283998"
905,"NCT00278005","Infection in DiGeorge Following CHD Surgery",,"Terminated","No Results Available","DiGeorge Syndrome|Congenital Heart Defects","","","Children's Healthcare of Atlanta","All","up to 15 Years   (Child)","","400","Other","Observational","Time Perspective: Retrospective","05-134","January 1998","March 2008","March 2008","January 18, 2006","null","March 16, 2012","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00278005"
906,"NCT00277992","Growth in Children With HLHS",,"Terminated","No Results Available","Congenital Disorders","","","Children's Healthcare of Atlanta","All","up to 21 Years   (Child, Adult)","","100","Other","Observational","Observational Model: Defined Population|Observational Model: Natural History|Time Perspective: Longitudinal|Time Perspective: Retrospective","05-107","January 2001","null","null","January 18, 2006","null","May 23, 2007","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00277992"
907,"NCT00277966","Cath Lab Performance Improvement",,"Withdrawn","No Results Available","Congenital Disorders","","","Children's Healthcare of Atlanta","All","up to 21 Years   (Child, Adult)","","0","Other","Observational","Time Perspective: Retrospective","05-051","January 2004","January 2004","January 2004","January 18, 2006","null","August 9, 2016","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00277966"
908,"NCT00277953","MRI Review of Tracheal Dimensions",,"Terminated","No Results Available","Congenital Disorders","","","Children's Healthcare of Atlanta","All","up to 21 Years   (Child, Adult)","","75","Other","Observational","Observational Model: Defined Population|Observational Model: Natural History|Time Perspective: Longitudinal|Time Perspective: Retrospective","04-047","null","null","null","January 18, 2006","null","May 4, 2007","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00277953"
909,"NCT00277940","Aortic Arch Reconstruction",,"Terminated","No Results Available","Congenital Disorders","","","Children's Healthcare of Atlanta","All","up to 6 Years   (Child)","","36","Other","Observational","Time Perspective: Retrospective","03-042","null","null","null","January 18, 2006","null","July 6, 2011","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00277940"
910,"NCT00277927","Mild Valvar Pulmonary Stenosis",,"Terminated","No Results Available","Congenital Disorders","","","Children's Healthcare of Atlanta","All","up to 2 Years   (Child)","","146","Other","Observational","Time Perspective: Retrospective","04-035","January 1984","null","December 2007","January 18, 2006","null","July 6, 2011","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00277927"
911,"NCT00277901","MRI Assessment of RV Function: Patients With TOF or Aortic Coarctation",,"Completed","No Results Available","Congenital Disorders","","(1) Determine Right and left ventricular volumes during all phases of the cardiac cycle.","Children's Healthcare of Atlanta","All","up to 21 Years   (Child, Adult)","","390","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","02-122","March 2002","July 2009","July 2009","January 18, 2006","null","December 2, 2014","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00277901"
912,"NCT00276250","Islet Transplantation Using Abatacept",,"Completed","Has Results","Type 1 Diabetes Mellitus","Drug: Efalizumab|Drug: Abatacept|Drug: Belatacept","The Number of Insulin-independent Subjects at Day 75 (± 5 Days) Following the First Islet Cell Transplantation|Number of Insulin-independent Subjects Following Islet Transplantation|Number of Subjects With HbA1C Less Than 6.5%|Number of Subjects With HbA1C Levels < 6.5%|Number of Subjects With HbA1C < 6.5%|Number of Participants With Endogenous Insulin Production Post-transplant, Assessed by Fasting C-peptide Levels|The Number of Study Participants Exhibiting a Successful Response to a Standard Mixed Meal Test, Measured by Stimulated C-peptide Levels After Islet Transplant.|Number of Subjects With Normal Renal Function, as Measured by Serum Creatinine Levels","Emory University|Juvenile Diabetes Research Foundation","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","5","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00021852|1136-2005","December 2005","December 2014","December 2014","January 13, 2006","July 27, 2016","July 27, 2016","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00276250"
913,"NCT00275392","Vestibular Rehabilitation and Dizziness in Geriatric Patients",,"Completed","Has Results","Dizziness","Behavioral: Vestibular rehabilitation|Behavioral: Placebo","Dynamic Gait Index|Dynamic Visual Acuity","US Department of Veterans Affairs|VA Office of Research and Development","All","60 Years and older   (Adult, Older Adult)","Not Applicable","39","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","C4168-P","April 2006","August 2009","August 2009","January 11, 2006","October 17, 2014","December 9, 2014","Atlanta VA Medical and Rehab Center, Decatur, Decatur, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00275392"
914,"NCT00275223","Insulin Resistance in Severely Obese Patients",,"Completed","No Results Available","Obesity|Insulin Resistance|Diabetes","","","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","Female","18 Years to 65 Years   (Adult, Older Adult)","","48","NIH","Observational","Time Perspective: Prospective","R03 DK67167 (completed)","September 2004","null","null","January 11, 2006","null","March 18, 2010","Emory University Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00275223"
915,"NCT00272272","Fall Prevention in a Geriatric Nursing Home Setting Using the Music of Nolwenn Leroy",,"Completed","No Results Available","Ataxia","Behavioral: Music Therapy","Changes in Fall rate","Carrick Institute for Graduate Studies","All","50 Years and older   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","CI-01-01-06-01","December 2005","October 2006","March 2007","January 5, 2006","null","January 27, 2016","Budd Terrace Geriatric Nursing Home, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00272272"
916,"NCT00271375","Evaluating the Carter Institute Caregiver Education Program at the VA",,"Completed","Has Results","Caregivers","Behavioral: Caring For You, Caring For Me|Behavioral: Caring for you, caring for me + social worker|Behavioral: Control","To Evaluate User Satisfaction With and Perceived Utility of the ""Caring for You, Caring for Me"" Caregiver Educational Program Among Formal (VHA Staff) and Informal (Family) Caregivers Who Undergo the Program|Subjective Health|Physical Role Function|Physical Function|Depressive Symptoms|Caregiver Burden|Caregiver Satisfaction|Caregiver Mastery|Caregiver Efficacy|Personal Mastery|Perceived Social Support","VA Office of Research and Development","All","55 Years and older   (Adult, Older Adult)","Not Applicable","254","U.S. Fed","Interventional","Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: Single (Care Provider)|Primary Purpose: Health Services Research","E4044-R|IRB 2005-050240|IRB 278-2005","October 2005","August 2009","October 2009","December 30, 2005","May 30, 2016","May 30, 2016","VA Medical Center, Decatur, Decatur, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00271375"
917,"NCT00268112","Resynchronization of Left Ventricular Contraction After Reimplantation of Anomalous Left Coronary Artery",,"Terminated","No Results Available","Congenital Disorders","","","Children's Healthcare of Atlanta","All","up to 21 Years   (Child, Adult)","","3","Other","Observational","Time Perspective: Retrospective","05-203","January 2004","null","December 2006","December 22, 2005","null","March 16, 2012","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00268112"
918,"NCT00268099","Optimal Timing for Repair of Right-to-Left Shunt Lesions",,"Terminated","No Results Available","Congenital Disorders","","","Children's Healthcare of Atlanta","All","up to 18 Years   (Child, Adult)","","75","Other","Observational","Time Perspective: Retrospective","05-121","May 2005","null","November 2006","December 22, 2005","null","March 16, 2012","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00268099"
919,"NCT00268086","Constrictive Pericarditis in the Adult Congenital Cardiac Population",,"Terminated","No Results Available","Congenital Disorders","","","Children's Healthcare of Atlanta","All","18 Years and older   (Adult, Older Adult)","","15","Other","Observational","Observational Model: Defined Population|Observational Model: Natural History|Time Perspective: Longitudinal|Time Perspective: Retrospective","05-123","null","null","null","December 22, 2005","null","June 13, 2007","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00268086"
920,"NCT00268073","Incidence of Neo-Aortic Insufficiency",,"Terminated","No Results Available","Congenital Disorders","","","Children's Healthcare of Atlanta","All","up to 21 Years   (Child, Adult)","","null","Other","Observational","Observational Model: Defined Population|Observational Model: Natural History|Time Perspective: Longitudinal|Time Perspective: Retrospective","05-067","January 2002","null","null","December 22, 2005","null","May 7, 2007","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00268073"
921,"NCT00268060","Infant Medical Records: Case Report Proposal",,"Terminated","No Results Available","Congenital Disorders","","","Children's Healthcare of Atlanta","Male","up to 21 Years   (Child, Adult)","","1","Other","Observational","Observational Model: Defined Population|Observational Model: Natural History|Time Perspective: Longitudinal|Time Perspective: Retrospective","05-050","September 2004","null","null","December 22, 2005","null","May 7, 2007","Chldren's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00268060"
922,"NCT00268047","Pulmonary Resistance in Fontan Who Have Undergone Heart Transplantation",,"Terminated","No Results Available","Congenital Disorders","","","Children's Healthcare of Atlanta","All","up to 21 Years   (Child, Adult)","","50","Other","Observational","Time Perspective: Retrospective","03-068","null","null","null","December 22, 2005","null","July 6, 2011","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00268047"
923,"NCT00268034","Left Ventricular Aneurysms in Children",,"Terminated","No Results Available","Congenital Disorders","","","Children's Healthcare of Atlanta","All","up to 21 Years   (Child, Adult)","","5","Other","Observational","Observational Model: Defined Population|Observational Model: Natural History|Time Perspective: Longitudinal|Time Perspective: Retrospective","04-073","June 2002","null","null","December 22, 2005","null","May 7, 2007","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00268034"
924,"NCT00268021","Automated Cardioverter Defibrillator in Children",,"Completed","No Results Available","Congenital Disorders","","","Children's Healthcare of Atlanta","All","up to 21 Years   (Child, Adult)","","34","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","04-082","January 1998","null","null","December 22, 2005","null","December 2, 2014","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00268021"
925,"NCT00268008","Children and Adolescents Receiving Mechanical and Prosthetic Valves",,"Terminated","No Results Available","Congenital Disorders","","","Children's Healthcare of Atlanta","All","up to 21 Years   (Child, Adult)","","300","Other","Observational","Observational Model: Defined Population|Observational Model: Natural History|Time Perspective: Longitudinal|Time Perspective: Retrospective","05-033","January 1976","null","null","December 22, 2005","null","May 7, 2007","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00268008"
926,"NCT00267995","Ross Aortic Valve Replacement Patients",,"Terminated","No Results Available","Congenital Disorders","","","Children's Healthcare of Atlanta","All","up to 21 Years   (Child, Adult)","","75","Other","Observational","Time Perspective: Retrospective","03-047","December 1994","null","null","December 22, 2005","null","July 6, 2011","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00267995"
927,"NCT00267982","Radiofrequency Ablation of Ectopic Atrial Tachycardia",,"Terminated","No Results Available","Congenital Disorders","","","Children's Healthcare of Atlanta","All","up to 21 Years   (Child, Adult)","","25","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","03-064","August 1992","August 2003","February 2008","December 22, 2005","null","July 6, 2011","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00267982"
928,"NCT00267462","Hypertrophic Myopathy in Children",,"Terminated","No Results Available","Congenital Disorders","","","Children's Healthcare of Atlanta","All","up to 21 Years   (Child, Adult)","","75","Other","Observational","Observational Model: Defined Population|Observational Model: Natural History|Time Perspective: Longitudinal|Time Perspective: Retrospective","05-034","January 1996","null","null","December 21, 2005","null","May 7, 2007","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00267462"
929,"NCT00267423","Biventricular Pacing in the Pediatric Population",,"Terminated","No Results Available","Congenital Disorders","","","Children's Healthcare of Atlanta","All","up to 21 Years   (Child, Adult)","","12","Other","Observational","Observational Model: Defined Population|Observational Model: Natural History|Time Perspective: Longitudinal|Time Perspective: Retrospective","04-040","January 2002","null","null","December 21, 2005","null","May 4, 2007","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00267423"
930,"NCT00267397","Prevalence and Clinical Spectrum of the 22q11 Deletion",,"Terminated","No Results Available","Congenital Disorders","","","Children's Healthcare of Atlanta","All","up to 6 Years   (Child)","","null","Other","Observational","Observational Model: Defined Population|Observational Model: Natural History|Time Perspective: Longitudinal|Time Perspective: Retrospective","01-107","January 1967","null","December 2006","December 21, 2005","null","May 4, 2007","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00267397"
931,"NCT00266968","Outcomes of Children With Congenital Single Ventricle Heart",,"Completed","No Results Available","Congenital Disorders","","We propose to do a retrospective chart review of patient data including a review of their invasive and non-invasive studies.","Children's Healthcare of Atlanta","All","up to 21 Years   (Child, Adult)","","200","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","03-005","January 2000","December 2013","December 2013","December 20, 2005","null","December 2, 2014","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00266968"
932,"NCT00266955","Retrospective of Children With ADHD and Cardiac Symptoms",,"Terminated","No Results Available","Congenital Disorders","","","Children's Healthcare of Atlanta","All","up to 18 Years   (Child, Adult)","","10","Other","Observational","Time Perspective: Retrospective","04-111","January 1999","null","September 2007","December 20, 2005","null","July 6, 2011","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00266955"
933,"NCT00266942","Intra-Atrial vs. Extra-Cardiac Technique During Fontan Operation",,"Terminated","No Results Available","Congenital Disorders","","","Children's Healthcare of Atlanta","All","up to 18 Years   (Child, Adult)","","400","Other","Observational","Observational Model: Defined Population|Observational Model: Natural History|Time Perspective: Longitudinal|Time Perspective: Retrospective","05-109","January 1990","null","January 2007","December 20, 2005","null","May 23, 2007","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00266942"
934,"NCT00266916","Percutaneous Interventions in Adults With CHD",,"Terminated","No Results Available","Congenital Disorders","","","Children's Healthcare of Atlanta","All","18 Years and older   (Adult, Older Adult)","","9","Other","Observational","Observational Model: Defined Population|Observational Model: Natural History|Time Perspective: Longitudinal|Time Perspective: Retrospective","05-138","January 1996","null","August 2006","December 20, 2005","null","May 23, 2007","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00266916"
935,"NCT00266903","Eisenmenger's Syndrome in Adults With CHD",,"Completed","No Results Available","Congenital Disorders","","Review the outcome of treatment with endothelin receptor antagonists (bosentan or sitaxsetan) alone or in combination with Sildenafil (a PDE-5 inhibitor) in adult patients with pulmonary hypertension due to congenital heart disease","Children's Healthcare of Atlanta","All","18 Years and older   (Adult, Older Adult)","","48","Other","Observational","Time Perspective: Retrospective","05-118","January 1996","January 2008","January 2008","December 20, 2005","null","December 2, 2014","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00266903"
936,"NCT00265720","Colorectal Cancer Screening Intervention Trial",,"Completed","No Results Available","Colorectal Cancer|Colorectal Cancer Screening","Other: Control|Other: Reduced out of pocket expense|Behavioral: one on one education|Behavioral: Group education","Colorectal Cancer Screening Rate; This measurement(Impact) is taken 90 days from last intervention session. If a person is not screened, an additional measurement(Post-Impact) is taken 90 days from the Impact.|Knowledge, Attitudes and Beliefs; this measurement is taken at baseline and post intervention session. Sessions vary by intervention group after the initial recruitment sessions:","Morehouse School of Medicine|Centers for Disease Control and Prevention","All","50 Years and older   (Adult, Older Adult)","Not Applicable","360","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)","H57/CCH420680-05","March 2003","July 2007","July 2007","December 15, 2005","null","February 4, 2009","Morehouse School of Medicine, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00265720"
937,"NCT00263978","Defibrotide Compassionate Use for Patients With Life Threatening Veno-Occlusive Disease of the Liver",,"No longer available","No Results Available","Liver Diseases","Drug: Defibrotide","","Emory University","All","1 Year to 22 Years   (Child, Adult)","","null","Other","Expanded Access","","0966-2005","November 2005","June 2009","June 2009","December 12, 2005","null","July 1, 2014","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00263978"
938,"NCT00262509","Emergency Egress and Information System for Persons With Vision Loss",,"Terminated","Has Results","Blindness","Device: Egress Badge","Time to Exit Building","US Department of Veterans Affairs|VA Office of Research and Development","All","18 Years and older   (Adult, Older Adult)","Not Applicable","17","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)","C3905-R","September 2008","December 2008","April 2009","December 6, 2005","February 11, 2014","February 11, 2014","Atlanta VA Medical and Rehab Center, Decatur, Decatur, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00262509"
939,"NCT00261989","Pulse Oximetry Readings and Hourly Variation in Oximetry Readings With CHD",,"Terminated","No Results Available","Congenital Disorders","","","Children's Healthcare of Atlanta","All","Child, Adult, Older Adult","","1000","Other","Observational","Time Perspective: Retrospective","05-198","November 2005","null","September 2007","December 6, 2005","null","July 6, 2011","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00261989"
940,"NCT00260780","An STD Prevention Intervention for Men Newly Released From Jail",,"Completed","No Results Available","Sexually Transmitted Diseases|Risk Behavior","Behavioral: The MISTERS Intervention for Post Jail Release Men","Change in risk behaviors|Reported STDs","Centers for Disease Control and Prevention|STAND, Inc.","Male","18 Years to 60 Years   (Adult)","Not Applicable","300","U.S. Fed|Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","CDC-NCHSTP-3728|U52/CCU422491|H25/CCH404332-11","June 2001","null","June 2004","December 2, 2005","null","December 2, 2005","STAND, Inc., Decatur, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00260780"
941,"NCT00257543","SALT: Alternative Donor Bone Marrow and Cord Blood Transplantation for High Risk Sickle Cell Disease",,"Terminated","No Results Available","Sickle Cell Disease","Procedure: Alternative donor bone marrow and cord blood","To determine the frequency of donor engraftment after alternate donor transplantation in children with severe sickle cell disease.","Emory University","All","up to 16 Years   (Child)","Early Phase 1","3","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","876-2003","January 2006","August 2012","August 2012","November 23, 2005","null","September 17, 2013","Children's Healthcare of Altanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00257543"
942,"NCT00257517","Multisite Feeding Study: Home Surveillance and Feeding Strategies in Infants With Complex Single Ventricle",,"Completed","No Results Available","Congenital Disorders","","weight gain","Emory University","All","up to 30 Days   (Child)","","20","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IRB00021873","October 2005","January 2010","June 2010","November 23, 2005","null","February 13, 2014","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00257517"
943,"NCT00254826","Yellow Fever Virus Vaccine and Immune Globulin Study",,"Completed","No Results Available","Viremia","Biological: YF-VAX® plus saline|Biological: 17D YF Vaccine plus Ig,","Compare the proportion of participants developing viremia between the group receiving the yellow fever vaccine/saline and yellow fever vaccine with human immune globulin.|Compare the viremia levels between the group of vaccinees receiving yellow fever vaccine with the group receiving yellow fever vaccine with human immune globulin.|Compare the dynamics of T cell activation, cytokine response and dendritic cell response in vaccinees during primary response to yellow fever vaccine to vaccinees given yellow fever vaccine given in combination with human immune globulin.|Compare the geometric mean neutralizing antibody titer in the group of yellow fever vaccinees with the group of vaccinees receiving yellow fever vaccine in combination with human immune globulin.","Emory University|Sanofi Pasteur, a Sanofi Company|Centers for Disease Control and Prevention","All","18 Years to 40 Years   (Adult)","Phase 1","80","Other|Industry|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","IRB00045982","June 2006","November 2008","November 2008","November 17, 2005","null","December 4, 2013","Emory Vaccine Center-The Hope Clinic and The Pediatric ID Clinic, Decatur, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00254826"
944,"NCT00253773","Metabolic Effects of Chemical Interactions in Toxicity",,"Completed","No Results Available","Oxidative Stress","Drug: acetominophen, sulfer amino acids; cysteine and methionine","individual thiol and disulfide components; GSH/GSSG and Cys/CySS redox state; urinary output of taurine and sulfate","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","18 Years to 40 Years   (Adult)","Not Applicable","15","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single|Primary Purpose: Diagnostic","ES12929 (completed)|DK66008","January 2005","null","November 2007","November 15, 2005","null","January 13, 2010","Emory University Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00253773"
945,"NCT00253760","Metabolic Analysis in Human Sulfur Amino Acid Deficiency",,"Completed","No Results Available","Oxidative Stress|Diabetes|Heart Diseases","Drug: dietary amino acids; cysteine and methionine","redox state of the two central low molecular weight thiol-disulfide pools, i.e., GSH/GSSG and cysteine (Cys)/cystine (CySS)|a global metabolic spectrum detectable by H-NMR","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","18 Years to 40 Years   (Adult)","Not Applicable","15","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","R03 DK66008 (completed 2007)","February 2004","null","February 2007","November 15, 2005","null","March 18, 2010","Emory University Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00253760"
946,"NCT00253045","Motivating HIV+ Women: Risk Reduction and ART Adherence","KHARMA","Completed","No Results Available","HIV|AIDS","Behavioral: Motivational groups","Adherence to antiretroviral therapy|Use of Risk Reduction Behaviors|Clinical indicators|Self-Efficacy|Outcome Expectancy|Personal Goals","Emory University","Female","18 Years to 85 Years   (Adult, Older Adult)","Not Applicable","207","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","IRB00045905|1R01NR008094-01A1","August 2004","January 2008","January 2008","November 15, 2005","null","September 17, 2013","Nell Hodgson Woodruff School of Nursing, Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00253045"
947,"NCT00253019","A Comparison of Continuation Rates for Three Hormonal Contraceptive Methods",,"Completed","Has Results","Contraception","","Continuation Rates","Emory University","Female","13 Years to 45 Years   (Child, Adult)","","321","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","518-2003","October 2004","November 2005","November 2005","November 15, 2005","August 9, 2013","August 21, 2013","Grady Memorial Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00253019"
948,"NCT00249067","Retrospective Evaluation of Carvedilol Versus Captopril in CHF Patients",,"Terminated","No Results Available","Heart Failure|Heart Murmurs","","","Children's Healthcare of Atlanta","All","up to 18 Years   (Child, Adult)","","50","Other","Observational","Observational Model: Defined Population|Observational Model: Natural History|Time Perspective: Longitudinal|Time Perspective: Retrospective","05.178","October 2005","null","October 2005","November 7, 2005","null","June 13, 2007","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00249067"
949,"NCT00248768","Accelerated Transcranial Magnetic Stimulation (TMS) for Depression","ATMS","Completed","No Results Available","Depression","Device: Transcranial magnetic Stimulator","Hamilton Depression Scale","US Department of Veterans Affairs|VA Office of Research and Development","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","20","U.S. Fed","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","B3357-R|Emory IRB 601-2004","February 2005","January 2009","June 2009","November 4, 2005","null","September 19, 2014","Atlanta VA Medical and Rehab Center, Decatur, Decatur, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00248768"
950,"NCT00248248","DOXIL for Consolidation Therapy in Ovarian Cancer.",,"Completed","No Results Available","Ovarian Neoplasm","Drug: liposomal doxorubicin","Development, frequency, and severity of hand-foot syndrome with every two week therapy|One-year progression free survival","Southeastern Gynecologic Oncology|Ortho Biotech, Inc.","Female","18 Years and older   (Adult, Older Adult)","Phase 2","45","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SEGO_DOXIL_CONS2005","October 2005","October 2011","October 2011","November 3, 2005","null","October 12, 2011","Southeastern Gynecologic Oncology, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00248248"
951,"NCT00244478","Soy, Bone and Health in College Females",,"Completed","No Results Available","Osteoporosis|Obesity","Dietary Supplement: Soy Protein Dietary Supplement|Dietary Supplement: Placebo","Bone specific alkaline phosphatase, N-telopeptide, osteocalcin, pyridinoline, deoxypyridinoline, height, weight, waist circumference, fat mass, fat-free soft tissue mass and bone mass will be measured at baseline, 8- and 16-weeks.|Leptin, adipose tissue vascular endothelial growth factors, angiopoietins, and cytokines will be measured in the serum at baseline, 8- and 16-weeks. The impact of soy on satiety and depression will be measured at baseline, 8- and 16-weeks.","University of Georgia","Female","18 Years to 19 Years   (Adult)","Not Applicable","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","10-20-2005-FOCUS","October 2005","March 2006","March 2006","October 26, 2005","null","September 25, 2015","The University of Georgia, Athens, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00244478"
952,"NCT00243802","Markers of Oxidative Stress Present in Left Atrial Appendage Tissue in Patients With Atrial Fibrillation",,"Terminated","No Results Available","Atrial Fibrillation|Atrial Flutter|Inflammation","","Oxidative Stress","Emory University","All","18 Years to 65 Years   (Adult, Older Adult)","","23","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","310-2005","May 2005","February 2008","February 2008","October 25, 2005","null","September 27, 2013","Emory University Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00243802"
953,"NCT00243776","Molecular and Cellular Characterization of Cardiac Tissue in Postnatal Development",,"Recruiting","No Results Available","Congenital Heart Disease|Tetralogy of Fallot","","Calcium Current Measures|Change in structural, functional and metabolic maturation of Human pluripotent stem cell derived Cardiomyocytes (hPSC-CMs)","Emory University|National Heart, Lung, and Blood Institute (NHLBI)","All","up to 18 Years   (Child, Adult)","","600","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","IRB00005500|R01HL077485|35328","April 2005","January 31, 2020","January 31, 2020","October 25, 2005","null","September 21, 2018","Emory University School of Medicine, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00243776"
954,"NCT00239603","Efficacy Study of the OV-Watch™ Personal Fertility Monitor for Women Using Clomiphene Citrate.",,"Completed","No Results Available","Infertility|Anovulation|Polycystic Ovary Syndrome","Device: OV-Watch","","Emory University|HealthWatchSystems, Inc.","Female","21 Years to 42 Years   (Adult)","","40","Other|Industry","Observational","Observational Model: Defined Population|Observational Model: Natural History|Time Perspective: Longitudinal|Time Perspective: Prospective","867-2005","October 2005","null","June 2007","October 17, 2005","null","April 17, 2007","Emory Reproductive Center, Crawford Long Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00239603"
955,"NCT00239551","Effect of Prevacid on Prostaglandin Levels in Patient With Stress Ulcer",,"Completed","No Results Available","Stomach Ulcer","Drug: Prevacid","the effect of Prevacid on prostaglandin levels at 8 weeks|esophagogastroduodenal endoscopy(EGD) with biopsy at day 1; EGD with biopsy at 8 weeks","Emory University|TAP Pharmaceutical Products Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 4","30","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","623-2005","October 2005","October 2006","December 2007","October 17, 2005","null","July 31, 2013","Emory University School of Medicine, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00239551"
956,"NCT00238823","Cryoablation Versus Radiofrequency Ablation",,"Terminated","No Results Available","Congenital Disorders","","","Children's Healthcare of Atlanta","All","Child, Adult, Older Adult","","50","Other","Observational","Observational Model: Defined Population|Observational Model: Natural History|Time Perspective: Longitudinal|Time Perspective: Retrospective","05-108","January 2004","null","December 2004","October 14, 2005","null","May 23, 2007","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00238823"
957,"NCT00238810","Relationship of Brain Natriuretic Peptide (BNP) Levels to Cardiac Diagnosis, Operation Performed, Post-operative Course and Outcome",,"Completed","No Results Available","Congenital Heart Disease","","define BNP levels in the pediatric cardiac defect population and to evaluate the relationship of those levels with cardiac diagnosis, operation performed, post-operative course and outcome.","Children's Healthcare of Atlanta","All","Child, Adult, Older Adult","","20","Other","Observational","Time Perspective: Retrospective","05.068","April 2005","November 2014","November 2014","October 14, 2005","null","December 2, 2014","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00238810"
958,"NCT00237757","Rehabilitation Team Functioning and Patient Outcomes",,"Completed","No Results Available","Stroke","Behavioral: Information feedback","functional gain as measured by motor FIM score","US Department of Veterans Affairs|VA Office of Research and Development","All","Child, Adult, Older Adult","Not Applicable","31","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","O3225-R","January 2002","January 2004","September 2009","October 12, 2005","null","July 3, 2013","VA Medical Center, Decatur, Decatur, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00237757"
959,"NCT00237055","Infectious Agents in Pediatric Crohn's",,"Completed","No Results Available","Crohn's Disease|Inflammatory Bowel Disease","","","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","6 Months to 18 Years   (Child, Adult)","","500","NIH","Observational","Time Perspective: Prospective","R03 DK64544 (completed)|NIDDK R03 DK64544","August 2004","null","September 2006","October 12, 2005","null","March 18, 2010","Emory University School of Medicine; Emory Children's Center, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00237055"
960,"NCT00231374","Measure of Cerebrospinal Fluid (CSF) Pressure Variation With Patient Positioning",,"Withdrawn","No Results Available","Back Pain","Procedure: Myelogram","CSF pressure measurements on 5 patients having a cervical myelogram in 3 positions.|CSF pressure measurements on 5 patients having a lumbar myelogram in 2 positions.|Safety measurements of one position over another.","Emory University","All","18 Years to 64 Years   (Adult)","Not Applicable","0","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","0489-2005","September 2005","September 2007","September 2007","October 4, 2005","null","January 9, 2014","Emory Orthopaedics & Spine Center, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00231374"
961,"NCT00231348","Nefazodone in the Treatment of Social Phobia",,"Completed","No Results Available","Social Anxiety Disorder (SAD)","Drug: Nefazodone","","Emory University|Bristol-Myers Squibb","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","24","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0707-1997","null","null","April 2000","October 4, 2005","null","November 13, 2013","Emory University Depatment of Psychiatry and Behavioral Sciences, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00231348"
962,"NCT00231309","Granulocyte Colony Stimulating Factor (G-CSF) for Bone Marrow Transplant (BMT)",,"Completed","Has Results","Hematologic Diseases|Hematologic Malignancies","Drug: Granulocyte Colony Stimulating Factor","Numbers of Participants With Disease-free Survival.|Hospital Length of Stay","Emory University","All","up to 55 Years   (Child, Adult)","Not Applicable","10","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0561-2003","July 2003","November 2011","November 2011","October 4, 2005","August 19, 2014","August 22, 2014","Children's Healthcare of Atlanta/Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00231309"
963,"NCT00229905","Child With Anomalous Drainage of IVC to Left Atrium",,"Terminated","No Results Available","Congenital Disorders","","","Children's Healthcare of Atlanta","Male","Child, Adult, Older Adult","","1","Other","Observational","Time Perspective: Retrospective","05-042","March 2005","null","November 2006","September 30, 2005","null","March 16, 2012","Children's Healthcare of Atlanta at Egleston, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00229905"
964,"NCT00229892","Incisions for Cardiac Surgery",,"Terminated","No Results Available","Cardiac Surgery|Cardiac Diseases","","","Children's Healthcare of Atlanta","All","Child, Adult, Older Adult","","90","Other","Observational","Time Perspective: Retrospective","04-120","February 2005","null","September 2006","September 30, 2005","null","November 18, 2011","Children's Healthcare of Atlanta at Egleston, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00229892"
965,"NCT00229879","Rare Tumor Case Review",,"Terminated","No Results Available","Intrapericardial Teratoma Tumor|Tumors","","","Children's Healthcare of Atlanta","All","Child, Adult, Older Adult","","null","Other","Observational","Time Perspective: Retrospective","04-119","December 2004","null","September 2006","September 30, 2005","null","March 16, 2012","Children's Healthcare of Atlanta at Egleston, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00229879"
966,"NCT00229866","Feeding After Neonate Surgery Review",,"Terminated","No Results Available","Congenital Disorders","","","Children's Healthcare of Atlanta","All","Child, Adult, Older Adult","","90","Other","Observational","Time Perspective: Retrospective","04-072","August 2005","null","June 2006","September 30, 2005","null","July 6, 2011","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00229866"
967,"NCT00229853","Thoracoscopic Vascular Rings Chart Review",,"Terminated","No Results Available","Cardiovascular Abnormalities","","","Children's Healthcare of Atlanta","All","Child, Adult, Older Adult","","47","Other","Observational","Time Perspective: Retrospective","04-069","August 2004","null","July 2007","September 30, 2005","null","July 6, 2011","Children's Healthcare of Atlanta at Egleston, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00229853"
968,"NCT00229840","Evaluation of Functional MRI and DTI (Imaging Techniques) in Children With Epilepsy and Focal Brain Lesions",,"Completed","No Results Available","Epilepsy","Procedure: Functional MRI, Diffusion Tensor Imaging","","Children's Healthcare of Atlanta","All","4 Years to 21 Years   (Child, Adult)","Not Applicable","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","Functional MRI","February 2006","April 2008","April 2008","September 30, 2005","null","June 27, 2011","Children's Healthcare of Atlanta at Scottish Rite, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00229840"
969,"NCT00229827","Optimal Timing for Repair of Left to Right Shunt Lesions",,"Terminated","No Results Available","Ventricular Septal Defects|Persistent Common Atrioventricular Canal","","","Children's Healthcare of Atlanta","All","Child, Adult, Older Adult","","200","Other","Observational","Time Perspective: Retrospective","05-092","May 2005","null","August 2007","September 30, 2005","null","March 16, 2012","Children's Healthcare of Atlanta at Egleston, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00229827"
970,"NCT00229814","Study of Brain Tumors (Tectal Tumors) Using Magnetic Resonance Imaging",,"Withdrawn","No Results Available","Tectal Plate Glioma","","","Children's Healthcare of Atlanta","All","4 Years to 18 Years   (Child, Adult)","","0","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","Tectal Tumors MRS","August 2005","December 2007","December 2007","September 30, 2005","null","September 24, 2012","Children's Healthcare of Atlanta at Scottish Rite, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00229814"
971,"NCT00229801","Evaluation of Kidney Function in Children With Brain Tumors",,"Withdrawn","No Results Available","Brain Tumor","Radiation: MRI","","Children's Healthcare of Atlanta","All","up to 18 Years   (Child, Adult)","Not Applicable","0","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","Renal Function/Brain Tumors","June 2004","July 2008","July 2008","September 30, 2005","null","September 24, 2012","Children's Healthcare of Atlanta at Scottish Rite, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00229801"
972,"NCT00229788","Impact of Race and Re-Transplantation",,"Terminated","No Results Available","Orthotopic Heart Transplantation","","","Children's Healthcare of Atlanta","All","up to 18 Years   (Child, Adult)","","null","Other","Observational","Observational Model: Defined Population|Observational Model: Natural History|Time Perspective: Longitudinal|Time Perspective: Retrospective","05.018","March 2005","null","null","September 30, 2005","null","June 13, 2007","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00229788"
973,"NCT00229762","Racial Disparities in Pneumococcal Vaccination in Managed Care",,"Completed","No Results Available","Pneumococcal Disease Prevention","Behavioral: phone call from nurses - informational only","pneumococcal vaccination coverage","Centers for Disease Control and Prevention|Kaiser Permanente","All","18 Years and older   (Adult, Older Adult)","Not Applicable","7000","U.S. Fed|Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single|Primary Purpose: Educational/Counseling/Training","CDC-NIP-4252|000HCJ4-2004-07797","March 2004","null","June 2005","September 30, 2005","null","September 30, 2005","Kaiser Permanente, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00229762"
974,"NCT00228852","IMM 0212: Busulfan With Fludarabine and Antithymocyte Globulin as Preparative Therapy for Hematopoietic Stem Cell Transplant for the Treatment of Severe Congenital T-Cell Immunodeficiency",,"Completed","No Results Available","T-Cell Immune Deficiency Diseases|Severe Combined Immunodeficiency","Drug: Busulfan, Fludarabine and ATG","","Emory University","All","Child, Adult, Older Adult","Phase 1|Phase 2","null","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)","296-2003","null","null","November 2006","September 29, 2005","null","June 30, 2009","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00228852"
975,"NCT00228839","GVH 022P: Study Using Anti Tumor Necrosis Factor Antibody (Infliximab) for Treatment of Acute Graft Versus Host Disease",,"Completed","No Results Available","Graft vs Host Disease","Drug: Infliximab","","Emory University","All","up to 18 Years   (Child, Adult)","Phase 1","null","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","540-2003","null","null","October 2006","September 29, 2005","null","June 30, 2009","Children's Healthcare of Atlanta/Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00228839"
976,"NCT00228813","G-CSF PMRD: Granulocyte Colony Stimulating Factor (G-CSF) Stimulated Bone Marrow and In Vivo T-Cell Depletion in Patients With Hematologic Malignancies or Bone Marrow Failure Syndrome","G-CSF PMRD","Terminated","Has Results","Hematologic Malignancies","Drug: Granulocyte Colony Stimulating Factor","Engraftment Rate|Incidence of Acute Graft-versus-host Disease|Incidence of Chronic Graft-versus-host Disease","Emory University","All","up to 22 Years   (Child, Adult)","Not Applicable","8","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00021819|0159-2004","April 2004","January 2015","January 2015","September 29, 2005","July 6, 2016","September 11, 2017","Children's Healthcare of Atlanta/Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00228813"
977,"NCT00228696","National Wilm's Tumor Study Late Effects",,"Withdrawn","No Results Available","Wilm's Tumor","Other: none, screening only","To determine if survivors from Wilms tumors or their offspring are at risk for adverse medical conditions.","Emory University","All","18 Years to 85 Years   (Adult, Older Adult)","Not Applicable","0","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","IRB00024842","September 2005","December 2010","December 2011","September 29, 2005","null","November 26, 2013","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00228696"
978,"NCT00228683","Hepatoblastoma Biology Study and Tissue Bank",,"Withdrawn","No Results Available","Hepatoblastoma","Procedure: Biology Study and Tissue Banking","To collect and bank Hepatoblastoma specimens.","Emory University","All","6 Months to 21 Years   (Child, Adult)","Not Applicable","0","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)","IRB00024899","September 2005","January 2015","January 2015","September 29, 2005","null","November 26, 2013","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00228683"
979,"NCT00228670","Herpesvirus in Idiopathic Pulmonary Fibrosis",,"Completed","No Results Available","Lung Diseases|Herpesvirus Infections","","Viral load","Emory University","All","Child, Adult, Older Adult","","41","Other","Observational","Observational Model: Other|Time Perspective: Prospective","IRB00041094|IPF","July 2005","August 2012","August 2012","September 29, 2005","null","May 11, 2017","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00228670"
980,"NCT00228644","Effect of Sulfur Amino Acid Depletion and Acetaminophen on Plasma Glutatione",,"Completed","No Results Available","Healthy","","","Emory University|National Institutes of Health (NIH)","All","18 Months to 40 Years   (Child, Adult)","","15","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","501-2004","July 2005","null","January 2009","September 29, 2005","null","January 30, 2009","Emory University Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00228644"
981,"NCT00228631","Analysis of T-Cell Immune Reconstitution Following Allogeneic Hematopoietic BMT for Severe SCD",,"Completed","No Results Available","Sickle Cell Disease","","To determine the rate of T cell immune reconstitution in children with sickle cell disease","Emory University","All","6 Months to 21 Years   (Child, Adult)","","7","Other","Observational","Observational Model: Cohort","IRB00021821|21821 (formerly 849-2005)","September 2005","August 2011","July 2012","September 29, 2005","null","May 26, 2014","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00228631"
982,"NCT00228618","Dietary Effects of Sulfur Amino Acids",,"Completed","No Results Available","Healthy","","","Emory University|National Institutes of Health (NIH)","All","18 Years to 40 Years   (Adult)","","20","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","1098-2003","January 2005","null","January 2009","September 29, 2005","null","January 30, 2009","Emory University Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00228618"
983,"NCT00215098","Chylothorax Following Heart Surgery",,"Terminated","No Results Available","Chylothorax","","","Children's Healthcare of Atlanta","All","Child, Adult, Older Adult","","70","Other","Observational","Time Perspective: Retrospective","05-093","May 2005","null","November 2006","September 22, 2005","null","March 16, 2012","Children's Healthcare of Atlanta at Egleston, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00215098"
984,"NCT00215085","Cardiac Tumors in Children",,"Terminated","No Results Available","Congenital Heart Disease","","","Children's Healthcare of Atlanta","All","Child, Adult, Older Adult","","70","Other","Observational","Time Perspective: Retrospective","05-091","May 2005","null","November 2006","September 22, 2005","null","March 16, 2012","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00215085"
985,"NCT00215072","Death Following Congenital Heart Surgery",,"Terminated","No Results Available","Congenital Heart Surgery|Congenital Heart Defects","","","Children's Healthcare of Atlanta","All","Child, Adult, Older Adult","","40","Other","Observational","Time Perspective: Retrospective","05-090","July 2005","null","February 2007","September 22, 2005","null","March 16, 2012","Children's Healthcare of Atlanta at Egleston, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00215072"
986,"NCT00215033","Relationship Between EBV and PTLD",,"Terminated","No Results Available","Pediatric Heart Transplant","","","Children's Healthcare of Atlanta","All","Child, Adult, Older Adult","","160","Other","Observational","Time Perspective: Retrospective","05-089","April 2005","null","May 2006","September 22, 2005","null","March 16, 2012","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00215033"
987,"NCT00214617","Effect of Crestor on Lipoprotein Metabolism in Humans",,"Completed","No Results Available","Hypercholesterolemia","Drug: Rosuvastatin at 5 mg/day and 40 mg/day","Rate of production of VLDL apoB|Rate of clearance of VLDL apoB|Rate of production of LDL apoB|Rate of clearance of LDL apoB|Rate of production of HDL apoA-I|Rate of clearance of HDL apoA-I|Activity of cholesteryl ester transfer protein","Atlanta Research and Education Foundation|AstraZeneca","All","50 Years to 75 Years   (Adult, Older Adult)","Phase 4","8","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AREF_Le_IRUSROSU 0021|IRUSROSU 0021","January 2005","null","February 2006","September 22, 2005","null","June 20, 2017","Atlanta Research and Education Foundation, Decatur, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00214617"
988,"NCT00211562","Adjunctive Supplementation of Antioxidants (Vitamins E + C) Plus Omega-3 Fatty Acids",,"Terminated","No Results Available","Schizophrenia","Drug: Olanzapine, Omega 3, Vitamin E+C","PANSS|BMI|Blood samples|Cognitive assessments","Augusta University|Eli Lilly and Company|Medical Service Line ABRC|US Department of Veterans Affairs","All","18 Years to 55 Years   (Adult)","Phase 3","20","Other|Industry|U.S. Fed","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Omega-3 Fatty Acids","October 2005","January 2006","null","September 21, 2005","null","October 24, 2012","VA Medical Center, Augusta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00211562"
989,"NCT00211081","Spironolactone in Patients With Single Ventricle Heart",,"Completed","Has Results","Congenital Disorders","Drug: Spironolactone (drug)","Change in Flow Mediated Dilation|C-Reactive Protein Level|Interleukin-6 (IL-6) Level|Interleukin 1 Beta (IL1b) Level|Interleukin-10 (IL10) Level|Tumor Necrosis Factor-Alpha (TNF-a) Level|Change in 6 Minute Walk Test Score","Emory University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","12","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0954-2004","November 2004","June 2008","June 2008","September 21, 2005","December 16, 2014","November 6, 2017","Emory Clinic, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00211081"
990,"NCT00209196","Quality of Life in Pediatric Transplant Recipients",,"Completed","No Results Available","Kidney Transplantation|Liver Transplantation|Heart Transplantation|Lung Transplantation|Heart-Lung Transplantation","","Pediatric Quality of Life Measure (Peds QL)","Emory University","All","11 Years to 18 Years   (Child, Adult)","","65","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","IRB00045836","May 2005","July 2007","January 2015","September 21, 2005","null","February 11, 2015","Children's Healthcare of Atlanta, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00209196"
991,"NCT00209170","Depression-Diabetes Mechanisms: Urban African Americans",,"Completed","Has Results","Diabetes|Depression","Behavioral: Beating the Blues|Drug: Escitalopram|Drug: Placebo","Response of Participants, Defined by Change in the 21-item Hamilton Depression Rating Scale (HDRS) From Baseline to Week 24","Emory University|National Institute of Mental Health (NIMH)","All","18 Years to 81 Years   (Adult, Older Adult)","Phase 4","20","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRB00001092|R01MH069254-03","May 2004","May 2008","May 2008","September 21, 2005","July 29, 2015","July 29, 2015","Grady Hospital Diabetes Clinic, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00209170"
992,"NCT00209131","Efficacy of Flomax to Improve Stone Passage Following Shock Wave Lithotripsy",,"Terminated","Has Results","Urolithiasis","Drug: Flomax|Drug: Sugar pill","Time to Passage of Stone Fragments|Medical Evaluation","Emory University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0128-2005","April 2005","February 2009","February 2009","September 21, 2005","July 9, 2012","October 28, 2013","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00209131"
993,"NCT00209105","Characterizing Psychological Consequences of Childhood Trauma",,"Completed","No Results Available","Major Depressive Disorder","Drug: DEX-CRF stimulation test|Behavioral: Psychosocial stress induction|Procedure: Brain imaging of sad mood , self-reference, reward|Behavioral: Acoustic startle","Pathophysiological pathways (e.g., blood chemicals, physiological measures, brain images, behavioral measures), as assessed by diagnostic tests","Emory University|National Institute of Mental Health (NIMH)","All","18 Years to 45 Years   (Adult)","","113","Other|NIH","Observational","Observational Model: Case-Only|Time Perspective: Prospective","IRB00021800|P50MH058922|572-2004|DATR A3-NSC","January 2005","December 2009","March 2011","September 21, 2005","null","November 13, 2013","General Clinical Research Center at Emory University Hospital, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00209105"
994,"NCT00209079","Phase II Trial of Gleevec and Taxotere as a Combined Regimen for Advanced Gastric Adenocarcinoma",,"Terminated","No Results Available","Gastric Adenocarcinoma","Drug: Gleevec, Taxotere","Determine if combination of Gleevec and Taxotere is effective treatment for incurable stomach cancer.|Determine toxicity of combination of Gleevec and Taxotere.","Emory University|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 2","5","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0804-2004","September 2004","April 2007","April 2007","September 21, 2005","null","December 31, 2007","Emory University Winship Cancer Institute, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00209079"
995,"NCT00209066","Treatment of Reduced Heart Rate Variability Associated With Major Depression With Electroconvulsive Therapy",,"Completed","No Results Available","Major Depressive Disorder","","","Emory University|The Dana Foundation","All","18 Years to 90 Years   (Adult, Older Adult)","","50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","0422-1998|98052113","November 1998","null","April 2005","September 21, 2005","null","November 19, 2013","Emory University School of Medicine, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00209066"
996,"NCT00209053","SMART Trial Longitudinal Follow-Up:Off-Pump Versus On-Pump Coronary Artery Bypass Surgery",,"Completed","No Results Available","Coronary Artery Disease","Procedure: Coronary Artery Bypass","after > 5 years, graft patency determined by non-invasive dual 64 slice multi-detector computed tomographic coronary angiography and cardiac positron emission tomography.|Secondary outcomes will be measured by; a battery of neuropsychological tests, MRI, NIH stroke scale, questionnaires, cardiac PET scanning, NYHA and CCS classifications and Medicare DRG's.","Emory University|Medtronic|Boston Scientific Corporation","All","18 Years and older   (Adult, Older Adult)","Not Applicable","87","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","0517-1999","January 2007","March 2009","March 2009","September 21, 2005","null","October 16, 2013","Emory Healthcare/EmoryUniversity, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00209053"
997,"NCT00209040","Fear Potentiation and Fear Inhibition in Posttraumatic Stress Disorder",,"Active, not recruiting","No Results Available","Posttraumatic Stress Disorder","Procedure: acoustic startle testing","fear potentiation of acoustic startle","Emory University","All","18 Years to 80 Years   (Adult, Older Adult)","","250","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IRB00000983","January 2001","December 2018","January 2019","September 21, 2005","null","November 29, 2017","Atlanta VA Medical Center, Decatur, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00209040"
998,"NCT00209027","The Effects of Aripiprazole on the Processing of Rewards in Schizophrenia",,"Terminated","Has Results","Schizophrenia","Other: fMRI|Drug: Aripiprazole","BOLD Activation During fMRI Scanning During Performance of a Monetary Reward Task","Emory University|Bristol-Myers Squibb","Male","20 Years to 50 Years   (Adult)","Not Applicable","20","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","IRB00024777|570-024","April 2005","December 2010","April 2011","September 21, 2005","June 18, 2012","December 6, 2013","Atlanta VA Medical Center, Decatur, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00209027"
999,"NCT00209014","Phase II Trial of Thalidomide in Refractory/Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin's Disease",,"Terminated","No Results Available","B-Cell Lymphoma|Hodgkin's Disease","Drug: Thalidomide","","Emory University|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","2","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0544-2003","July 2003","null","June 2006","September 21, 2005","null","May 7, 2009","Emory University Winship Cancer Institute, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00209014"
1000,"NCT00209001","Efficacy of Acupuncture for Hot Flashes in Women Treated With Hormonal Therapy for Breast Cancer",,"Terminated","No Results Available","Breast Cancer","Procedure: Acupuncture|Procedure: Sham acupuncture therapy","Define efficacy of acupuncture to points of the enhanced Ming Men technique for relief of hot flashes after hormonal therapy for breast cancer.","Emory University","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","7","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0533-2003","July 2003","December 2007","December 2007","September 21, 2005","null","July 13, 2015","Emory University Winship Cancer Institute, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00209001"
